Food, brands and grocery newsletter for the week of June 11, 2026. A Fed study relayed on the tape warns the real tariff pass-through is still ahead, while Dollar Tree and Walmart flag a low-end consumer that has run out of room.

Food: Brands, Private Label & Grocery

Week of June 11, 2026: Grocery's Tariff Bill Isn't Paid Yet, and Shoppers Are Tapped

The cost shock everyone keeps declaring "behind us" is, by the tape this week, still sitting in front of the register. The provocative line of the week came from a Federal Reserve study, relayed on a podcast: retailers ate most of 2025's tariff hit to keep you loyal, and the real pass-through is still coming. Pair that with a dollar-store chain admitting its own customers can no longer afford groceries, and you have the central tension for the group: margins held together with productivity duct tape, sitting on top of a consumer who's run out of room.

TL;DR

• The pass-through isn't over. The week's loudest message: 2025 tariff absorption protected customer relationships, not P&Ls forever, and the full price impact is "still working its way through the system." Bearish for center-store gross margins into 2H26.
• The bottom has cracked. When Dollar Tree says shoppers can't afford food, and Walmart flags tax-refund cash running dry, this isn't trade-down-to-private-label, it's demand destruction at the low end.
• Brands still pull, but the floor is rising. Operators insist consumers still reach for brands; meanwhile retailers are quietly testing higher price floors even as wholesale costs revert. Sticky shelf prices = the margin offset hiding in plain sight.

What's new

1. The Fed says the worst of food inflation is ahead, not behind. On The NEXT BIG THING with Keith D. Terry (June 10), host Keith Terry walked through BLS and Tax Foundation data, coffee +27% YoY, ground beef +18%, orange juice +22%, beef/veal ~27%, an average tariff cost of $1,500 per household, then dropped the kicker: a March 2026 Fed study found "many retailers absorb tariff costs through most of 2025 to protect customer relationships… the full pass-through is still coming." If true, the Street's "pricing laps in 2026" relief thesis is early.

2. Dollar Tree's tell, and Walmart's own warning. Eurodollar University (June 8): "When Dollar Tree says that its customers could no longer afford to buy food from dollar stores, you know you've got big problems." Jeff Snider notes real personal disposable income went negative in January and flags Walmart's own caution that "tax refund money is running out… which has us concerned about what the coming quarters look like." Read it as a low-end demand cliff, not a tidy share rotation into store brands.

3. The sticky-shelf-price margin engine. Odd Lots (June 11, with Baldor Specialty Foods' procurement chief Jacob Kremple): tomatoes hit a record $2.69/lb (+40% YoY) after two Florida freezes "took 80% of the crop in Florida out completely." But the durable insight is the floor that doesn't fall back: retailers test "a new price floor… maybe I'm going to charge the consumer a little bit more than I traditionally used to," holding $1.99 where they once dropped to $1.49. Grocery EBITDA margins have crept to 4–7% partly because chains are now "advertising and marketing companies… selling customer data."

4. Costco's fuel flywheel, Walmart's last-mile push. Remarkable Retail (June 9): Costco net sales +12% and comps +9.8%, but roughly a third of that comp was gasoline, the membership-gated loss-leader that drags traffic into the box; chicken up 26–27% is pressuring the $4.99 rotisserie. Walmart e-commerce grew +26% with store-fulfilled delivery +45%, and 30-minute delivery now reaches 60% of US households across 33 markets and 100,000 SKUs. That's the closest thing this week to an online-grocery-gets-profitable data point.

5. Brands still pull, if you earn the shelf. The CPG Guys (June 10, with WK Kellogg CGO Doug VandeVelde) pitched the pivot from "breakfast" to "functional wellness" (95% of Americans miss daily fiber; "just as many people trying to get more fiber as they were trying to get more protein"), backed by a $500M supply-chain modernization and the brand's first cereal Super Bowl ad in 15 years. The hosts noted the main cereal competitor "looks like… publicly reported data is struggling," a relative-share tell worth filing.

The debate

The bear case got the microphone this week, and it's coherent. Cost side: tariff absorption is a borrowed margin, not a saved one, the Fed read on The NEXT BIG THING says the pass-through still lands in 2H26. Demand side: Eurodollar University argues the low-end consumer is past trade-down and into outright cutting, bad for unit volumes regardless of price. And The Trade Guys (June 9) show the input-cost base isn't easing either: diesel over $5/gallon, fertilizer up, US ag exports to China collapsing from $24B to $8B.

The bull rebuttal is thinner but real, and it's mostly about who can hold price. The Boston Fed's Six Hundred Atlantic (June 4) makes the productivity-offset case: facing tariffs ~5x larger than 2018's (+12pp vs +2.5pp), "firms responded… by becoming notably more productive… allowing firms to preserve their profit margins and not to pass on those costs." Add the sticky price floors from Odd Lots and the brand-pull insistence from operators, and the scaled players have levers. The catch, in the Fed's own words: the productivity offset "cannot persist indefinitely."

The two bull pillars this newsletter usually watches, cocoa/coffee rolling off into 2026 margin relief, and MFC plus retail media making online grocery durably profitable, were essentially not voiced this week. Coffee showed up only as a +27% CPI print, not a supply-relief story, and no one made the quick-commerce contribution-margin case. Absence of the argument isn't evidence against it; it's a gap to fill before leaning bullish.

The names in play

WK Kellogg (K) is the cleanest single-name signal, an operator narrating an execution rebound and a struggling primary competitor. Costco (COST) screens strong on the headline comp, but strip the gas and protein-cost creep and the quality of that print softens. Walmart (WMT) is the paradox of the week: best-in-class delivery economics and the company flagging its own demand worry. Dollar Tree (DLTR) is the canary, its admission is the macro tell, not a buy signal. For anyone expressing defense, Schwab Network (June 4) framed a tactical rotation into staples via XLP (top holdings WMT, COST, P&G). And on the emerging-brand side, In the Sauce (June 11, with Adam Siskin) is a useful reality check on private-label fear: brands still win consumer pull, but "most brands, even at 50 to 100 million, are struggling to be at" healthy EBITDA, and Costco's co-pack model is a genuine commoditization risk.

Read-throughs

• Grocers (KR, ACI): the retail-media/data-monetization tailwind is now visibly lifting grocery EBITDA toward 4–7% (Odd Lots), a structural margin story even as core grocery stays thin.
• Confectioners & packaged coffee (HSY, KDP, SBUX): coffee +27% YoY is a COGS headwind with no supply-relief narrative voiced this week, watch hedge timing.
• Ag & origin economies: China permanently sourcing soybeans from Brazil/Argentina ("these markets are gone") is a durable demand hole for US grain handlers (The Trade Guys).
• Away-from-home to at-home: a basic NY burger has gone from ~$14–15 (2019) to $22–23, but restaurant food is only ~30% of cost, the widening value gap favors grocery traffic and branded at-home (Odd Lots).
• Quiet this week: quick commerce (DASH, CART), MFC automation vendors, retail-media take rates, and private-label pure-plays (THS) drew no dedicated coverage.

Operator and insider commentary (WK Kellogg, Baldor, In the Sauce) is flagged separately from pundit/analyst opinion throughout. Threads with no tape this week, private-label pure-plays, cocoa/coffee origin supply, quick commerce, retail-media take rates, were left out rather than filled.

Gold and precious-metals newsletter for the week of June 11, 2026. Both gold and silver snapped through their 200-day moving averages, and the podcast tape split between technicians calling it a washout and the debasement crowd shrugging off the drawdown as noise in a decade-long story.

The Debasement Trade

Week of June 11, 2026: Gold's 200-Day Breaks, Bear Market or Buying Op?

This was the week the tape finally bit. After a parabolic run that carried gold and silver to fresh records earlier in the year, both metals snapped through their 200-day moving averages, dragging the miners down with them. The podcast feed split cleanly into two camps: technicians arguing whether this is a washout or the start of something worse, and the debasement crowd shrugging that none of it changes the ten-year story. Here's the tape.

What Actually Happened

The trigger was macro, not metal. A surprisingly hot May jobs report, roughly 172,000 jobs, nearly double expectations, pushed Treasury yields and the dollar up and yanked rate-cut bets off the table just as markets brace for Kevin Warsh's first Fed meeting. On Money Metals' Weekly Market Wrap (June 5), Stephen Gleason pegged gold at $4,372 (down 4% on the week, support $4,365, resistance $4,600), silver at $69.77 (-7%), platinum at $1,831 (-5%) and palladium at $1,282 (-6%). Guest Axel Merck's framing was the sharpest: the market is pricing the Iran conflict "as a shock, not as a structural change," so long real rates have risen even as war fear flares, and gold ultimately competes against the long-run purchasing power of the currency, not the headline.

The Pundits, Technicians and Macro Voices

(Opinion and analysis from commentators and strategists, not company insiders.)

The technicians mostly read the break as a flush, not a funeral. On The KE Report (June 9), Dave Erfle of Junior Miner Junkie called it "a false breakdown for the breakout" and "basically a washout," noting the bullish percent index for the miners "hit zero today… it hasn't hit zero since late 2015." His fundamental point cuts against the price action: the miners "made more profits last year than they'd made in the previous 18 years combined," still earning roughly $3,000-an-ounce margins on gold that averaged $3,500 in 2025. Craig Hemke made the same argument on The KE Report (June 8), blaming the equity bloodbath on the machines: even at "$4,300 gold and $70 silver," top-tier producers pulling metal out of the ground for $2,000 less are minting $2,000–$2,500 per ounce, "and anybody would look at that and go, this is a pretty good stock."

The debasement bulls were unmoved. Larry Lepard, on Mining Stock Education (June 9), conceded Friday "was like getting kicked in the gut… almost like a global margin call," but insisted "the monetary debasement is very, very much baked in the cake and they really can't stop it." His view: a 1970s-style decade, gold to "10, 15, 20" thousand, and silver equities that "should easily double, maybe triple" (his fund, he noted, was up 175% in 2025). Larry McDonald turned it into a trade on MacroVoices #536 (June 11): with a wounded consumer leaving the Fed unable to hike, he sees gold at $6,500 an ounce a year out and frames the miners as a "hot money flush," Agnico, he said, trades ~40% off highs at 5.9x EV/EBITDA with $6–7B of free cash flow and a $2B buyback, a setup he scores as "10, 15% down and 200% up." He also flagged the under-discussed near-term headwind: energy-shocked emerging-market central banks (Turkey among them) have been selling gold to raise cash.

Not everyone is bulled up near-term. Luke Gromen, on Forward Guidance (June 11), argued Warsh faces "a very simple choice, the dollar or the bond market, they're gonna have to sacrifice one," and dismissed the "disinflationary growth" pitch (cut front-end rates, grow out of it via AI) as trying to "ride two horses with one ass." With CPI headline back above 4%, his near-term read is darker than the gold permabulls': "I think gold and Bitcoin are telling us something wicked this way comes… it's bad for bonds, it's bad for stocks, it's bad for risk, it's bad for gold, it's bad for Bitcoin." Worth holding that tension: the structural bull and the cyclical caution can both be right.

On the structural side, the de-dollarization theme keeps recurring. The gold-dealer channel ITM Trading (June 4), promotional, so weigh accordingly, anchored its episode on an ECB report that, it says, showed gold overtaking U.S. Treasuries as the largest global reserve asset "for the first time in 30 years," with central banks buying straight through the price pullback for gold's lack of counterparty risk.

The Silver and PGM Corner

Silver took the harder hit. On In It To Win It (June 7), Steve Barton clocked silver down 8.9% on the week off a textbook bear-flag breakdown, the silver-miner ETF (SIL) off 15.4% and PSLV down 10.6%; he sees support near $64, then $62, with the low-$50s in play if those fail. The gold/silver ratio widened to 63:1 from 59:1, while platinum/silver at 26:1 he called "a smoking deal" versus a historical extreme near 150:1. The PGM complex stayed grim: on WorldWide Markets with Simon Brown (June 9), Brown described platinum and palladium charts as "bleak," with palladium back in its ~900–1,200 range and every South African PGM miner trading lower.

From the Operators

(Company management and insiders, project updates, not market opinions.)

While the pundits debated the tape, the people actually building mines kept building. The standout was New Found Gold CEO Keith Boyle on Company Interviews (June 11), describing the shift "from explorer into operator mode": Hammerdown is ramping to commercial production at 700 tonnes/day, recoveries in the high 80s, targeting 20–25k oz/year at $2,500 AISC, "a $40 to $50 million a year cash flow generator" meant to self-fund a 90,000-metre drill program while a $220M raise pushes the larger Queensway toward production "towards the end of next year." On the resource front, West Red Lake Gold Mines' Will Robinson reported on The KE Report (June 9) a 70% jump in indicated ounces at Rowan to 334,000 oz at 13 g/t, at a discovery cost of just C$17.60/oz. Founders Metals' Colin Padgett detailed high-grade Suriname hits (Upper Antino 17.2 g/t over 3.6m) inside a 70,000-metre program on The KE Report (June 4); Banyan Gold's Tarek Christie walked through a Yukon acquisition and the 8.6M-oz AurMac asset on The KE Report (June 5); and San Lorenzo Gold's Al Kroontje flagged 17+ g/t intercepts over a kilometre at his Chilean Salvador project on Mining Stock Daily (June 10). On the silver side, Silver Tiger Metals' Glen Strathearn put El Tigre on track for a 2027 first pour against an $800M NPV on Company Interviews (June 10).

The Bottom Line

The operators are running their playbook as if $4,300 gold is a gift, because for their cost structures it is. The pundits are split between "buy the washout" and Gromen's warning that the next one-to-two months get ugly for everything. The one thread both camps share: nobody serious thinks the debasement story died this week, they think the price did, briefly. Watch Warsh next week, the gold/silver ratio at 63:1, and whether that bullish-percent-index zero marks a floor or just the first floor.

Sources this week: every figure and quote above is drawn from the linked podcast episode, all published June 4–11, 2026. Operator commentary is segregated from pundit opinion by design.

AI drug discovery newsletter for the week of June 11, 2026. The platform debate moved on real insider tape: a CZ Biohub protein language model designed cryo-EM-validated nanomolar antibodies, NVIDIA called simulation assay-grade and named Schrodinger, and the first AI-formulated oral drug entered Phase 1.

AI Drug Discovery Weekly

Week of June 11, 2026: An Open-Source Protein Model Designs Validated Antibodies

This week the platform debate finally produced physical output rather than slideware. The clearest signal came from an insider conversation outside the listed coverage names: a CZ Biohub protein language model that designs single-chain antibodies with nanomolar binding affinity, cryo-EM validated. Layered on top, NVIDIA's biopharma BD lead called free-energy-perturbation simulation assay-grade and named Schrodinger as the live example, the first self-described AI-formulated oral drug entered Phase 1 with regulators leaning in, and a cancer foundation-model pitch reframed the commercial wedge as patient selection rather than molecule design. Here is what the tape said.

TL;DR

• On No Priors, Mark Zuckerberg and CZ Biohub's Alex Rives walked through an open-source protein language model that designs nanomolar single-chain antibodies, cryo-EM validated, a direct read-through to the wet-lab-first antibody platforms (ABCL, ABSI).
• NVIDIA's biopharma BD lead said FEP molecular simulation is now "basically as good and as predictive as running experimental assays," and name-checked Schrodinger's tox panel as the live example, the most pointed validation SDGR's physics-based pitch has gotten on a podcast in weeks.
• CRDMO Quotient Sciences began a Phase 1 study of what it calls the first AI-formulated oral drug after MHRA clearance, while a Pistoia Alliance poll showed 42% of clinical-trial respondents already see early ROI even as trust and regulatory uncertainty remain the top adoption barrier.

What's new

1. Zuckerberg and CZ Biohub open-source a protein model that designs validated antibodies. On No Priors' Biohub: The Future of Biology is Open-Source (Jun 10), Head of Science Alex Rives (ex-Evolutionary Scale) described a protein language model trained on billions of sequences that hits state-of-the-art structure prediction "especially on protein-protein interactions and protein-antibody interactions, which is really critical for therapeutic design," and has been used to design single-chain antibodies with nanomolar binding affinities validated by cryo-EM. Rives framed antibody design as an "emergent property" of a general protein model. Why it matters: an open-source engine that replaces "hundreds of thousands or millions of antibodies" in a screen with a compute instance is a structural threat to the moat narrative under AbCellera and Absci. Mark Zuckerberg and Priscilla Chan positioned the release as a discovery engine free to anyone.

2. NVIDIA says simulation now rivals the wet lab, and points at Schrodinger. On Once a Scientist Ep. 95 (Jun 10), Stacie Calad-Thomson, NVIDIA's head of BioPharma Labs & Manufacturing BD, said FEP molecular simulations are "basically as good and as predictive as running experimental assays now," citing Schrodinger's tox panel running ~100 off-target tox predictions computationally. She described NVIDIA as an ecosystem enabler, hosting open-source models on BioNeMo, with pharma "licensing those models" and fine-tuning on proprietary data: "we've seen a lot of deals this year." Why it matters: this is third-party validation of SDGR's core claim from the most credible compute vendor in the space. She also flagged the real bottleneck as lab-instrument connectivity, not compute, a tell on where the next capex goes.

3. First "AI-formulated" oral drug enters Phase 1; regulators lean in. On The Drug Discovery World Podcast, DDW Highlights, 9 June 2026, a Pistoia Alliance poll found 50% of clinical-trial respondents cite trust and regulatory uncertainty as the top barrier to AI adoption, while 42% already see early ROI. CRDMO Quotient Sciences began a Phase 1 study of what it calls the first AI-formulated oral drug after MHRA clearance; MHRA, Danish and Swedish regulators signaled openness, with Pistoia's Dr. Becky Upton stressing "validated, auditable and explainable approaches, not black box models." Why it matters: the bottleneck for AI-bio multiples is regulatory acceptance, and the agencies are now publicly constructive.

4. A pan-cancer "foundation model" pitch for trial enrichment. On BIO from the BAYOU Ep. 140 (Jun 10), Genialis CEO Dr. Rafael Rosengarten described an RNA-seq-based cancer foundation model that decomposes biology into modular "Lego brick" models, letting clinical predictors train on as few as 50 patients, aimed at "the most pernicious bottleneck in drug development," trial failure. Why it matters: this is the commercial wedge, using AI to pick the right patients rather than design the molecule, and it is the version of "AI in pharma" with the clearest near-term P&L.

The debate

Bull: The platform is finally producing physical output, not slideware. Validated nanomolar antibodies from a model, FEP simulation at assay-grade accuracy, a first AI-formulated drug in the clinic, and regulators actively writing the rulebook. If the cost of a credible drug candidate keeps falling, the public picks-and-shovels names (compute, physics-based software, biosimulation) compound while discovery economics improve industry-wide.

Bear: The week's best evidence came from a non-profit (CZ Biohub) and a chip vendor (NVIDIA), not from the listed AI-bio names whose stocks need the wins. Open-sourcing the antibody-design engine is precisely the commoditization risk that compresses the moat under ABCL and ABSI. And the Pistoia data is blunt: half the industry still doesn't trust the tools. Validated binders and AI formulations are not approved drugs or revenue. With RXRX at $3.15 and SDGR at $14.60, both near 52-week lows and burning cash, the market is pricing skepticism, not a platform re-rate.

Stocks in play

• Recursion (RXRX), $3.15, +3.6% on the day, market cap ~$1.4B, near the $2.77 52-week low (high $7.18). Bull: scaled phenomics plus compute, optionality on pipeline readouts. Bear: cash burn against a sub-$1.50 EPS loss; the open-source-model news cuts against proprietary-data moats. Next catalyst: clinical pipeline readouts and any partnership refresh.
• Schrodinger (SDGR), $14.60, +3.2%, market cap ~$1.1B, 52-week range $10.95–$26.45. Bull: NVIDIA publicly validated FEP-as-assay and cited SDGR's tox panel by name; software-plus-pipeline model. Bear: stock sits near the low; proprietary-program value still unproven; simulation parity claims help the category, not necessarily the licensor. Next catalyst: software bookings cadence and proprietary pipeline progress.
• Eli Lilly (LLY), $1,160.95, +2.2%, market cap ~$1.09T. Bull: retatrutide TRIUMPH-1 showed ~28.3% weight loss at 80 weeks plus knee-OA and sleep-apnea benefit; Jefferies lifted its target to $1,350 (Buy); $1B+ AlzeCure Alzheimer's licensing deal; Ebglyss atopic-dermatitis approval. Bear: the tape was GLP-1 and licensing, not AI; GLP-1 employer-coverage cuts in 2027 (~10% of covering employers) are a demand overhang. Next catalyst: GLP-1 coverage policy and any TuneLab external-partner disclosure.
• NVIDIA (NVDA), the week's connective tissue: BioNeMo hosting, "a lot of deals this year," and the FEP-parity claim make NVDA the toll-taker on every AI-bio workflow. Watch: model-licensing deal flow as a leading indicator for the category.

Read-throughs

• Antibody-discovery platforms (ABCL, ABSI): the CZ Biohub open-source antibody model is the competitive read-through to watch, generative design as a free utility pressures differentiated-data moats.
• Compute and infrastructure (NVDA): ecosystem-enabler positioning and rising model-licensing deal volume; lab-instrument connectivity flagged as the next bottleneck (read-through to lab-automation and informatics vendors).
• Physics-based and biosimulation (SDGR): FEP-as-assay validation lifts the category narrative.
• AI diagnostics and trial enrichment: the clearest near-term revenue path is patient selection and trial design, not de novo molecule generation, per the Genialis cancer foundation-model pitch.

What changed vs last week

This is the first edition of AI Drug Discovery Weekly, so there is no prior issue to reconcile against; treat this as the baseline. One framing to carry forward: this week the most consequential AI-bio progress came from a non-profit (CZ Biohub) and a compute vendor (NVIDIA), with the regulatory door opening via the first AI-formulated drug in the clinic. We will track next week whether the public names start converting that platform momentum into disclosed wins, or whether open-source commoditization keeps the value capture upstream of the equities.

AI capex and the bubble debate newsletter for the week of June 11, 2026. Oracle's capex blowout finally spooked the tape, but the operators pouring concrete and signing power contracts still sound supply-starved.

AI Capex & The Bubble Debate

Week of June 11, 2026: Oracle's Capex Bill Scares the Tape, Power Still Wins

Funny week. The same buildout that's supposed to re-rate every landlord with a power cord finally sent a chill through the tape, Oracle spending more than 100% of revenue on capex will do that. But peel back the panic and the operators who actually pour the concrete and sign the power contracts sound as supply-starved as ever. The gap between the screen reaction and the ground truth is where our edge lives this week.

TL;DR

• Oracle's capex blowout ($90–95B against ~$90B of revenue) became the whole market's Rorschach test, bears called it the top, operators called it Tuesday. Either way it's the loudest "is AI overbuilt?" debate we've heard all year.
• Power is still the binding constraint, full stop. Microsoft's own infra chief says you can't find a spare gigawatt on any grid; the response is to network smaller data centers together. That's the bull case for behind-the-meter power and the merchant nuclear fleet, said out loud by the buyer.
• Industrial is quietly bifurcating: record-low new warehouse supply (a tailwind), but the first give-back of pandemic-era rent gains and 8%+ distribution vacancy (a yellow flag). Don't sleep on the rent line.

What's New

Oracle turned the AI-capex question into a market-wide gut check. On Squawk on the Street (Jun 11), the desk walked through FY27 net cash outlay of "about $70 billion," an RPO that "was gigantic, it's $850 billion," and the Michigan Stargate build: "$16 billion to build it... $30, $35 billion to outfit it... almost $50 billion for a gigawatt." For a landlord, that last number is the thesis, replacement cost is exploding, which is bullish for stabilized assets and brutal for anyone underwriting new development math.

The bear translation showed up fast, and it's about tokens, not just dollars. Narwhal Capital's PMs, on The Morning Market Briefing (Jun 11), flagged that Oracle is "about ready to spend over 100% of revenue on CapEx," then made the point that should worry every DC bull:

"If tokens is what you measure GPU throughput and AI usage in, it's the first indication to me that maybe we're overbuilding... we have too much supply of tokens and not enough demand."

That ties to OpenAI reportedly weighing "drastic" price cuts, The Rundown (Jun 11) also noted Oracle is now "the biggest corporate borrower in America outside of banks, with about $117 billion in bond debt" and "more than half of the $638 billion backlog... from a single customer, which is OpenAI." Single-tenant concentration, financed with debt. File that.

But the buyer of all this capacity says the constraint is still physics, not demand. Microsoft's Alistair Spears (GM, Azure Infrastructure, 19 years there) gave the cleanest operator read of the week on Tech Disruptors (Jun 9):

"It's very hard right now to find a spare gigawatt or five gigawatts on any single energy grid. And so the approach now... is really distributed training... network smaller data centers together."

He added that long-term land and energy contracts are "measured in decades... 10 or 20-year investments." This is a hyperscaler telling you the bottleneck is power and steel, not a shortage of tenants.

The private-capital crowd quantified the wall, and the failure rate. On Tech Disruptors (Jun 11), Apollo's Rob Bittencourt sized five-hyperscaler capex going "from below $100 billion" in 2019 to "over $750 billion," with a total AI infrastructure need of "five to six trillion dollars," addressable "only... through investment grade rated financing." Same episode, Helix Digital CEO Adam Selitsky (ex-AWS CEO, now partnered with KKR, Nvidia and Vistra) dropped the stat the bears will quote for months:

"Over 25% of data center projects which are announced now are not actually delivering, and that number seems to be increasing."

Translation: the announced pipeline is not the real pipeline. That's bullish for existing, powered, leased assets and bearish for the speculative-supply narrative.

Industrial isn't the clean "record-low supply" story everyone repeats. Two operators, two angles. Link Logistics CEO Luke Petherbridge (Blackstone's ~400M sq ft platform) on Inside the ICE House (Jun 8) called new supply "record low... like a decade low," with demand driven by e-commerce and "this infrastructure build out, whether it's data centres, whether it's power," even spillover land "transitioning to a data center." Bullish. But Moody's Analytics' Ermengarde Jabir, on America's Commercial Real Estate Show (Jun 10), flagged the crack: distribution vacancy "push above 8%," cap rates backing up to "6.4%, 6.5%," and, the line that matters,

"This is the first time in the entire period of growth... post 2020 for the sector where the sector has given back its pandemic era gains in terms of rent growth."

Low supply protects occupancy; it doesn't guarantee the mark-to-market spreads PLD/REXR bulls are modeling.

The Debate

Bull frame (well-voiced this week): Power is genuinely scarce, a hyperscaler infra chief, a former AWS CEO, and the merchant-nuclear story all said it independently. Constellation gets framed as "the largest supplier of 24-7 carbon-free power to hyperscale AI data centers via long-term PPAs" (InvestTalk, Jun 11), and Jensen Huang's "the choke point here is on the power side... we need something like a thousand times more power" got requoted on Market News with Rodney Lake (Jun 11). Add record-low industrial supply, and you have landlords sitting on irreplaceable, power-adjacent dirt.

Bear frame (also well-voiced): Capex is lapping revenue, financed with record debt and dilutive equity, against demand that may be softening at the token level. The Trepp team, on The TreppWire Podcast (Jun 5), cited "a JP Morgan analysis [that] found that more than 60% of data center capacity planned for completion in 2027 is not yet even under construction," and asked whether the $4T hyperscaler spend "gets pushed out to 2035, 2037." Pair that with the 25%-don't-deliver stat and the OpenAI price-cut chatter, and the bear case isn't "no demand," it's "the new-build economics break before the demand shows up."

Net: a rare week where both sides are argued by people who move the numbers. The bull case comes from buyers and builders of power; the bear case from allocators staring at the financing stack. That tells you where to point diligence: power offtake and balance-sheet capacity, not headline demand.

Read-throughs

• Utilities / merchant nuclear: CEG is the podcast favorite as the AI-power proxy, but note it's "down 31.41%" YTD with a ~$90B cap and a Three Mile Island restart "delayed by transmission interconnection challenges" (InvestTalk, Jun 11). Vistra surfaced only as Helix's ~50 GW power partner (Tech Disruptors, Jun 11).
• Electrical / cooling gear: thin tape, Vertiv got a passing nod as an "obvious beneficiary" of "hundreds of billions... in new data centers" (Motley Fool Hidden Gems Investing, Jun 9); no backlog color on GE Vernova, Eaton, or ABB.
• Carriers / towers: AT&T's Shawn Hakl (Telco in 20, Jun 9) framed AT&T as "the connectivity layer for AI workloads via fiber, fixed wireless, and last-mile," capex tilting to fiber/edge, not macro-tower density. Quietly unhelpful for the tower-leasing thesis.
• Freight (a warehouse-demand tell): FTR's Avery Weiss (FTR | State of Freight, Jun 9) has broker spot rates at "another all-time high... risen for 20 straight weeks," dry-van "55% higher than... the same week last year," loads "around 57% higher." Tightening freight usually leads tightening warehouse demand, a quiet positive for industrial occupancy.

What Changed

The tone, not the numbers. For a year the AI-capex story was unalloyed "they'll spend whatever it takes." This week, for the first time, insiders started pricing failure: Selitsky's 25%-don't-deliver, Narwhal's token-oversupply tell, the IG-financing-is-the-only-way framing. The demand bulls didn't blink; the financing bulls did. That's the subtle shift to watch into next quarter.

Industrials podcast recap for the week of June 1-8, 2026. The conglomerate breakup thesis was the week's strongest single industrials theme, anchored on Honeywell's four-way split and benchmarked against GE's 2023-24 separations, with AI-driven electrification and geopolitics framing the rest of the tape.

Industrials Weekly

Week of June 1-8, 2026: The Conglomerate Breakup Playbook, From GE to Honeywell's Four-Way Split

Five podcast episodes carried US industrials content this week, and the center of gravity was unmistakable: the conglomerate breakup and value-unlock thesis, anchored on Honeywell's four-way split and benchmarked against GE's completed separations. One episode, Brew Markets, "SpaceX's Unorthodox IPO & The Honeywell Spinoffs," June 4, delivered the deep, company-specific industrials work. The other four were macro and markets episodes where industrials surfaced as sector rotation, utility trades, or geopolitical read-throughs. The bottoms-up sub-sectors (freight and rails, machinery, HVAC pure-plays, defense primes by ticker, aerospace OEMs, construction and engineering) were largely quiet, so what follows leans on the themes the tape actually carried.

TL;DR

• The conglomerate breakup and value-unlock thesis was the week's single strongest industrials theme, anchored on Honeywell's four-way split (automation HON, aerospace HONA, advanced materials SOLS, quantum QNT) and benchmarked against GE's 2023-24 separations. Ann Berry called it a generalizable, durable playbook (Brew Markets, June 4).
• AI-driven electrification and data center CapEx remains the dominant macro driver of industrial earnings, cited at $800-900B in 2026 and above $1T in 2027, with GE Vernova (GEV) and Solstice (SOLS) the named beneficiaries. Skilled-trades labor (a need for roughly 500,000 electricians over three years) is the binding constraint (Thoughtful Money, June 6).
• The biggest active debate: is the AI and data center CapEx cycle durable or a bubble? Bulls (Roberts, Taggart, Berry) see it underpinning earnings; the bear case relayed from Michael Burry flags shorter GPU life and "burned tokens," with the bubble expression showing up in NVDA and PLTR (Cash Daddies, June 2).
• Defense is a structural multi-year uplift theme (Gulf hardening plus a European "generational shift" after Germany's debt-brake lift), but no US prime tickers were discussed by name, only Honeywell Aerospace as a spin beneficiary (Insights Now, June 4).
• Iran war and input costs: worst-is-over versus just-delayed. As of June 6, oil, fertilizer, and urea had pulled back sharply ("fears didn't materialize"), but JPM was internally modeling $4-5 per gallon gas for the rest of 2026 and warned a Strait of Hormuz reopening takes "weeks and really months" (Thoughtful Money, June 6; Insights Now, June 4).
• ISM Manufacturing (released Monday June 1) is back in expansion above 50, but the signal is contested. Akil Stokes argued recent order growth is tariff front-running and inventory stocking rather than genuine demand (The Trading Coach, June 1).
• Tariffs and Trump 2.0 are framed as structural, not cyclical ("haven't seen anything like it since the 1930s"), with three Section 301 investigations concluding this summer and the current posture seen as durable through the term (Insights Now, June 4).
• Reshoring is being actively funded by the "One Big Beautiful Bill" 100% bonus depreciation, described as "unleashing a lot of money" into new-plant investment (Thoughtful Money, June 6).
• China and rare earths are flagged as a fixable but acute vulnerability, with 80-90% of rare-earth and critical-mineral imports sourced from the PRC, feeding "everything from your iPhone to the most sophisticated missile" (Insights Now, June 4).
• Sector rotation into industrials is starting. Lance Roberts flagged industrials and financials as "big laggards" finally beginning to "pick up the weight" (Thoughtful Money, June 6).

Section 1: Dominant Themes

Conglomerate breakup and value unlock (the week's strongest single industrials theme). The Honeywell four-way split (automation HON, aerospace HONA, advanced materials SOLS, quantum QNT) was the central case study, benchmarked against GE's 2023-2024 separations. Ann Berry framed it as a generalizable playbook: "I have a sneaking suspicion that conglomerates in whatever industry it's in are going to be taking a good hard look at themselves to see if there's ways to unlock value by separating. It's going to continue as a theme." (Brew Markets, June 4)

AI-driven electrification and the data center buildout, still the dominant macro driver of industrial earnings. Adam Taggart cited CapEx of "$800-900 billion in 2026 and above a trillion next year" as the lynchpin of GDP and earnings revisions; Lance Roberts concurred that "a lot of the uptick that we have in earnings right now and economic growth data is from the CapEx spending that's occurring" (Thoughtful Money, June 6). GE Vernova and Solstice Advanced Materials were the two specific industrial beneficiaries named (Brew Markets, June 4). Skilled-trades labor (electricians, plumbers) was flagged as a binding constraint, with Roberts noting "we need 500,000 electricians over the next 3 years."

Defense spending, a structural Gulf and Europe uplift, but no US prime tickers discussed by name. Derek Chalet of the JPM Center for Geopolitics flagged "a big spike in defense spending in the coming years as the Gulf seeks to harden themselves further" and a "generational shift" in European defense following Germany's debt-brake lift (Insights Now, June 4). Ann Berry tied this directly to the Honeywell Aerospace spin thesis: "Defense, of course, getting a ton of attention given what's going on in the Middle East and in Ukraine" (Brew Markets, June 4).

Iran war impact, fading near-term inflation panic but Hormuz remains the swing factor. As of June 6, Roberts noted that "oil prices have come down, fertilizer prices, urea prices have come down fairly sharply. A lot of the big fears that were supposed to happen with the Iran crisis didn't really materialize yet" (Thoughtful Money, June 6). But as of June 4, Chalet warned: "Even the best case scenario is it's going to take weeks and really months for the Strait of Hormuz to get back open," with JPM internally forecasting "$4 to $5 gas prices per gallon for the rest of 2026," and roughly 15-20% of Qatari LNG offline, potentially "for years" (Insights Now, June 4).

ISM and PMI prints, manufacturing back in expansion but signal quality contested. The ISM Manufacturing PMI was released Monday June 1. Akil Stokes characterized the recent improvement but flagged: "some of the recent increases in orders appear to be businesses stocking up on inventory ahead of potential tariffs and supply chain disruptions, that's the cause of these orders versus your normal, genuine consumer demand" (The Trading Coach, June 1). Roberts confirmed expansion ("It's well above 50") but warned his weighted 70/30 services-manufacturing composite is "borderline contractionary territory" and only just turning up (Thoughtful Money, June 6).

Tariffs and Trump 2.0, structural rather than cyclical. Chalet: "The U.S. has fundamentally changed its approach, we haven't seen anything like it since the 1930s in terms of just the overall global tariff rate," and he characterized current posture as durable: "where we end up on trade kind of at the end of President Trump's second term is more or less where we're going to be for a while" (Insights Now, June 4). Three Section 301 investigations are concluding this summer. Stokes confirmed tariffs "are still on the agenda" and continue to drive inventory pre-buying (The Trading Coach, June 1).

Reshoring and onshoring, funded by "One Big Beautiful Bill" bonus depreciation. Taggart: "Things like bonus depreciation, where you get to expense the expense of an investment in a new plant or whatever, 100% in year 1, that is unleashing a lot of money into the economy" (Thoughtful Money, June 6). Chalet framed rare-earth and critical-mineral supply chain de-risking as "a fixable problem" and an emerging multi-year capex theme, noting that "80, 90 percent of some of the imports of these rare earths and critical minerals is sourced from the PRC. And those go to everything from your iPhone to the most sophisticated missile that the U.S. military has" (Insights Now, June 4). He also noted a US-China trade truce reportedly extended after a Trump-Xi Beijing summit, with a reciprocal Washington summit penciled for the third week of September 2026.

Aerospace supply chain capacity, addressed indirectly via the HONA spin. A $19B backlog up 20% YoY, 90% of global aircraft using Honeywell navigation systems, and a 44% commercial aftermarket mix (Brew Markets, June 4). No direct OEM (BA, Airbus, suppliers) commentary.

Sector rotation into industrials. Roberts: "Industrials, financials, those are fine. Those have been big laggards. And we're starting to finally see financials, healthcare, and energy kind of start to pick up the weight here a little bit" (Thoughtful Money, June 6).

Section 2: Active Debates

Debate 1: Is the AI and data center CapEx cycle a durable industrial earnings driver or a bubble?

On the durable side, as of June 6, Lance Roberts and Adam Taggart aligned that "a lot of the uptick that we have in earnings right now and economic growth data is from the CapEx spending that's occurring," with Taggart projecting "$800-900 billion in 2026 and above a trillion next year" (Thoughtful Money, June 6). Ann Berry pointed to GEV's stock being "on a complete tear, just given the anticipated demand from data centers for driving AI consumption" (Brew Markets, June 4).

On the bubble side, as of June 2, Johnny Woodard relayed Michael Burry's thesis: "GPU life is shorter than they're accounting for. Nvidia's boom may be more cyclical, not permanent. A lot of the tokens are just going to be burned and not necessarily create profits. The bubble expression is in stocks like Nvidia and Palantir" (Cash Daddies, June 2). Even Taggart, on the bull side, flagged the asymmetric risk: "if it's only $700 billion, that's going to be a really big deal because so much of those earnings expectations are based on that money getting spent." The contested data point is the forward CapEx run-rate, roughly $700B downside versus a $1.2T base case for 2027.

Debate 2: Is the ISM Manufacturing print a clean read on real demand?

On the clean-signal side, Taggart (June 6): "The ISM Manufacturing Index is like the highest it's been in a whole bunch of years" (Thoughtful Money, June 6). On the distorted-signal side, Stokes (June 1) argued the orders increase "appears to be businesses stocking up on inventory ahead of potential tariffs and supply chain disruptions, versus your normal, genuine consumer demand" (The Trading Coach, June 1). Roberts (June 6) implicitly agreed by emphasizing his services-weighted composite is only "borderline contractionary." The contested data point is how much of recent order growth is tariff front-running versus organic.

Debate 3: Iran war impact on industrial input costs, is the worst over or just delayed?

On the worst-is-over side, Roberts (June 6) pointed to oil, fertilizer, and urea prices coming down "fairly sharply" with the big feared shocks not yet materializing (Thoughtful Money, June 6). On the still-to-come side, Chalet (June 4) said the Strait reopening will take "weeks and really months" even in the best case, with JPM internally modeling "$4 to $5 gas prices per gallon for the rest of 2026" (Insights Now, June 4). Howie Dewey (June 2) was blunter: "oil spiking. Oil's going through the roof. Gas is going back up" (Cash Daddies, June 2). The contested data point is whether the Iran-Israel-US truce holds and on what timeline Hormuz reopens.

Debate 4: Are conglomerate breakups still creating value, or is the easy alpha gone?

On the pro-breakup side, Ann Berry walked through the GE precedent: an original roughly $90-100B market cap became GE Aerospace (above $320B) plus GE Vernova (about $250B) plus GE Healthcare (about $30B), totaling roughly $600B today. "When this thesis of separating to create value works, the sum of the parts bigger than the whole, when it works, it really works" (Brew Markets, June 4). Her own caveat: ETFs have eroded both the diversification rationale and the historical implied conglomerate discount ("now with ETFs, you can already do that kind of investing where you're exposed to different companies"). No explicit bear took the other side this week.

Section 3: Stocks Mentioned

Conglomerates / Multi-Industry

HON (Honeywell International). Breakup-thesis neutral to bullish. The automation pure-play retains the HON ticker plus a 49% QNT stake, with "all of the distractions that occur as part of a conglomerate are eliminated." Ann Berry: "Honeywell, spinning off its jet sensors from its home thermostats" (Brew Markets, June 4).

GE (General Electric / GE Aerospace post-breakup). Bullish on the completed breakup outcome, sum of parts (roughly $600B) versus the original roughly $90-100B pre-2023. Ann Berry: "When this thesis of separating to create value works, the sum of the parts bigger than the whole, when it works, it really works" (Brew Markets, June 4).

Aerospace & Defense

HONA (Honeywell Aerospace Technologies, spin listing June 29, 2026). Bullish. Described as set to be "one of the largest publicly listed pure play aerospace and defense companies": 2025 revenue above $17B, adjusted EBIT above $4B, a $19B backlog up 20% YoY, "90% of global aircraft use Honeywell navigation systems," and a 44% commercial aftermarket (high-margin recurring razor/razor-blade). A direct beneficiary of Mideast and Ukraine defense demand. Ann Berry: "Defense, of course, getting a ton of attention given what's going on in the Middle East and in Ukraine" (Brew Markets, June 4).

PLTR (Palantir), defense-IT angle. Bull view from Howie Dewey: "Look at Palantir. They're not going away. They're just signing contracts left and right with the government." Bear view: the Burry thesis cited PLTR as having "bubble expression" alongside Nvidia, relayed by Johnny Woodard (Cash Daddies, June 2).

Electrical Equipment & Power (AI / Data Center)

GEV (GE Vernova). Bullish, a pure-play beneficiary of AI data center electrification demand. Spun in 2024 and "on a complete tear," currently around $250B market cap per the speaker's GE sum-of-parts math. Ann Berry: "GE Vernova, the energy arm spun off in 2024. That one's actually been on the complete tear, that stock, just given the anticipated demand from data centers for driving AI consumption" (Brew Markets, June 4).

Advanced Materials / Industrial Specialty (Data Center / Semis Adjacent)

SOLS (Solstice Advanced Materials, the HON spin from October 2025). Bullish, roughly $13.5B market cap with shares up 60% since the spin. Specialty chemicals (refrigerants, HVAC-adjacent), pharma packaging, data center cooling systems, and semiconductor manufacturing materials. Ann Berry: "Not just like an old school manufacturing arm, they're really on the forefront of tech and part of that AI trade" (Brew Markets, June 4).

QNT (Quantinuum, the Honeywell quantum spin, IPO'd June 4, 2026). Neutral to speculative. Q1 2026 net loss of roughly $136M on $5.2M revenue; market cap touched $14B intraday on IPO; $100M Commerce Department funding received last month; HON retains 49%. Primarily academic customers. Ann Berry: "A lot of them are serving academic institutions. The revenue numbers aren't big. Their cash burn rate is pretty large" (Brew Markets, June 4).

Utilities (Adjacent to Electrical / Power)

DUK (Duke Energy). Sold by Lance Roberts in a portfolio swap into AEP: "We had a position in Duke Energy. We had about a 2% position in Duke, so we sold that and we swapped that to a 3% position in American Electric Power" (Thoughtful Money, June 6).

AEP (American Electric Power). Bullish, increased to a 3% portfolio weight from the DUK swap. Roberts cited "a little bit better performance, a little bit better positioning in the portfolio for American Electric Power" (Thoughtful Money, June 6).

Sub-sectors With Zero Ticker-Level Coverage This Week

Defense primes (LMT, RTX, NOC, GD, LDOS) were discussed thematically (Gulf and European spend, Honeywell aero) but no ticker was named. Aerospace OEMs and suppliers (BA, HEI, TDG, SPR), machinery (CAT, DE, AGCO, CNH, PCAR), HVAC and building products (CARR, LII, TT, JCI, with SOLS touching refrigerants tangentially), transports, freight, rails and trucking (UNP, CSX, NSC, FDX, UPS, ODFL, JBHT), and construction and engineering (PWR, MTZ, J, EME, FIX) saw none named. The narrative this week was dominated by the Honeywell breakup, AI and data center electrification, and geopolitics (Iran, tariffs, defense uplift) rather than bottoms-up industrial company analysis.

Digital ads and retail media newsletter for the week of June 7, 2026. eMarketer's call that Meta's ad business overtakes Google's by year-end gets an airing on the podcast tape, alongside the clearest operator evidence yet that agentic ad buying has crossed from pilot to production at brand scale.

Digital Ads & Retail Media

Week of June 7, 2026: Meta Set to Pass Google in Ads by Year-End

TL;DR

• The week's one big number: eMarketer's call, surfaced on FT Tech Tonic, that Meta's ad business overtakes Google's by the end of 2026, and the podcast tape is full of operator evidence for why.
• Agentic buying went from slideware to live spend. A $1B DTC brand now runs 100% of its Meta budget through an AI media buyer, and both Meta and Google are quietly retiring manual ad products. The agency middle is being squeezed in real time.
• Meta-heavy week. Coverage concentrated on Meta and AI-search structure. The podcasts this week did not take up Amazon Ads, The Trade Desk, retail media networks, CTV names, AppLovin, or the ad-measurement complex, so this issue stays on the names that actually drew discussion.

What's new

1. eMarketer's "Meta passes Google" call gets an airing, and a mechanism. On the FT's Tech Tonic - "AI Labs: Zuckerberg's $100bn gamble" (June 3), FT journalist Hannah Murphy noted Meta's ads business "remains strong and in fact is forecast to take over Google by the end of the year by eMarketer," and is bankrolling "hundreds of billions of dollars" of AI spend. Colleague Cristina Criddle added the sharper point: the AI that already runs Meta's ad engine is mature and underappreciated, "it's just not the sexy kind of AI." Why it matters: the bull case on META has quietly shifted from "feed personalization" to "Meta owns the first-party data that OpenAI or Anthropic would love to have."

2. A $1B brand is now 100% agentic on Meta. On the DTC Podcast (June 3), True Classic CEO Ben Diamond disclosed that all of the brand's Meta spend now runs through an agentic AI buyer, live ~6 weeks and "at parity" with human management. "Meta is our largest channel… if we trust this system with our largest channel, it's exciting." He also claims AI creative has "cut our production costs by millions of dollars." This is the clearest operator data point yet that Advantage+-style automation is taking over the actual buying decision, not just assisting it.

3. Google is killing its own manual ad products. On The Marketing AI SparkCast (June 1), Aby Varma reported Google is retiring Dynamic Search Ads in favor of "AI Max," with migration starting "around September" 2026, after already retiring standard text ads and responsive image ads earlier this year. Same episode: Varma says OpenAI launched a self-serve ChatGPT ad manager at ads.openai.com in May ("any brand can buy ads directly inside ChatGPT, cost per click, no minimum spend"), with "WPP, Publicis, Omnicom, Dentsu already integrated." (These are Varma's cited figures, not independently verified, treat as directional.)

4. Meta opens its ad stack to outside AI. Varma also flagged that Meta launched "AI connectors" in beta, letting advertisers "manage Meta campaigns, audiences, creative, and reporting directly through AI tools like Claude and ChatGPT using Meta's own MCP server." On Creator's MBA (June 2), an operator demoed exactly this, pulling live campaign metrics into Claude and having the AI flag that video creative cost "62% more per lead." Small workflow, big read-through: AI assistants may quietly disintermediate attribution vendors.

5. The "impressions and price both up" claim. On Chit Chat Stocks (June 5), Ryan Henderson claimed Meta grew "impressions like high teens and price per ad… high teens percentage" last quarter, "pretty astounding," since the two usually move inversely. He went further: "I would not be surprised if Meta was generating higher advertising revenue than Google… in three, five years." Co-host Brett Schaefer pushed back that Alphabet enjoys the same AI-efficiency tailwind, and called the two "very, very close" at 18x vs. 32x EV/EBIT. (Henderson's growth figures are his recollection of a prior quarter, unverified, flag accordingly.)

The line of the week, from FT's Criddle: if "we're sending off our agent to go do something for us, it will show that agent an ad." Agentic shopping isn't just a threat to the ad model, it may be the next ad surface.

The debate

Bull, AI tooling is expanding the pie and deepening the moat. The walled gardens get better as buying automates: ROAS rises, more budget flows to whoever owns the data and the algorithm, and the brands themselves volunteer that machines now beat humans (True Classic at 100% agentic). Meta's claimed simultaneous lift in both impressions and price-per-ad, if real, is the dream scenario, because it means AI is creating demand, not just reallocating it. First-party, cross-app data is the scarce asset, and Meta and Google sit on the largest pools.

Bear, automation commoditizes the buyer and AI-search hollows the funnel. The same tooling that lifts ROAS strips agencies and attribution vendors of their reason to exist (note the Hyros-displacement aside on Creator's MBA, and SparkCast's warning that AI now handles "the buying and the bidding and the optimization entirely on its own"). More dangerous is the top of the funnel: Varma's cited stats, "almost 60% of all US searches now end without a single click," #1 organic CTR falling "from 27% down to as low as 11%" where an AI answer appears, describe a world where the search ad unit itself is being rebuilt mid-flight. Google retiring its own manual formats is both confident and risky. And OpenAI selling ads inside ChatGPT means a new auction is opening that didn't exist a year ago.

Stocks in play

Meta (META). Bull: AI ad engine is mature and self-funding the capex; operators report automation at parity-or-better; eMarketer sees it passing Google this year. Bear: "98% of revenue is through advertising" (Morning Brew Daily, June 4) is concentration risk, and its non-ad track record is poor, hosts noted ~$80B of metaverse spend "effectively gone," Portal and crypto flops. Watch: Q2 print, whether the impressions-and-pricing-both-up pattern actually shows up in reported family-of-apps revenue and ad pricing.

Alphabet (GOOGL). Bull: same AI-efficiency tailwind as Meta; Berkshire reportedly bought the dip (per Chit Chat Stocks); cheaper at ~18x vs Meta's ~32x EV/EBIT on the hosts' framing. Bear: it is the most exposed to AI-search click destruction and is voluntarily ripping out legacy ad products into "AI Max." Watch: the September AI Max / Dynamic Search Ads migration, and any disclosure on AI Overviews monetization vs. cannibalization.

No other ticker drew substantive podcast discussion this week.

Read-throughs

Bluntly: there weren't any this week. Emerging platforms (RDDT, PINS, SNAP, APP): zero coverage. Retail-media operators (WMT Connect, CART) and the ~$129B retail-media theme: zero coverage, not a single mention. CTV / streaming (Roku, Disney, Netflix, WBD) and the open-internet / TTD Kokai / UID2 story: zero coverage. Ad-measurement vendors (DV, IAS, RAMP, CRTO, MGNI, PUBM): zero coverage. The only adjacent signal worth banking is indirect: privacy-driven measurement pain remains real, Triple Whale's Maxx Blank said Apple's ATT "took the wheels out of advertising in terms of what you could see," which is the structural tailwind under the entire identity/measurement complex even though none of the public names were named.

What changed vs. last week

The center of gravity moved to the operator and practitioner level this week, DTC brands, agencies, and small-business workflows, rather than market-structure or sell-side commentary. The genuinely new, investable thread vs. recent weeks: agentic buying crossed from pilot to production at brand scale (True Classic at 100% of Meta spend), and OpenAI's self-serve ad manager moved from rumor to launched product. The discussion clustered on Meta and AI-search structure, with the names above drawing the substantive coverage.

Metals, critical minerals and ag inputs newsletter for the week of June 7, 2026. Copper printed its fourth straight weekly all-time-high close while a Hormuz-driven sulfuric-acid shortage emerged as the shared chokepoint linking copper leaching, laterite nickel, and phosphate fertilizer.

Materials Weekly

Week of June 7, 2026: Copper Rips to Records, Hormuz Puts Fertilizer Back in Play

Materials Weekly, Metals, Critical Minerals & Ag Inputs | Week ending June 7, 2026

Quiet week on the tape, loud week in the chatter. Copper printed its fourth straight weekly all-time-high close, and almost every podcast that touched commodities kept circling back to one second-order story: the Strait of Hormuz closure is choking sulfuric acid, and that single input quietly links copper leaching, laterite nickel, and, out of nowhere, fertilizer. Steel and the big ag-input names were largely absent from the audio this week, so we've flagged those gaps honestly rather than padding. Here's what the smart commodity voices were actually saying.

TL;DR

• Copper made new all-time highs (~$6.57–$6.70/lb) on a "dire" supply story and resilient AI/power demand; it's up 40–45% over twelve months and was called "the rock star for Q2."
• The sleeper risk is sulfuric acid. A Hormuz-driven shortage is now cited as a real constraint on SX-EW copper, laterite nickel margins, and phosphate fertilizer production, a genuinely under-discussed read-through.
• Critical minerals are trading "like the AI trade," with experts warning of "flavor of the month" risk even as DoD/DoE push permitting and funding programs.
• Fertilizer is "back in vogue" for the first time in years, driven by the same acid bottleneck, not by crop demand.

What's new

Copper is the headline. Craig Hemke pegged it at $6.57/lb with four consecutive weekly all-time-high closes and a fresh monthly record into end-May, up 3% intraday on the day he recorded while gold fell $70–100 (The KE Report). Dave Erfle had it at $6.65/lb, "a very strong price," with the view that copper is "setting up to be something like gold did a year earlier" (The KE Report). Quantix's Don Casturo went furthest, citing ~$6.70/lb and calling the supply picture "dire" against "fairly resilient" demand (Commodity Culture).

On supply, Casturo quantified it: the market "lost 1.5 million tons of production last year between outages in mines like Grasberg and Cobre Panama, which are extending into 2026," roughly 6–8% of mine supply (Commodity Culture). Sultan Ameerali described smelter treatment charges collapsing to the point that "these smelters…are taking the inputs for free…there's a definite shortage there" (Mining Stock Daily).

On demand, Peter Boockvar tied roughly half of US 2026 GDP growth to AI/data-center buildout, with hyperscaler spend "over $800 billion currently, over a trillion next year," his primary bull case for copper, aluminum and steel (The KE Report). Ameerali put it more bluntly: "every trade is an AI trade. And in particular with copper, just industrialization and…build out" (Mining Stock Daily).

The debate

Not everyone is all-in on copper as the cleanest deficit story. Boockvar pushed back on the consensus, arguing copper's supply-demand imbalance is "more in line" than the genuinely acute deficits he sees in platinum and silver, i.e., the copper deficit thesis is "less extreme" than the crowd believes (The KE Report). The other live debate is equity vs. metal: David Morgan flagged that copper mining equities are not following the metal higher, a potential mispricing if the price holds (Soar Financially), though the KE Report tape shows some producers ripping (see below), so the dispersion is wide.

On rare earths, the bull/skeptic split is sharper. Shad is constructive, "I really like MP Materials," expecting more government money, while Boockvar warns Western projects must compete with Chinese producers who run "not at profit, but to just provide magnets both internally and externally," leaving him uncertain "on the quality of rare earths as an investment in the coming years" (The KE Report).

The names in play

Copper producers (12-month equity performance, per KE Report hosts): Lundin Mining up >200%, Southern Copper (SCCO) up >100%, Antofagasta up >124% over twelve months but negative over the trailing three, and Freeport-McMoRan (FCX) up 67%, described as "underlevered to the copper move" (The KE Report).

Copper M&A/strategics: HudBay Minerals is acquiring Arizona Sonoran Copper at an all-time-high valuation ("a perfect scenario" exit); Faraday Copper is partnered with BHP in Arizona; and Teck, Rio Tinto and BHP are all active backing junior developers (The KE Report). Ameerali plays it via Surge Copper (Bird deposit, BC; ~20% held by African Rainbow Minerals), PFS due end-Q2 2026, run at $6–$7/lb sensitivity (Mining Stock Daily).

Rare earths/critical minerals: MP Materials (MP), Lynas, Energy Fuels (uranium + REE) and Neo Performance Materials ("done incredibly well"). On antimony: Mandalay Resources merged into Alkane Resources, and America's Gold and Silver is partnered with US Antimony on an Idaho circuit (The KE Report).

Battery metals: Ameerali exited Nickel 28 (NKL), a JV in the Ramu laterite project in PNG, specifically over sulfuric-acid margin risk, noting "the nickel market is pretty well supplied" with Indonesia as the swing producer (Mining Stock Daily). Mosaic (MOS) was cited as having been "pummeled" in May on the same acid shortage (Mining Stock Daily).

Read-throughs

The most actionable cross-current is sulfuric acid as a shared chokepoint. Boockvar (citing Robert Friedland) framed the Hormuz-driven acid shortage as a "nobody thought about" second-order hit to heap-leach/SX-EW copper (The KE Report). The same input drives Ameerali out of laterite nickel and crushed Mosaic's stock (Mining Stock Daily). Translation: a single Middle East supply line now connects copper cathode, nickel and phosphate fertilizer, worth screening for acid-intensive process exposure across the materials book.

Second read-through: fertilizer is back as a macro trade, not an ag-demand trade. Shad: "guess what's back in vogue? Fertilizer. We haven't talked about fertilizer in years, but the Strait of Hormuz closure has put that on," he's meeting potash and phosphate names again (The KE Report).

What changed

• New high regime in copper: four straight weekly record closes is a fresh data point, not a continuation (The KE Report).
• Hormuz closure is now the dominant supply narrative across metals and ag, replacing the prior China-demand framing; Boockvar says the bottlenecks "will flow through for years" (The KE Report).
• Critical-mineral velocity warning: Corey noted these stocks now move "like the AI trade" and it's "hard to get the pricing on things like antimony or tungsten," a fresh caution flag, not a thesis (The KE Report).
• Notable silence: no meaningful podcast coverage this week of steel mills (NUE/STLD/CLF), aluminum names (AA/CENX), or the big fertilizer caps (NTR/CF/CTVA), and no Section 232 tariff specifics. We'll flag if that changes.

Biotech pipeline newsletter for the week of June 7, 2026, covering gene/cell editing, neuro and tools. Beam's chief scientist argues in-vivo base editing now has a biomarker-endpoint shortcut to accelerated approval, while a frontline neurology pharmacist gives an unvarnished read on how the anti-amyloid launches are actually landing in clinic.

Biotech Pipeline: Gene/Cell, Neuro & Tools

Week of June 7, 2026: The Biomarker Fast Lane, In-Vivo Editing's Regulatory Unlock

Quiet week on the tape, but the two voices that did show up were both operators, not pundits, and that is exactly the kind of week worth reading closely. Beam's chief scientist made the case that in-vivo base editing now has a regulatory shortcut, while a frontline neurologist gave the most unvarnished read yet on how the anti-amyloid launches are actually landing in clinic. No deal, no data drop, just two people who do the work telling you what they see.

TL;DR

• Beam says it has FDA alignment on an accelerated-approval path for BEAM-302 (alpha-1 antitrypsin deficiency) using a biomarker endpoint, Z-AAT to M-AAT conversion, not a clinical outcome. If biomarker endpoints become the norm for one-time genetic fixes, the timeline-to-market for the whole in-vivo category compresses. (Cell & Gene: The Podcast, Jun 5)
• The real-world Leqembi SubQ story is slower than the slide decks. A University of Maryland neurology pharmacist says the SubQ initiation-dose decision slipped ~3 months to roughly August 2026, and the few eligible patients he's moved have chosen the monthly IV anyway. (Pharmacy Focus, Jun 4)
• The amyloid class got a hostile Cochrane review in late April, and the people prescribing the drugs are not blinking. Frontline read: keep offering them. (Pharmacy Focus, Jun 4)

What's new

Beam's pitch this week was less about a molecule and more about a pathway. On the June 5 Cell & Gene podcast, CSO Gopi Shanker told host Erin Harris that Beam has FDA alignment on an accelerated approval route for BEAM-302 in AATD built on a biomarker endpoint, the conversion of disease-causing Z-AAT protein to normal M-AAT at the DNA and protein level, rather than a years-long clinical-outcome trial. His framing of where this goes:

"For modalities such as ours, where we're directly addressing the underlying genetic cause of disease, I do think and I hope that this will become the standard in the future." Gopi Shanker, Beam Therapeutics, Cell & Gene: The Podcast, June 5, 2026

That is the sentence to underline. If the agency keeps blessing biomarker endpoints for one-shot genetic corrections, the cost-and-time hurdle that has kept in-vivo editing a perpetual "someday" story comes down. (Cell & Gene)

Beam also told on itself about delivery, the part of the field everyone underweights. Shanker was candid that lipid nanoparticles, Beam's deliberate early bet over viral vectors, have one stubborn limit: "The main limitation… with LNPs is that the delivery is largely limited to the liver." The fix Beam is pushing is targeted LNPs, adding a homing moiety to reach non-liver tissue, first demonstrated in T cells through sister company Orbital Therapeutics (since acquired by BMS), and now aimed at long-term blood stem cells in the bone marrow for an in-vivo sickle-cell program, with CNS and muscle named as the next frontiers. Liver programs (BEAM-301, -302, and the newly disclosed BEAM-304 in PKU) run on standard LNPs; everything past the liver depends on the targeted version working. (Cell & Gene)

Meanwhile, the anti-amyloid launch is meeting the friction of actual practice. Dr. Milad Sobanian, a neurology clinical-pharmacy specialist at the University of Maryland, walked through the Leqembi subcutaneous story on the June 4 Pharmacy Focus episode. The maintenance SubQ formulation is approved; the initiation-dose SubQ decision was pushed out about three months, to roughly August 2026, because, in his read, the FDA wants more on dosing and ARIA risk, since "you're getting potentially more drug into the patient because of the weekly injections... increased risk of ARIA." And the kicker for anyone modeling a fast SubQ conversion: among his eligible patients, "the small number that have actually transitioned over opted for the monthly infusions." (Pharmacy Focus)

On Kisunla, the same clinician sees a quiet preference forming, patients leaning toward donanemab's monthly IV over biweekly dosing, partly because "there's a potential completion date" for the course. Single-center and anecdotal, but it's texture a launch tracker won't give you. (Pharmacy Focus)

The debate

On editing, the tape was one-sided this week, and honesty requires saying so. The only gene-editing voice was Beam's own CSO, making Beam's own case. The bull argument is clean: biomarker-based accelerated approval shrinks timelines, targeted LNPs crack the liver ceiling, and a one-time IV infusion "vastly simplifies the process." The bear case, confirmatory-trial risk on biomarker approvals, the gap between a targeting platform shown in T cells and proven editing of bone-marrow stem cells in humans, and the fact that a CSO is a motivated narrator, was not voiced by any independent party this week. Weigh the optimism accordingly; nobody pushed back on the record.

On amyloid, there is a genuine fight, and it's worth steel-manning both poles. A Cochrane review published in late April took an aggressive line against the anti-amyloid antibody class. Sobanian's rebuttal is methodological, not defensive: he argues the review pooled mechanistically different agents, including the withdrawn aducanumab, and, in earlier trials, didn't even require patients to be amyloid-positive. His bottom line on whether the review changes practice: it is "not something that we were going to stop offering for anybody." The bear pole still stands on its own merits, though: the absolute benefit is modest (his own number: "about a 27 to 29 percent slowing... about five months over 18 months"), ARIA "can be severe and has led to deaths," and there are published case reports of fatal hemorrhage when these patients are later exposed to thrombolytics. A real drug with a real safety budget, not a miracle and not a fraud. (Pharmacy Focus)

Read-throughs

• In-vivo editing peers (NTLA, VERV, CRSP, Prime, REGN collaborations). Beam's biomarker-pathway claim, if it holds, is a category tailwind, the regulatory clock is the shared bottleneck for every one-shot in-vivo program, not just Beam's. Watch whether peers echo the same FDA posture on their own calls. (Cell & Gene)
• LNP / non-viral delivery and the targeting race. The "LNP only reaches the liver" admission is the honest constraint behind every in-vivo valuation. Whoever solves extra-hepatic targeting unlocks CNS and muscle indications the liver-bound cohort can't touch; BMS buying Orbital is a tell that strategics are paying for delivery IP, not just editors. (Cell & Gene)
• Leqembi (BIIB/Eisai) and Kisunla (LLY) launch curves. If frontline prescribers are steering even eligible patients to IV over SubQ, the SubQ-driven convenience re-rating may be slower and lumpier than consensus. The ~August initiation-dose decision is the near-term catalyst to mark. (Pharmacy Focus)
• Blood biomarker diagnostics. Sobanian frames plasma biomarkers as a community-setting "screening or step-up tool," not a replacement for amyloid PET as the gold standard. An "and-also," not an "instead-of," for the diagnostics names levered to the amyloid workup. (Pharmacy Focus)

What didn't show up

Life-science tools and bioprocessing went dark this week. No podcast coverage of Thermo Fisher, Danaher, Agilent, Revvity, Sartorius, Repligen, Bruker, Waters, or Illumina, nothing fresh on single-use book-to-bill, destock-to-restock, NGS pricing, or the China/NIH funding overhang. No tape, no read; we'll pick the thread back up when the next tools data point lands rather than manufacture a signal from silence.

The Semiconductor Podcast Briefing for May 31 to Jun 6, 2026. NVIDIA's Computex keynote and the ARM-based RTX Spark PC chip defined the tape, Huawei captured roughly half of China's AI chip market, and Micron crossed $1,000 even as DRAM and NAND took a May breather.

Semiconductor Podcast Briefing

May 31 to Jun 6, 2026: NVDA Computex RTX Spark PC Chip, Huawei Takes ~50% of China AI Chips, Memory Tightness (MU > $1,000)

The defining catalyst this week was NVIDIA's Computex 2026 keynote (May 31 to Jun 1), where Jensen Huang announced the ARM-based RTX Spark/N1X PC chip, declared the Vera Rubin platform in full production, and made an off-hand "next trillion-dollar company" call-out to Marvell. Coverage skewed heavily to AI chip demand, foundry/manufacturing, and China indigenization. Analog/auto/industrial semis, semi-cap equipment, and M&A were largely absent, itself a signal that the AI/PC narrative is crowding out the broader cyclical complex.

TL;DR: Five Things That Mattered This Week

• Computex defined the tape. NVDA unveiled the RTX Spark superchip (Blackwell RTX GPU, 6,144 CUDA cores, 1 petaflop AI, 20-core Grace CPU with MediaTek, 128GB unified memory) for fall 2026 PCs with Microsoft, Dell, HP, Lenovo. NVDA +4%, ARM +16%, INTC and AMD down materially on the day. NVDA also claims ~$20B of CPU revenue this fiscal year.
• Power, not silicon, is the binding constraint. NVIDIA's own Energy MD said grid interconnection, not chip supply, is the bottleneck. Stargate Michigan is a 1.4 GW, $45-50B all-in (incl. GPUs) single project; Alphabet guided to $180-190B of 2026 capex and announced a ~$80B equity raise (incl. $10B from Berkshire at $351.81/share) to fund more.
• Memory remains structurally tight, but May softened. Micron opened above $1,000 for the first time (Jun 1); Cramer says the market is "way memory short." Counter-signal: DRAM/NAND took a "breather" in May, with NAND pricing flat.
• China indigenization is no longer hypothetical. Huawei has captured ~50% of China's ~$21B AI chip market in 2026; Jensen himself "largely conceded" the market. Chinese semi ETFs are up ~40% YTD. Caveat: even the bull case has Huawei producing only ~4% of NVDA's aggregate compute.
• Bubble vs. broadening debate intensified. Bull: enterprise demand broadening (HPE +24% on its biggest beat since 2018, Dell traditional servers +92% YoY, Lenovo infra +37%). Bear: Burry comparing to "final months of 1999," only 2 of 11 S&P sectors at record highs, chips alone driving +16% of the S&P's 2-month move, and even Cramer trimming AVGO.

1. AI Chip Demand & Hyperscaler CapEx (NVDA, AMD, AVGO, MRVL)

NVIDIA Computex Keynote / RTX Spark PC Chip

Jim Cramer (CNBC host, Mad Money), on Squawk on the Street (Jun 1, 2026):

"This is an ARM-based revolution... A direct slap, by the way, on AMD and Intel having a PC chip that just doesn't work."

Cramer believed Google/Amazon "have to respond" to the NVDA-Microsoft PC chip collaboration, and paraphrased Jensen on hyperscaler custom chips (Trainium/TPU): "He just says basically will cost you a lot, run hot and not help."

Ian King (Bloomberg semiconductor reporter), on Bloomberg Tech (Jun 1, 2026):

"This has been rumored for a long time that NVIDIA would directly get into this market with a CPU. And now we've finally seen it... if AI is coming to the laptop, if we're going to start talking to our laptops... we'll need a different kind of chip."

Contrarian view (same speaker): "ARM in the PC is not there. NVIDIA itself tried it more than a decade ago. It didn't work out. So this isn't a revolutionary idea at a fundamental level."

Matt Frankel (Motley Fool contributor), on Motley Fool Hidden Gems Investing (Jun 1, 2026):

"I really see this chip fulfilling a niche, not capturing a big share of the PC market. I still see AMD and Intel as having a pretty defensible moat, essentially a duopoly in the CPU space for PCs... I could see a single-digit share, at least in the next few years."

Frankel notes Qualcomm's ARM-based PC chips reached only ~10% of the $800+ US Windows laptop market despite years on sale.

Rachel Warren (Motley Fool contributor), on Motley Fool Hidden Gems Investing (Jun 1, 2026):

"NVIDIA, they're projecting $20 billion in CPU revenue this fiscal year... we already have independent benchmarks that are showing that their custom design outperforms Intel's flagship design by over 55%. It edges out AMD's top chip by 11% in raw enterprise workloads."

(The $20B CPU revenue figure and benchmarks are NVDA's own claims, not independently verified.)

Steven Sinofsky (former President, Windows Division, Microsoft; a16z), on The a16z Show (Jun 2, 2026), directionally bearish for hyperscaler inference growth:

"This world where you're all gated on dollars per token is a thing that's gonna move to your own device... Anytime there's a resource constraint that you have to pay for, it moves to your device and becomes free."

NVIDIA Valuation & Buyside Positioning

CJ Mews (Senior Managing Director, Cantor Fitzgerald), on Squawk on the Street, 10am hour (Jun 2, 2026):

"The name that has been kind of left for dead in AI is the obvious name in NVIDIA... they're going to do $15 to $16 next year, which means you're paying, you know, 14 to 15 times today, which is below almost anything in our coverage, excluding memory with Micron and SanDisk... long-onlys are underweight. And I think as we go through this Vera Rubin product cycle... you're going to have positive momentum cause investors to chase it."

Marvell (MRVL): Jensen's "Next Trillion-Dollar" Comment

Jim Cramer (CNBC), on Squawk on the Street (Jun 2, 2026):

"No one is a bigger fan of Marvell and Matt Murphy than I am until I came in today and discovered that Jensen was."

Jensen told the Computex audience MRVL would be "the next trillion-dollar company"; MRVL traded up ~18-27% intraday on the comment. Contrarian view, David Faber (CNBC, same episode): "That's not news. That's just him being nice in the moment."

Christina Parsonevles (CNBC tech reporter), on Squawk on the Street, 10am hour (Jun 2, 2026), quoting Marvell CEO Matt Murphy:

"Murphy said the next bottleneck in AI isn't compute or memory. It's going to be connectivity, which is where Marvell plays a role. And the shift from copper to optical connect is already underway. And Marvell is completely at the center of that."

CJ Mews (Cantor Fitzgerald), on Squawk on the Street (Jun 2, 2026):

"Amazon Tranium is their largest customer... Microsoft Maya will start to ramp in the second half of 2027. And it does appear that they've won a Google XPU attach business that could be meaningful."

Contrarian framing: Mews holds a neutral rating with a $220 PT, calling the trillion-dollar comment "aspirational, figurative, not literative," noting it would require ~5x from current levels.

Broadcom (AVGO)

Jim Cramer (CNBC), on Squawk on the Street (Jun 2, 2026), trimming a +300% position:

"Broadcom, okay? I'm a cheap date. I said, shave a little Broadcom. Shave a little AVGO. But we have like 300% on it."

AVGO market cap cited at ~$2.26 trillion. AVGO reported Jun 3 (after the latest episodes in this set), with no post-earnings podcast coverage yet available.

Hyperscaler CapEx: Stargate / Oracle / Alphabet / SoftBank

David Faber (CNBC, reporting live from Stargate Saline Township, Michigan), on Squawk on the Street (Jun 1, 2026):

"We're up to, I think, as much as $500 billion, $300 billion committed by Oracle itself."

Stargate Michigan: 1,000-acre site, $16B construction, 1.4 GW (nuclear-plant scale). On Jun 2, Faber quoted Oracle CEO Clay Magouyrk that the project is "on schedule or ahead," and sized a single Stargate project at "$45 billion to $50 billion on one project."

On Alphabet's capital raise (Faber & Cramer, Squawk on the Street, Jun 2, 2026):

Faber: "They have $180 to $190 billion in CapEx expected for $26, but it's going to go higher in $27... strong demand for its AI solutions... at levels that are exceeding the company's available supply."

GOOGL announced a ~$80B equity raise ($10B from Berkshire at $351.81/share, $40B ATM, ~$30B public offering). Contrarian view, Cramer: "I don't like the confluence... I will right now put AMC, the same sentence as Alphabet," flagging the raise as a euphoria/negative signal.

Masayoshi Son (CEO, SoftBank), on Squawk on the Street (Jun 1, 2026):

"I think this is like more than 10x, probably 50x bigger than dot-com... AI will be, this is the beginning. And the future of the profit and growth opportunities, tremendous."

"There may be some correction, but that would be a best investment opportunity time to me."

Power as the Real Bottleneck

Marc Spieler (Senior Managing Director, Energy Industries, NVIDIA), on ARC Energy Ideas (Jun 2, 2026):

"The constraints on the system is our ability to build these AI factories and provide the power that's required... the interconnection in order to hook up to the grid and get the power that you need is taking a lot longer than what we'd hoped."

Buyside Positioning: Diversifying Beyond NVDA

Matt Whitmer (Portfolio Manager, Allspring Global Investments), on Bloomberg Tech (Jun 1, 2026):

"We think diversification is going to be important going forward. Concentration risk is real. So we're taking a holistic approach to tech and the AI ecosystem as those CapEx dollars start to spread across the AI value chain."

Enterprise Server Demand Broadening (HPE, DELL, Lenovo)

Christina Parsonevles (CNBC), on Squawk on the Street (Jun 2, 2026):

"For the past two years, the spending cycle was dominated by hyperscalers. What this crop of earnings is showing is that enterprise demand is now becoming a meaningful contributor... customers just aren't blinking."

HPE server beat by ~$1B; Dell traditional server +92% YoY at $8.5B; Lenovo infrastructure +37%. Contrarian: Morgan Stanley cautious on HPE sustainability; Bernstein notes HPE +71% / DELL +80% since May 22, so upside may be priced in.

2. Memory Pricing (HBM, DRAM, NAND: MU, SK Hynix, Samsung)

Jim Cramer (CNBC), on Squawk on the Street (Jun 1, 2026):

"I think that people underestimated this shortage. It's just going on and on... we're just way memory short."

Micron opened above $1,000 for the first time on Jun 1, 2026.

Matt Whitmer (PM, Allspring Global Investments), on Bloomberg Tech (Jun 1, 2026):

"These cycles... are going to continue to evolve and move out further down the timeline... these clean rooms, there's only a few of them out there... these greenfields are going to take two to three years before they come online. So I think the memory names are going to continue to drive pricing in the direction that they needed to do for the stocks to work."

Counter-signal, Ed Ludlow (Bloomberg), on Bloomberg Tech (Jun 1, 2026):

"I got some DRAM and NAND flash data. We took a kind of breather in May. Pricing slowed down flat on NAND."

HBM tightness was indirectly confirmed via Intel's design choices. Brian McCullough (host, Tech Brew Ride Home), citing Tom's Hardware, on Tech Brew Ride Home (Jun 1, 2026):

"Going with LPDDR5X doesn't put pressure on valuable advanced packaging capacity or compete with higher-end accelerators for scarce HBM."

Contrarian view, Steven Sinofsky (a16z), on The a16z Show (Jun 2, 2026):

"Having lived through like a half-dozen component shortage things, you just sort of wait them out... whether it's been DRAM or hard drives or processor shortage, all of these things, we've had them come and go."

China DRAM supply risk, Alice Han (China Decode co-host), on Prof G Pod (Jun 2, 2026):

"It's interesting that we'll have CXMT, which is a big memory DRAM supplier, coming online probably this year."

3. Semiconductor Capital Equipment / WFE (ASML, AMAT, LRCX, KLAC)

Coverage was thin, with one direct mention this week.

Matt Whitmer (PM, Allspring Global Investments), on Bloomberg Tech (Jun 1, 2026):

"ASML, I think, is a great example of that. It's going to play an important part of the build out and their ability to help provide what these big customers need to drive those product sets in the right direction."

ASML cited as Whitmer's top non-US semi idea. No commentary this week on AMAT, LRCX, or KLAC.

4. Foundry / Manufacturing (TSM, INTC, GFS)

TSMC: Sold Out at the Leading Edge

CJ Mews (Senior MD, Cantor Fitzgerald), on Squawk on the Street (Jun 2, 2026):

"The biggest one near term is that TSMC is sold out, right? So if you're NVIDIA or AMD and you're deciding to build a CPU over a GPU or an accelerator... you can't have both."

Sean Hollister (Senior Editor, The Verge), on The Vergecast (Jun 2, 2026):

"It is 6000 plus GPU cores, it's 20 CPU cores, it's made on a TSMC3 process. MediaTek is NVIDIA's partner... This is a MediaTek chip with NVIDIA IP on it, manufactured by TSMC. And they're not saying where. So we have to assume not here in the United States or they would make a big deal with that."

Intel: Crescent Island, Panther Lake, New CEO

Brian McCullough (host, Tech Brew Ride Home, citing Tom's Hardware), on Tech Brew Ride Home (Jun 1, 2026) detailed Crescent Island specs: G3P GPU, 350W TDP, 160GB LPDDR5X (up to 480GB via partners), 684 GB/s bandwidth, H2 2026 launch.

An unnamed host, on The Elon Musk Update (Jun 1, 2026):

"It took about 18 months for them to develop it, and it's going to be manufactured in Intel's own fabs... They've surged more than 200% this year alone. They have a new CEO, Lip-Bu Tan, who replaced Pat Gelsinger last year and is aggressively rebuilding their AI silicon roadmap."

(The +200% YTD figure comes from a host with no stated financial credentials, so treat it as unverified.)

Contrarian framings on Intel:

• Steven Sinofsky (a16z), The a16z Show (Jun 2): "Intel and NVIDIA are just gonna drive the prices to each other, and only one of them can really afford the battle."
• Matt Frankel (Motley Fool), Motley Fool Hidden Gems (Jun 1): "With Intel, the jury's still out. That stock has run up so much, but it's really based on future potential, not any sales that it's generating so far."

5. Analog / Auto / Industrial Semis (TXN, ADI, MCHP, ON, NXPI, STM)

No material coverage this week. None of the indexed conversations touched analog, auto, or industrial semiconductor names, itself a data point on how completely the AI/PC narrative is crowding out the broader cyclical semi complex.

6. China / Export Controls / Tariff Impact

Jim Cramer (CNBC), on Squawk on the Street (Jun 2, 2026):

"...they did not let NVIDIA be able to be sold in China, so therefore... they're going to write on Huawei, I think was a critical mistake, because they're going to now develop their own. We needed to make it so that they were hobbled and we were in charge and we failed to do that."

An unnamed host, on The Elon Musk Update (Jun 1, 2026), on a possible Intel China-access angle:

"The chips might actually qualify to be sold in China under the US export controls. That is a really big revenue door. It's largely closed to Nvidia and AMD because of a lot of the trade tension with Beijing."

Alice Han (China Decode co-host), on Prof G Pod (Jun 2, 2026), on a possible thaw signal:

"Jensen Huang just got announced that he is on the board to Tsinghua University's School of Economics and Management, on which the Apple CEO Tim Cook is also a member. Maybe this is a signal that things are heading in a more positive direction."

7. Earnings & Post-Earnings Reactions

No MU, NVDA, AMD, or TSM earnings reactions fell in this 7-day window.

8. M&A Chatter

No M&A activity, rumors, or activist commentary in the chip space across the conversations this week.

9. Cyclicality / Inventory / Peak-Trough Debates

Jim Cramer (CNBC), on Squawk on the Street (Jun 1, 2026), dismissing the bubble call:

"Now... the bubble, they're not going to get the return. That ended. That ended with SoftBank. That ended right now with Jensen. If I hear the bubble, the bubble, the bubble, I'm going to bring them some bubbles..."

Contrarian view, Carl Quintanilla (same episode): "Levered ETFs of single stocks, the SK Hynix. I mean, that points to speculative enthusiasm."

Zaid Admani (The Rundown), on The Rundown (Jun 1, 2026):

"This rally is very concentrated in tech and AI... chip stocks alone pushed the S&P up 16% over the past couple months."

"Even Michael Burry is out here saying that the current market feels like the final months of 1999."

Only 2 of 11 S&P sectors were at record highs as of Jun 1, 2026. By the Jun 2 conversation, Cramer himself had turned more cautious on individual names, trimming AVGO after a +300% gain and likening Alphabet's $80B equity raise to an "AMC ATM."

PC market cyclicality, Mandeep Singh (Bloomberg Intelligence analyst), on Bloomberg Tech (Jun 1, 2026): IDC forecasts the PC market down 11% in CY2026, but Singh views NVDA's AI PC entry as a premium-segment growth driver despite the cyclical weakness.

10. China Indigenization (SMIC, CXMT, Huawei) & Impact on US Names

The most substantive non-Computex theme of the week came from the Prof G Pod's China Decode episode.

James Kynge (China Decode co-host), on Prof G Pod (Jun 2, 2026):

"Already, Jensen Huang... has said that his company has largely conceded, those are his words, largely conceded China's AI chip market to Huawei. In 2026 so far, Huawei has captured around 50% of the Chinese market for AI chips."

China AI chip market is ~$21B in 2026, projected by Morgan Stanley to reach ~$67B by 2030. On Huawei's "Tao Scaling Law" (from chip head He Tingbo):

"...we're moving to a new way of assessing the compute power of a chip... not to miniaturize the chip, because we're already reaching the limits of physics, it is to cluster the chips, to stack the chips in a clever way and focus on the other parts of the chip, such as the wires and the arrangement design..."

On the export-control workaround:

"Even if China doesn't get its hands on these Blackwell, it can stack these chips and scale these chips, the Huawei indigenous chips... electricity is so much cheaper in certain parts of China, and that you can run data centers close to the Gobi Desert using solar power..."

Contrarian view, Alice Han (same episode): citing Council on Foreign Relations data, "in the most bullish scenario, Huawei can only produce about 4% of the aggregate AI compute that Nvidia can produce." US chips remain ~5x more powerful per unit.

Han also flagged Chinese semi ETFs "up at least 40% year-to-date... outpaced the AI stocks and the Shanghai and Hong Kong composite indices," and raised the open question of whether Huawei, HuaHong, and SMIC can scale foundry capacity to meet domestic demand.

Indirect chip-demand implication, Brian McCullough (host, Tech Brew Ride Home), on Tech Brew Ride Home (Jun 1, 2026): MiniMax's M3 costs "only 12 cents per 1 million input tokens compared with $5 for Opus 4.7," roughly 1/40th the price; cheaper inference could mix-shift workloads toward less GPU-intensive deployments.

What I'm Watching Next Week

• AVGO post-earnings reaction. Results landed Jun 3. Watch for podcast and sell-side reaction, whether the AI/custom-silicon (XPU) narrative gets fresh fuel or a "sell the news" fade after the recent run.
• The DRAM/NAND May "breather" vs. the structural-tightness narrative. Ed Ludlow's flat-NAND data point sits uneasily against Cramer and Whitmer's "way memory short" thesis. Watch June pricing data and any MU commentary into its next print, plus the timing of CXMT's DRAM capacity coming online.
• Alphabet's $80B equity raise as a sentiment tell. If other hyperscalers follow with capital raises to fund capex, that capital intensity could become the bear case's anchor. Watch how the buyside reads it (genuine demand vs. euphoria signal).
• Power/grid-interconnection bottleneck. With NVIDIA itself naming the grid as the binding constraint, watch Stargate Michigan permitting/power milestones and any utility/IPP commentary on AI data-center interconnection queues.
• US-China chip thaw signals. Jensen joining Tsinghua's board (alongside Tim Cook) and any movement on NVDA China-sales rules, against the backdrop of Huawei's ~50% domestic share and Chinese semi ETFs +40% YTD.

Managed care newsletter for the week of May 30 to June 6, 2026. A new CMS rule caps Medicaid state-directed and supplemental payments at 100% to 110% of Medicare by 2029, and PBM reform crossed from theme into signed legislation, while operator guidance stayed off tape.

Managed Care Under Pressure

Week of May 30 – June 6, 2026: Medicaid payment-cap rule lands

TL;DR

• Policy tape, not operator tape. This week's managed-care signal came from the policy side, a policy analyst's read, a generalist investor show, and a CVS-sponsored episode, rather than from the operators or the sell side. The names themselves stayed quiet; the rule changes did not.
• The one thing that moves numbers: a new CMS rule capping Medicaid state-directed and supplemental payments at 100% of Medicare rates (expansion states) and 110% (non-expansion) by 2029, described as "effectively cutting payments roughly in half" versus current commercial-rate benchmarks. Negative read-through to Medicaid MCO rate adequacy (CNC, MOH, ELV) and to hospital partners (HCA) who book state-directed payments as revenue.
• "The end of PBMs as they were created" is now the recurring frame: Tennessee's FAIR-RX Act, a mirror federal bill, the FTC's CVS findings, and GLP-1s routing around the wholesale channel. Live overhang for CVS (Caremark) and CI (Express Scripts); structurally relevant to UNH (Optum Rx).

What's new

Ranked by what is actionable for the book.

1. Medicaid state-directed payment caps, the most concrete negative this week. On Health:Further, policy analyst Emily Evans detailed a CMS/White House rule, released the day after Senator Cassidy lost his primary (week of roughly May 20), capping state-directed and supplemental payments at 100% of Medicare for expansion states and 110% for non-expansion states by 2029 (Health:Further, ep. 192, 2026-05-30). Evans framed the mechanism plainly: plans agree to be taxed, the state raises revenue, a roughly 1:1 federal match flows back through MCOs to hospitals and nursing homes; the federal share of Medicaid has risen from roughly 50% in the 1990s to 70% to 80% today. She noted HCA's revenue per Medicaid admission "hockey sticks" on state-directed payments, quantifying the provider-side exposure. Why it matters: this is incremental to the "one big, beautiful bill" (which hit the managed-care and state-directed side); the new rule additionally squeezes fee-for-service supplemental payments. It pressures the funding plumbing under Medicaid MCO rate adequacy with a hard 2029 phase-in.

2. PBM model unwind hardens from theme to legislation. Same episode: Evans flagged Tennessee's signed FAIR-RX Act (illegal for one company to own both a PBM and a pharmacy in-state), a bipartisan federal mirror bill now introduced, and the FTC finding that CVS's PBM paid independent pharmacies less than its own retail pharmacies for the same drugs (Health:Further, 2026-05-30). Her call: "I think we are looking at the end of PBMs as they were originally created," citing UNH moving to fixed fees, CI having already sold its PBM, and CVS as "the last big one." Why it matters: keeps regulatory tail risk live on Caremark (CVS) and Express Scripts (CI) economics into the election-season legislative calendar.

3. CVS Caremark's own defense, operator voice, but sponsored. On a CVS-sponsored A Health Podyssey episode, James Marjota, Chief Growth Officer at CVS Caremark, argued pharmacy benefits are now "more than 50% of the cost that typical plan sponsors are spending," that specialty is "close to 50% of the cost... but only 2-3% of members," and claimed "over 90% adoption and conversion to the biosimilar" (context: adalimumab) "saving our customers $1.8 billion plus" (A Health Podyssey, 2026-06-03). Why it matters: it is the only operator voice on tape, but it is paid placement with no adversarial counter, no Aetna MLR, no strategic-review detail. Treat as promotional, not as a guidance datapoint.

4. UNH vertical-integration and DOJ framing resurfaces (pundit). On Telltales, generalist investor-hosts argued UNH's vertical integration could be "the largest antitrust case of all time" and that AI is being used to "game the medical coding system... to get the maximum reimbursement for Medicare" (Telltales, 2026-06-03). Why it matters: it keeps the DOJ MA-coding overhang in the narrative, but these are pundits, not sector specialists, and UNH is referenced only in passing. Sentiment, not signal.

5. GLP-1s routing around the channel. Evans noted GLP-1s now available "for free or near almost nothing" vs. "$1,300 a few months ago," with Hims, Lilly Direct, GoodRx, and Amazon One Medical selling "outside of PBMs, outside of this wholesale channel" (Health:Further, 2026-05-30). Why it matters: cuts two ways. Direct-to-consumer disintermediation pressures PBM rebate economics, but falling net GLP-1 prices ease the MLR cost-trend math if utilization migrates off the medical and pharmacy benefit.

The debate

Bull, utilization and MA funding have bottomed. Q1'26 absorbed the worst of post-pandemic normalization plus V28 Year 2; 2027 bids are filed into a more constructive CMS benchmark posture; the 2026 AEP cuts pruned unprofitable membership; Star settlements crystallize the QBP backstop. On this view FY26 EPS is the trough and you are paid to own the names through the next bid cycle. Nothing on tape this week added to the bull ledger.

Bear, structurally higher trend plus a hostile policy and legal backdrop. This week fed the bear: the Medicaid payment-cap rule is a fresh, datable funding squeeze with a 2029 cliff; PBM reform moved from theme to signed law plus a federal bill; the DOJ and coding narrative persists. Layer that on structurally higher trend (GLP-1, behavioral, outpatient migration), V28's FY27 bite, RADV cash recoveries, and the enhanced-ACA-subsidy cliff, and the bear case is that valuations need a numbers reset, not a sum-of-the-parts rerate.

The pull-quote of the week, from a policy analyst, not an operator: "I think we are looking at the end of PBMs as they were originally created."

Stocks in play

UNH: Bull: Optum Health margin recovery into FY27, RADV/DOJ tail priced in. Bear: DOJ MA-coding overhang (kept alive on tape this week, pundit-level), V28, Star reset risk; Optum Rx caught in the PBM-model unwind. Next catalyst: Q2'26 print (MLR vs. guide, FY26 EPS reiteration), DOJ procedural updates.

CVS: Bull: Aetna MA repricing into 2027, Caremark scale, strategic-review optionality. Bear: PBM reform now legislative (FAIR-RX plus federal mirror bill, FTC findings), 340B litigation ($250M hospital suit alleged), MA membership still mispriced. Next catalyst: Q2'26 Aetna MLR, strategic-review disclosure, PBM legislative calendar.

HUM: Bull: cleanest 2027 MA bid leverage. Bear: highest beta to MA funding and trend; Medicaid sale execution. Next catalyst: Q2'26 MLR, 2027 bid color. No podcast signal this week.

ELV: Bull: Carelon services growth offsetting MA pressure. Bear: Medicaid acuity now layered with the state-directed payment-cap rule; enhanced-subsidy cliff. Next catalyst: Q2'26 Medicaid/MA MLR splits, 2027 exchange filings. No company-specific tape.

CNC: Bull: Medicaid acuity reset largely behind, exchange margins resilient. Bear: the SDP cap rule pressures the Medicaid rate floor into 2029; enhanced-subsidy expiration. Next catalyst: Q2'26 HBR by segment, state rate updates. Read-through only, not named on tape.

MOH: Bull: disciplined Medicaid underwriting, contract wins. Bear: most Medicaid-levered to the SDP cap dynamic; state rate timing. Next catalyst: Q2'26 MCR, RFP wins and losses. Read-through only.

CI: Bull: Evernorth growth, MA exit removed drag. Bear: Express Scripts squarely in the "end of PBMs" frame. Next catalyst: Q2'26 Evernorth growth, PBM legislative calendar.

Read-throughs

• Medicaid/exchange (CNC, MOH, ELV): the SDP and supplemental cap rule is the new, datable negative. Watch state rate filings for how quickly the 2029 caps get discounted into MCO rates, and watch hospital lobbying to reverse it (Health:Further, 2026-05-30). ACA out-of-pocket maximums rising roughly 30% in 2027 (to roughly $15,000 individual and roughly $31,000 family per Evans) compounds the affordability and attrition risk into the subsidy cliff.
• PBMs and Optum-style arms (CVS, CI, UNH): reform is now signed law in one state plus a federal mirror bill; the rebate model is unwinding regardless of legislation (Health:Further, 2026-05-30). CVS's own operator defense (A Health Podyssey, 2026-06-03) is the rebuttal, but sponsored.
• Hospitals and providers: the mirror trade is live. The SDP cap is a direct hit to provider Medicaid revenue (HCA's per-admission revenue "hockey sticks" on these payments), the offsetting risk to a long-facilities and short-payers framing.
• GLP-1 cost exposure: falling net prices and DTC channels (Health:Further, 2026-05-30) are a mixed read. Eases MLR cost-trend if utilization migrates off-benefit, pressures PBM rebate capture.

What changed vs last week

Last week (May 23–30) was a fully quiet tape, zero citations. This week the policy channel woke up. The incremental items versus last week's standing setup: (1) a concrete, datable Medicaid state-directed and supplemental payment-cap rule (100% to 110% of Medicare by 2029) that did not exist on tape last week; (2) PBM reform crossing from theme into signed legislation (Tennessee FAIR-RX) plus a federal bill; (3) the CVS 340B hospital litigation ($250M alleged) surfacing. What did not change: still no operator guidance, no sell-side or buy-side MCO commentary, and no tape on the 2027 MA Rate Notice, V28, RADV, Star ratings litigation, MA enrollment and benefit cuts, or HUM/ELV/CNC/MOH company-specifics. The MA-funding-versus-trend debate going into Q2'26 prints remains the core argument; this week added to the Medicaid and PBM legs, not the MA leg.

Healthcare policy newsletter for the week of June 6, 2026. The IRA pill penalty is already bending pharma capital toward biologics and rare-disease franchises, Medicaid's real cliff is back-loaded to 2027 as provider bankruptcies climb, and most-favored-nation pricing remains vibes rather than legislation.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of June 6, 2026: IRA's Pill Penalty Bites; Medicaid's 2027 Cliff Looms

Intro

A quiet week on the wires, a loud one on the tape. The policy that's reshaping pharma capital allocation didn't make headlines, it surfaced in a departing CEO's three-decade post-mortem on the IRA, and in a VC's offhand read of Medicaid filings. The throughline: the most consequential healthcare-policy effects right now are the ones you can't see, the drug lifecycle investments that never happen, the Medicaid coverage that hasn't yet been pulled. Below, what the operators are actually saying, separated from what the pundits are guessing.

TL;DR

• The IRA "pill penalty" is already steering capital toward biologics and rare-disease franchises, and away from the kind of decade-long lifecycle investment that built Keytruda. Operator view, not punditry.
• Medicaid's pain is back-end-loaded to 2027. Provider bankruptcies are already rising; the "one big beautiful bill" rate cuts, work requirements, and redeterminations haven't even bitten yet. Centene, Molina, and the hospital names sit on that fault line.
• MFN remains vibes, not legislation. No draft text, 17 bespoke White House deals as the only template, and a credible insider read that it stalls this session.

What's new

1. The pill penalty is distorting R&D in real time, Alkermes' Richard Pops, The BioCentury Show (May 28). Pops (CEO, PhRMA board, ran PDUFA negotiations for 20+ years, an operator and insider) laid out the math: "post IRA, nine years of exclusivity versus 13 years... If you draw a curve of the revenue profile of a drug over its life... and you clip off the back four years, that's half of the revenues. So from a purely economic perspective, you should develop biologics instead of small molecules." Why it matters: this is a sourced, first-person account of capital allocation being bent by policy, "a powerful incentive to shift allocation of capital separate from the scientific underpinnings."

2. Medicaid's real cliff is 2027, and providers are already cracking, Steve Krause, The Heart of Healthcare (June 1). Krause (healthcare VC, an operator and insider) flagged that "chapter 11 filings for healthcare providers rose 33% in Q1 of 2026... the impact of the one big beautiful bill hasn't really been even felt yet... 2027, because that's when the things like provider rate cuts, work requirements, eligibility redeterminations actually kick in that will lead to churning of millions of people off Medicaid coverage." (The 33% figure is his claim, unsourced.) Why it matters: the market is pricing the policy; the cash-flow hit lands a year later.

3. ACA subsidy expiration is already shrinking insurer membership, Krause, same episode. "The lack of individual subsidies... led to less members using ACA, which tends to be lower-income members... we've seen the impact that that's had on value-based care providers who deal in those markets."

4. Part D's manufacturer liability nearly broke a mid-cap, Pops, BioCentury. An under-discussed mechanic: "one of the features of the Part D redesign was the exposure of manufacturers to a 20% liability in the catastrophic phase, which previously hadn't existed." For Alkermes, "that would have taken us from a 0% liability to a 20% tax on our revenues... from being profitable to being not profitable." A phased ramp was negotiated, "still quite painful, but it would have been catastrophic."

5. The IRA is also an M&A accelerant, John Flavin, CNBC Fast Money (May 29). Flavin (CEO, Portal Innovation, an operator and insider): "ironically, the Inflation Reduction Act has driven a lot of pharma into making deals... because that window for being able to monetize the huge investment is shortening... $75 billion up to this particular date in 2026" (his figure). He also pegged "30 percent of licensing this year... attributed to Chinese assets," mostly oncology.

The debate

Does the IRA fix a real problem or destroy more value than it captures? The tape supports both sides, and notably, both from credible voices.

Steel-manning the reform case (Steve Osden, BioCentury Washington editor, a pundit): the logic is "pretty simple. Get countries outside of the United States to pay their fair share for R&D. Make sure that big companies don't have monopolies on pricing indefinitely... reshore manufacturing." Indefinite monopoly pricing and US patients subsidizing the world are genuine grievances; negotiation and reference pricing are the blunt instruments to end them.

Steel-manning the industry case (Pops, an operator): the penalty doesn't lower the cost of good medicine, it changes which medicines get made. "If it's a toss-up between a small molecule embodiment and a biologic, you go with a biologic. Even though that's not going to be better for the patient." And it kills the Keytruda playbook outright: "What you can't do is... invest over a decade in indication after indication... Because there's a finite, you light a fuse, it's a nine-year fuse." His punchline for any new founder: "you would make biologics for rare populations that are paid for by commercial payers. It's simple."

The honest read: this is an operator describing observed behavior change vs. a commentator describing policy intent. Weight accordingly.

The names in play

• LLY dominated the chatter, but mostly as an AI/GLP-1 momentum story, not a policy one. On The Pomp Podcast (May 30), Jordi Visser (a pundit) claimed "their revenues are up 55% year over year... a trillion dollar company" (treat the 55% as an unverified podcast number) and framed GLP-1 pricing through Jevons paradox: "their stock would be up significantly more if they could actually sell this to more people, even though the price would come down."
• MRK is the IRA case study (Keytruda's lifecycle, per Pops) and the patent-cliff poster child. Fast Money's Steve Grasso (a pundit) argued small-cap biotech (XBI) is outperforming large-cap "by six to one... because all of these companies are going to have to be buying every little company."
• PFE, a "business development deal... up to $10 billion focused on 12 potential therapeutic programs in the ADC space" (Flavin).
• NVO, Tim Seymour (a pundit) called it a "perennial disappointment... I can't believe how cheap it is... I think they should do an acquisition."

Read-throughs

• PBMs / formulary: Pops' MFN warning is the sharpest read-through, even a company that doesn't sell abroad gets hurt if a competitor's MFN rebate makes "formularies... incented to use that drug because they get paid a large rebate." Plus existing friction: antipsychotic patients "required to fail on multiple generics, sometimes as many as five" before access.
• Biosimilars / generics: the pill penalty structurally favors biologics, a tailwind for biologic franchises, a headwind for small-molecule innovators competing against generics.
• Ex-US: MFN's reach is the live risk; Alkermes simply "don't sell our drugs in Europe... at any price", a model others may copy if reference pricing arrives.
• Medicaid / exchange insurers (CNC, MOH, UNH, CVS, CI): the 2027 redetermination/rate-cut cliff is the dominant overhang; Medicaid-heavy books (Centene, Molina) and ACA-exposed lines are most levered to it.
• Optum-style services / VBC: the CMS ACCESS model is the constructive item, "Humana, United, Cigna, CVS, and Centene pledged to align their own payments to the same model framework by the year 2028" (Krause). Payers following CMS is the playbook.
• Hospitals (HCA, THC, UHS): directly in the path of the +33% provider Ch. 11 trend and 2027 Medicaid rate cuts.
• GLP-1 insurer cost exposure: notably absent from this week's tape, the conversation was all manufacturer-side (LLY pricing), not payer-side cost trend. A gap, not a signal.

What changed

• PDUFA 8 negotiations are done, "a return to basics," per Pops; text expected later in 2026. Watch against a backdrop he describes as an FDA "nadir," with reviewers walking out and a two-to-three-year training lag to replace them.
• A precedent was set: 17 CEOs cutting "bespoke deals" directly with the White House. Pops' worry: "Are future presidents going to be able to resist the urge to do the same thing... calling companies in to do negotiation over the pricing of specific drugs?"
• MFN status: still no legislation. "There is no MFN draft legislation. We don't know what MFN actually is," and Pops thinks it "less likely to happen in this legislative session."

Operator and insider commentary (Pops, Flavin, Krause) is weighted above pundit views (Visser, Pompliano, Fast Money traders); claims not sourced to filings are flagged as such.

Creator economy and digital ads newsletter for the week of May 31 to June 6, 2026. A $1B DTC brand confirmed it runs 100% of its Meta ad budget through AI agents, eMarketer sees Meta passing Google in ads by year-end, and the Meta One subscription stack was confirmed additive with zero ad relief.

The Creator Economy

Week of May 31 – Jun 6, 2026: A $1B brand hands 100% of Meta ads to AI

TL;DR

• A $1B+ DTC brand (True Classic) just confirmed it runs 100% of its Meta ad budget through AI agents, and Google and TikTok are next. The Advantage+/Andromeda thesis stopped being a slide and became an operator's standing policy.
• eMarketer now forecasts Meta's ad business overtakes Google's by year-end 2026, even as Meta pours "hundreds of billions" into AI and dangles a ~$10B talent fund with packages worth "hundreds of millions" per researcher.
• The Meta One subscription stack is confirmed additive, with no ad reduction. Instagram+/Facebook+ at $3.99, WhatsApp+ at $2.99, layered on top of a fully intact ad load.

What's new

1. The single biggest tell of the week: a $1B brand handed its entire Meta ad budget to an AI agent. On the DTC Podcast (Jun 3), Ben Diamond, CEO of True Classic (a $1B+ apparel brand, and himself ex-Facebook) said flatly: "A hundred percent of Meta is going through it [the agentic media buyer]. But we are in the process of enabling the rest. So like Google and TikTok... Meta is our largest channel." This is the first public confirmation from a nine-figure ad-budget decision-maker that Meta's AI ad stack is good enough to trust unsupervised, human in the loop, but "getting the reps," as Triple Whale COO Maxx Blank put it. For META, this is the live-fire validation of Advantage+/Andromeda the bulls have been waiting for. Note the operator's caveat, though: Blank said AI is "at least... at parity with a team", parity, not outperformance, yet.

2. eMarketer says Meta's ad business overtakes Google by end of 2026. On FT Tech Tonic (Jun 3), FT's Hannah Murphy noted the ad business "remains strong and in fact is forecast to take over Google by the end of the year by eMarketer." That is the punchline beneath the AI-capex anxiety: Murphy and colleagues pegged Meta's AI spend at "hundreds of billions of dollars," a reported ~$10B talent fund, and individual researcher packages "worth hundreds of millions of dollars." FT's Cristina Criddle was blunt on the frontier-model question, "I don't think Meta is going to be the winner... it's quite late to this", but conceded the real lever is distribution and integration across Instagram/Facebook/WhatsApp, not benchmark wins.

3. The Meta One stack is confirmed: additive ARPU, zero ad relief. On ABC's Download This Show (Jun 5), the Guardian's Josh Taylor confirmed Instagram+ and Facebook+ at "about US $3.99 each, and WhatsApp Plus... about $2.99 US a month." Researcher Seamus Byrne nailed the investor-relevant point: "There is nothing to do with reducing the amount of ads... you will still see exactly the same number of ads if you sign up for Plus." Taylor's read on the why: Meta is "hemorrhaging cash" on AI and "looking to how they can get as much out of their existing products as possible." Squeeze, not pivot.

4. YouTube turns both monetization knobs at once. TechLinked (Jun 6) confirmed YouTube Premium's April-announced price hikes "come into effect this month, and users are still pissed," arriving alongside 30-second unskippable ads on the free tier, with several observers "speculating that the advent of 30-second unskippable ads are a tactic to force people to upgrade." Price up on subs, pain up on free: a classic dual-pronged ARPU push for GOOGL.

5. Regulators put a leash on Google's AI search, and it cuts both ways for publishers. Per Grumpy Old Geeks (Jun 5), the UK CMA will require Google to provide clearer attribution in AI search, let publishers opt out of AI Overviews, and not penalize opt-outs in ranking, with 9 months to comply and mandatory accuracy reports. Co-host Brian Schulmeister's wry rejoinder captures the trap: "if you do that [opt out], nobody will ever see your shit." The same episode flagged Meta's Q1 2026 revenue at "more than $56.3 billion" (cited in a Malaysia-ban context) and the Spotify-relevant Luminate data below.

The debate

Bull case for the platforms. Engagement is durable and Meta is monetizing it on two new axes at once. The True Classic confirmation means the AI ad machine is now trusted with 100% of a nine-figure budget (DTC Podcast, Jun 3), pure switching-cost moat for SMBs once they hand over the keys. Diamond also said AI content has cut his "production costs by millions of dollars" and is "just as performative as real stuff" in paid, a margin tailwind, not just a CPM threat. Stack the confirmed-additive Meta One subscriptions on top, and the eMarketer call that Meta passes Google in ads (FT Tech Tonic, Jun 3), and the print looks defensible.

Bear case. The creator-payout and content-quality squeeze is real. Spotify's Luminate data, "roughly one-third of all streams in 2026 are going to songs at least 10 years old, and nearly 17%... over 20 years old" (Grumpy Old Geeks, Jun 5), is a flashing sign that new-creator economics are deteriorating, with AI-generated bands "making it onto the playlist." Schulmeister: "There's no money to be made in music anymore unless you're one of the top percent." AI-content supply expansion (Diamond can re-skin a New York shoot into Mexico City in a "20-second exercise") pressures CPMs even as it cuts costs. And the agentic shift commoditizes the very ad-tech middle layer, Diamond's "low grade software has been completely commoditized. It's out."

The honest split is unchanged from last week, just sharper: durable engagement is real, but incremental margin per new engagement keeps thinning, and now the brands themselves are automating away the human judgment that used to defend pricing.

Stocks in play

META, Bull: First operator confirmation of 100% agentic ad spend at a $1B brand; Meta One subscriptions are confirmed additive on top of an intact ad load; eMarketer sees Meta passing Google in ads by year-end. Bear: "Hundreds of billions" of AI capex with talent walking out the door (Yann LeCun, Joelle Pineau departures per FT); AI-generated ad supply pressures CPMs; subscriptions are marginal against a multi-hundred-billion ad base. Next to watch: any disclosure on Advantage+/agentic ad penetration and Meta One attach rate; whether Q2 confirms eMarketer's ads-overtake-Google trajectory.

GOOGL, Bull: Dual monetization push live (Premium price hikes plus 30s unskippable ads); still the default search distribution. Bear: UK CMA forcing AI Overview opt-outs and attribution (9-month clock); agentic ad budgets are coming after Meta (True Classic does Google "next"), so Meta gets first-mover lock-in; search-quality complaints persist. Next to watch: YouTube Premium churn/upgrade data post price hike; CMA compliance specifics.

SPOT, Bull: Nothing incremental this week. Bear: Catalog-age data (1/3 of streams ≥10yr old) and AI-band playlist infiltration signal worsening long-tail creator economics and content-quality risk. Next to watch: any per-stream payout or AI-music policy disclosure.

RDDT, Bull/Bear: Zero direct podcast coverage this week, narrative thin (last week's Meta "Forum" data-play read-through has gone quiet). Next to watch: new AI data-licensing deal flow.

SNAP, Bull: None this week. Bear: Surfaced only in the Kentucky school-district settlement framework (~$8M, one of 1,300+ complaints). Next to watch: Snapchat+ run-rate and any Spotlight payout update.

PINS, Bull/Bear: No coverage for the second straight week. The agentic-commerce shift toward Meta/TikTok remains the structural read-through against PINS' shoppable thesis. Next to watch: affiliate take-rate commentary on next print.

Read-throughs

TikTok / ByteDance: True Classic is "actively evaluating" TikTok Shop Live and will enable agentic ads on TikTok next (DTC Podcast, Jun 3), TikTok stays in the consideration set but is behind Meta in the agentic queue. No US ban/divestiture chatter on the tapes this week; overhang quiet but unresolved. Creator tooling / ad-tech: Triple Whale now sits on 60,000 stores and is pushing "SaaS to RaaS" (results-as-a-service) as the action layer above Meta/Google ad APIs, the layer capturing value as raw ad-buying commoditizes. Audio/AI-music: Suno raised $400M at a $5.4B valuation, against an estimated "$30 billion worth of lawsuits" (Grumpy Old Geeks, Jun 5), the AI-music supply threat to SPOT economics is now well-funded. Creator commerce: Shopify surfaced only via the True Classic merchant case (1M+ purchases, 190 countries), Mobi2 reportedly outperforming Shopify Sidekick on operational queries. Payments rails (Stripe Connect, Shopify Collabs): no direct mentions this week.

What changed vs last week

• NEW, the agentic-ads thesis got its first operator proof point. Last week (May 30) the AI ad-tooling story was pundit color (Brooke Shelton stacking tools to push "hundreds of ads in an hour"). This week a $1B brand confirmed 100% of Meta spend is agentic, a material escalation from speculation to standing policy.
• CONFIRMED and extended on Meta One. Last week reported the stack pricing ($3.99 Instagram+/Facebook+, $2.99 WhatsApp+). This week independently confirmed the same pricing and the key investor point that there is no ad reduction, additive ARPU. New this week: eMarketer's call that Meta overtakes Google in ad revenue by year-end, the ~$10B talent fund, and Q1 2026 revenue "more than $56.3 billion."
• TikTok Shop cooled on the tapes. Last week led with GaryVee's $25–40B GMV projection. This week TikTok Shop appears only as a $1B brand's "evaluating" item, no fresh GMV data. Share-shift narrative intact but quieter.
• Regulation moved. New this week: the UK CMA's 9-month order on Google AI search (attribution, opt-outs, accuracy reports), a concrete regulatory catalyst that didn't exist in last week's issue.
• SPOT flipped from bull color to bear color. Last week SPOT got the Jay Shetty/Netflix premium-content positive; this week it's catalog-age decay and AI-band playlist infiltration.
• Still quiet: RDDT (gone silent vs last week's "Forum" read-through), PINS (zero for the second week), and creator-tooling names (Substack/Beehiiv/Patreon), only Patreon/YouTube memberships got a passing mention.

Connectivity, space and satellite newsletter for the week of May 29 to June 5, 2026. SpaceX filed the largest IPO in history at a $1.77T valuation reframed as an AI-compute story, Blue Origin's New Glenn exploded on its pad and broke AST SpaceMobile's launch math, and SpaceX booked over $6.5B of Space Force defense awards in a single week.

The Satellite & Space-Comms Race

Week of May 29 – June 5, 2026: SpaceX files $1.77T IPO; Blue Origin blast cripples ASTS launches

Two rockets went up this week, one literally, one in valuation. SpaceX dropped an S-1 that would be the largest public offering in human history, and Blue Origin's New Glenn dropped a fireball on its own pad. The first electrified the entire space complex; the second knocked roughly a quarter off AST SpaceMobile in two sessions. If you own anything in this universe, both numbers are now your problem.

One housekeeping note up front, because it matters for how you weight what follows: the deepest AST coverage this week came from retail/enthusiast podcasts hosted by self-disclosed ASTS longs. The reporting is detailed and often sharp, but treat their cash balances, satellite counts, and "carrier is switching to us" claims as leads to verify against filings, not gospel. Speakers are tagged throughout. All figures USD unless noted.

TL;DR

• SpaceX filed for a ~$1.77T IPO (fixed $135/share, ~$75B raise, sub-5% float, June 11 pricing), and the S-1 reframes the company as an AI-compute story, with AI capex now exceeding Starlink plus launch spend combined (Bloomberg Businessweek; Elon Musk Podcast).
• Blue Origin's New Glenn exploded on the pad at LC-36 (~May 29), taking out a launch line AST was counting on for its 45-satellite year-end goal. ASTS fell ~24% over two days (The Rundown).
• SpaceX booked >$6.5B of Space Force defense awards in a single week ($4.16B Golden Dome S-BAMTI plus $2.29B military comms backbone), the cleanest validation yet of the space-defense thesis (Astronomy Daily).

What's new

1. The biggest IPO ever, and it's quietly an AI trade. Bloomberg's Anthony Hughes laid out the structure: $1.77T market value, $75B raise, a fixed $135/share (not a range), 555M shares, sub-5% float, June 11 pricing, and a one-year Musk lockup (Bloomberg Businessweek). The tell for our universe is the capital allocation: per the S-1 as relayed on the Elon Musk Podcast, AI capex hit $12.7B, exceeding the combined ~$8B for Starlink plus rocket launches, and Anthropic alone is paying ~$1.25B/month ($15B/yr) for compute, terminable on 90 days' notice. Why it moves numbers: if SpaceX is starving space capex to feed GPUs, that is a structural read-through positive for every D2D competitor that needs SpaceX to slow down.

"Right now, the AI business itself is still the smallest business at SpaceX. It's really Starlink and what Starlink enables." Morgan Brennan, CNBC (The Pomp Podcast)

2. New Glenn blew up, and AST's launch math broke with it. The dominant hard-asset story of the week. The New Glenn pad explosion at LC-36 around May 29 has CEO Dave Limp insisting damage was "far less catastrophic than it looked" and pledging "we will fly again before the end of this year" (Astronomy Daily). Money manager Andrew Horowitz was blunter, calling it "a massive fireball" with pad repair "upwards of a year" (DHUnplugged). AST-focused hosts split the difference at a 6 to 7 month outage, pushing first ASTS New Glenn launches to ~Jan to Feb 2027 and putting the 45-satellite year-end target at risk (revised range floated at 25 to 40) (Anpanman, retail enthusiast host).

3. Golden Dome starts writing checks. US Space Force awarded SpaceX a $4.16B Space-Based Airborne Moving Target Indicator (S-BAMTI) contract under the Trump Golden Dome initiative, plus a separate $2.29B "Space Data Network Backbone" award, over $6.5B in one week (Astronomy Daily). There is a 9-vendor S-BAMTI pool with 8 names withheld, an open lottery ticket for other satellite-defense names. Tying in: AST reportedly hired a 28-year Raytheon missile-defense radar veteran to run federal programs (Kook's Weekly, retail enthusiast host), read as Golden Dome positioning.

4. An unverified bombshell on Globalstar. CNBC's Morgan Brennan stated, as fact, that Globalstar is "getting purchased by Amazon as they're rolling out their Starlink competitor, Leo" (The Pomp Podcast). No price, no close date, and no corroboration anywhere else on the tape. If true it's a take-out event for GSAT holders; until a filing or press release confirms it, treat it as a single anchor's offhand claim, not a catalyst.

The debate: is the D2D TAM real, or a retail mirage?

Bull. AST hosts size the direct-to-device prize at "$750 billion commercial plus well over a trillion including military" and argue ASTS delivers 100 to 200 Mbps/cell against Starlink's ~7 Mbps Direct-to-Cell (Kook's Weekly, retail enthusiast host). The kicker: Starlink's D2D is allegedly gated by EchoStar spectrum until 2028 and Starship reusability until "2029, 2030," so AST has a multi-year runway with the carriers in its corner (Anpanman, retail enthusiast host).

Bear. Every one of those numbers comes from self-disclosed longs on enthusiast podcasts; the bandwidth and timeline claims are unverified. Meanwhile the bear case got concrete this week: AST is pre-revenue, its anchor launcher is grounded for the better part of a year, and the 45-satellite target is slipping in real time. The market's -24% vote is the steel-man. And the most credible institutional voices (Brennan, Bloomberg, Horowitz) spent the week talking about SpaceX and rockets, not about anyone's D2D TAM.

Stocks in play

• ASTS. Bull: >$3B to ~$4B cash (no near-term ATM), Brazil 10x10 MHz spectrum award, Raytheon defense hire, possible EU 2 GHz MSS reallocation in its favor. Bear: New Glenn outage breaks the 45-sat plan; competitive and cash claims are retail-sourced. Next catalyst: BB8 to BB10 Falcon 9 launch targeted mid-June, batch 2 early July (Anpanman, End of Smash-and-Grab).
• RKLB. Bull: Horowitz is long for himself and clients, calling it a stock that "is going to ride the coattails of SpaceX" (DHUnplugged); Brennan calls it the re-rating poster child. Bear: a reported "structural crack during testing" on Neutron, and Neutron tops out at ~3 BlueBirds expendable (Anpanman). Next catalyst: Neutron test progress.
• GSAT. Bull: the (unverified) Amazon take-out; Apple SOS partnership. Bear: thesis rests on one unconfirmed claim. Next catalyst: an actual filing confirming or killing the Amazon story.
• SpaceX (private). Bull: >$6.5B defense awards, Starlink >$11.4B revenue (>60% of $18B+). Bear: ~$5B net loss (xAI), >$41B accumulated deficit, Anthropic's 90-day-cancelable $15B/yr. Next catalyst: June 11 pricing / June 12 listing.

Read-throughs

• Carriers (VZ, T, TMUS): Oppenheimer reportedly downgraded AT&T, flagging Starlink fixed wireless as a "bigger and bigger" broadband threat and preferring VZ and TMUS (How the SpaceX IPO Valuation Impacts the Space Sector, secondhand). A retail host's claim that T-Mobile is pivoting from Starlink to ASTS for D2D would be thesis-defining if true, but it's unverified; corroborate against MNO press before acting.
• EchoStar / SATS: a SpaceX-IPO derivative via the SpaceX equity Ergen took for spectrum, "beneficiary if it goes well, down if it disappoints" (same episode). EU 2 GHz MSS rules read as a negative for SATS/Viasat (Kook's Weekly). The clean pair: long ASTS / short SATS on European spectrum.
• Iridium (IRDM): Quiet week on IRDM, one glancing "competitor" mention, no substance.
• Launch & component suppliers: Firefly (FLY) and Filtronic (London-listed SpaceX supplier) flagged as Tema NASA ETF holdings by CEO Maurits Pot (ETF Spotlight); Intuitive Machines launched an ATM equity raise (~June 3) into the rally; ULA's Vulcan is grounded on two SRB nozzle anomalies (return Aug to Sep); Relativity's Terran R is the wildcard at a claimed ~68 BlueBirds per flight.
• SpaceX private-market anchor: Tema marks SpaceX at a $1.3T cost basis vs. the ~$1.77T S-1 and $2T+ Polymarket-implied, the sentiment gauge for how much froth is already in the print (ETF Spotlight).

What changed vs last week

Last week's issue isn't available in the archive for a clean line-by-line diff, so I'll flag it honestly rather than invent a comparison. The two new facts that reset the board this week: (1) the New Glenn explosion converted AST's "launch-agnostic" story from a strength into a near-term liability, and (2) the SpaceX S-1 made the AI-capex-over-space-capex shift explicit, a fresh tailwind argument for the D2D challengers. The Amazon/Globalstar and T-Mobile/ASTS claims are the two highest-impact unconfirmed items; both need a filing to graduate from chatter to catalyst.

Housing, builders, rentals and affordability newsletter for the week of June 5, 2026. Berkshire is reportedly buying homebuilder Taylor Morrison in the post-Buffett era, while on-the-ground operators keep hammering the same point: this is a transaction freeze, not a price crash, and the scale builders hold the keys.

Housing: Builders, Rentals & Affordability

Week of June 5, 2026: Berkshire buys a homebuilder as the market stays frozen

Quiet week on the housing pods, but not an empty one. The single loudest signal came from an unlikely place, Omaha, while the on-the-ground operators kept hammering the same point they've made all spring: this isn't a price crash, it's a transaction freeze, and the builders are the only ones with the keys to thaw it. Pour a coffee; this one's short.

TL;DR

• Berkshire is reportedly buying Taylor Morrison (TMHC), a post-Buffett housing endorsement, though deal terms weren't disclosed on the show that broke it down. Verify before you trade it.
• Builders are winning on rate, not price. D.R. Horton is dangling ~4.99% buydowns that beat resale by ~$20K, and deliberately rationing starts to protect margin over pace.
• Rates are stuck in the mid-6s and the lock-in wall is still 50%+ of mortgages sub-4%. Sales near post-GFC lows; prices still grinding +1% YoY. Frozen, not falling.

What's new

1. Berkshire's housing bet. On The Canadian Investor (early June), hosts Simon, Braden and Dan (all pundits, not insiders) walked through Berkshire's announced plan to acquire homebuilder Taylor Morrison under new CEO Greg Abel, reading it as a deliberate, strategic pivot toward U.S. housing in the post-Buffett era. The catch: only the episode description was accessible, so there's no quoted price, premium, or financing structure, and no TMHC operational color. If true, it's the most important housing capital-allocation signal of the year, a permanent-capital buyer stepping into a builder at trough transaction volumes. Treat the terms as unconfirmed until primary documents land.

2. D.R. Horton is creating scarcity on purpose. On More Than More (June 5), a Des Moines agent panel flagged DHI advertising ~4.99% 30-year buydowns that save a buyer roughly $20,000 versus a comparable resale, "no one can touch that deal." More interesting was the strategy read: Jason argued DHI is "slowly digging holes… slowly putting new builds up because they want the fight," concluding "they're making more money by doing it this way than having a whole bunch of homes sitting there." That's the margin-over-pace playbook stated in plain English by someone watching the lots fill up. A smaller local builder was offering only a 2-1 temporary buydown, a reminder the permanent-rate buydown is a scale-builder weapon the regionals can't match.

3. The freeze is the story, again. Same Des Moines panel (citing third-party data): existing-home sales running ~4M annualized, "near the lowest activity level since the aftermath of the Great Recession," yet median price still ~$418K, +1% YoY, with 30-plus straight months of annual gains and inventory around 4.4 months. The lock-in math underneath it: 50.6% of mortgages sub-4%, 27% at 4–6%, 21.9% at 6%+. Until that distribution moves, supply stays scarce and builders keep the whip hand.

The operator vs. the pundits

Worth separating, because this week the only actual industry operator on tape was Adam Rose, a regional retail loan officer (Western Ohio Mortgage), on The Mortgage Guy (June 3). His pipeline put rates in the "mid sixes." His no-crash case rests on structure, not hope: QM/ATR underwriting (not 2008's NINA loans), 30-year fixed dominance (no teaser-ARM reset bomb), and chronic undersupply from the 2008–2019 building gap. His cost-of-waiting anecdote lands: a home that was ~$210K in 2022 at 4-handle rates is ~$300K today in the mid-6s, the patient buyer lost on both axes. Everyone else this week, the Des Moines crew, the Canadian hosts, was a pundit. Useful color, but not management guidance.

The debate (such as it is)

The tape this week was lopsided toward the constructive side, so I won't manufacture a symmetric fight. The bull backstop is intact: record-tight resale supply, a 50%+ sub-4% lock-in wall that won't break at these rates, builders with the balance sheets to buy down rates and the discipline to ration starts, and now a permanent-capital buyer (Berkshire) validating the asset class at low volumes.

The bear case got only glancing support, all of it regional and unverified: one panelist's call that "we see seven before five" on rates, a claim that "foreclosure volumes double every six months over the next 18 months" (which his own co-hosts pushed back on), and a Sun Belt soft spot, ~40% of Tampa listings reportedly took a price cut in a 30-day May window. That's the air-pocket risk in miniature: where supply has caught up, incentives and price cuts follow fast. But it stayed anecdotal this week, no institutional voice put numbers behind a national affordability-ceiling thesis.

Read-throughs

• Builder peers (LEN, PHM, TOL, NVR, KBH, MTH, TMHC): the DHI scarcity/buydown read is the operative one, scale builders are choosing margin protection over volume, and a Berkshire bid for Taylor Morrison reprices the takeout optionality across the smaller-cap names.
• Mortgage originators / title (RKT, UWMC, PFSI, COOP, FAF, FNF): builder buydown intensity steers purchase volume toward builders' captive lenders and away from the open retail channel, incrementally tougher for independents; title volumes stay starved at 4M-sales run-rates.
• Building products & appliances (BLDR, MAS, FBIN, WHR, SHW, LP): slow-walked starts cap single-family volume; the read-through is muted demand, not a cliff, watch starts cadence, not just permits.
• Agency MBS / mortgage REITs (NLY, AGNC, MFA, RITM): no fresh commentary this week; the "mid-6s, range-bound" rate view keeps the carry trade intact but offers no spread catalyst.
• Home improvement (HD, LOW, FND): the transaction freeze is the structural tailwind for repair-and-remodel, people who can't move, improve, though nobody put a number on it this week.

What changed

Honestly, not much versus prior weeks on the fundamentals, rates, lock-in, and the freeze narrative are right where they've been. The one genuinely new variable is Berkshire reportedly stepping into homebuilding via Taylor Morrison. If confirmed, that's a structural change in who owns the asset class at the bottom of the cycle, and it deserves your attention more than any single data point this week.

Thin slate this week, the institutional housing shows were quiet, so this is weighted toward regional practitioners. All figures above are podcast-sourced claims, not verified disclosures; the Berkshire/Taylor Morrison terms in particular need primary-source confirmation before you act on them.

Pharma and biotech newsletter for the week ending Friday, June 5, 2026. Pfizer's up-to-$10.5B Innovent oncology collaboration headlines a dealmaking sprint, Lilly fires off four licensing deals in five days, and ASCO derisks the SMID takeout targets while Eli Lilly's CEO frames GLP-1 dominance on The Prof G Pod.

The Biotech Patent Cliff & M&A

Week ending Friday, June 5, 2026: Pfizer's $10.5B Innovent Deal Headlines a Dealmaking Sprint

The operators got busy this week even as the commentary stayed light. The clearest investor read came from Eli Lilly CEO David Ricks on The Prof G Pod, so this issue leans on what the companies actually did: term sheets, FDA letters, and an ASCO data dump.

TL;DR

• Pfizer wrote the biggest check of the week, up to $10.5B for 12 early-stage Innovent oncology programs ($650M upfront), the clearest sign yet that a cliff-exposed buyer is filling the Eliquis hole with bolt-on biology, not a megamerger.
• Lilly is deploying anyway, with four licensing deals in five days (Haisco, Hanmi, Ascidian, Camurus) plus two pending heme acquisitions. The firepower-rich buyer with no near-term cliff is still the most aggressive shopper.
• ASCO handed the SMID targets their valuations. Revolution Medicines (+11%) and Summit (+5%) both posted plenary survival wins. The takeout candidates just got more expensive and more derisked at the same time.

What's New

1. Pfizer's $10.5B Innovent collaboration, the cliff-fill blueprint. Pfizer and Innovent Biologics struck a global licensing and collaboration deal across 12 early-stage oncology programs, antibody-drug conjugates and multi-specific antibodies. Innovent gets $650M upfront and is eligible for up to $9.85B in development, regulatory and commercial milestones, plus up to double-digit royalties; the structure mixes outright ex-China licenses with co-develop and co-commercialize arrangements in the US and Europe. The deal is expected to close in Q3. Why it moves the thesis: this is exactly the playbook the bull case demands of Pfizer, buy early-stage optionality cheaply rather than overpay for a de-risked single asset. It's oncology pipeline depth to backfill the Eliquis LOE without bloating the balance sheet.

2. Lilly's five-day licensing sprint. The firepower buyer with the least urgent cliff was the busiest dealmaker: a drug-discovery collaboration with Haisco worth up to $3.05B ($87M upfront and near-term, up to $2.97B milestones); exclusive ex-Korea rights to Hanmi's long-acting GLP-2 sonefpeglutide ($75M upfront, up to $1.185B milestones); RNA exon-editing rights from Ascidian for kidney targets (up to $1.9B); and an option exercise to add amylin receptor agonists to the Camurus long-acting cardiometabolic deal (up to $290M development and regulatory plus $580M sales milestones). Lilly also flagged its pending acquisitions of Ajax Therapeutics and Kelonia Therapeutics in hematology. Why it matters: Lilly isn't buying to plug a hole, it's buying to widen an already-dominant cardiometabolic and oncology lead. That's the supercycle in microcosm.

3. ASCO derisked two of our top takeout targets. Revolution Medicines (RVMD) posted full Phase 3 RASolute 302 data for oral RAS(ON) inhibitor daraxonrasib in second-line metastatic pancreatic cancer: a 60% reduction in the risk of death, median OS 13.2 months vs ~6.6 months on chemo, presented at the ASCO plenary with simultaneous NEJM publication. Shares jumped ~11% to $174.50; sell-side piled on (Oppenheimer and H.C. Wainwright both to $195, RBC to $182). Summit (SMMT) delivered HARMONi-6 overall-survival data for ivonescimab vs tislelizumab in first-line squamous NSCLC, a 34% reduction in risk of death, presented at the ASCO plenary and published in The Lancet, plus a 70.8% ORR in a separate Phase 2 colorectal cohort; the stock rose 5% to $18.41. Why it matters: both are now harder to buy on the cheap, but the strategic logic for a large-cap acquirer just strengthened.

4. Merck quietly fortified the Keytruda moat. Two items bear directly on Merck's biggest cliff. The Moderna-partnered mRNA cancer vaccine intismeran autogene posted 5-year KEYNOTE-942 melanoma data: a 49% reduction in recurrence-or-death and a 59% reduction in distant-metastasis-or-death on top of Keytruda. And calderasib, an oral KRAS G12C inhibitor, won FDA Breakthrough Therapy designation in first-line KRAS-G12C/PD-L1+ NSCLC in combination with Keytruda. Why it matters: the IV-to-subcutaneous defense gets the headlines, but extending Keytruda into combination franchises with their own IP runways is the more durable answer to the 2028 biologic cliff.

5. The operator clip, Lilly's Ricks on GLP-1 dominance. David Ricks, Chair and CEO of Eli Lilly, on The Prof G Pod: "products like Zepbound or our new one Foundeo, they work. People lose weight. Almost everybody who takes them loses weight… obesity is kind of like a nodal health condition for more than 200 chronic diseases." Why it matters: Ricks naming a new product ("Foundeo") alongside Zepbound underscores why Lilly feels no pressure to do obesity M&A, and meanwhile Novo just launched the oral Wegovy pill in the UAE (~17% weight loss over 64 weeks), its first market outside the US.

The Debate

The supercycle bull: This week is the thesis in action. A cliff-exposed buyer (Pfizer) and a firepower buyer (Lilly) deployed real capital into early-stage biology, ASCO derisked the next generation of acquisition targets, and the FDA issued draft guidance to accelerate cell and gene therapy submissions. Targets are validated, capital is moving, and the regulator is leaning in. Buy the buyers and the best-in-class SMID assets.

The cliff-erosion bear: Look closer and almost none of this week's deals were acquisitions, they were licensing deals and milestones-heavy options. That's what you do when you're nervous about valuations and the IRA. ASCO wins make the obvious targets pricier, not cheaper, and AstraZeneca's CARES program missed its primary endpoint in the overall AL amyloidosis population (kappa subgroup salvage only), a reminder that late-stage biology still breaks. And the silence on FTC posture and IRA pill-penalty mechanics isn't comfort, it's an unpriced overhang.

My take: The bears are right that this was a licensing week, not an M&A week, but that's a tell, not a refutation. When the strategics are this willing to pay $650M to $3B upfront for Phase 1 assets, the appetite for the de-risked Phase 3 names (RVMD, SMMT) is only building. The ASCO pop in those two is the market front-running a bid, not pricing one out. I'd rather own the validated target into a richer print than wait for a "cheap" entry that the data just erased.

Stocks in Play

Read-Throughs

• Takeout targets: ASCO turned RVMD and SMMT from "story stocks" into "validated assets." Expect the rumor mill to reactivate, a derisked oral RAS franchise (RVMD) and a PD-(L)1xVEGF bispecific (SMMT) are exactly what cliff-exposed large caps say they want.
• The PD-(L)1xVEGF arms race is real: Summit's ivonescimab OS win and the BMY/BioNTech pumitamig Phase 2 (ORR 63.6% non-squamous / 72.7% squamous) put the whole bispecific class in play. Watch who else (Merck, Pfizer) needs to buy in.
• SMID sentiment / XBI: IBB rose 0.3% even on a down healthcare tape. Plenary-stage wins plus a friendlier FDA cell and gene posture is the cocktail SMID sentiment has been waiting for.
• Bankers and CROs: A week this thick with cross-border licensing (Innovent, Haisco, Hanmi, all China and Korea-originated) signals the BD pipes are wide open. Good for advisory fees; watch for FTC and CFIUS commentary that hasn't yet surfaced.

What Changed vs Last Week

This is the first issue of The Biotech Patent Cliff & M&A in this format, so there's no prior week to mark to. Two things to file for next Friday: whether the Pfizer/Innovent and Lilly deals draw any FTC or CFIUS noise (no antitrust pushback has surfaced yet), and whether the RVMD and SMMT ASCO pops convert into actual takeout chatter or fade. We'll track both.

Banks, rates and the CRE wall for the week of June 5, 2026. Jamie Dimon frames JPMorgan as rate-agnostic, leans higher-for-longer on structural inflation, and flags very low credit spreads as a risk rather than a comfort ahead of mid-June stress-test results.

Banks: Rates, Deregulation & the CRE Wall

Week of June 5, 2026: Dimon says JPM is built for 2% or 8% rates

TL;DR

• The cleanest large-bank signal this week came from Jamie Dimon at the Reagan Economic Forum. He framed JPMorgan as rate-agnostic, leaned higher-for-longer on inflation, and flagged credit spreads as a risk rather than a comfort.
• Dimon's one durable signal is "higher-for-longer." He laid out a stack of structural inflation drivers and said "the die may have been cast," which, if right, slows the pace of Fed cuts and protects large-bank NII longer than the curve assumes.
• He also waved a small yellow flag on credit. Spreads are "very low," and Dimon calls that a risk, not a comfort. File it for the back half of the year, not for next week.

What's new

1. Dimon frames JPM as rate-agnostic, and that is the point. On The Investopedia Express with Caleb Silver (episode: "The Future of the American Economy," 2026-06-01), Dimon put it plainly:

"Interest rates are gravity to asset prices… We can handle whatever it is… So JP Morgan can handle rates at 2%, rates at 8%. We're not betting our company in either one."

Why it moves the thesis: into a cut cycle, the bear case on money-center banks is that asset yields roll over faster than deposit costs and NIM gets squeezed. Dimon is telling you JPM has hedged the path rather than positioned for one outcome. That is a quiet positive for JPM's NII durability relative to peers carrying more long-end duration risk, and it is exactly the posture you want from the balance sheet you most want to own when nobody can call the front end. Source: The Future of the American Economy.

2. The "higher-for-longer" lean is the actionable macro call. Dimon walked through why he thinks inflation stays sticky:

"Health care is going up. For us, it's going up 10% a year… the remilitarization of the world is kind of inflationary. AI spending in the short run is inflationary… I think that there's a cumulative effect of spending all this money, which may have, the die may have been cast."

Why it moves numbers: every quarter the Fed cuts more slowly than priced is another quarter of elevated reinvestment yields on the securities book and asset-sensitive loan portfolios. Dimon is the most-watched bank operator alive telling you the cut path may be shallower than the strip. That is bullish bank NII at the margin. Source: The Future of the American Economy.

3. The credit caveat. Dimon on valuations and spreads:

"earnings are up 15%, 20% this year… credit spreads are very low. So I look at all that as actually a risk… if something goes wrong, those asset prices can come down."

Why it matters: he gave no JPM-specific charge-off or reserve guidance, so treat this as directional, not a data point. But it is the CEO of the biggest bank telling you the credit backdrop is priced for perfection. That is a reserve-build narrative waiting for a catalyst. Source: The Future of the American Economy.

The debate

"JP Morgan can handle rates at 2%, rates at 8%." (Jamie Dimon)

Bull NII case. Deposit repricing lags the front end on the way down. If the Fed cuts slowly, Dimon's structural-inflation thesis, asset yields drift lower gently while the securities book keeps rolling maturing low-coupon paper into higher reinvestment rates, and a steeper curve widens the spread banks earn. In that world NII grinds higher into the cut cycle and consensus is too conservative.

Bear NIM case. The mirror image. Cuts compress loan and floating-rate asset yields immediately, but deposit costs stay sticky because high-yield savings balances do not reprice down without a fight and CDs roll at rates customers locked in. Layer on soft loan demand, no volume to offset price, and margins compress more than guidance implies. The tell will be deposit beta on the way down, a number that did not surface on tape this week and is precisely the gap to close with IR before earnings.

Stocks in play

JPMorgan (JPM). Bull: rate-agnostic balance sheet, best-in-class hedging discipline, and a CEO publicly comfortable across a 2%-to-8% band (source). Bear: it is the consensus long and the premium multiple leaves little room for a credit-normalization scare Dimon himself flagged. Next catalyst: mid-June stress-test results and the capital-return update that follows.

Bank of America (BAC). No new tape on BAC this week. Bull (standing): the AOCI-recovery story as the curve cooperates. Bear (standing): longest securities-book duration among the money-centers leaves it most exposed if the long end backs up on Dimon's inflation thesis. Next catalyst: stress test, then Q2 NII guide.

Wells Fargo (WFC). No new tape on WFC this week. Bull (standing): self-help efficiency story plus capital return. Bear (standing): most rate-sensitive NII line of the four, a faster-than-expected cut path bites here first. Next catalyst: stress test and buyback cadence.

Citigroup (C). No new tape on C this week. Bull (standing): restructuring and capital-return optionality at a discount to tangible book. Bear (standing): execution risk and the thinnest margin for error if credit turns. Next catalyst: stress test and the next leg of the simplification update.

Read-throughs

• Super-regionals (USB, PNC, TFC): the Dimon read-through is indirect, a shallower cut path helps the regionals' NII recovery too, but they carry less hedging firepower than JPM, so the deposit-beta question matters more for them, not less. Close it with IR.
• Deposit competition: the single most important undisclosed variable into the cut cycle. No number, no read.
• Capital-markets fees (IB pipeline, trading): watch for FICC/equities and DCM/ECM/M&A color to resurface once stress-test capital is freed up.
• CRE and consumer credit: Dimon's "spreads are very low" macro flag is the live read (source). Watch office-versus-multifamily and card-delinquency specifics next.

What changed vs last week

Last week's read leaned hike, with the macro tape arguing the Fed's next move could be up and JPM dominating the long-form bank conversation. This week Dimon refines that into a balance-sheet posture rather than a directional bet: JPM is built for either tail, the inflation drivers keep him higher-for-longer, and the new wrinkle is his explicit credit-spread caution. Expect the picture to fill in materially around the mid-June stress-test results.

Powering-AI newsletter for the week of May 29 to June 4, 2026. The power-scarcity bull case for data-center landlords got reinforced from gas-turbine lead times, grid load growth, and capacity that demand keeps outrunning, while Google's $80B equity raise opened the first real crack in the hyperscaler self-funding story.

Powering AI: Grid, Gas, Generation & Nuclear

Week of May 29 – Jun 4, 2026: Power Is the Bottleneck and the Trade

Quiet week on the tape for the landlords themselves, nobody sat down to talk EQIX leasing or Prologis rent spreads. But the conversation upstream got loud, and it's the conversation that ultimately writes the data-center REIT story: who can power the boxes, and who can afford to keep building them. Two threads ran through everything this week, power is the binding constraint, and the bill is finally big enough to make even the hyperscalers flinch.

TL;DR

• The power-scarcity bull case for landlords got reinforced from three directions: gas-turbine lead times, grid load growth, and capacity that demand keeps outrunning.
• The bear case showed up too, and it's a financing story: Google raising $80B of equity to fund capex has the Street asking whether Microsoft, Oracle and Meta are next.
• 2027 capex guidance is shaping up as the single catalyst the whole complex is leaning on. A deceleration there is the risk that matters.

What's new

Power demand is shifting from a flat line to a 3–4% CAGR, for twenty years. On The HC Commodities Podcast, McKinsey senior partner Erikhans Kok framed the AI buildout as one slice of a synchronized global capex super-cycle, with US power demand going from "flat-ish for the last 20 years" to "3% to 4% CAGR year-over-year for the next 20 years," and roughly "$3 trillion in data centers, $3 trillion in energy/utilities" inside a ~$15T US capex wave (The HC Commodities Podcast, Jun 2). If that load curve is even directionally right, the scarce, powered, permitted megawatt is the asset, and that's exactly what the best DC landlords are sitting on.

Hendry's "own the bottleneck" thesis: 18-month gas turbines and capacity that can't be filled. Former macro manager Hugh Hendry, on The ACID Capitalist Podcast, pointed at the supply chain rather than the demand: "Microsoft openly admitted it. Tens of billions in Azure demand… couldn't be fulfilled fast enough. Because the capacity for the power wasn't there," alongside 18-month gas-turbine lead times (The ACID Capitalist Podcast, May 29). When the constraint is power and steel, whoever already controls interconnect and shells captures the scarcity premium.

Google's $80B equity raise is the first real crack in the "they can self-fund forever" story. On The Morning Market Briefing, the hosts zeroed in on Google raising $80B of equity (stock off ~3% on the news), arguing "this company should not be having to raise equity capital. Plain and simple," and flagging a 2027 Google capex forecast ">$300 billion, which will put them into a massive deficit next year on the cash front" (The Morning Market Briefing, Jun 2). Their punchline matters for landlords: "I have questions about Microsoft, Oracle and Meta… Are they going to have to come out and issue stock?" Tenant balance-sheet stress is the channel through which a capex air-pocket would eventually hit pre-leasing and development economics.

The buyers are leasing, not buying, and the lease checks are enormous. On TFTC, AOT Invest PM John Tinsman walked through the economics: xAI's Colossus 1 at 300 MW built in 122 days for "$3–4 billion, some people say as high as $7 billion," with Anthropic paying "$1.6 to $1.9 billion a month in compute… ~$15 billion a year" for capacity (TFTC, Jun 1). He also relayed Morgan Stanley's estimate that hyperscaler capex "nearly doubled to $805 billion for 2026 headed towards $1.1 trillion in 2027." Those leasing dollars are the lifeblood of the colocation model; the question the bears keep circling is how durable the rent is if compute ROI ever normalizes.

The debate

This week the debate was entirely a pundit affair, no REIT executive, hyperscaler ops lead, or utility insider took the mic inside the window, so read the conviction accordingly.

Bull frame, scarcity re-rates the landlords. Kok's two-decade 3–4% power CAGR, Hendry's 18-month turbines and unfillable Azure demand, and Tinsman's view that this is "one of the longest CapEx cycles that's ever been in the history of the world" all point the same way: demand is real, the binding constraint is power and equipment, and whoever owns powered, permitted capacity collects the premium. Hendry's framing is the cleanest version of the trade, own the bottlenecks: "power, cooling, copper, fiber, glass, bandwidth."

"The hyperscalers… spent $600 billion, which is why they'll spend a trillion dollars over the next 12 months." Hugh Hendry, The ACID Capitalist Podcast, May 29

Bear frame, the bill, and the self-build. The bear case didn't argue demand is fake; it argued the financing is getting expensive and the tenants may route around the landlord. Google reaching for $80B of equity is the financing tell (The Morning Market Briefing, Jun 2). And the self-build risk is visible in the same xAI story the bulls cite: Colossus running on "35 industrial gas turbines… off the grid," per Hendry, a tenant generating its own power and building its own shell is a tenant that doesn't need a REIT (The ACID Capitalist Podcast, May 29). The honest read: the strongest bear isn't oversupply yet, it's that the marginal megawatt of demand is increasingly being self-supplied behind the meter.

Read-throughs

• Utilities & IPPs / power supply. The clearest beneficiary of the week's narrative is generation, not real estate. Kok singled out gas-fired baseload as the near-term answer and cited a NextEra/Dominion plan to spend a combined "$58 billion per year" (The HC Commodities Podcast, Jun 2). Behind-the-meter gas is now a recurring theme, bullish for turbine and power supply chains, ambiguous for grid-dependent colo.
• Fiber, glass and optics. Hendry flagged Nvidia's ~$4B photonics commitment (split across Coherent and Lumentum), a Meta–Corning ~$6B optical-cable deal, and Corning up "54% in a month" (The ACID Capitalist Podcast, May 29). Interconnect intensity inside and between campuses keeps rising, a quiet positive for the interconnection-heavy DC model.
• Labor as a schedule risk. Kok's point that electricians (and, per the macro crowd, plumbers) are now the gating resource is worth holding onto, it argues development timelines slip and stabilized yields on new supply come slower than the build pipeline implies (The HC Commodities Podcast, Jun 2). Slower supply is, on balance, friendly to incumbent landlords' pricing.

What changed

The tone on financing flipped. For most of this cycle the consensus was that hyperscaler free cash flow could absorb any capex number you cared to write down. This week, with Google issuing equity, the question moved from "how big is the spend" to "how do they pay for it," and the next read on that comes when 2027 capex budgets land. Tinsman's relayed Morgan Stanley path of $805B in 2026 toward $1.1T in 2027 (TFTC, Jun 1) is the number the whole complex is now underwriting. If 2027 guidance decelerates, the power-scarcity trade and the landlord re-rating both lose their best argument at once.

Gold and precious-metals podcast newsletter for the week of June 4, 2026 (coverage May 29 to June 3). Gold overtook U.S. Treasuries as the top central-bank reserve asset for the first time in roughly thirty years, yet spot churned lower as war headlines and a possible PBOC liquidity brake competed with the structural debasement thesis.

Gold & The Debasement Trade

Week of June 4, 2026: Gold's Monetary Reset Meets the Smoke of War

A strange thing happened this week: the most bullish structural news for gold in three decades landed on the tape, and gold went down. That tension, a generational monetary reset playing out underneath a fog of war headlines, is the whole story this week.

The headline number, repeated across the gold podcast ecosystem: for the first time in roughly thirty years, gold has overtaken U.S. Treasuries as the single most important reserve asset held by central banks. On Mining Stock Daily's Tuesday briefing, Trevor Hall pegged it at roughly $4T in central-bank gold versus $3.9T in U.S. bonds, citing more than 1,000 tonnes of net central-bank buying last year (Mining Stock Daily, Jun 2). Nomi Prins framed the same milestone through the ECB's lens, gold is now "the top reserve currency of central banks in the world," held "as a long-term investment in their independent monetary system" (Palisades Gold Radio, Jun 3).

And yet spot gold spent the week churning in the $4,500–$4,600 zone, Mining Stock Daily quoted $4,559 on Tuesday, Money Metals $4,577 the prior Friday (Money Metals, May 29), well off the $5,400–$5,500 print Prins says preceded the late-February Iran/Hormuz escalation. Silver traded $70–$80 (Money Metals: $76.39, support flagged at $71); platinum $1,936, palladium $1,378.

The Bull Chorus: A Monetary Cycle, Not a Price Cycle

The most articulate framing came from Ronni Stoeferle of Incrementum, whose "In Gold We Trust" report this year is subtitled "Back to the Monetary Future." His central question: "Are we in a normal gold cycle or a monetary cycle where we are actually at the beginning or right in the middle of a monetary revaluation of gold?" He reframed last year's ~65% dollar gain not as gold rising but as "an enormous loss of purchasing power of the dollar measured in gold," and placed us in the "public participation phase… probably like in the sixth inning." His tell that this is no longer a contrarian trade: Morgan Stanley has rolled out a 60-20-20 portfolio (60 equities / 20 bonds / 20 gold) (Wealthion, Jun 2).

The fiscal-dominance case ran through nearly every episode. Michael Howell laid out the plumbing: with ~50% of U.S. debt maturing inside two years and the Treasury refinancing "$600 billion a week," debt growing 7–8% a year, "the only route out is monetization." His distinction is worth keeping: gold hedges monetary inflation, not CPI, "If you want to protect your income, think about CPI. If you want to protect your wealth, think about monetary inflation" (Julia La Roche Show, Jun 2). Chris Whalen, still "a buyer of precious metals," put it more bluntly: "the Fed has to grow their balance sheet because the federal debt is growing… We may be closer to QE5 than [Treasury Secretary] Besant knows" (Julia La Roche Show, May 30).

Private investor Sultan Ameerali captured why the bulls think the setup is heads-they-win: incoming Fed Chair Warsh "can't raise rates, that would make the deficit unsustainable. You can't really lower it… either run it hot the way Trump wants to or keep it where it is. Either one is a good position for gold to be in" (Mining Stock Daily, Jun 3). Prins is sticking to $6,000/oz by year-end: "I don't see that changing" (Palisades, Jun 3).

The Dissent: It's China, and the Brakes Are On

The most valuable counterweight this week came from Michael Green, who pushed directly against the Western debasement narrative: "The big driver of gold has not been what has been happening from the Fed or from the ECB… It's basically been China," with the Shanghai Gold Exchange now "the marginal price of world bullion." His warning: PBOC liquidity has "fallen off a cliff" in recent weeks, and "if the Chinese authorities hit the brakes on liquidity injections, that will undermine the gold market" (Wealthion, Jun 3). (Note: this episode is titled as a Michael Howell interview but the transcript reads as Green, flagging for transparency.) Tellingly, Howell himself made the same Shanghai-over-COMEX point and confirmed the PBOC "put their foot on the brake quite quickly in the last four to six weeks."

The cleaner bear voice was technician Chris Vermeulen, who calls the move "parabolic" and a "blow-off euphoric phase." His measured-move target is $3,600 gold, about 18% below current, and $39–$40 silver, with GDXJ facing another ~25% downside. He frames it as "about a 50/50 coin toss" between that flush and an $8,000–$8,500 melt-up, "which is why we're standing on the sidelines" (Palisades, May 29). Several bulls would welcome that dip, Tracy Shuchart: "I'd like to see it a little bit lower to buy more" (Mining Stock Daily, May 29).

A recurring near-term headwind: a hawkish Fed. Howell, Green, and Whalen all expect a hike within twelve months, Whalen "wouldn't be surprised to see a majority of the committee in favor of a rate hike in July." Money Metals' Mike Meharry pushed back that even so, "real interest rates are still falling," and "there is still a bull market in gold going on under the surface, but it is being obscured by the smoke of war headlines" (Money Metals, Jun 3).

From the Operators

Two mining CEOs sat down this week, and the read-through is consistent: capital is flowing back to developers, and rigs are scarce because gold is high.

• Newcore Gold (TSX-V: NCAU) CEO Luke Alexander closed a $15M CAD bought deal (~2.5x oversubscribed, upsized from $10M) and expanded the Enchi drill program in Ghana from 60,000m to 80,000m across four rigs, with a PFS due by end of June: "We are on track to have the PFS out by the end of this month." His ground-level tell on the gold environment: "rigs are not the easiest thing to come by" (Mining Stock Daily, Jun 2).
• Radisson Mining (TSX-V: RDS) CEO Matt Manson closed $25M CAD and drilled the never-tested 800m gap at O'Brien (Quebec), hitting 7.5 g/t over 9.7m including 52.75 g/t. His framing of the team: "We're all mine developers… we're here because we see a mine here, not because we see a fun exploration project" (Mining Stock Daily, Jun 1).

On the seniors, Kai Hoffman of Soar Financial made the value case: Q1 2026 margins of "~$3,000/oz" against all-in costs of $1,800–$2,000, with "Barrick, Newmont, net cash position. We haven't seen that in ages." Yet generalist money still won't engage, he relayed a fund manager who "doesn't invest in non-cash-flowing companies" while dismissing Agnico Eagle's billions in free cash flow (Money Metals, May 29).

M&A Watch

The week's activist event: Elliott Management ($80B) published a 39-page letter pushing for a sale of Northern Star Resources, Australia's largest gold miner, citing "world-class assets [that] destroyed value by poor execution," seven guidance misses in four years and KCGM mill costs blown from A$250M to over A$1.5B. Elliott pegs fair value at A$42B vs. a ~A$27B market cap, and names Agnico Eagle, Gold Fields, AngloGold, and Newmont as logical buyers (Mining Stock Daily, Jun 2).

The Tell I'm Watching

Two clocks are ticking against each other. The structural clock, central banks, fiscal dominance, the monetary revaluation thesis, only points one way. The liquidity clock, governed by the PBOC and a possibly-hawkish first Warsh FOMC, can override it for months. If Green and Howell are right that Shanghai is now setting the price, the single most important variable for gold this summer isn't the U.S. deficit, it's whether Beijing takes its foot off the brake.

One housekeeping note: no dedicated royalty/streaming commentary (Franco-Nevada, Wheaton, Royal Gold) surfaced by name in this week's tape, only generic praise for the model's "write-a-big-check" optionality from Ameerali.

Sources are this week's podcast episodes, linked inline. Pundit opinion (analysts, fund managers, newsletter writers) is kept separate from operator/insider commentary (mining CEOs). Nothing here is investment advice.

Food, brands, private label and grocery newsletter for the week of June 4, 2026. Kraft Heinz's North America CMO put all four center-store bear pillars on the table in one breath, private label, SNAP cuts, tariffs, and GLP-1s, while signaling brand spend over deeper promotion and validating the retail-media flywheel.

Food: Brands, Private Label & Grocery

Week of June 4, 2026: A Kraft Heinz CMO just named every bear

The most useful read on center-store demand this week came from inside the building. Kraft Heinz's North America CMO sat down and, without being asked to play bear, ticked off all four of the things keeping center-store shorts in the money. When the executive whose job is to sell you national brands tells you private label, SNAP, tariffs, and GLP-1s are hitting at the same time, you write it down.

TL;DR

• An operator confirmed the bear case. KHC's CMO named private label, SNAP cuts, tariffs, and GLP-1s as concurrent center-store headwinds, framing private-label share gains as structural, not cyclical.
• The lever is brand spend, not promo. Management signaled it won't keep cutting to defend the quarter, read that as marketing dollars over deeper price-offs.
• Ad budgets keep migrating. The same exec validated the CPG dollar flow into Instacart, Walmart Connect, and Kroger Precision Marketing, a quiet positive for CART and the retail-media complex.

What's new

Kraft Heinz NA CMO Todd Kaplan laid out the demand backdrop in plain terms on The Speed of Culture Podcast. (From the Pantry to the Game Day: How Kraft Heinz Keeps Iconic Brands at the Center of Culture, aired June 2, 2026; Kaplan is a sitting operator, host Matt Britton the pundit.) His words:

"Right now it's a very crazy time in CPG. You have the rise of private label as the economic pressures are coming more and more. You have SNAP benefits…changing… You have tariffs coming and going… whether it's GLP-1s, whether it's protein."

That is an insider putting all four bear pillars on the table in one breath. It moves the thesis because it is operator confirmation, not another sell-side desk recycling the elasticity slide. He went further on private label specifically, calling it "the rise of private label as the economic pressures are coming more and more," i.e., structural share migration, not a recession blip that laps out.

The response function matters as much as the diagnosis. Kaplan: "you can't just run a business quarter to quarter or eventually you're going to run out of steam if you just keep cutting." Translation for the model: KHC is signaling brand and marketing investment over another leg of promotional intensity. If you were modeling a price-war race-to-the-bottom across center-store, this is a mild pushback, the national brands would rather spend on demand than torch the price ladder. He cited the 5-year global NFL deal (20+ brands, activated at the Draft in Pittsburgh) and "Power Mac," a protein-and-fiber Mac & Cheese built explicitly for the GLP-1/protein shopper, as where the dollars are going.

The retail-media flywheel got operator validation. Kaplan called Instacart "a huge partner of ours" and said "that lower part of the funnel and e-commerce in particular has been growing like crazy," confirming KHC is leaning into retail media across Walmart.com, Kroger, and Instacart "to help drive basket and conversion." No take rates or attach rates, but advertiser-side confirmation that the budget reallocation into RMNs is still running through mid-2026.

The debate

The standing bull/bear in this space is well rehearsed: volumes recover as pricing laps and cocoa/coffee roll off into 2026 margin relief, with MFCs and retail media making online grocery durably profitable, versus a structural deflation/de-stock reset where record ~21% private label erodes pricing power and hedge lags grind margins.

This week the bear case got the more credible voice. Kaplan's "all four at once" framing is the de-stock/private-label-erosion case stated by the side that has every incentive to downplay it. The bull rebuttal, that pricing laps clean and commodities cooperate, lacked a fresh origin-supply or hedge-roll datapoint to lean on either way. So take the asymmetry for what it is: when the operator voice reinforces the short thesis on volumes while quietly defending the margin path (spend, don't slash), the cleaner read is selective, bearish center-store volumes, more constructive on the players capturing the ad dollar.

Read-throughs

• Private-label names (THS, plus Kirkland/Great Value/Kroger Our Brands): A national-brand CMO calling private-label gains "structural" is a tailwind tell for the co-manufacturers and store-brand programs.
• Retail media / online grocery (CART, and WMT Connect / KPM): Operator confirmation that CPG conversion dollars keep flowing in, incrementally positive for Instacart's ad take.
• Center-store CPG (KHC and peers, CAG, CPB, K, MDLZ): The "invest, don't cut" posture caps how much promo relief flows to the P&L near term; watch whether peers echo it into next print.
• GLP-1 reformulation: "Power Mac" is a template, protein/fiber line extensions are now an offensive play across center-store, not just a defensive one.

What to watch next

The hedge-lag-into-COGS story on cocoa and coffee sits where it did, lean on prior origin data until fresh tape arrives. Kroger/Albertsons fallout and format share, plus foodservice read-throughs, are unchanged for now. These are the threads most likely to produce next week's headline.

AI drug discovery newsletter for the week of May 28 to June 4, 2026. Isomorphic Labs' $2.1B raise at a reported ~$10B valuation crystallized the bull/bear fault line, with 173 AI-originated programs in the clinic and none yet approved, while Eli Lilly's CAIO laid out a de-risking-not-speed thesis and Recursion and Schrödinger rallied without a word of podcast coverage.

AI Drug Discovery

Week of May 28 – Jun 4, 2026: 173 programs, zero approvals, the $10B question AI biotech can't yet answer

TL;DR

• The week's center of gravity was Isomorphic Labs' $2.1B raise at a reported ~$10B valuation, a pre-clinical company with no approved drug, which crystallized the bull/bear fault line in AI drug discovery. The hinge statistic: 173 AI-originated drug programs are in clinical development and none has yet been approved The Heart of Healthcare.
• The real debate has moved past "does AI work" to where in the value chain it pays off, discovery vs. the clinic, and whether technology or regulation is the binding constraint.
• Eli Lilly (LLY) was the only coverage name with both substantive AI strategy commentary (CAIO Thomas Fuchs) and a heavy week of business development, four licensing/discovery deals, closing at an all-time-high-adjacent $1,125.38 (+4.3% on the day).
• Recursion (RXRX, $3.80, +9.5%) and Schrödinger (SDGR, $15.85, +6.2%) rallied hard on the day but were entirely absent from the podcast conversation, worth flagging given how loud the broader AI-biotech narrative was.

What's new

Isomorphic Labs dominates the tape. On The Heart of Healthcare, digital-health investor Hallie Tecco walked through the DeepMind spinout's $2.1B round, backed by VCs and sovereign wealth funds, at a valuation she called "astronomical for a pre-clinical discovery company" (~$10B). Its named pharma partners: Novartis, Eli Lilly, and Johnson & Johnson The Heart of Healthcare.

The regulatory backdrop got messier. Per the same episode, the FDA launched a real-time clinical-trial review pilot with AstraZeneca and Amgen, cloud-based review of safety signals and endpoints as they accrue, which the FDA's chief AI officer claimed could cut trial duration in half. But FDA Commissioner Marty Makary resigned (reportedly over pressure to approve flavored e-cigarettes), and co-host Steve Krause relayed that biotech investors "are just kind of almost beside themselves. They need to have some predictability in this agency" The Heart of Healthcare.

Frontier-AI labs keep wiring into pharma. Tecco noted Anthropic appointed Novartis's CEO to its board, a signal that foundation-model companies are taking drug discovery seriously The Heart of Healthcare. Separately, on Possible, Reid Hoffman pitched his startup Manus AI as a "drug discovery factory for monopolies," claiming it has "already discovered novel chemistry" and replicated a decade of prior work "in hours" via a proprietary RL system he called "SIDRL" Possible. (Caveat: Hoffman is a Manus co-founder, and no candidates or financials were disclosed.)

The debate: does AI actually deliver ROI in pharma R&D?

This is no longer a bull-vs-bear binary; it splits on three axes.

Where does AI pay off? Eli Lilly's Chief AI Officer Thomas Fuchs drew the sharpest line. AI's value, he argued, is de-risking, not speed: "The goal is not to accelerate that dramatically because... biology has to play out. You cannot accelerate biology... What you can do is you can de-risk it by actually coming up with better molecules, safer molecules" The AI in Business Podcast. Tecco made the bear-side corollary: AI names cluster in discovery, "not the most expensive phase", the costly work is trials, cohort selection, and safety/efficacy, "where biology still does what biology does", leaving a capital gap: "who's going to fund the expensive piece?" The Heart of Healthcare.

Tech or regulation as the binding constraint? Logos LP's Peter Mantas delivered the week's most contrarian framing on This Week in Intelligent Investing. He is wildly bullish on the input, "AI just brings the cost of knowledge to zero... the number one beneficiary [is] biotech", predicting "the biggest biotech bubble we've ever seen, make 2021 look like child's play." Yet he insists the bottleneck is not technology: "The only way you break Eroom's Law is changes in regulation. Not technological disruption... if our regulators and policymakers don't address that problem, then AI, all it does is just create a queue" This Week in Intelligent Investing.

Is the hype redeemable? The blunt skeptic was Peyton Greenside, CEO of Big Hat Bioscience, quoted via Stat News: "AI in drug development is powerful, but it's overhyped", she doubts AI compresses the full development timeline the way the narrative claims The Heart of Healthcare. Against that, Hoffman leans on TAM: drugs are "essentially legal 20-year-long monopolies," and he uses GLP-1s, multiple players each generating tens of billions, as proof the category isn't winner-take-all Possible.

One quieter but consequential disagreement: Fuchs's architectural view that the productive engines are "molecular models, diffusion models, generative flow models", not LLMs, which Lilly uses "mostly just to orchestrate work", cuts against the "foundation models will solve biology" framing implicit in much of the bull case. "Language models will never be able to be actually a good scientist," he said The AI in Business Podcast.

Stocks in play

Eli Lilly (LLY), $1,125.38, +4.3%, ~$1.06T mkt cap. The clearest read on how an incumbent operationalizes AI. Fuchs disclosed Lilly is deploying an NVIDIA DGX SuperPOD B300 with 1,000 B300 GPUs, "the most powerful supercomputer in our industry", and framed Lilly's decades of unpublished negative experimental data as a structural moat: "we know a lot of things that do not work, and that helps us... build better molecules" The AI in Business Podcast. Its TuneLab hub hosts validated internal and partner models. The fundamental tape was busy too: Lilly's Retevno hit its primary endpoint in a Phase 3 NSCLC trial (83% reduction in recurrence/death vs. placebo) and the company signed four BD deals this week, including a discovery collaboration with Haisco worth up to $3.05B and an RNA-editing deal with Ascidian worth up to $1.9B.

Recursion (RXRX), $3.80, +9.5%, $1.7B mkt cap. Shares popped on the day but trade near the low end of a $2.77–$7.18 52-week range, and the company is loss-making (trailing EPS -$1.16). Notably, RXRX drew zero podcast commentary this week even as Isomorphic's raise dominated the AI-biotech conversation, a narrative-share gap to monitor.

Schrödinger (SDGR), $15.85, +6.2%, $1.2B mkt cap. Also rallied (off a $10.95–$27.63 range, trailing EPS -$1.40) with no podcast coverage. The physics-based platform story simply wasn't part of the week's discourse.

Read-throughs

• Isomorphic's ~$10B mark is the comp that pressures the publics. If a pre-clinical platform with no approval commands ~$10B private, it sharpens, rather than supports, scrutiny of public AI-biotech multiples; the bear read (Tecco, Greenside) is that discovery-stage value is being capitalized before the expensive clinical proof exists The Heart of Healthcare.
• LLY is a partner, not a pure-play, and that's the point. Lilly sits inside Isomorphic's partner roster and runs its own B300/TuneLab stack, capturing AI optionality while its GLP-1 franchise funds the expensive clinical phases others can't The AI in Business Podcast. Hoffman's own GLP-1 market-structure argument inadvertently underwrites Lilly's incumbency Possible.
• Regulation, not models, may set the clock. Mantas's "AI just creates a queue" thesis plus the Makary resignation argue that FDA throughput and predictability, not algorithmic progress, gate near-term value capture. The AstraZeneca/Amgen real-time-review pilot is the offsetting positive to watch This Week in Intelligent Investing.
• "De-risking, not acceleration" reframes the KPI. If Fuchs is right, the metric that matters isn't shorter timelines but higher Phase 2/3 success rates, a slower-burn, harder-to-see catalyst than the market's "compress a decade to two years" narrative The AI in Business Podcast.

What changed vs last week

This is the inaugural issue of AI Drug Discovery Weekly, so there is no prior baseline to compare against. Going forward this section will track week-over-week shifts in narrative, valuation, and the bull/bear balance. Two markers to carry into next week: (1) whether the 173-programs / zero-approvals statistic moves, and (2) whether Recursion or Schrödinger re-enter the podcast conversation after a week of silence despite sharp share-price moves.

Payments, fintech and crypto newsletter for the week of May 25 to June 1, 2026. Enterprise stablecoin volumes turned into real P&L this week, ZeroHash lined up an OCC trust charter aimed straight at Circle's regulatory moat, and the disintermediation-vs-co-option debate got named voices on both sides.

Stablecoins Eat Banking

Week of May 25 – Jun 1, 2026: Enterprise stablecoin rails go live, Circle's moat thins

TL;DR

• Enterprise stablecoin volumes stopped being a slide and became a P&L. Jeeves disclosed >50–60% of its cross-border payment volume settles on USDC, TPV scaling from ~$400M two years ago to >$3B today with ~$6B guided by YE26. Rain (Dragonfly) hit ~$80–90M ARR growing 40% month-over-month. Visa stablecoin settlement is reportedly "doubling every few months."
• ZeroHash is about to get an OCC national trust bank charter engineered around the GENIUS Act $10B threshold and is signing the marquee logos (Morgan Stanley, Stripe, Interactive Brokers, OnePay/Walmart, Gusto). That is a direct, named challenge to CRCL's regulatory-moat narrative.
• Clarity Act floor vote has slipped from June to July as the consensus base case. Jamie Dimon went on Fox Business and explicitly vowed to fight the bill; JPM simultaneously filed a GENIUS-compliant tokenized treasury MMF. Classic dual posture.

What's new

1. Jeeves' GENIUS-driven pivot, operator confirmation, not narrative. Dalip Tasman (CEO, Jeeves) on The a16z Show (2026-05-28): "As soon as the Genius Act passed... Stablecoin, stablecoin founder mode. We're going to go build this whole thing." First clean operator-level evidence the GENIUS Act is translating into enterprise, not retail, deployment decisions. Jeeves now holds full Mastercard principal membership in MX/BR/CO with ARS-to-USDC-to-MA-swipe and zero FX fee. The forward plan, collapse 25 country pre-funded FX pools into a single USDC pool, then collateralize $1–3B of receivables on-chain, is a concrete signal of institutional working-capital demand for USDC.

2. ZeroHash's OCC charter is the CRCL-moat event of the quarter. Edward Woodford (ZeroHash) on Fintech Business Podcast (2026-05-27): trust charter coming "very, very shortly," explicitly designed as white-label stablecoin issuance for institutions trying to scale past the GENIUS $10B threshold without becoming a bank themselves. Disclosed live clients: Morgan Stanley, Stripe (payouts to GCash/Nubank/Revolut), Gusto, Interactive Brokers, Public.com, TastyTrade, OnePay (Walmart spinout). In two months of the IBKR stablecoin account-funding product alone, customers in >100 countries funded accounts via stablecoins. The Circle "we own the OCC pathway" thesis just got a credible second entrant aimed at the largest customers.

3. State Street goes live (not pilot) on-chain. Kim Hartfeld (Global Head of Digital and Cash, State Street IM) on Tokenized (2026-05-25): launched the State Street Galaxy On-Chain Liquidity Sweep Fund, first live institutional product, with Galaxy Digital sub-advising. "We cannot underestimate the impact that Genius has had on this space." Pull-quote from Hartfeld on whether stablecoins are disintermediating banks: "not yet." That is the co-option camp's flag in the ground: incumbents move on-chain and try to keep the $500B cash AUM.

4. SoFiUSD is the first public live test of the GENIUS interest-bearing workaround. Nic Carter (Castle Island) on On The Brink with Castle Island (2026-05-29): SoFiUSD is engineered as a hybrid, stablecoin off-platform, tokenized deposit on-platform, because "you can't pay interest with a stablecoin under the new interpretation" but you can deliver yield via a deposit token. First articulated bank-chartered playbook for routing around the GENIUS interest ban. Same week, Cash App (SQ) finally launched USDC stablecoin rewards. Walsh: "They should have been doing this at least five years ago."

5. Dimon goes public, and JPM files anyway. Thinking Crypto (2026-05-30) clipped Dimon on Fox Business: "It allows them to effectively pay interest on deposits, stablecoins or something like that without the protection... the banks will not accept it that way... if we lose, we lose and we'll live." He also conceded "stablecoin can be a legitimate payment system." The host flagged a JPM filing for a GENIUS-compliant tokenized treasury MMF (unverified). Read: JPM is opposing the bill while building the products that the bill would enable.

The debate

Steel-manned, the cleanest opposed pair is Rob Hadick (Dragonfly) vs Kim Hartfeld (State Street), both on tape this week.

Disintermediation (Hadick, Empire, 2026-05-29): "Global banks that serve SMBs and retail consumers far better than have existed ever... it's going to happen because of stable coins." Rain at $80–90M ARR / 40% MoM, Visa settlement doubling every few months, and Jeeves at >50% USDC volume are the live receipts. The economics currently extracted by issuer banks and correspondent rails migrate to new networks and ultimately to merchants and customers.

Co-option (Hartfeld, Tokenized, 2026-05-25): Intermediary layers are "not yet" being cut out: institutions move on-chain through their own products and keep the customer. State Street launches the on-chain sweep fund. Mastercard takes a NY BitLicense. Visa, Stripe, Standard Chartered run validator nodes on Tempo. MoneyGram is the anchor remittance validator with 500,000 physical cash-out locations. The infrastructure layer goes on-chain; the franchise layer doesn't move.

Carter sharpens the bear-for-banks angle: deposit-token structures (SoFiUSD, JPMD) are defensive, banks forced to compete with their own deposit franchise under the GENIUS interest ban. The Tokenized panel reads the same fact pattern as offensive, banks capturing the new infrastructure layer. Both camps agree the structures are emerging. They disagree on who keeps the spread.

Stocks in play

• CRCL (Circle), QUIET this week at the issuer-economics level. Bull: USDC the default rail at Jeeves and Cash App; rails-doubling at Visa. Bear: ZeroHash trust charter directly attacks the OCC moat; euro-stablecoin traction "minimal" per Deaton (Tokenized) because MiCA reserves are unprofitable; no episode this week defended CRCL NIM under Fed cuts. Catalyst: GENIUS rulemaking on BSA/AML, plus any further large-institution white-label win for ZeroHash.
• COIN (Coinbase), QUIET. Only tangential mention. Catalyst: any restatement of the 50/50 USDC reserve-yield split as Fed cuts compress reserve NIM.
• V (Visa). Bull: settlement volume "doubling every few months" (Hadick); validator on Tempo; on-network strategy intact. Bear: Jeeves-style principal-member fintechs issuing under their own bin with zero FX fee compress issuer-bank economics. Watch: VTAP enterprise pilots converting to live.
• MA (Mastercard). Bull: NY BitLicense received this week; MTN footprint extending. Bear: same issuer-bank compression dynamic as V. Watch: MTN settlement TPV disclosure.
• JPM. Bull: Dimon's posture is delay-while-we-build; Kinexys/JPMD live; tokenized treasury MMF in the queue. Bear: deposit-token cannibalizes own franchise; Clarity Act passage is a thesis hit. Watch: Senate floor vote.
• SOFI. Bull: first US bank-chartered issuer to publicly thread the GENIUS interest-prohibition needle via SoFiUSD's hybrid structure. Bear: regulatory interpretation could narrow the workaround. Watch: SoFiUSD on-platform balances next print.
• PYPL (PYUSD), QUIET on tape despite material news in the window (Solana launch, 70-market expansion per web context). Silence on the actionability front is itself the signal.
• Tether. Bull: Roel's concentrated thesis, durable remittance/regulatory-arb wedge. Bear: GENIUS foreign-issuer rulemaking still pending; USAT firewall untested.
• HOOD. AI agent only; stablecoin-tangential. Effectively QUIET on the stablecoin axis.
• SQ/XYZ. Cash App USDC rewards live; reverses prior posture.
• GLXY. Sub-advisor on the State Street fund; NY BitLicense; Novogratz publicly pressuring Senate.
• MGI. Anchor remittance validator on Tempo, Stripe streaming partnership. The "remittance companies die" trade just got harder to hold.
• QUIET this week: COIN, CRCL (economics), PYPL, FI, FIS, GPN, C, BAC, WFC, GS, BK, Anchorage, Fireblocks.

Read-throughs

• Card networks / interchange: V and MA are not being disintermediated this week, they are issuing licenses, running validator nodes, and getting NYDFS sign-off. Compression risk migrates to issuer banks, not networks.
• Money-center and correspondent banks: Jeeves' >50% USDC and the planned single-pool model is the live correspondent-banking compression. JPM's stance suggests this is now a recognized P&L threat.
• Payment processors (FI, FIS, GPN): Completely silent on tape this week. That is conspicuous given Stripe's Tempo build-out around them.
• Custody / exchange infrastructure: ZeroHash is the consolidation story, OCC trust plus named institutional clients. BitGo is marketing "stablecoin-as-a-service" against GENIUS. Anchorage and Fireblocks quiet.
• T-bill demand from reserves: Not directly quantified this week, but Carter's framing of GENIUS stablecoins as "effectively government money funds" is the cleanest statement of the demand mechanism, reserve composition is now statutorily anchored to USTs.

What changed vs last week

This is issue one of Stablecoins Eat Banking, so there is no prior week to update or contradict. The baseline is set: enterprise stablecoin rails are live and measurable, ZeroHash is positioned to challenge Circle, Clarity Act timing is July not June, and the disintermediation-vs-co-option debate now has named voices on both sides with live products to point to.

QSR and restaurant newsletter for the week of June 1, 2026. The NRA's own survey now puts restaurant-level margins at 2-4%, and a private-operator CEO articulates the fast-casual bifurcation thesis as the sector splits into a hospitality leg and an efficiency leg.

QSR & Restaurant Value Wars

Week of June 1, 2026: Industry Margins Are 2-4%, Fast Casual Splits in Two

Two things landed on the pods this week that I think actually matter. First, the NRA's CEO went on tape and put a number on industry profitability that is 100-200 basis points below the historic norm: the trade body's own data now says restaurant-level margins are 2-4%, not 3-5%. Second, a private operator with $3.76M AUVs sat down with Sam Oches and said out loud what the public-market sell side is still tiptoeing around: fast casual is breaking into two structurally different businesses, and the one that wins on hospitality and ticket is pulling away from the one that wins on speed and discount. If you own anything from CMG to CAVA to SG to CMG-adjacent franchisees, this is your week to do the bifurcation work.

TL;DR

• Industry profitability is now 2-4%, per the NRA's State of the Industry survey. That's compressed from a historic 3-5% range, and the NRA's CEO said it on tape: "1 percentage point is huge." Re-underwrite your franchisee cash-on-cash assumptions (A Deeper Dive, "How restaurants can handle the K-shaped economy").
• Premium fast casual is winning at $3.76M AUVs and ~20% unit growth, and the operator is doing it with zero discounting and no loyalty program. Mendocino Farms' CEO and CMO laid out the bifurcation thesis, with Sam Oches landing the line of the week (Take-Away with Sam Oches, Mendocino Farms CEO and CMO).
• Red Lobster's "comeback" is a live case study in casual-dining K-shape pain, and the alt-data feeds are disagreeing by 19 points on whether the new value promo is working. Read-through to DRI, EAT, BLMN, CAKE (Art of Supply, "Red Lobster's Comeback Gamble").

What's new

1. The NRA's own number on margin compression, the most important industry data point of the quarter. On A Deeper Dive, "How restaurants can handle the K-shaped economy" (May 27, recorded at the NRA Show), Michelle Korsmo, CEO of the trade body that surveys roughly a million operators a year, laid it out as cleanly as it gets:

"Profitability is normally 3% to 5%. Our last state of the industry survey shows profitability 2 to 4%. And when you're at that kind of tight margin, 1 percentage point is huge."

That is a 100-200 basis point compression at the industry level, and Korsmo paired it with the K-shape framing in operator vocabulary, not sell-side vocabulary: "Those that are making less than $50,000 are really being hurt by the affordability crunch to a point where it's changing a lot of really normal choice behaviors." On a typical $1.5M box, 1 point of restaurant-level margin is $15K, the difference between a remodel cycle and a franchisee phone call to the regional manager.

2. The fast-casual bifurcation thesis got its operator-CEO articulation. On Take-Away with Sam Oches, "Mendocino Farms CEO and CMO on building the future of fast casual" (May 26), Kevin Miles ran the numbers: Mendocino Farms grew ~20% to ~$300M in revenue last year, ~$3.76M AUVs per the Technomic Top 500, ~100 units finishing 2026, then "16 locations this year and 18 next year… a little north of 20% unit growth." All corporate-owned. Then he framed the strategic split:

"Fast casual is sort of breaking into two parts… you've got the dish up, the speed, the go through a line, build your own, make it more like this efficiency… and then there's going to be this fast casual with hospitality and plates and silverware and bowls and service and beer and wine and this elevation or call it premium if you will."

CMO Alicia Mowder added the anti-LTO posture that is the entire pitch in one sentence: "We don't do discounts. We're not a discount driven brand. We're not focused on any of the kind of standard churn and burn LTOs." Sam Oches closed it with the framing the public-market sell side hasn't yet adopted but should:

"I don't think it's any coincidence that two of the hottest brands in America are Chili's and Taco Bell. And I think they represent the two sides of that bifurcation."

Pin that quote. If the bifurcation is real, EAT (Chili's experience trade-up) and YUM-Taco Bell (efficiency-and-value trade-down) are both winners, and the squeezed middle, Panera, SG, fast-casual hybrids without a clear posture, is where the underperformance lives.

3. The casual-dining K-shape has a live case study, and the alt-data feeds are giving you opposite reads. On Art of Supply, "Red Lobster's Comeback Gamble" (May 28), host Kelly Barner walked through the post-bankruptcy financials: U.S. sales of $1.6B across 520 locations, down 6% from 2024, and a $52M net loss in FY2025. The buy-side-relevant part isn't Red Lobster itself (Fortress owns it, it's private), it's the alt-data divergence on the new Endless Shrimp value promo. Per the episode:

"According to Placer.ai, visits to Red Lobster locations have increased by more than 18% since the promotion began."

But Advan Research showed traffic "down almost 1% during the first week." That's a 19-point spread on the same data window across two of the most widely used alt-data providers. If you have been triangulating CMG or BLMN traffic via either Placer or Advan for the upcoming print, this should be a fire-alarm-level reminder to either run both or weight neither too heavily.

Same episode: Barner pulled the BLS print, "food away from home rose 3.6% over the last 12 months. With full-service restaurants… it's up 3.8%." Useful pricing-power benchmark for DRI, EAT, BLMN, CAKE.

4. Korsmo also said the quiet thing about Washington and about drive-thru AI. On USMCA renegotiation: "anybody that says they have confidence when working with the Trump administration is lying." That is as blunt as a trade-body CEO gets on the record, and it crystallizes the real food-cost tail risk on names with material Mexican-produce dependence: CMG (avocado), YUM (Taco Bell produce), and the downstream pass-throughs at SYY, USFD, PFGC. On drive-thru AI: "We're not necessarily seeing a great consumer reaction on AI in the drive-thru all the time because they want to talk to a person. So I'm going to use my technology spend somewhere else." That is a modest negative for the Presto / Yum-voice-AI / Wendy's FreshAI narrative: operators are reallocating tech budget toward predictive scheduling and ordering, not voice front-end.

The debate

Bull side of bifurcation. If Mendocino's Miles is right that fast casual is structurally splitting, then the long trade is both legs: CMG / CAVA / WING on the speed-and-throughput side, EAT (Chili's experience trade-up) on the casual side. The premium fast-casual leg sustains 20%+ unit growth at $3.5M+ AUVs without discounting; the efficiency leg defends share on value-meal arithmetic. The losers are the brands that try to straddle: fast-casual hybrids without a clear posture, casual-dining boxes that haven't picked a lane.

Bear side. Korsmo's 2-4% margin number says the entire operator base is one bad COGS quarter away from contraction, regardless of which lane they're in. The Red Lobster framing, Bloomberg-cited "20% chronically unprofitable restaurants draining away most of the profit that the other 80% of the chain can bring in," is a portrait that fits every casual-dining chain at the tail of its real-estate book. If BLS food-away-from-home is +3.8% and traffic data is contested at best, then pricing power is being supplied to defend revenue rather than build it. Add USMCA tail risk on Mexican produce and the bear has a clean line: margin floor, not margin expansion.

The names in play

CMG and CAVA, bull, with a caveat. Mendocino's bifurcation thesis is supportive of both; they live on the same side of the split. But Sam Oches noted both posted negative comps in 2025, and the burden of proof is on the next traffic print to show throughput recovery vs. just ticket. The CMG avocado-from-Mexico tail risk got a fresh asterisk this week courtesy of Korsmo's USMCA line.

EAT (Brinker), bull on bifurcation. This is the second week in a row the trade-press chorus has held up Chili's as the affirmative case for the casual-dining experience trade-up. Last week it was Maze and Byrne with the parental-gaze framing; this week it's Sam Oches naming Chili's as one of two brands carrying their side of the bifurcation. The Niccol-style operational reset story has now been ratified by enough independent voices to call it consensus among the people who actually watch this sector.

YUM (Taco Bell), bull on the value/efficiency leg; Pizza Hut still the drag. The bifurcation framing helps Taco Bell directly. Pizza Hut still has last week's -8.2% comp problem sitting on it.

DRI, BLMN, CAKE, bear watchlist. The Red Lobster post-mortem is not a Red Lobster problem; it is a casual-dining tail-real-estate problem dressed up as one operator. If 20% of any chain's boxes are chronically unprofitable and dragging down the other 80%, the refranchising / pruning case strengthens with every cycle of K-shape pressure.

TOST, neutral; aggregator squeeze thesis still intact from last week. Korsmo's drive-thru-AI commentary is a slight cross-current to Toast's voice-AI ambitions, but the core anti-aggregator thesis from last week's Counter Global pitch is undisturbed.

Read-throughs

• Alt-data providers. Placer.ai +18%, Advan -1% on Red Lobster Endless Shrimp. If you run a quantamental restaurant pod, this is the week to add a divergence check. Anyone whose model triangulates traffic through one provider should be hedged with the other or rebuilt around card-data feeds.
• Suppliers (TSN, PPC, CALM, SYY, USFD, PFGC). BLS full-service food CPI of +3.8% YoY says pricing power is still being passed through at the operator level. USMCA renegotiation risk is the macro variable Korsmo just elevated to top-of-list. Pass-through suppliers (SYY, USFD, PFGC) are insulated; primary producers with cross-border exposure are not.
• Franchisees. A 2-4% industry margin is a refranchising signal for the large systems and a buyer's signal for disciplined private operators. Mendocino's 100% corporate model is the opposite trade: it works because their box prints $3.76M AUVs and they can afford to keep it on-book.
• Loyalty platforms / digital. Mendocino is the second operator I've heard this month say their brand doesn't need a loyalty program. If the premium-fast-casual lane is making that bet credibly, the consensus "loyalty penetration drives ARPU" thesis at SBUX, CMG, and MCD needs a sanity check on what it actually delivers beyond first-party data.
• Drive-thru AI. Korsmo's "consumers want to talk to a person" framing is the most candid pushback I've heard from an industry voice. Mark Presto and the Yum voice-AI thesis down a half-notch.

What changed this week

Last week was about pizza category breakage and the Toast anti-aggregator thesis. This week the conversation moved up one level on both axes: the NRA put an industry-wide margin number on the table (and it's worse than the sell side has been modeling), and a credible private-operator CEO articulated the fast-casual bifurcation that has been showing up in scattered comp prints for two quarters. If you're long the squeezed middle, this week made your position harder to hold; if you're long either end of the bifurcation barbell (Taco Bell on one side, Chili's on the other), the case got materially stronger.

Pharma and biotech newsletter for the week of May 28 to June 1, 2026. FDA Commissioner Marty Makary resigns and biotech loses its predictability anchor, while ASCO 2026 puts oncology back center stage and operators name the Inflation Reduction Act as the forcing function behind a roughly $75B pharma M&A wave.

The Biotech Patent Cliff & M&A

Week of June 1, 2026: Makary Out, ASCO Ignites a Pharma M&A Wave

TL;DR

• FDA Commissioner Marty Makary resigned after roughly a year, reportedly over White House pressure on flavored e-cigarette approvals. Biotech investors are "beside themselves," per The Heart of Healthcare, the regulatory predictability anchor is gone.
• ASCO 2026 kickoff put oncology back center stage. Roughly $75B of pharma M&A YTD 2026 cited on CNBC Fast Money, with the Inflation Reduction Act explicitly named as the dealmaking catalyst: IRA is now the M&A narrative, not just the margin narrative.
• Quiet week on the IRA Round 2 file itself. Zero podcast discussion of the 15-drug 2027 list, the Part B inclusion mechanism, the EPIC Act, MFN tariffs, or PBM reform. No GLP-1 negotiation commentary either. Plan accordingly into Q2 prints.

What's New

FDA commissioner resigns; biotech loses its predictability anchor. Hallie Tecco and Steve Krause spent most of "Digital Health Download" on FDA chaos. Makary lasted about a year; Krause, an operator-side digital-health investor, was blunt: "I know my friends who invest in biotech, it's like they're just kind of almost besides themselves. They need to have some predictability in this agency." Chris Klomp is reportedly involved in selecting the next commissioner. Tecco's framing was bleaker still: "Every single FDA decision has really come down to being something that's a political or cultural debate. We can't just look at the data and the science anymore" (The Heart of Healthcare, June 1, 2026). This is the week's single biggest catalyst: every clinical-stage and label-expansion thesis just got a wider error bar.

IRA explicitly named as the M&A catalyst. On CNBC's Fast Money ASCO setup, biotech operator John Flavin (CEO, Portal Innovation) tied the deal flurry directly to the negotiation framework: "the Inflation Reduction Act has driven a lot of pharma into making deals as well because that window for being able to monetize the huge investment is shortening." He pegged YTD 2026 pharma M&A at roughly $75B with ~30% of licensing flowing through Chinese assets, predominantly oncology (CNBC Fast Money, May 29, 2026). Numbers are unverified, but the narrative attribution matters: operators are now openly naming IRA as the forcing function.

Keytruda patent cliff back in retail tape chatter. Steve Grasso on Fast Money: "If you look at the patent cliff and you look at Merck in particular losing Keytruda…" No new data on the subcutaneous Keytruda Qlex line extension, the small-molecule-vs-biologic Round 2 question that matters for the franchise. But cliff anxiety is now retail-tape material, which historically front-runs sell-side downgrades by a quarter (CNBC Fast Money, May 29, 2026).

CMS ACCESS model went live: UNH, CVS, CI, HUM, CNC all aligned by 2028. The chronic-care payment model selected 150 providers/digital-health companies for recurring Medicare payments. The aligned payer list is the read-through; notably, Hinge Health CEO Dan Perez publicly opted out, calling it a risk to "one of the most vulnerable patient populations." On Medicaid, Krause warned the "one big beautiful bill" cuts "hasn't really been even felt yet," provider rate cuts and eligibility redeterminations don't bite until 2027 (The Heart of Healthcare, June 1, 2026).

The dog that didn't bark. Zero podcast discussion this week of the IRA Round 2 selected list, Part B inclusion (the 2028 mechanism), the EPIC Act, MFN executive orders, pharma tariffs, PBM reform, or biosimilar uptake. GLP-1 Medicare pricing also absent. This is a "no debate" week, not a "no signal" week: the policy file went quiet while the tape rotated into ASCO setups and FDA leadership.

The Debate

Steel-man bull: manageable modeled headwind. Round 1 MFPs are already in 2026 plan formularies; the cash-flow hit is in the numbers and largely behind us. Round 2 adds 15 drugs effective 2028, a 2027 P&L event, fully discountable, and the buyside has had 18 months to model it. Flavin's framing actually argues IRA is creating shareholder value by forcing portfolio refresh and accelerating M&A. FDA chaos hurts clinical-stage biotech far more than large-cap branded pharma carrying fully approved, reimbursed franchises.

Steel-man bear: structural US margin compression. A politicized FDA turns label expansions and lifecycle extensions, the bridge mechanism large pharma uses to defend post-LOE franchises, into coin flips. Layer on the still-live MFN executive orders and tariff threats (no fresh commentary this week, but the policy stack hasn't gone away) and US gross-to-net erosion compounds. Round 2's expansion to Part B physician-administered drugs widens the kill zone meaningfully: Keytruda IV is the obvious 2030 target, and the subcutaneous conversion strategy is now an FDA-political question, not just a regulatory one. The small-mol-vs-biologic R&D pullback is real even if no executive said so on tape this week.

Stocks in Play

• LLY: Bull: ASCO setup constructive; Crossbridge Bio ADC tuck-in and vaccine deal expand pipeline; Isomorphic Labs AI partnership cited as a real edge. Seymour and Flavin both bullish on tape. Bear: Trulicity already in MFP; Mounjaro/Zepbound Medicare exposure compounds annually. Watch: ASCO data flow over the next two weeks.
• NVO: Bull: Feinerman: "I just can't believe how cheap it is." Seymour long. Bear: Seymour again: "perennial disappointment at this point… They should do an acquisition. They've tried." GLP-1 negotiation timing remains the overhang. Watch: M&A activity; Ozempic Medicare spend trajectory into Round 3.
• PFE: Bull: Seymour: "I'm hanging tough on Pfizer, who again has an interesting flag planted in the oncology space." Flavin cited an alleged "up to $10 billion" ADC BD deal, unverified. Bear: Eliquis already negotiated; Ibrance Round 3 risk; oncology pivot still unproven. Watch: confirmation (or refutation) of the Flavin ADC number.
• MRK: Bull: Moderna/Merck melanoma vaccine progressing. Bear: Grasso explicitly flagged the Keytruda cliff; subcutaneous conversion now carries political dependency on the next FDA commissioner. Watch: Keytruda Qlex regulatory tone post-Makary.
• JNJ: Bull: Justin Klein on InvestTalk framed it as "a value stock. Good one to own over the long, long term," citing ~22x current / ~19x forward P/E, ~7%/10% EPS growth, ~26% ROE. Isomorphic Labs partner. Bear: Stelara biosimilar erosion accelerating; Imbruvica in MFP. Watch: Q2 print for MedTech vs Pharma divergence.
• AZN: Named in the FDA real-time AI trial review pilot; the agency's chief AI officer suggested trials "could compress overall trial duration… they think they can cut it in half potentially." Bull-skewed for Tagrisso franchise defense. Watch: pilot scope updates.
• BMY, ABBV: Not discussed on tape this week. No new datapoints.

Read-Throughs

PBMs / managed care (CVS, CI, UNH, HUM, CNC): All aligned with the CMS ACCESS model by 2028, a soft positive for incumbent payers, but the bigger Medicaid story is the 2027 rate cuts and redeterminations no one has fully modeled. No PBM-reform-specific commentary this week (The Heart of Healthcare, June 1, 2026).

Biosimilars / TEVA: No coverage. Notable absence given live Stelara dynamics.

Small-mol vs biologic R&D mix: Indirect read, the ADC/biologic skew in Flavin's M&A description is consistent with the pill-penalty thesis, but no executive said so on tape this week.

Ex-US strategy: The single most striking ex-US datapoint was Flavin's claim that ~30% of licensing this year is from Chinese assets. Pharma is increasingly sourcing from China, not just selling there.

What Changed vs Last Week

This is the inaugural run of the newsletter. No prior baseline.

G10 FX newsletter for the week of June 1, 2026. Across the FX tape the sell-side capitulated on the euro, the Bank of England edged dovish, and the cheapest vol in three years sits right under the yen, while CHF stayed conspicuously silent.

G10 FX: EUR, GBP, CHF & the Yen Carry

Week of June 1, 2026: Wall Street Bails on the Euro

Three things rhymed across the FX-relevant pods this past week: the sell-side capitulating on the euro, a quiet dovish pivot at the Bank of England, and a tail-risk drumbeat that the cheapest vol in three years sits right under the yen. CHF was conspicuously silent. Treat that silence as data, not omission.

TL;DR

• JPM cut its H2 2026 €/$ forecast from ~1.20 to 1.13–1.15 on stagflationary EU PMIs and a real-yield decoupling.
• Governor Bailey is publicly accepting above-target UK inflation as the labour market cracks, the biggest BoE tonal shift in months.
• 1M ¥/$ vol sits below 7% while Michael Gayed warns of an "Aug-2024-redux" carry unwind; cross-yen looks under-priced.

What's new

1. JPM bails on the euro. Ineska Kristovova let it slip on JPMorgan's At Any Rate, EM Fixed Income (May 28): "Before they were looking at 120 ranges and now it's 113, 115 in the second half of 2026." That is a 5–7 big-figure haircut from one of the largest dealer desks. Meera Chandan reinforced it the next day on At Any Rate, Global FX (May 29): short-term fair value sits at €/$ 1.08–1.14, and her team has cut eurozone growth for "the 7th consecutive time in three months."

2. Bailey edges dovish. Per Jeff Snider on Eurodollar University (May 31), Bailey signalled via Bloomberg that policymakers "may have to accept inflation staying above their target… because the economy and labour market are indeed weakening." Snider's words: "That's a huge shift from a leading hawkish institution." The front of the gilt curve has barely moved on it.

3. France cracked, and Europe noticed. Pat Locke on JPM's Global FX (May 29): "The French PMIs last week were just terrible. And that was confirmed today in the first quarter GDP print for France, which contracted not unexpectedly." Snider added French household spending −0.5% in April and Germany cutting 2026 growth expectations. The Bund-Treasury real-yield gap has narrowed ~50bp without €/$ following, that's the wedge a JPM-style downgrade is trading.

4. Gayed flags a reverse carry crash. On ITM Trading Podcast, "Japan's Panic / Reverse Carry Trade Crash" (May 29), Michael Gayed argued every MoF/BoJ intervention has been a slow-bleed failure: "No amount of money that Japan is throwing at this to save the yen is working… they probably need to bring out a bigger bazooka." His analog is Aug 3–5, 2024. "I think it's going to happen again, probably longer and deeper."

5. Carry's still working, just thinner. Lad Jankovic on the same JPM Global FX (May 29) flagged the global FX vol index below 6.50, post-COVID lows, as still supportive of carry, with NZD upgraded after the RBNZ surprised hawkish (Locke's team pulled forward 100bp of hikes to start July). Best idea on tape: "Cross-Yen is kind of interesting in places like Aussie-Yen, and optionalising those expressions could be interesting."

The debate

Bull-€ steel-man. Nomura's Josie Anderson on The Week Ahead is calling an ECB hike in June, full stop. German CPI re-accelerating to 3.0%, ECB speakers "continuing to advocate" for it. If she's right, every €/$ short on the JPM desk gets squeezed and the 1.18–1.20 zone re-opens.

"We're expecting a June hike at the next meeting and speak generally has continued to advocate for that while also highlighting data dependence." (Josie Anderson, Nomura)

Bear-€ steel-man. Locke, Chandan, and Snider are converging: growth deteriorating, real-yield gap narrowing, French politics fragile, and even if energy gives ECB a hawkish print, the underlying impulse is dovish. Chandan would fade any Iran-deal €/$ pop (~+2%).

Carry vs anti-carry. Jankovic and Kristovova: low-vol regime intact, just less headroom. Gayed: structural funder ¥ is one global wobble away from snapping. Both can be right on different horizons. The cleanest expression of that asymmetry is what Jankovic actually says aloud: run the carry, but optionalise it on cross-yen because the vol is too cheap not to.

Trades in play

Only where the tape pointed at one:

• Fade €/$ pops (Chandan, JPM, May 29), particularly any Iran-deal rally.
• Optionalise AUD/JPY carry via cheap 1M vol (Jankovic, May 29), run the carry with paid-for downside.
• Fade elevated EUR/GBP skew if an Iran deal removes the UK political overlay (Jankovic, same episode).
• NZD long vs low-yielding G10 on the brought-forward RBNZ cycle (Locke, same episode).

Read-throughs

• Bund-Treasury spread. ~50bp of real-yield narrowing without spot €/$ following is the wedge JPM is now monetising.
• Cross-¥ / EUR-JPY. The optionalised carry lives here; sub-7% 1M ¥/$ vol is the cheapest tail hedge available.
• Gilts vs Treasuries. Bailey's pivot is gilt-positive at the front end; UK fiscal credibility and the Burnham/Labour leadership thread (flagged by Anderson and Saxo's John Hardy on Market Call, May 22) caps it at the long end.
• Nikkei. Direct Aug-2024-redux hedge if Gayed is right; long USD/JPY puts double-cover.
• CHF, the silence. Spot near 11-year highs and not a single podcast voice this week touched it. Either complacency, or the desks are saving it for paid notes. Worth a separate channel check; don't write a thesis off a vacuum.

What changed

• JPM €/$ H2 target: ~1.20 to 1.13–1.15.
• JPM RBNZ call: hike cycle pulled forward to July, 100bp cumulative.
• BoE function: leading hawk to dovish-accepting (Bailey, via Snider).
• ECB June meeting becomes the cleanest two-way risk left in G10, JPM dovish, Nomura hike. Size accordingly.

Drug pricing and IRA newsletter for the week of May 25 to June 1, 2026. Five of the ten Round 1 manufacturers have already cut list price, with AbbVie's Imbruvica taken all the way down to MFP, the first concrete sign the IRA bleeds into commercial gross-to-net.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of May 25 – June 1, 2026: Half of Round 1 Manufacturers Already Cut WAC; ABBV to MFP

TL;DR

• Five of the ten Round 1 manufacturers have already lowered list price, with AbbVie's Imbruvica taken all the way down to MFP, the first concrete sign that the IRA bleeds into commercial gross-to-net, not just Medicare.
• Forty drugs are now on the negotiation list and the 2028 cohort includes Part B for the first time, confirmed by a former HHS/CMS general counsel, who is still calling Round 1 P&L impact "too soon to tell" at 5.5 months in.
• A quiet week. Three episodes touched IRA at all out of ~500 scanned. No new GLP-1 (NVO/LLY) tape, no Stelara biosimilar update, no EPIC Act movement. If you need GLP-1 or biosimilar signal this week, the podcast tape is dry.

What's New

1. ABBV took Imbruvica's WAC to MFP, and PBMs will follow it down. Stephen Miller, VP of Pharmacy Services at 340B Health and the most operator-y voice of the week, said on the May 27 episode of 340B Insight that "half of the manufacturers for the 2026 drugs, so 5 of the 10, lowered their WAC or wholesale acquisition cost price significantly. Some all the way down to MFP as I talked about the example with AbbVie's [Im]bruvica" (340B Insight, May 2026). His non-obvious read-through: "Insurance, PBMs are going to max the reimbursement down to that rate as well", i.e. the IRA price effectively leaks into commercial reimbursement once WAC moves. This is the tradeable insight of the week; check whether MRK (Januvia), BMY/PFE (Eliquis), AZN (Farxiga), and LLY (Jardiance) have made comparable WAC moves.

2. Round 2 manufacturers are taking modest 2026 price. Same episode: Round 2 list prices have risen "0% to 6%, with most in the 2-4% range" for 2026 (340B Insight, May 2026), well below the historical 6–8% playbook, consistent with manufacturers managing optics into negotiation. Miller also flagged that 4 of the 10 Round 1 drugs will drop off the IRA list at the start of 2027 per CMS guidance, which begins to set up the LOE/biosimilar cliff narrative.

3. Forty drugs on the list; Part B in the 2028 cohort. Tom Barker (Foley Hoag partner, former Acting GC of HHS, former CLO of CMS) on DC EKG with Joe Grogan (former Trump White House DPC director): "There are now 40 drugs that have been selected for negotiation... this year, for the first time, Part B drugs are subject to negotiation" (DC EKG, May 2026). The Part B inclusion is the structural change that opens up physician-administered oncology and immunology franchises, most obviously Keytruda's IV formulation for MRK in 2028.

4. MFN models are coming, but still undefined. Barker: "the B and D models are going to be mandatory, and those are going to take effect at some point in the next year or so" (DC EKG, May 2026), referring to the "Globe" and "Guard" Part B demonstrations and the "Generous" Part D model. Richard Pops, CEO of Alkermes, on The BioCentury Show: "We don't know what MFN actually is... based on the 17 bespoke deals that have been done, is there a central tendency among them or is each of them actually a bespoke deal?" (The BioCentury Show, May 2026). Translation: MFN remains a fat-tail risk the market cannot price.

5. Part D premium cap is the unspoken 2027 risk. Barker flagged that Part D "premiums are artificially capped... When that cap comes off, there is the potential for a huge increase in Part D premiums" (DC EKG, May 2026), a sleeper read-through for the MA-PD plan economics at UNH, CVS (Aetna), CI, and HUM.

The Debate

Bull (manageable modeled headwind). Round 1 is 5.5 months in and Barker, an actual former CMS general counsel, is still saying "it's too soon to tell" (DC EKG, May 2026). Round 2 manufacturers are taking single-digit list price into negotiation, four of the Round 1 drugs roll off the list in 2027, and the actual MFP cuts are already in every sell-side model. The story is well-known and largely priced.

Bear (structural US margin compression with a small-mol R&D pullback). The tape from operators argues the cost is bigger than priced in three directions. One, commercial gross-to-net is now coupled to MFP: once WAC drops, PBMs reset reimbursement, so the IRA is not a Medicare-only headwind. Two, the pill penalty is rewriting the R&D mix; Pops' framing is the clearest articulation of the capital-allocation math: "Post IRA, nine years of exclusivity versus 13 years of exclusivity. If you draw a curve of the revenue profile of a drug over its life with the ramp and the plateau and you clip off the back four years, that's half of the revenues. So from a purely economic perspective, you should develop biologics instead of small molecules" (The BioCentury Show, May 2026). Three, mandatory MFN Part B and Part D models on a 12-month horizon, plus Part B negotiation in the 2028 cohort, layer two more leg-downs onto US franchise NPVs. Bear take: today's MFP is a floor, not a ceiling.

Stocks in Play

No episode this week named a per-franchise revenue-at-risk number. These are watch items, not fresh estimates.

Read-Throughs

• PBMs / managed care (CVS, CI, UNH, HUM). Miller's claim that PBMs will "max the reimbursement down to that [MFP] rate" (340B Insight, May 2026) is a net-neutral-to-positive read for Caremark/ESI/Optum Rx (lower acquisition cost), but Part D plan economics get more complicated when the premium cap rolls off. Watch 2027 MA-PD bids.
• Hospitals / 340B (HCA, THC, CYH). The 340B ceiling-price lag is two quarters: Jan 1 WAC cuts hit hospital 340B savings July 1. Litigation update from Barker: HRSA rebate model struck down in Maine (Dec 2025 proposal); new RFP comment period closed; state-law preemption wins for manufacturers in North Dakota and the 4th Circuit on West Virginia (DC EKG, May 2026). 340B is now an "$80 billion program", larger than every drug program except Part D.
• Small-mol biotech (ALKS, VRTX, INCY, mid-cap pipelines). Pops disclosed that the original Part D catastrophic-phase manufacturer liability change "would have taken us from a 0% liability to a 20% tax on our revenues. It would have taken us from being profitable to being not profitable" (The BioCentury Show, May 2026). Mid-cap small-molecule names with concentrated Part D exposure remain the most idiosyncratic risk under the structural IRA architecture.
• Ex-US / European launch strategy. Pops surfaced a subtle MFN exposure for companies that don't sell in Europe: if a competitor does at a lower price, rebate clawbacks could still apply. Not modelable yet but worth tagging.

What Changed vs Last Week

This is the inaugural run of this newsletter, no prior week to compare against. Going forward, we will flag delta-vs-prior-week here. If a future week is quiet, we'll say so plainly.

Dollar and FX newsletter for the week of June 1, 2026. The week's dollar tailwind was made overseas: Canada in technical recession, France contracting, the BoE making peace with above-target inflation, and the BoJ as the last hawk standing, with the rate-differential math running through the crosses.

The Dollar: Direction, Reserves & Positioning

Week of June 1, 2026: G10 cracks first, the dollar's accidental tailwind

Last week the dollar story sat inside the Eccles Building, with Warsh's first FOMC and Musalem's hawkish play-by-play setting the table. This week the camera swung abroad, and what it found is uglier than anything happening in Washington. Canada is in technical recession, France just printed a surprise GDP contraction, the Bank of England is publicly making peace with above-target inflation, and the BoJ is the only major central bank with a credible hawkish case left. None of this was a "dollar" trade on the pods. It is one anyway.

TL;DR

• The dollar's tailwind this week was made overseas. G10 ex-US, Canada, France, Germany, Sweden, the UK, all rolled in the same direction. None of it was framed as a USD trade on the tape, but the rate-differential math runs through the cross.
• The pundit tape on the dollar regime went almost silent. No episode this week put numbers on CFTC positioning, the cross-currency basis, COFER, stablecoins, or DXY. After a noisy May, the macro-pod community looked away.
• The one Fed-independence "exclusive" of the week came from a gold dealer and should be priced as such. A specific quote attributed to Warsh is uncorroborated; we flag it rather than amplify it.

What's new

1. The BoJ is the last hawk standing, and ex-subsidy inflation is doing the talking. On NAB's Morning Call, NAB FX strategist Rodrigo Catril walked through the Tokyo data dump and the BoJ's new ex-subsidy inflation measure, which is running at 2.8%, well above target, and read it as the Bank quietly preparing the ground. "From an inflationary perspective the bank is kind of telling us that they're very much aware of these price pressures," Catril said, framing the June 2026 meeting as the live hike window. If you trade USD/JPY, the carry math is finally moving against the long-dollar leg from the Tokyo side (NAB Morning Call, Just a nod from Donald, May 28).

2. Canada's technical recession is being called a global warning, not a Canada story. On Eurodollar University, Jeff Snider made the case that Canada, two consecutive negative GDP quarters from Q4 2025, 83,900 jobs lost in February 2026 and another ~25,000 in January, is the canary, not the outlier. France's Q1 GDP printed unexpectedly negative; April household spending was -0.5%; Sweden's Riksbank is holding through another negative GDP print; Germany cut its 2026 growth forecasts. "Canada's technical recession is not strictly a Canada-only story. It is a global warning… within the wider, broader economic decay that we keep seeing all over the place," Snider said. He's a commentator, not a desk head, but the data points he's stacking are real, and they're all on the same side of the ledger (Eurodollar University, Canada Sends HUGE WARNING, May 31).

3. The Bank of England blinked before it hiked. Same Snider episode, the cleanest single tell of the week: BoE Governor Bailey signaled the BoE may tolerate above-target inflation to support a weakening labor market, a hawkish-to-dovish pivot without having actually pulled the trigger on a single hike. "As soon as the energy shock started and petroleum prices shot up, the Bank of England was at the forefront of saying, rate hikes, rate hikes, rate hikes… Well, now, just a couple months later, they're already changing their tune when they haven't even hiked any rates yet," Snider noted. Sterling's real-rate cushion vs. the dollar just got thinner without the Fed doing anything (Eurodollar University, Canada Sends HUGE WARNING, May 31).

4. Inside the FOMC, "wait and see" is the new center. Catril read New York Fed President John Williams from Reykjavik as the median voice on the committee: Williams "thinks policy is still a little bit restrictive and well positioned to sort of see how things play out, so he's more along the lines of let's wait and see." That's a notable downshift in tone from last week's Musalem/Dudley hawkish chorus. The US data Catril worked through fits the same picture: Core PCE +3.3% YoY, +0.2% MoM for April; Q1 GDP revised down to +1.6% annualized from +2.0%; corporate profits -0.4% vs. +5.7% expected. Not enough to force a cut, not enough to force a hike, a "stay parked" tape (NAB Morning Call, Just a nod from Donald, May 28).

5. A gold-dealer-sourced Fed scoop you should not run with. ITM Trading's Taylor Kenney spent her episode arguing Warsh is engineering a Friedmanite "regime change" at the Fed and may pivot to trimmed-mean inflation as the operative metric (headline CPI sits at 3.8% in her telling). Provocative if true. The problem: a specific Warsh quote, "You'd have to have a PhD from an elite institution to believe that inflation doesn't have anything to do with money," is unsourced, and ITM is a physical-gold dealer whose every claim funnels back to a buy-bullion conclusion. We're noting the episode because it is the only Fed-independence narrative on the tape this week, not because it is institutional-grade. Treat it as a vibe check on retail gold marketing, not a Warsh signal (ITM Trading, The Fed's New Plan to Shrink $40T, May 31).

The debate

The bull-dollar case wrote itself this week, even though nobody on the tape made it explicitly. If Canada, France, Sweden, the UK and Germany are all slowing while the US data is "stay parked," the cross-rate math favors the buck mechanically. Catril is the closest thing to an operator on the tape and his sketch, Williams patient, BoE pivoting dovish, BoJ the lone hawk, is the rate-differential argument for a stronger USD on the EUR, GBP, CAD legs, with USD/JPY as the one cross where the dollar's tailwind goes the other way.

The bear-dollar case was barely voiced, and the one episode that tried isn't a great messenger. Kenney's debasement thesis ("the Fed can either protect the currency or protect the debt") is the only structural-USD-bear narrative on the week's tape, and it comes from a commercial source pitching physical metal. The Boockvar/Whalen/Pento camp that anchored last week's bear case was off the air this window. If you're short the dollar here, the silence is even louder than last week.

The honest read: the structural-downtrend, sell-rallies camp had nothing to say this week. The crowded-USD-short / real-yield-support camp had everything to say, they just didn't say it about the dollar. They said it about Canada and France and the UK. Same trade, different ticket.

The trades in play

What the tape actually pointed to:

• Long yen against the dollar, the only directly named USD cross expression of the week, via the BoJ June hike setup. Catril didn't quote USD/JPY, but his framing on BoJ ex-subsidy inflation at 2.8% is the cleanest pod endorsement of the trade (NAB Morning Call).
• Long physical gold, only as a commercial pitch (Kenney/ITM), not as a desk view. Note the source.
• No EUR/USD, no DXY, no EM FX, no basis, no positioning trade was named on the pods this week. If you run those books, that absence is the data.

Read-throughs

• EUR and GBP. The clearest read-through of the week, and nobody on the pods drew the line. France in surprise contraction, Germany cutting its 2026 growth forecast, BoE pivoting dovish without a single hike, full Eurozone CPI due the week after this issue, the rate-differential setup is dollar-supportive on the EUR and GBP cross with or without a Fed hike.
• CAD. Catril marked USD/CAD higher (CAD -0.4% on the May 28 session) into the Canadian recession print; Snider treated Canada as the leading indicator for the rest of the bloc. Bilateral fundamentals point the same way the spot tape did.
• JPY. The one cross where the dollar's tailwind reverses. Catril is the cleanest source on the tape building the BoJ June hike case via the 2.8% ex-subsidy print.
• Gold. Only voiced by a commercial gold dealer. No central-bank gold-buying figures, no Shanghai Gold Exchange data, no gold/USD level. The structural reserve-rotation case that Boockvar built last week was off the tape this week.
• Stablecoins / GENIUS Act / digital-dollar T-bill bid. Zero coverage on the pods this week. Same gap as last week. Treat as an unaddressed risk if your book sits on the front-end-bill demand channel.
• CFTC positioning, cross-currency basis, COFER reserve share, midterm risk premium. Zero coverage. The macro-pod community is not currently focused on any of these.

What changed

• The center of gravity moved abroad. Last week the dollar story was Warsh, Musalem, Dudley, Desai, an inside-the-FOMC argument. This week it's BoE pivoting, BoJ stalking, Canada cracking, France contracting. Same direction for the dollar, very different mechanism.
• The operator microphone went quiet. Last week we had four heavyweight institutional voices (Musalem, Dudley, Desai, Cembalest) saying the same hawkish thing. This week the only operator-class voice on the tape is a sell-side FX strategist at NAB, and his read is "wait and see," not "hike."
• The pundit microphone went almost silent on USD debasement. Whalen, Pento, Boockvar, last week's chorus, were off this window. The lone bearish-USD voice was a commercial gold dealer. If the bear case can't field a starter this week, that itself is a tell on the dollar narrative's tactical pulse.

A useful caveat: Monday May 25 was Memorial Day in the US, which thinned the institutional sell-side podcast supply. Some of the silence is calendar. Not all of it.

AI accelerators and custom-silicon newsletter for the week of June 1, 2026 (strict window May 25 to Jun 1, with operator tape from May 18 to 22 flagged inline). Cerebras' Andrew Feldman claims CUDA has lost ~70% of frontier training share, Jensen Huang names a triple supply bottleneck, and Gavin Baker leans into the connectivity picks-and-shovels.

Custom Silicon vs Nvidia

Week of May 25 – Jun 1, 2026: Feldman says CUDA lost 70% of frontier training

A note on the tape: the strict 7-day window (May 25 – Jun 1) was thin, three in-window episodes, dominated by post-earnings pundit commentary. The week before (May 18–22) carried the operator weight: Cerebras' Andrew Feldman on Odd Lots, Jensen Huang with Michael Dell on Bloomberg Intelligence, Gavin Baker on All-In. I've included that material with dates flagged inline, per the 14-day fallback rule.

TL;DR

• Cerebras CEO Andrew Feldman claims CUDA has lost roughly 70% of frontier training share to TPU and Trainium in twelve months, and discloses a binding AWS term sheet for disaggregated inference (Trainium prefill + Cerebras decode). Treat the share number as a claim from an interested party; the multi-vendor footprint at Anthropic is corroborated three ways.
• Jensen Huang, in his own words after the $81.6B / +85% YoY Q1 print: CoWoS-R, CoWoS-L, CoWoS-S, HBM and 3nm are all supply-constrained. The cap on Nvidia's near-term revenue is TSMC and Hynix, not demand.
• Atreides' Gavin Baker has Astera Labs at 7.4% of book, second-largest position behind QQQ puts. The same Baker who is the loudest voice pushing back on the ASIC bull case is leaning hard into the picks-and-shovels.

What's New

1. Cerebras CEO says CUDA's training moat is half-gone, and an AWS binding term sheet to back it up. Andrew Feldman, twice in one week, on Tech Disruptors and Odd Lots: "A year ago, 100% of the large US state-of-the-art frontier models had been trained with a CUDA flow. And they have since lost 70% of the market share." He then disclosed a March 2026 binding term sheet under which AWS will run a disaggregated inference architecture: Trainium for prefill, Cerebras CS3 for decode, served through Bedrock (Tech Disruptors, 2026-05-28; Odd Lots, 2026-05-21). If true, AWS itself is conceding Trainium can't carry fast-inference decode, a material qualifier for any Trainium share model.

2. Anthropic is now multi-vendor: Trainium + TPU + Nvidia. Three independent confirmations in one week. Feldman: "Anthropic's models, trained on Trainium, no CUDA. Served on TPUs, on Trainium, and on GPUs" (Odd Lots). Jensen on Squawk on the Street: "This year, we had the benefit of also winning Anthropic" (Squawk, 2026-05-21). And David Faber, citing the fresh SpaceX S-1: Anthropic is paying $1.25B a month, $15B a year, to xAI to rent Memphis Blackwell capacity. The "Anthropic = Trainium exclusive" narrative is dead. Project Rainier GW figures were not refreshed this week.

3. Jensen names the triple bottleneck: CoWoS, HBM and 3nm. On Bloomberg Intelligence with Michael Dell (2026-05-18): "The CoWoS is lined up with the HBM, which is lined up with the Grace Blackwells… CoWoS-R, the CoWoS-L, the CoWoS-S. All of it is all lined up. The silicon photonics is lined up. Everything is all lined up. It's just that the demand is much greater than the overall capacity of the world." Feldman, independently, named the same triple, HBM, CoWoS, TSMC 3nm, as the binding constraint on every vendor including the ASIC houses. Two operators from opposite ends of the value chain agreeing on the same three chokepoints is about as good a confirmation as you get outside of an earnings call.

4. Atreides has ALAB at 7.4%, second position behind QQQ puts. Josh Kale unpacking Gavin Baker's latest 13F on Limitless (2026-05-28): "As AI clusters scale to hundreds of thousands of chips, the bottleneck stops becoming GPUs specifically. But it starts becoming that transfer window… the plumbing system that Astera Labs builds." Worth noting the same Baker, on All-In, is the most vocal pundit pushing back on the broader ASIC bull case, he wants the connectivity attach regardless of who wins the compute war.

5. Synopsys CEO discloses a license-plus-royalty pivot on hyperscaler IP. Sasim Ghazi on Squawk on the Street (2026-05-28): "Today they pay us as a license and that's it… We don't get paid on volume and success. So it's going to be a license plus a royalty, which will increase the opportunity of monetization." If hyperscaler XPU programs are sticky enough that Synopsys can finally charge royalties, that says something about the durability of the in-house silicon stack, and adds incremental cost into the ASIC TCO bridge that bulls don't usually model.

The Debate

Steel-man for ASICs (Feldman, Boone, Goldberg). TPU and Trainium are demonstrably shipping at frontier labs. CUDA's training moat has visibly cracked inside twelve months. Citizens' Andrew Boone, on The Exchange (2026-05-19), is modelling TPU revenue from "$3 billion… this year, up to $25 billion by 2027," validated by the Google-Blackstone $5B JV. Seaport's Jay Goldberg, the only sell rating on the Street, on the same show: "Anytime NVIDIA doesn't get a deal, it's gone to Google's TPUs."

Steel-man for the merchant. Gavin Baker on All-In (2026-05-22): Broadcom guided +143% YoY for AI semis, but Nvidia's Western (ex-China) AI revenue is still growing faster on an apples basis. None of the hyperscaler ASICs have submitted to MLPerf, until there is a clean GB300 vs TPU v7 vs Trainium 3 benchmark, the perf-per-dollar claims are unverified. Bloomberg Intelligence's Kunjan Sabani on Bloomberg Tech (2026-05-21): the ~50% of NVDA revenue not flowing to the four hyperscalers, sovereigns, neoclouds, enterprises, AI labs, faces zero ASIC competition. That's the monopolistic margin pool.

Where I come out this week: the ASIC footprint at frontier labs is now real and broad, and that's largely already in the AVGO and GOOGL multiples. What is not yet in Nvidia's number is the upside from Jensen explicitly saying he's supply-constrained across three independent variables, that's a quarter or two of revisions if TSMC and Hynix capacity lands as planned. Long NVDA, long ALAB, watch the ASIC names off any benchmark catalyst.

Stocks in Play

• NVDA: Bull: $81.6B / +85% YoY, 75% GM, $91B Q2 guide ±2%, $80B buyback, dividend +25x (per Baker on All-In). Jensen says supply is the cap. Bear: Culper Research alleging >20% of FY26 revenue routed to China via Megaspeed, with firsthand Taiwan/Singapore sourcing on rack-level diversion (per Better Offline, 2026-05-20). Vera Rubin Ultra "Kyber" 1MW racks may strand existing data center designs. Watch: MLPerf GB300 submissions; Megaspeed regulatory follow-through.
• AVGO: Bull: +143% AI semi guide for the coming quarter. Bear: still slower than NVDA Western. Watch: XPU customer-list disclosures, OpenAI Stargate confirmation.
• GOOGL: Bull: Boone's $3B to $25B TPU revenue curve; Anthropic serving on TPU confirmed. Bear: no external customer beyond Anthropic disclosed this week. Watch: TPU v7 / Ironwood deployment metrics; Apple and SSI rumours.
• AMZN: Bull: Trainium v3 is in market; Anthropic still a Trainium training customer. Bear: the Cerebras prefill/decode split implies Trainium decode weakness AWS itself acknowledges. Watch: Project Rainier GW disclosure; re:Invent 2026 messaging.
• MSFT: Bull: The Information reportedly has Anthropic in talks for Maia (per Cramer). Bear: zero volume or yield colour this week. Watch: Maia 2 silicon timing.
• META: Bull: still in the custom-silicon design cycle via Synopsys IP. Bear: zero MTIA v2 volume disclosure. Watch: MTIA v2 inference deployment scale.
• ARM: Bull: Vera CPU tag-along narrative. Bear: no new Neoverse-in-XPU or v9 royalty mix data this week. Watch: XPU royalty disclosures next print.
• ALAB: Bull: Atreides 7.4% conviction position; structural connectivity attach as clusters scale. Bear: no new design-win color. Watch: TPU/Trainium/Maia attach rates; Scorpio fabric ramp.

Read-throughs

• TSMC: Jensen and Feldman both name 3nm and CoWoS as the binding constraint. Capex cycle still tight.
• SK Hynix / Micron / Samsung: per Kale on Limitless, Hynix allegedly fielding $50–$100B HBM forward-supply offers from Google and Microsoft, ~70% operating margins (a figure the podcast left unsourced).
• SNPS: license-plus-royalty pivot is a structural margin lift if it sticks.
• Alchip / GUC: radio silence this week. Material information gap for any ASIC-services thesis.
• Cerebras: strong operator color, but with a recent IPO and a Trainium piggyback deal. Discount the share claims accordingly.

What Changed vs Last Week

This is the inaugural issue, so there is no prior to diff against. From next issue we'll track: TPU revenue ramp vs Boone's $3B to $25B curve, Anthropic vendor-mix shifts, any MLPerf submissions from the ASIC camp, and CoWoS / HBM capacity prints out of TSMC and Hynix.

Wafer-fab-equipment newsletter for the week of May 31, 2026. Three deals land at once (AMAT carving out ASMPT's panel-level deposition, Onto taking a stake in Rigaku, and the Excelis-Veeco merger clearing final hurdles) pulling advanced packaging back into focus on an otherwise one-sided tape.

The Semiconductor Equipment Brief

Week of May 31, 2026

Three deals in one week dragged advanced packaging back into the spotlight: Applied Materials carving out ASMPT's panel-level deposition business, Onto Innovation taking a quarter of Rigaku's X-ray metrology franchise, and the long-pending Excelis-Veeco merger finally pushing through final regulatory hurdles. None of these are blockbusters in isolation. Together, they sketch out where the WFE incumbents see the next leg of fab spending: not on the lithography stage where ASML already monopolizes the conversation, but on the packaging side, where AI workloads are forcing toolmakers to treat heterogeneous integration as a real revenue category. Operators stayed off the mic this week, so the read here is necessarily a pundit framing, and we flag that up front.

TL;DR

• AMAT is bolting on ASMPT's "NEXT" panel-level packaging deposition franchise, a deliberately narrow carve-out to dodge antitrust scrutiny while extending the AMAT advanced-packaging stack.
• Onto Innovation took a 27% stake in Rigaku (X-ray metrology for 3D-stack and advanced-packaging QC), funded by convertible debt: quiet consolidation in the most defensive corner of WFE.
• The Excelis-Veeco merger is in final approval, awaiting China sign-off, with combined revenue at close estimated at ~US$1.5B vs. ~US$1.7B combined 2024, confirming a cycle trough through the merger window.

What's New

Packaging gets the M&A action, not litho. Nicholas Rossolillo on the Chip Stock Investor Podcast (pundit/host) walked through Applied Materials' announced acquisition of ASMPT's "NEXT" segment, the deposition franchise focused on panel-level (square, not round) substrates. The framing was deliberate: Rossolillo argued AMAT structured this as a narrow carve-out specifically because buying ASMPT outright "would definitely run into antitrust issues." It's a way to consolidate share in panel-level packaging tools (the bottleneck behind every AI accelerator that needs 3D stacking) without inviting a regulator review.

Onto-Rigaku is the quieter, more interesting trade. Same episode: Onto Innovation took a 27% equity stake in Rigaku, the Japanese X-ray imaging house whose tools sit at the center of 3D-stack and advanced-packaging QC. Convertible-debt funded. Rossolillo's view was that metrology remains "one of the more durable segments" of WFE (recurring service revenue, software attach) and that ONTO "is still an interesting one to us here" despite elevated multiples. The Rigaku move isn't a takeout; it's a foothold in an adjacent metrology specialty Onto can later consolidate or partner around. Worth flagging given Onto's earlier Kulicke & Soffa equipment carve-out: the company is methodically building a packaging-metrology suite.

Excelis + Veeco crossing the line at the trough. Rossolillo flagged that the Excelis-Veeco merger is in final-approval stages, with China regulatory sign-off the last gate and an expected H2 2026 close. The number worth holding in your head: combined revenue at close estimated at ~US$1.5B, versus a 2024 combined figure of US$1.7B. That's a deal closing into a cyclical revenue trough, the kind of bottom-of-cycle consolidation that historically produces the cleanest synergy math on the other side, if you believe the broader WFE up-cycle thesis. Pundit framing only: no operator voices on the merger this week.

The Debate

This week's tape, frankly, only voiced one side. Rossolillo's stance is constructive: "26 and 2027 are going to be record revenue years" for the Fab Five (ASML, AMAT, LRCX, TEL, KLAC), which he claims still command "about 70% of annual fab equipment spending" (unverified pundit figure). He flagged "a hiccup around 2028… not necessarily going to be like a bear market… but maybe some sort of mid-bull market cycle downturn for semiconductors," followed by a resumed leg higher into end of decade. The demand-side underpinning was a paraphrase of recent TSMC commentary: "we're going to need a lot more semiconductors for the next three to five years. Please keep expanding fab capacity."

The bear case (Intel 18A actually catching, Samsung GAA closing the yield gap, a China pull-forward unwinding, mature-node digestion, Taiwan-Strait tail risk) did not get voiced on the pods this week. That doesn't make it wrong; it means no guest argued it, and we won't manufacture a counter-source to make the section feel balanced. Read the bull framing accordingly: it's pundit consensus filling a quiet tape, not stress-tested by an adversarial operator.

Read-throughs

• CoWoS / advanced packaging. AMAT-ASMPT NEXT and Onto-Rigaku both signal that incumbent WFE players see panel-level packaging and 3D-stack metrology as the next durable revenue category. Watch how AMAT presents NEXT in its first post-close quarter: segment disclosure here will tell you whether they're chasing a meaningful TAM or buying optionality.
• Metrology defensibility. Onto's methodical roll-up (Kulicke & Soffa equipment, now Rigaku) reinforces the thesis that metrology is the most recurring, services-rich pocket of WFE. Pair-trade implication for those who want it: long ONTO / short pure-deposition-and-etch names if you want AI-packaging exposure without the cyclical bookings volatility.
• No operator color on EUV, High-NA, 2026 WFE dollar prints, leading-edge intensity, or China mix. ASML, LRCX, and KLAC appeared this week only inside aggregate Fab-Five framing. Bigger reads on these threads will likely surface around the next earnings cycle.
• Quantum hardware: silent. No IBM Starling, Google Willow, IonQ, Rigetti, PsiQuantum, Quantinuum, D-Wave, or Atom Computing clips on the week's tape. The long-dated frontier thread (quantum roadmaps pulling on advanced packaging and cryogenic control) went uncovered.

What Changed

The marginal new fact this week is the cluster of WFE M&A: AMAT-ASMPT-NEXT, Onto-Rigaku, and Excelis-Veeco's final-approval phase all surfacing together. M&A clustering at a cycle trough is a more reliable signal than any single deal in isolation; it usually means buyers see the bottom and are getting in front of the next leg. We'd weight that more heavily than the pundit "record 2026/27" framing it traveled alongside.

Sources

• Chip Stock Investor Podcast - Wafer Fab Equipment, M&A Moves & The Lab 7 You've Never Heard Of, May 29, 2026

Travel, Airlines & Leisure investor newsletter for May 25–31, 2026. The podcast tape repriced the whole complex at once: the FAA flagged a dangerous summer schedule, Doug Parker explained Berkshire's Delta refinery bet, and Brian Chesky quietly turned Airbnb into a full-blown OTA.

Travel, Airlines & Leisure Weekly

Week of May 25–31, 2026

Travel / Airlines / Leisure, week ending May 31, 2026

Three things happened on the podcast circuit this week that tell you everything about how the travel complex is being repriced in real time. A regulator effectively said the sky isn't safe for the summer schedule. A retired airline CEO walked listeners through why Buffett just dropped $2.6B on Delta. And Brian Chesky quietly turned Airbnb into a full-blown OTA while everyone was watching Google's keynote. Let's go.

✈️ The FAA just told you summer 2026 is going to be a mess

If you only listen to one episode this week, make it the FAA Administrator's sit-down with Scott McCartney on Airlines Confidential. Bryan Bedford, the ex-Republic Airways CEO now running the FAA, disclosed that the agency's internal digital twin (built on a Palantir/Thales/Sabre bake-off) is already hitting 96–97% R² predictive accuracy on the National Airspace System. And it is screaming about June. In Bedford's own words, the model is flagging "flight trajectories that are actually designed to collide with one another."

That is not a metaphor. The FAA is running 11,000 controllers against a 12,600 staffing target, ATC overtime is up 85% versus 2019, and LGA spent two days of Memorial Day week on single-runway operations because a sinkhole opened near Runway 4-22. The cavalry ($12.5B of modernization, 313 facilities collapsing into a cloud-consolidated stack, possibly anchored at Sabre's Southlake campus) does not arrive until end of 2028. If you're modeling Q3 unit revenue, you should be widening your IROPs and irregular-ops cost buckets, not narrowing them.

💰 Why Berkshire bought Delta: Doug Parker basically tells you

In a separate Airlines Confidential episode, former American/US Airways CEO Doug Parker did something I haven't seen anyone else on the Street do cleanly: he explained the thesis behind Berkshire's freshly disclosed $2.6B Delta stake (avg cost $66.50). Parker's read: Buffett is buying the refinery.

The jet fuel crack spread has blown out from a historical ~$6/bbl to roughly $100/bbl post-Hormuz, and Parker frames it bluntly:

"Brent has gone from $75 to $105, it's really gone from $75 to $205 a barrel. It's more than doubled."

Delta's Trainer refinery is the only owned hedge in the industry. April CPI confirmed the pass-through is going through: airfares +20.9% YoY, +2.7% MoM seasonally adjusted. Parker thinks Q2 industry revenues print double-digit YoY growth on modest capacity ("I can't remember when we've had one like this") and is openly warning carriers not to cut capacity because "cash on cash flying airplanes is a positive thing even in tough environments."

Read this as a cost-shock cycle, not a demand-shock cycle. Premium-mix winners (DAL, UAL) get to enjoy the fare-elasticity gift; the LCCs that already failed the cost test (more on that below) are the ones who don't get a second chance.

🛬 Spirit is dead. The cleanup is going to cost the lessors.

The post-mortem on Spirit keeps getting uglier. McCartney walked through March numbers on the Copa episode of Airlines Confidential: $240M of cash burn in one month, a $157M operating loss (5x February), $256M of revenue against $412M of operating costs. As McCartney put it, "lenders and creditors were subsidizing fares to the tune of $50 to $60 per passenger." That's not a business; that's a liquidation.

The juicier read-through, though, is the engine crisis. Per the unsecured creditors' filing, "only a handful of the debtor's leased aircraft currently have their assigned engines installed." One Carlyle-owned A320 has one engine in Orlando and the other at an MRO. Another A320's engines are sitting in Chicago and on a Newark plane. Wind-down budget alone: $217M. If you're long Pratt & Whitney's GTF program or any A320neo lessor, the secondary-market disruption from this alone is a multi-quarter overhang.

Meanwhile Allegiant closed its $1.5B Sun Country deal (195 aircraft, 175 cities), the first real post-Spirit LCC consolidation move. And Frontier's Q1 net loss of $272M, ancillary per pax down 9% YoY to $65.24, with total CASM +35%, prompted Henry Hardeveldt's line that "this is a sign that Frontier's core customers are hurting." JetBlue, per Skift's Spirit liquidation post-mortem, is effectively absorbing Spirit "on the cheap and in parts" at FLL and LGA Marine Air Terminal.

🏨 Airbnb just became an OTA. Nobody was watching.

While Google IO was committing to agentic hotel bookings and the OpenAI people were admitting they "built a shopping experience and people didn't want it," Brian Chesky used his Summer Release to roll out car rental, expanded hotels (boutique, "not a Holiday Inn"), Instacart-powered grocery, and scaled landmark experiences. That's four of the five OTA verticals in one keynote. Flights are the only thing left. As Seth Borko quipped on Skift, "How many millions of people are going to go to the Golden Gate Bridge? Let's take 15% off of 10 million transactions instead of six." That math is what kills the founding ethos but pays for the next leg of the stock.

Expedia, very much aware, is buying CarTrawler for ~$350M. Booking sold 86M car-rental days TTM (Borko's back-of-envelope: ~$6B in gross bookings at $70/day), and management is now claiming "low teens" US room-night growth and 8.8M alternative-accommodation listings (+9% YoY) growing faster than ABNB "quarter after quarter." For the first time in a decade, the OTA stack is collapsing toward a single product spec.

The watch item: only 1.5% of Expedia traffic currently comes through AI/agent surfaces (per CEO Ariane Gorin), only 2% of hotel chains use agentic AI at scale, and only 2% of young leisure travelers will let AI book for them. The OTAs are not yet being disintermediated; they're being given time to build the B2A ("Business to Agent") rails. Whoever owns those rails owns the next decade.

🛏️ Lodging: K-shaped, brutally

Tamara Lohan at Hyatt told Hospitality Daily that Hyatt is now "70% in luxury" versus 40–50% at Hilton and Marriott, explicitly framed around CEO Mark Hoplamazian's "K-shaped economy" Fortune piece. Unbound Collection grew +9.3% YoY in property count.

The other side of the K is grim. Skift's hotel-owner crisis episode ran the math: since the 2017 Park/Hilton spinoff, HLT is +468% and PK is -22%. Mid-scale and economy occupancy is down roughly 300 bps on top of the secular ~2% softness as immigration/geopolitical backlash bites. Franchise fees are still 5–6% of top-line gross, ADR growth is running below inflation, the 2027 maturity wall is refinancing 3% paper into 6.5–7% paper, and PIP requirements are colliding with tariff-driven construction inflation. Nancy Patel, a franchisee, is running her own overnight shifts and asking on tape, "Will we need a brand in the future? Maybe not." That's the trade: long the IP, short the bricks.

🔭 What I'm watching next week

US inbound was -14% YoY in April per Skift's data piece. Canada finally turned green (+1.4%) off a -30% base, but the EU is still down 10–14%. The June World Cup is the inbound stress test; data lands in July. If it disappoints, the "America 250" narrative dies, and the hotel REIT short gets very loud.

This was a fat tape, and it cut one way: a cost-shock cycle that rewards premium-mix carriers and IP-light asset owners while punishing the LCCs and the bricks. Matterfact will keep tracking whether the World Cup inbound print confirms or breaks the read.

Sources

• Airlines Confidential, FAA Administrator episode
• Airlines Confidential, Doug Parker / Berkshire-Delta episode
• Airlines Confidential, Copa episode (Spirit post-mortem)
• Skift, Spirit liquidation post-mortem
• OpenAI shopping experience admission
• Airbnb Summer Release coverage
• Hospitality Daily, Hyatt / Tamara Lohan episode
• Skift, hotel-owner crisis episode
• Skift, US inbound data piece

Tesla investor newsletter for May 27–31, 2026. Podcasts split between an ARK-led SpaceX merger bull case and a hard-data bear case as Reuters questions the FSD safety math and Bloomberg pegs Tesla at 42 Texas robotaxis to Waymo's 577.

The Tesla Investor Brief

Week of May 27–31, 2026

This Week's Big Picture

Tesla's podcast week split into two camps with little middle ground. The bulls, led by ARK Invest, treated SpaceX's imminent IPO as the trigger for a value-unlocking merger and framed Tesla as a future RoboTaxi cash machine. The bears (Pivot, Stage Zero, Loftus Peak) got rare external validation this week: a Reuters investigation questioning Tesla's Full Self-Driving safety math, and Bloomberg data showing just 42 Tesla robotaxis operating in Texas against Waymo's 577. Below is the synthesis.

🔥 This Week's Dominant Story: The SpaceX-Tesla Merger Question

With SpaceX's IPO expected around June 12, the podcast circuit converged on one question: will Elon Musk merge his crown jewel with Tesla? The narrative was validated mid-week when early SpaceX investor Peter Diamandis told Bloomberg that Tesla and SpaceX may eventually merge after SpaceX's IPO, a move that would consolidate Musk's control across his companies.

FYI - For Your Innovation (ARK Invest), May 28, 2026

ARK Invest's Tasha Keeney and Brett Winton offered the most bullish framing of the week. Keeney called a SpaceX-Tesla combination "likely" within roughly two years once SpaceX shares unlock for price discovery post-IPO. Winton went further, calling a merger within two years "more likely than not," arguing that cross-board approvals on commercial ties are "cumbersome and not great from a strategic logic perspective."

Their thesis: Tesla "would have so much cash and won't know what to do with it from RoboTaxi," making it the natural funder of SpaceX's "high ROIC" AI and satellite buildout post-merger. Keeney also flagged that Tesla wants "XAI models to be the orchestration layer" for both RoboTaxi and Optimus.

Pivot (Kara Swisher and Scott Galloway), May 29, 2026

The bear case came through loud and clear. Kara Swisher said the merger "makes complete sense... It makes sense to hide a bunch of stuff," referencing prior cross-company transactions like SpaceX buying Cybertrucks. Scott Galloway used a memorable Snow White analogy: SpaceX is the attractive asset, but acquirers would have to "take on these seven weirdos who are expensive and neurotic" (Tesla, XAI, etc.).

The Paul Barron Crypto Show, May 29, 2026

Guest Evan Aldo put merger probability at "70-80%." An additional commentator argued SpaceX's $2T valuation is "deliberate so that they can have leverage to do the merger of equals," predicting Musk would move within days post-IPO.

🚖 Robotaxi Reality Check: Numbers Get Worse

This week's podcast bearishness on Tesla's robotaxi business got fresh ammunition from a stunning data point: Tesla has only 42 vehicles operating as robotaxis in Texas nearly a year after service launched, compared to Waymo's 577 robotaxis there, according to Bloomberg citing Texas DMV data unveiled for the first time under new rules that took effect this week.

Elon Musk Podcast (Stage Zero), May 28, 2026

Hosts claimed active unsupervised vehicles in Austin dropped from 19 to 13, with the global unsupervised fleet at just 20 cars, figures that now look conservative against Bloomberg's confirmed 42 in all of Texas. They reported wait times exceeding 15 minutes 50% of the time in their three-week Austin test.

Most damaging: hosts claimed Tesla "doubled Utah labeling staff" to manually pre-map the Austin geofence, directly contradicting Tesla's vision-only, generalized AI marketing. Quote of the week: "If the system requires intense manual pre-mapping of a single area just to function poorly, the underlying vision-only hardware might be hitting a hard ceiling."

Pivot, May 29, 2026

Scott Galloway stated Tesla's SF robotaxi service still uses a safety monitor in the front seat and that Tesla has "cut back" robotaxis in Austin. He compared this unfavorably to Waymo: "I'm staying in Beverly Hills. If I go to my deck, I can see a Waymo. They're everywhere in LA."

⚠️ FSD Safety Claims Under Scrutiny

Reuters reporting this week powerfully validated several bear-podcast critiques. A Reuters investigation reported that Tesla's "Full Self-Driving" safety claims rely on flawed methodology and internal concerns about system reliability, including skepticism from former data labelers and engineers about its real-world driving performance. Critically, Reuters found the safety claims rested on a flawed comparison that may have overstated performance by roughly a factor of three, because Tesla compared airbag-deployment crashes in its vehicles against broader federal tow-truck crash data that already includes less severe incidents.

This directly corroborates Stage Zero's May 28 podcast claim that Tesla's "10x safer than human" statistic collapses to about 3x when normalized for airbag-deployment comparisons. They also claimed 7 of 9 Tesla data labelers said they wouldn't trust FSD to drive them, now backed by Reuters reporting on labeler skepticism.

🌍 European Sales: Conflicting Signals

A notable conflict emerged between podcast narratives and actual reported data this week.

Pivot (May 29): Galloway claimed Tesla sales in Europe have fallen for 13 consecutive months (Norway down 90%, Netherlands down 80%, UK down 50%) while BYD registrations are up 260%.

However, the actual April data tells a different headline story: Tesla reported another month of sales growth in Europe in April, with new vehicle registrations rising 46.5% year over year to 10,654 vehicles across Europe, while EU sales advanced more than 67% to 9,169 units.

That said, Galloway's competitive concern remains valid: Chinese automakers continued to post strong growth in Europe, with BYD sales more than doubling to 27,008 vehicles and Leapmotor reporting a 407% increase. BYD is now outselling Tesla in Europe by more than 2.5x.

🇨🇳 China Competition: A Recurring Bear Theme

Equity Mates Investing Podcast, May 28, 2026

Anshu Sharma of Loftus Peak (which hasn't held Tesla since 2021) argued that better and cheaper exposure to Tesla's themes is available elsewhere: Pony.ai and WeRide rival Tesla and Waymo in China at scale, Unitree and Ubitec are producing humanoids at scale, and "Tesla takes about 40 minutes to charge. You have BYD and [CATL] companies which are charging at five minutes."

Quote: "All those four areas to me at this point in time, I don't know what Tesla is doing there, but I'm getting better exposure on all those in China right now at scale, at the best technology."

💰 Valuation Debate

• Galloway (Pivot, May 29): Tesla trades at 192x forward earnings vs. Apple at 33x. "Stocks are like brands, part promise and part performance. No one gets more cheap capital on the promise part than Elon Musk... And the performance is so far behind the promise."
• Stage Zero (May 28): Framed Tesla's "trillion-dollar valuation" as resting entirely on a scaling-software premise contradicted by manual mapping and regulatory friction.
• Evan Aldo (Paul Barron Show, May 29, Bull): Tesla "is going to hit 600 and then probably eventually 900 by the end of this decade."

📊 New Regulatory and Macro Headwinds This Week

Beyond podcast commentary, several developments will likely dominate next week's coverage:

1. USMCA Tariff Risk: The Trump administration is anticipated to propose a change to the USMCA that would mandate half of the components and materials in an automobile come from U.S. sources to qualify for reduced tariffs, greatly increasing the number of U.S. components required in cars made under the pact. Tesla is among the publicly traded companies that would be affected, alongside Ford, GM, Honda, Lucid, Rivian, Stellantis, Toyota and Volkswagen.
2. Sweden Labor Update: Tesla's long-running labor strike in Sweden has been scaled back, with union IF Metall ending walkouts at workshops in Malmo and Uppsala. The dispute began in 2023 over a collective bargaining agreement, but the broader strike continues across Sweden, with support actions from Nordic labor groups disrupting vehicle servicing, ports, and logistics.
3. SpaceX IPO Delay Risk: The FAA has ordered SpaceX to investigate the May 22 Starship booster failure, delaying further test launches pending regulatory approval and reducing the likelihood of another launch before the company's expected mid-June IPO, which could push back the merger timeline ARK and others discussed this week.

🎯 Featured Names from Influencer Watchlist

• ✅ Cathie Wood / ARK Invest (via Brett Winton and Tasha Keeney): bullish merger and RoboTaxi thesis.
• ✅ Scott Galloway (Pivot): decisively bearish on valuation, Europe, and Cybertruck.
• ❌ Dan Ives, Adam Jonas, Elon Musk, Sandy Munro: no major podcast appearances captured this week.

Bottom Line

The week was unusually polarized. The bull camp (ARK, crypto and macro commentators) sees the imminent SpaceX IPO as a catalyst for a value-unlocking merger and frames Tesla as a future RoboTaxi cash machine. The bear camp (Galloway, Swisher, Stage Zero, Loftus Peak) got significant external validation this week from Reuters' FSD safety investigation and Bloomberg's stark 42-vs-577 robotaxi count. With Chinese EV makers continuing to gain European share and new USMCA tariff requirements looming, the operational bear case has hard data behind it heading into June.

Sources

• News from May 27–29, 2026 (Bloomberg, Reuters, TechCrunch, WSJ)
• FYI - For Your Innovation Podcast, May 28, 2026
• Pivot Podcast, May 29, 2026
• The Paul Barron Crypto Show, May 29, 2026
• Elon Musk Podcast (Stage Zero), May 28, 2026
• Equity Mates Investing Podcast, May 28, 2026

The Semis & AI Infrastructure podcast recap for May 25-31, 2026. Memory is the story of the week as Micron and SK Hynix cross $1T and Dell's blowout becomes the proxy for AI-infrastructure breadth, while the debate shifts from whether demand is real to whether the tape is paying too much for it.

Semis & AI Infrastructure Podcast Recap

Week of May 25-31, 2026

🧠 Top of Mind This Week

Memory is the story of the week. Micron and SK Hynix both crossed $1T market cap, UBS triple-banked MU's price target from $535 to $1,625, and every operator and strategist on the tape called HBM/DRAM/NAND the binding constraint of the AI build-out for "at least two years." Dell's blowout (AI server guide raised from $50B to $60B, FY revenue guide to $167B, AI-optimized server revenue +757% YoY) became the proxy for how broad and how supply-constrained AI infrastructure has become. The bull-bear debate has shifted from "is the demand real" (consensus says yes) to "are we paying too much for it" (SOX 69% above its 200DMA, unprecedented in 25 years, vs. earnings growth that has actually kept pace).

🔑 Dominant Themes

• Memory supercycle, with a 1999 echo. MU and SK Hynix entered the trillion-dollar club; SanDisk is up roughly 600% YTD; UBS price target on MU went to $1,625. Bulls (Chisholm, Cramer, Mui) point to long-term agreements, sold-out capacity through 2027, and HBM as the AI choke point. Bears (Boockvar) note MU at about 9x P/S vs. its 1999 peak of about 8x, and the pull-forward signal from CDW and others suggesting double or triple ordering.
• Dell as the canary for AI server demand breadth. AI server revenue $16.1B (+757% YoY), backlog growing, demand spread across neoclouds, sovereigns, and enterprise. CFO David Kennedy on Bloomberg Tech: "as we move from training models into inferencing, those inferencing workloads are creating a net new environment, a net new TAM." Truist's Nicknum is the dissenter, citing pull-forward and a valuation now at an S&P multiple vs. a historical 9x.
• Memory shortages cascading into broader hardware inflation. Dell is warning of lead times up to a year on memory, CPUs, and HDDs. BI's Woojin Ho: traditional server costs up 200-300% YoY; PCs up about 20% YoY in H2 2026. Beneficiaries include SMCI, HPE, ARM, and the WFE complex (AMAT, LRCX, KLAC all on allocation).
• Anthropic and the private-credit-funded AI capex stack. Anthropic ARR went from $9B (Jan) to $47-50B (May), raising $65B at roughly $965B valuation, with Apollo and Blackstone leading what could be the largest private credit deal ever (around $36B) to finance chip and server purchases for neoclouds without balance sheets. SpaceX and xAI are projected to take in around $15B per year renting compute to Anthropic.
• NVIDIA: dominant fundamentals, stock disconnect, China zero. Vera Rubin is driving the Dell pipeline; Goldman calls semis the only profitable layer of the AI stack today. But Cramer: "just not performing... mind-numbing." Boockvar: "essentially zero market share in China," permanently. Multiple compression to 10-11x on 2027 estimates per Ben Rogers cited on CNBC.
• Huawei's "Tao Scaling Law," a non-EUV path to 1.4nm-equivalent. He Tingbo proposes "time scaling" vs. geometric scaling, targeting 1.4nm-equivalent performance by around 2031 (vs. TSMC's commercial 1.4nm in 2028). Read-through: a long-term threat to ASML's EUV monopoly and to NVIDIA's China-locked-out position. Ian (Telecoms.com): "leans toward taking it seriously"; one industry contact: "usual Huawei propaganda."

⚖️ Key Debates

Are semis in a bubble?

Michael Batnick (Compound and Friends): SOX 69% above 200DMA, unlike anything in 25 years; MU's $100B to $1T move evokes Cisco and Lucent in 2000. Denise Chisholm: aggregate CapEx/FCF still under 1x vs. 3.5-4x at the 2000 peak; price has actually lagged earnings growth over the past two years; she puts a 70% probability on semi outperformance over the next 12 months from a bottom-quartile valuation.

MU valuation: cyclical peak or structural re-rating?

Boockvar (bear): MU at about 9x P/S matches the 1999 cyclical peak; double and triple ordering inflates near-term signals; extra supply does not arrive until 2027-2028. Jake Silverman (BI, bull): LTAs and the AI tailwind make this 3-5 years of structural earnings, not a typical cycle.

Semis vs. software as a structural relative trade

Adam Parker (Excess Returns): "My North Star is still semis over software." CTO pricing pressure plus the need to invest in AI compresses software margins; he sees software revenue misses in 5-6 quarters. The counterview is that software is defensive given multi-year contracts (Parker rejects this).

Semi-cap equipment vs. memory

Gavin Baker (referenced by Parker): semi-cap is very expensive vs. DRAM, and they "can't both be right." Parker concedes directionally (MU around 7x vs. CAT around 30x is incongruous) but notes momentum keeps semis acting well.

AI productivity and job displacement pace

Carson Block (Muddy Waters): 15% knowledge-worker displacement in 3-5 years. Matthew Weir (Goldman): a 10-year gradual process; 25% of US tasks (not jobs) automatable; trend GDP rises to 2.4%.

NVIDIA stock vs. fundamentals

Cramer (bull on the business, bear on the action): the "biggest fundamental winner" but underperforming for two years; a "pitiful, helpless giant" on the tape. Faber and Quintanilla note 10-11x on 2027 numbers as the bull's defense.

Tao Scaling Law: innovation or propaganda?

Ian (Telecoms.com) takes it seriously and flags the geopolitical bargaining-chip motive. An anonymous industry contact dismisses it as Huawei propaganda. The implication for ASML's roughly €9.5B China DUV revenue is real either way.

AI capex sustainability

Bears (channeled by Brown): half the AI capex backlog comes from equity-funded OpenAI and Anthropic, a dot-com pattern. Chisholm: hyperscalers are FCF-positive above capex, so it is not systemic. Bradley Tusk: OpenAI at $13B revenue with $9B losses and a $1.4T debt stack is "irrational for retail."

📊 Stocks Discussed With Bull/Bear Angle

🎯 What Changed This Week

The framing across the tape moved from demand validation to valuation discipline. With memory names in the trillion-dollar club and the SOX a historic distance above trend, even the bulls (Chisholm, Parker, Silverman) are now arguing from earnings durability and underweight positioning rather than from cheapness. The bears (Boockvar, Nicknum) have a cleaner setup: pull-forward signals, 1999 P/S analogs, and a China door that stays shut for NVIDIA.

The other genuinely new read-through is structural: Huawei's "time scaling" pitch and Anthropic's private-credit-funded compute stack both point at the same question, which is who ultimately finances and supplies the next leg of the build-out if EUV and balance-sheet constraints bind.

Sources

• Bloomberg Intelligence, Dell Soars Most in Two Years on Outlook Fueled by AI Servers, May 29, 2026
• Bloomberg Intelligence, Memory Chip Frenzy Sends SK Hynix, Micron Into $1 Trillion Club, May 27, 2026
• Squawk on the Street, 9am Hour: Dell Soars on Blowout Quarter, Bulls Rule in May, Bearish Month for Oil, May 29, 2026
• Squawk on the Street, 9AM Hour: Salesforce Falls, Snowflake Soars, Fertitta Buys Caesars in $5.7B All-Cash Deal, May 28, 2026
• Chip Stock Investor Podcast, Wafer Fab Equipment, M&A Moves & The Lab 7 You've Never Heard Of, May 29, 2026
• Bloomberg Tech, SpaceX Lowers IPO Valuation Target, May 29, 2026
• Closing Bell, Closing Bell Overtime: The Rally Keeps Climbing As Stocks Post Strong End to May, May 29, 2026
• Telecoms.com Podcast, Huawei, VodafoneThree and EU, May 29, 2026
• The Compound and Friends, What if It's Still Early? With Denise Chisholm, May 29, 2026
• Excess Returns, Cheap Is a Warning, Not a Thesis | Adam Parker on What This Market Is Really Pricing, May 28, 2026
• RiskReversal Pod, Peter Boockvar Gives Us His "Boock Report" On The Markets, May 28, 2026

SaaS and software podcast recap for May 24–31, 2026. Operators and founders with proprietary data pushed back hard on the 'AI kills SaaS' narrative while public-market traders stayed split on whether the multiple reset is permanent.

The SaaS / Software Podcast Recap

Week of May 24–31, 2026

Top of Mind

The defining story this week was the "SaaSpocalypse" debate. Operators and founders with proprietary data (Ramp, Cisco, Hightouch, Toast, Every) overwhelmingly pushed back against the "AI kills SaaS" narrative, while public-market traders and value-focused podcasts remained split on whether the multiple reset is permanent. Pricing model evolution (seat to consumption/outcome), AI-native gross-margin compression, and the agent harness/orchestration layer as the new moat were the other dominant cross-podcast threads. Snowflake's earnings reaction flipped at least one prominent bear bullish on infrastructure software, and Toast was the highest-conviction long-form pitch of the week.

1. Dominant Themes

Theme 1: "Is SaaS Dead?" / SaaSpocalypse, the defining debate of the week

Operator and founder consensus runs strongly against the thesis; public-market commentators are more divided.

• Sean Barrett (CIO, Counter Global) on Business Breakdowns (May 29): "There's been a pretty severe debate in public markets around the SaaSpocalypse, SaaS is dead narrative. While we think there is a lot of disruption out there in the software space, particularly around coding and DevOps in some cases, there are also a handful of category killers, vertical market winners, and infrastructure software companies that are thriving and in a better spot now because of AI than they were a few years ago."
• Dan Shipper (CEO, Every) on Lenny's Podcast (May 24): "I think the SaaS-pocalypse is dumb. I would buy SaaS stocks right now... What agents do is increase the number of users of SaaS, not get rid of it."
• Ara Karazian (Lead Economist, Ramp) on The a16z Show (May 25): "SaaSpocalypse as a pronouncement has come way too soon and is typically not informed by actual business behavior." Ramp data (50K businesses, $100B annual spend): token-based pricing uptake at vendors offering it (HubSpot, Adobe) is only about 0.5% of spend.
• Tejas Manohar (co-CEO, Hightouch) on Marketecture (May 29): "I think the SaaS apocalypse is overblown. I think companies still want to buy or I'll say rent, pay per month or pay per year for software companies that can come in and solve business problems. But the stakes are higher."
• Jason Andrews (VP Engineering Ops, Cisco) on Tech Talks Daily (May 25): "The SaaS apocalypse that everybody talked about last quarter, and I'm like, guys, you're just going to do this all via cloud workflows... you still need that context. You still need these systems in place."
• Brian Beach (Stansberry Research) on Stansberry Investor Hour (May 26), the LeBron analogy: "If there was a magic pill that made you and me 50% better at basketball... that pill is also available to LeBron James and everyone else in the NBA. Microsoft is LeBron James."
• Counter-view, Ejaaz on Limitless (May 29) defines the term: "basically as Claude and ChatGPT end up upgrading their own models, they become able to replace a bunch of subscription software tools and services because they could just vibe code it or rebuild it from scratch. And this has led to a massive decline. I'm talking tens to hundreds of billions of dollars lost in the stock market for all these different SaaS products." The hosts flipped bullish after Snowflake earnings.
• Bear holdout on The Canadian Investor (around May 25): "I don't think we're ever going to see the 40, 50, 60x free cash flow multiples again. I think the moat around software is gone."
• Dan Nathan on RiskReversal (around May 22-23): "investors have just not bought into these SaaS companies, the transition that they're going to make and integrating the technology, the AI into their processes and their services and be able to monetize it."

Theme 2: Seat-based vs. consumption vs. outcome-based pricing

• Ramp data (a16z Show, May 25): seat-based contracts still 65–75% of spend; flat platform fees 20–30%; token-based pricing at vendors offering it about 0.5%. Karazian: the shift "requires a competitive forcing function, someone must go after others' lunch to make it stick. No incumbent is doing this aggressively yet."
• Kunal Agarwal (CFO, Gorgias) on AI to ROI: outcome-based pricing is "the only intellectually honest answer" for AI agents. Seat-based "misaligns incentives"; per-ticket "creates the wrong incentive to grow ticket volume rather than resolve issues." Gorgias charges only per resolution.
• Ajit Ghuman (Monetizely; ex-Twilio Segment) on Impact Pricing (May 25): "The anchor of per user pricing itself is going away... large employers have already started firing all of the users." He introduced an "Agentic Pricing Spectrum" framework (autonomy / operational breadth / output-to-cost curve) and predicts Salesforce moves off per-user pricing faster than expected.
• GitHub flat-rate to consumption shift (RiskReversal, May 24): "GitHub, which is owned by Microsoft, is dropping flat rate plans for usage-based billing across its products," cited as token-cost-driven repricing.
• Barrett on Toast (Business Breakdowns, May 29): "The whole business is consumption-based, so it aligns well with the customers. It aligns well with where the world's moving with AI."
• The Canadian Investor (May 25) cited a prediction that "upwards of 50% of SaaS companies will shift to hybrid usage or outcome-based pricing by 2030" and early data that "hybrid-based pricing is actually more lucrative than seat-based pricing."

Theme 3: AI agent monetization and the "harness layer" as moat

• Josh / Ejaaz on Limitless (May 29): the LLM wars are largely settled at the base-model layer, with value migrating to orchestration, "all of the peripherals required to turn the brain of an LLM into a full body, into something fully capable of doing agentic tasks that are long running." Ejaaz: "The current war that New Frontier is being fought on the rapper level with the harnesses." Cited as the source of Cursor and Cognition valuations.
• Tejas Manohar (Marketecture, May 29): "I actually believe that we have... close enough to general intelligence at this point... The problem in enterprises is it doesn't have the right context to succeed." MCP/API access alone is insufficient: "I don't believe MCPs and APIs just being given to agents is enough." Hightouch's wedge is structured ETL plus embeddings on top of warehouse data.
• Dan Shipper (Lenny's, May 24): flipped from personal agents to a company-wide "super agent." "The model for now is going to be a super agent, like one agent for the entire company." Cites Shopify ("River") and Ramp.
• Owner.com's CRO on SaaStr (May 26): a centralized "applied AI team" beats decentralized at 5-10x output. "Buy your infrastructure, build your intelligence." No one is at "Level 4" (recursively self-improving GTM AI) yet.

Theme 4: AI-native gross margin compression vs. traditional SaaS

• Agarwal (Gorgias) (AI to ROI): "AI agent gross margins are lower than traditional SaaS and that denying that fact is living in an alternate reality." LLM inference is about 55-60% of fully loaded cost per interaction. He built CFO-led governance with rolling 28-day LLM cost tracking per feature.
• Ramp data (a16z Show, May 25): token costs for high-intensity AI users have increased 13x year over year. "You project out that 13x and you get to an extremely unsustainable spend path." About 3% of AI spend on Ramp now flows through OpenRouter for multi-model cost optimization.
• Dan Nathan citing a "Hedgy Markets" tweet (RiskReversal, May 24): "Microsoft canceled its internal cloud code licenses this week after token-based billing made the cost untenable, even for a company with effectively infinite cloud resources." A Uber CTO memo allegedly said the company "burned through its entire 2026 AI budget in just four months." (Unverified.)

Theme 5: Software multiples compression, opportunity vs. permanent reset

• Barrett (Business Breakdowns, May 29), the 2015-16 analogy: "Public company software multiples collapsed to 3 or 4 times revenue, basically where they are today... It took about 18 months, and when you fast forward to early 2016, the category killers kept putting up numbers... and the stocks went parabolic."
• Beach (Stansberry, May 26): CRM down about 51% from its Dec 4, 2024 high. "For value guys, Dan, look carefully... a lot of these pretty good companies are down 30%, 40% heading into the year... It's a very interesting fishing pond for value investors."
• The Canadian Investor (May 25), opposing: Adobe down about 65% from 2024 highs. "It's not really operations right now. It's just the market has said we don't want to pay 40x for these companies, we want to pay 20x." Companies that "used to trade at anywhere from a 70% to 100% premium to the S&P 500 are actually now reverted to trading at discounted valuations."
• IGV debate (RiskReversal, May 24): Adami: "IGV, the software ETF has gotten off the mat... I still think there might be some gas in that software tank." Nathan: "I feel like you let go of the IGV here was a good trade off the low."

Theme 6: NRR resilience

• The Canadian Investor (May 25): NRR "hasn't really dipped at all. If it has dipped at some companies, it's usually, you know, maybe a percent or two. They went from like 110% to, let's say, 108%." Flags a renewal cliff: multi-year contracts mask churn that may surface at renegotiation.
• Toast (Business Breakdowns, May 29): Barrett rebuts the long-standing churn bear case, noting customers have structurally higher margins (15% vs. 10% industry), creating survivorship bias.

Theme 7: Vibe coding / AI coding tools, a productivity reality check

• Shipper's "Senior Engineer Benchmark" (Lenny's, May 24): most models score around 30/100 vs. human senior engineers at 85-90/100. GPT-5.5 scored about 62/100. Models patch rather than rearchitect.
• Andrews (Cisco) (Tech Talks Daily, May 25): the Cisco dev team did 28% fewer resources / 65% productivity gain, about 2x net. But on 400-500M lines of legacy code: "AI has not figured out how I can go that large of a code space yet."
• Ghuman (Impact Pricing, May 25) on Cursor: "The only strategy for these firms like Cursor to win is to change the habits of people and become a brand instead of actually adding more value. Or it's still a race to the bottom in terms of inference costs."

Theme 8: Vertical SaaS / category killers

• Toast (Business Breakdowns, May 29) and Owner.com (SaaStr, May 26), both restaurant vertical SaaS, both held up as proof points of vertical winners. Owner.com: about $100M ARR from $2M four years ago.

Theme 9: Shadow AI / agent governance

• Dave Sobel on Business of Tech (May 29): the Verizon 2026 DBIR found shadow AI use up 4x year over year. 67% of professional AI users go via personal or non-approved accounts. 28% of DLP violations involved proprietary code submitted to AI platforms. Gartner projects 40% of orgs will demote or decommission AI agents due to governance failures. An SNCC audit of 4,000 AI agent skills found that more than one third contained at least one security flaw.

2. Key Debates

Debate 1: Is the SaaSpocalypse real or overblown?

Overblown side (operator/data consensus):

• Shipper (Lenny's): "I would buy SaaS stocks. I think the SaaS apocalypse is dumb and SaaS stocks will be up majorly in the next couple of years." Every's own SaaS spend is up year over year despite being "extremely AI forward."
• Karazian (Ramp) (a16z): token-based pricing uptake under 1% even at vendors offering it.
• Manohar (Hightouch) (Marketecture).
• Beach (Stansberry) (Stansberry Investor Hour), primary research: a Salesforce customer told him "hey, what would you do if they raised the price 10% next year? They're like, I'm not even going to look at their invoice before I approve it."
• Barrett (Business Breakdowns), the 2015-16 historical analogy: vertical winners plus infra software "in a better spot now because of AI."

Structural issues side:

• Canadian Investor (May 25): "The moat around software is gone... I don't think we're ever going to see the 40, 50, 60x free cash flow multiples again."
• Nathan (RiskReversal): Salesforce, Workday, ServiceNow, Adobe, "these stocks have not been able to get out of their own way."
• Ejaaz (Limitless), partial: the SaaSpocalypse caused "tens to hundreds of billions of dollars lost," but Snowflake earnings flipped him bullish.

Debate 2: Durability of seat-based pricing

Seat-based is dying:

• Ghuman (Impact Pricing): "The anchor of per user pricing itself is going away... large employers have already started firing all of the users."
• Agarwal (Gorgias) (AI to ROI): seat-based "misaligns incentives."
• Canadian Investor: "If an agent can do the job of a dozen employees, you need one seat, not 12."

Seat-based is still dominant:

• Karazian (Ramp) (a16z): 65-75% of spend; token-based under 1% even where offered.
• Ghuman acknowledges Harvey AI ($11B valuation) is "selling by seat. Most of the world doesn't understand tokens," proving seat works for now even in AI-natives.

Debate 3: Can Salesforce / Agentforce monetize AI at scale?

Bear:

• Nathan (RiskReversal) citing a Bloomberg "SAASpocalypse" article: a Salesforce promo video shows patients using Agentforce "but a little of that AI functionality is actually live." On Benioff: "The lady doth protest too much, methinks."

Bull:

• Beach (Stansberry): a customer described Einstein as "fine... a neat trick" but switching costs are ironclad. "Salesforce down 50% has generally been a pretty good bet."
• Owner's CRO (SaaStr): "This is why I am like a pretty big bull on Salesforce. I think if you take that framework and you apply it to Salesforce, this is why I don't think that they are at a disruption risk."
• Canadian Investor (claim): "Salesforce is working on like $800 million+ in annual recurring revenue" from Agentforce.

Mixed: Ghuman predicted CRM moves off per-user pricing by 2028; "that happened in just one year from my providing that case study example."

Debate 4: AI capex, sustainable or at risk?

• Adami (RiskReversal): "these CapEx numbers are not written in stone... But we don't seem to be anywhere near that right now."
• Nathan (same episode): Microsoft canceling cloud code licenses, Uber blowing through its AI budget in 4 months. "It's been easy to make that call and not be right about that. I've been doing that for a while. At some point, it's going to happen."

Debate 5: AI-native margins vs. traditional SaaS

• Bear: Agarwal (Gorgias) (AI to ROI): "AI agent gross margins are lower than traditional SaaS and that denying that fact is living in an alternate reality." (around 55-60% inference cost)
• Bull: Shipper (Lenny's): when agents access SaaS via browser, "I'm using my tokens. I'm not using the vendors tokens. I'm not using the apps tokens." This could save SaaS margins.

Debate 6: Personal agents vs. company-wide super-agents

• Shipper (Lenny's): "completely flipped" from personal to super-agent. "The model for now is going to be a super agent, like one agent for the entire company."
• Owner's CRO (SaaStr): a centralized "applied AI team" produces output "5, 10X better" than decentralized.

3. Specific Names: Bull / Bear Stances by Ticker

Public

CRM, Salesforce

• BULL, Beach (Stansberry Investor Hour, May 26): down about 51% from its Dec 2024 high. "Salesforce is usually embedded into workflows, reporting, salesman compensation, forecasting, customer history, integrations, automations, compliance, making it impossible to live without." One customer workflow revamp "took over a year" to switch.
• BULL, Owner's CRO (SaaStr, May 26): "I am like a pretty big bull on Salesforce... they are [not] at a disruption risk."
• BEAR, Nathan (RiskReversal, May 24): Agentforce live functionality overstated; stock "can't get out of its own way."
• MIXED, Canadian Investor (May 25): Agentforce at $800M+ ARR (claim), but renewal cliff risk.
• MIXED, Ghuman (Impact Pricing): moving off per-user pricing faster than expected.

NOW, ServiceNow

• MIXED, Canadian Investor (May 25): "Companies like ServiceNow trading at pretty attractive valuations." But renewal cliff risk.
• BEAR, Nathan (RiskReversal) (May 24), grouped with CRM/WDAY/ADBE.

ADBE, Adobe

• BEAR, Canadian Investor (May 25): "Down... 65% from 2024 highs." Stock content business cannibalized: "You used to have to go and pay Adobe for stock footage... that has to be dead." Adobe disclosed stock footage revenue "declined faster than they thought."
• NEUTRAL, Karazian (Ramp) (a16z): token-based offering uptake only about 0.5%.
• NEUTRAL, Beach (Stansberry) (May 26): "Adobe was very early on kind of switching to SaaS."
• BEAR, Nathan (RiskReversal) (May 24): grouped.

ORCL, Oracle

• MIXED-BULL, Beach (Stansberry) (May 26): "Oracle was another one that people kind of assumed was going to fall away... It was just so ingrained."
• NEUTRAL, Adami (RiskReversal) (May 24): up 44% off lows.

MSFT, Microsoft

• BULL/NEUTRAL, Beach (Stansberry) (May 26): "Microsoft is LeBron James." It used the SaaS transition to build cloud infra and is repeating with AI.
• BEAR (near-term), Nathan (RiskReversal) (May 24): "Microsoft is in the crapper largely because they're software business, not because their AI exposure at the moment or their inability to use AI and Copilot's a big problem." Cited a tweet: "Microsoft canceled its internal cloud code licenses this week after token-based billing made the cost untenable."

WDAY, Workday

• BEAR, Nathan (RiskReversal) (May 24): "Workday is down over the last two years, 60 some percent from its all time highs. And it just seems like you get short covering when you get good news, but it's right back into the crapper."
• NEUTRAL, Sobel (Business of Tech) (May 29): a destination system for MCP-mediated context flow.

INTU, Intuit

• MIXED-BULL, Beach (Stansberry) (May 26): down significantly but the incumbent moat is intact.

SNOW, Snowflake

• BULL, Ejaaz / Josh on Limitless (May 29): the stock "jumps 30%" (about 35%) post-earnings. SNOW "defined a moat that sat on top of Claude and ChatGPT... they already have that data." A proof point that "not only are SaaS companies here to stay, but they also might be having or creating a defensible moat."
• NEUTRAL/BULL, Manohar (Hightouch) (Marketecture): the core warehouse underneath composable CDPs.

HUBS, HubSpot

• NEUTRAL, Karazian (Ramp) (a16z): token-based uptake about 0.5%.

TOST, Toast

• STRONG BULL, Sean Barrett (Counter Global, 15% position) on Business Breakdowns (May 29): about $12B EV, about $2B recurring gross profit, 35% EBITDA margins, 160K+ locations, about 20% US share, 18x 2027 GAAP PE at $22-23. DCF fair value about $50+. "AI is the best thing to happen to Toast since their founding, probably." Toast Grow: $500/mo to 8% revenue uplift to a claimed 20x ROI.

SHOP, Shopify

• Referenced (Toast analogy: "Shopify for restaurants"); Shipper's super-agent "River"; the Gorgias platform. No direct stance.

DASH, DoorDash

• MIXED, Barrett (Business Breakdowns, May 29): the POS pilot is a competitive concern; channel checks found zero customers would switch from Toast even if free.

TEAM, Atlassian

• BULL (implicit), Andrews (Cisco VP) (Tech Talks Daily, May 25): Cisco consolidated a 22K-person engineering org onto Atlassian; 54% tooling spend reduction; 40x faster reporting. "The folks here at Atlassian, we are about our products. Like, you have a multi-year roadmap. You understand the industry and the vision."

ZM, Zoom

• NEUTRAL, Sobel (Business of Tech, May 29): MCP expansion enables meeting artifacts to flow to Salesforce/ServiceNow/Workday.
• BEAR (implied), Ghuman (Impact Pricing): a threat to standalone meeting AI (Fathom), since Zoom can bundle for free.

DUOL, Duolingo

• BEAR, Beach (Stansberry) (May 26): down about 79% year over year. Low switching costs equal AI vulnerability. "80% for Duolingo, that might be just about right."

PLTR, Palantir

• BEAR (near-term), Nathan (RiskReversal) (May 24): "Palantir can't get out of its own way."

NVDA, NVIDIA

• NEUTRAL, Nathan (RiskReversal) (May 24): Q1 FY26 revenue $81.6B (+85% YoY), GMs 75%, EPS +95% YoY. Stock priced in.

META

• MIXED/BEAR on AI products, Ejaaz (Limitless, May 29): about $30B AI spend, "Meta's like backed into a corner right now." The $20 subscription tier is not competitive with Claude/ChatGPT.
• BEAR, Nathan (RiskReversal) (May 24): stock down about 25% from highs; 8K layoffs.

GOOGL, Google/Gemini

• UNDERRATED, Karazian (Ramp) (May 25): free Workspace Gemini integration causes undercounting in adoption metrics.
• Mixed signal, Limitless (May 29): Gemini 3.5 Flash at 28% on DeepSWE, "a pretty poor" result.

CSCO, Cisco, subject of Tech Talks Daily (May 25). No investment stance.

CSU.TO, Constellation Software / TOI.V, Topicus

• LONG (5% combined), Canadian Investor (May 25): "I would be elated if Constellation went back up to $5,000 in the next few years, but I just, I don't see it."

TWLO, Twilio

• NEUTRAL/utility, Owner's CRO (SaaStr): "Why would we try to go rebuild Twilio? They have spent immense amount of dollars on this critical piece of infrastructure."

RAMP, LiveRamp

• BEAR, Manohar (Hightouch) (Marketecture, May 29): being acquired by Publicis. Hightouch is "a plug-and-play replacement for the core LiveRamp technology." Its historic moat (the cookie graph) has eroded.

FI, Fiserv (Clover)

• BEAR, Barrett (Business Breakdowns, May 29): "Fiserv's been overleveraged... the stock has been a mess... they're not innovating, and customers have noticed, and so they've been losing share."

SQ, Block

• NEUTRAL / mild BEAR, Barrett (May 29): winning from legacy, not from Toast.

Brief mentions: AMZN/AWS (BULL on infra during a platform shift, per Beach); IBM (mild BULL on quantum, Adami); DNB (NEUTRAL, Sobel); PYPL (NEUTRAL connector, Sobel); BRZE (NEUTRAL integration, Manohar).

Coverage gaps this week: no substantive discussion of MDB, DDOG, NET, CRWD, PANW, ZS, OKTA, MNDY, DOCU, SMCI, or AMD. Security software M&A was not a meaningful theme.

Private

OpenAI

• BULL on Codex/GPT-5.5, Shipper (Lenny's): "OpenAI has gotten back the mandate of heaven a little bit." GPT-5.5: 62/100 on the senior-engineer benchmark.
• MIXED, Karazian (Ramp) (a16z): lost the #1 business adoption spot to Anthropic. About 80% of revenue is token-based, so there is no incentive for cost routing.
• Limitless (May 29): GPT 5.5/5.4 ranked #1 and #2 on the DeepSWE benchmark. ChatGPT Go ($5/mo India) added tens of millions of users.
• Canadian Investor (May 25): confidentially filing for an IPO.

Anthropic

• BULL near-term, Karazian (Ramp) (May 25): surpassed OpenAI as the most-used business model.
• BULL/MIXED, Shipper (Lenny's): "Anthropic was really doing it first" on agentic work surfaces (Claude Code to Cowork). OpenAI surpassed it near-term.
• Risk flag, Sobel (Business of Tech): accidentally exposed about 500K lines of TypeScript including permission enforcement logic to public NPM.
• Limitless (May 29): the Pope's "Magnifica Humanitas" specifically called out Anthropic. Partnering with SpaceX.

Cursor / Anysphere

• BULL, Karazian (Ramp) (a16z): displaced GitHub Copilot as the top dev tool. "That's the bull case for something like Cursor. Which can compete on the developer experience."
• BULL, Limitless (May 29) (unverified claim): "Going to result in a $60 billion acquisition 30 days after the IPO."
• MIXED, Shipper (Lenny's): a better Claude implementation than OpenAI/Anthropic, but "They've more distinctly chosen to be for programmers and that may limit how far they get." (Claim) "Cursor was just essentially acquired by SpaceX."
• BEAR on pricing power, Ghuman (Impact Pricing): "The only strategy for these firms like Cursor to win is to change the habits of people and become a brand." Recently moved to a Chinese open-source model.

Cognition / Devin

• BULL, Ejaaz (Limitless, May 29): "Cognition is probably second in the ranking of having or owning this particular type of [agent harness] mode... I'm pretty bullish, pretty excited on Cognition." Raised more than $1B at a $26B valuation. Uses 90% own code.

Hightouch

• BULL (self), Manohar (co-CEO) (Marketecture, May 29): raised $150M at $2.75B led by Goldman Sachs and Bain Capital Ventures (prior round $80M). 300+ integrations. Positioned as a LiveRamp replacement.

Gorgias

• BULL on direction, Agarwal (CFO) (AI to ROI): about 50% of the customer base is using the AI agent; resolution rate 60-80% for enterprise. MIXED on economics, structurally lower GMs.

Owner.com

• BULL, Owner's CRO (SaaStr, May 26): about $100M ARR from $2M four years ago. Outbound BDRs close more than $100K ARR/month each.

Harvey AI

• BULL, Ghuman (Impact Pricing): at an $11B valuation, "selling by seat. Most of the world doesn't understand tokens," proof that seat-based still works even in AI-native land.

Bottom Line

The week's tape was lopsided in one direction and contested in another. On whether AI kills SaaS, operators and founders with first-party data (Ramp, Cisco, Hightouch, Toast, Every) overwhelmingly said the SaaSpocalypse is overblown, and Snowflake's post-earnings jump gave the bulls a fresh public-market proof point. On whether the multiple reset is permanent, the value-and-trader camp (Canadian Investor, RiskReversal) stayed unconvinced, pointing to stuck large-cap names and gone-forever 40-60x cash-flow multiples. The cross-cutting tension that will define the next several quarters is pricing and margin: seat-based billing still dominates spend today, but outcome and consumption models, rising token costs, and structurally lower AI-native gross margins are the fault line every operator is now managing around.

Sources

• Business Breakdowns, May 29, 2026
• Lenny's Podcast, May 24, 2026
• The a16z Show, May 25, 2026
• Marketecture, May 29, 2026
• Tech Talks Daily, May 25, 2026
• Stansberry Investor Hour, May 26, 2026
• Limitless, May 29, 2026
• The Canadian Investor, May 25, 2026
• RiskReversal, May 24, 2026
• AI to ROI, May 2026
• Impact Pricing, May 25, 2026
• SaaStr 856, May 26, 2026
• Business of Tech, May 29, 2026

Private credit and alternatives newsletter for May 25–31, 2026. A quiet but pointed week as Apollo's two most senior voices, Marc Rowan and David Sambur, independently flag enterprise-software LBOs as the next credit-and-exit problem while parking the firm's growth in IG credit and ABF.

Private Credit & Alternatives

Week of May 25–31, 2026

A quiet week on the tape, but not an empty one. Apollo's two most senior voices, Marc Rowan on a16z and David Sambur on Bain's Dry Powder, spent the week, independently and without coordination on the air, putting a marker down on enterprise-software LBOs. Same firm, same diagnosis, same week. If you own a BDC with a software-heavy book, that's worth a coffee.

TL;DR

• Apollo (APO) just twice in five days flagged enterprise-software LBOs as the proximate source of the next credit-and-exit crisis. Rowan called expected PE returns there "disastrous." Sambur said creditors will end up taking some of them over in the next 1–3 years.
• The thesis that does travel on tape is permanent-capital plus ABF. Rowan: 80% of Apollo's >$1T AUM is now credit, "vast majority" investment grade, with data centers, chip financing, and robotics as the 2026 deployment story.
• Spreads outlook from Apollo's CEO: wider. Three words. He elaborated very little. Worth more than three words of attention.

What's New

Rowan to a16z: "I personally expect the returns from private equity in the ground to be disastrous." That's Marc Rowan, talking about the roughly 30% of the PE industry that's been pointed at enterprise software for a decade. His mechanism is simple and uncomfortable: people paid prices that "reflected a future that did not have AI in it," and the on-sale to the next buyer or the public market is "simply reduced." Translation for a credit book: those LBOs are the ones with the stretched cap structures, and the equity holders no longer have an obvious bid to refinance you out at par.

"We woke up eight, 12 weeks ago and figured out that AI was going to impact enterprise software. Really?", Rowan

Sambur on Dry Powder: creditors are about to inherit some software businesses. Same week, different show. The co-head of Apollo PE was even more concrete: "They're going to wait as long as their capital structures allow them to wait. Some of these businesses will be sold over the next 1 to 3 years... there'll be several of these that are not worth what the debt is and the creditors will take them over." That is a forecast of impairment, said calmly, by someone who would know. Bain's Hugh MacArthur framed the macro: "We've had the 4th straight year in 2025 where the DPI to NAV ratio for the LP community was less than 15%." LPs aren't getting their money back. That pressure has to go somewhere.

Daily NAV is happening, and the CEO is publicly worried about it. Rowan confirmed Apollo is rolling out daily mark-to-market across "a bunch of" products to reach the five new client buckets: individuals, insurers, the debt-and-equity bucket of institutions, traditional asset managers, and 401(k). Then he hedged it harder than I expected: "I've never seen a market in the world where you have transparency and price discovery that is not 10 times its size." Which is bullish for AUM and unsettling for liquidity terms, in the same sentence.

Data centers, chips, and robotics are the 2026 deployment story. Rowan was unusually specific: "If I look at the drivers of our business for this year, it is data centers. It is massive amounts of chip financing." He sized the wave at "$800 billion of capex from just four public companies this year" and warned Apollo and peers "are actually going to hit concentration limits" on hyperscaler names. The robotics line was new: he wants equipment-finance-style ABF, not venture equity, to fund the install base. That's a fee-and-spread engine for whoever underwrites it.

Apollo's syndicated-market exit has been a decade in the making. Sambur, on the same Bain podcast, casually noted Apollo built a "direct debt placement capability" starting "10 or 12 years ago" specifically to reduce reliance on the debt capital markets. The point being: this isn't a 2026 pivot. By the time the bank market reopens for software paper, the architecture has already shifted.

The Debate

The bear case had two clear voices this week, and they were both inside the same building. The bull case, that this is structurally a growing, well-underwritten, permanent-capital asset class whose democratization unlocks a durable, fee-rich runway, wasn't voiced on the pods we follow this week. So fair warning: I'm steel-manning what the tape gave me, not inventing a counter from thin air.

The bear, in their own words. Apollo's leadership is telling you that a decade of software LBOs were marked to a pre-AI, pre-400bps world, that 30% of the industry sits there, and that creditors are going to inherit some of them. The exit logjam is real: Sambur cited "32,000 unsold portfolio companies, and the average holding period went up from 5 years to 7 years." DPI/NAV stuck under 15% for four straight years. That isn't a vibe; that's working capital getting trapped.

The implicit bull. Rowan kept calling private credit "vast majority investment grade" and named Intel, Air France, EDF, AT&T, Meta, and BP Energy as the largest issuers of private IG, a deliberate, almost theatrical, distancing from the "press's very narrow definition of private credit being direct lending and BDCs." If you take him at his word, the cyclical risk is in a slice of the asset class, and the structural growth is in another (insurance-balance-sheet IG, ABF, hybrid equity). That's a self-serving framing, Apollo is the firm most positioned to benefit from it, but it's also a coherent one.

What's missing this week: a single guest pushing back. No BDC CEO on tape defending non-accrual trajectories, no rival on the wealth side talking up evergreen flows, no academic raising the gating question. That silence is itself a data point.

The Names in Play

Apollo (APO). Rowan's framework is doing the work of three pitch decks. The actionable read: he's flagging credit-cycle risk in the other guys' PE books while parking 80% of his own AUM in IG credit and insurance, and his "fastest-growing" segment, hybrid equity, is the bucket built to absorb private-but-safe assets that don't clear the alts return bar. Next catalyst: any concrete sizing of the daily-NAV product suite, and the next FRE growth print.

BDCs (ARCC, BXSL, OBDC, FSK). Nobody from the BDC side spoke on the tape this week. So the only honest read is the through-line from the Apollo episodes: software-LBO exposure is the line item to triage in the next 10-K and 10-Q cycle. The PIK-as-percent-of-investment-income trend hasn't been discussed on a podcast in this window; we'll watch for it.

Read-Throughs

• Direct lenders holding software paper are the cleanest read-through. Sambur said the quiet part on tape: "the creditors will take them over." Watch watch-list marks and PIK toggles in software-heavy books next print.
• Data-center and ABF borrowers are the structural winners. Apollo is publicly telling you it wants the paper; spreads should hold for credit-worthy hyperscaler-adjacent issuers even as Rowan flags wider spreads overall.
• The syndicated-loan / CLO market keeps losing share to direct placement. Apollo built the alternative ten years ago and is using it now.
• Insurance balance sheets are the structural buyer. Rowan: "We are willing to match low-cost retirement liabilities with safe long-term yield assets. Not risky long-term yield assets."
• Wealth and 401(k) distribution got a mention as a target market, not a development. No platform names (Morgan Stanley, Merrill, iCapital, CAIS) and no policy news on the tape this week.

What Changed

The thing that moved this week is the timeline on enterprise-software credit risk. Rowan dated Apollo's internal "wake-up" on AI-versus-software to "eight, 12 weeks ago," i.e., roughly early March 2026. That's the firm telling you the recognition has already happened internally; the public messaging is the lag. Sambur's 1-to-3-year framing for forced creditor takeovers is the first time I've heard an Apollo principal put a clock on it.

Sources

• Marc Rowan on Private Markets, Software Repricing, and Capital Allocation - The a16z Show, May 27, 2026
• Exiting Well in Tough Markets w/ Apollo's David Sambur - Dry Powder: The Private Equity Podcast (Bain & Company), May 26, 2026

Pharma, biotech, and life-sciences podcast recap for May 24–31, 2026. A thin, GLP-1-dominated week pits Novo Nordisk's Wegovy pill launch and aggressive list-price cuts against Eli Lilly's pipeline lead and an $18.6B diversification push.

Pharma / Biotech Podcast Recap

Week of May 24–31, 2026

This was a thin coverage week, heavily skewed toward GLP-1 and obesity. Four of the five substantive episodes clustered on the Eli Lilly versus Novo Nordisk obesity battleground, with new pipeline disclosures, aggressive pricing actions, and a CEO-level repositioning of Novo's strategy. Most other tracker themes (M&A outside Lilly, FDA and HHS policy, the IRA, tariffs, tools and CROs, medtech, gene therapy, oncology) were largely absent. Below is the synthesis, with the caveat that most insight is concentrated on the LLY/NVO axis.

🔥 Dominant Themes

Theme 1: GLP-1 / Obesity, Multi-Agonist Pipeline and Competitive Reset

The overwhelmingly dominant theme this week, surfaced across On The Pen, The Journal, Let's Talk Future (Oppenheimer), and Brew Markets.

• Novo's Wegovy pill (oral semaglutide) is the standout commercial story. On The Journal (May 27), NVO CEO Mike Doustdar said the pill generated more than 1.3M prescriptions in Q1 2026, calling it "the best product launch in US history in volume outside of a single vaccine." He claims 80% of users are new to Novo, framing it as market expansion rather than cannibalization. Efficacy of roughly 16.6–17% weight loss compares favorably to Lilly's oral Foundeo, and the pill helped Novo beat Wall Street earnings in the latest quarter.
• Novo is cutting list prices aggressively. Per Doustdar: a 50% Wegovy list-price cut to roughly $675 per month and an Ozempic cut of about 35%, both starting 2027. He frames this as closing the list-to-net gap rather than destroying margin.
• Triple agonists are the next battleground. On The Pen and The Journal both detailed Lilly's retatrutide (GLP-1 plus GIP plus glucagon) at roughly 28–30% weight loss in mid-to-late stage trials, with a launch targeted for early-to-mid 2027 and a pursuit of biologic designation (12-year exclusivity). Knapp's audience poll: 50% expect a $2,000–$4,000 list price, 25% expect above $4,000. Against that, Doustdar claimed Novo's UBT-251 (licensed from China's United Biotechnology for up to $2B) can, on apple-to-apple early data, beat retatrutide's 28% bar and is "best in class in a number of parameters."
• Asian challengers are years out. Hanmi's HM15275 (39.9% body-weight loss in obese mice) and Shanghai Minway's MWN-109 (oral triple agonist, Phase 1) are roughly 7–8 years away per Knapp.
• Tolerability and muscle loss are the emerging clinical frontier. Jay Olson on Let's Talk Future (May 27) noted that about 25% of SURMOUNT-1 (tirzepatide) weight loss was lean mass, and that lean-mass loss in older adults associates with roughly 30% higher all-cause mortality risk. He added that about half of GLP-1 starters discontinue due to side effects or needle fatigue. This frames the bull case for activin E pathway drugs (Wave Life Sciences, iBio) and longer-interval dosing (Amgen, every 2–3 months).
• A longevity reframing is taking hold. Olson cited a Lilly scientist calling GLP-1s "potentially the world's first longevity drug" and Novo's CSO presenting semaglutide as "a proven longevity medicine." He sees the consensus call of a $100B-plus obesity market by the mid-2030s as conservative.
• A GLP-1 and cancer signal surfaced. Former FDA Commissioner Scott Gottlieb on Squawk Pod (May 26) flagged observational studies suggesting possible cancer-risk reduction (anti-inflammatory effects, direct receptor effects, glycemic control), while cautioning against the failed metformin analogy: "I think there could be something real here."

Theme 2: Biotech M&A, Lilly's Pipeline Diversification Push

On Brew Markets (May 27), Ann Berry reported Lilly announcing roughly $18.6B in recent M&A funded by GLP-1 cash flows:

• About $3.8B for three vaccine developers (a push back into infectious disease)
• Up to $7.8B for Contessa Pharmaceuticals (sleep)
• Up to $7.0B for Colonia Therapeutics (oncology)

The strategy is framed as buying early-stage, de-risked assets rather than paying up for existing blockbusters. Lilly stock was up roughly 50% over the trailing twelve months as of May 26, and up about 1% on the announcement day.

Theme 3: PBM Reform and Drug Access

From On The Pen (May 27): Tennessee signed the Fair Rx Act prohibiting PBMs from owning pharmacies in-state. Knapp cited a state audit claim (unverified) that CVS Caremark reimbursed affiliated pharmacies up to 16,000% more than independents, and reported that Express Scripts generated roughly $30M in spread pricing from Tennessee employers. With more than 600 independent pharmacies closed in the state since 2017, Knapp expects copycat legislation and sees a structural threat to the PBM model.

Theme 4: FDA Leadership Change

From Squawk Pod (May 26): new acting FDA Commissioner Kyle Diamantis is a lawyer with prior food, beverage, and tobacco industry counsel experience. Gottlieb offered a strong endorsement, pushing back on the view that only a physician can run the agency as "outdated." The signal is regulatory continuity with career-staff alignment intact.

Theme 5: China Biotech as a Source of Licensable Assets

From On The Pen and The Journal (both May 27): Novo's UBT-251, licensed from United Biotechnology for up to $2B, is the centerpiece example, framed not as an existential threat but as a source of competitive depth for Big Pharma. Knapp read Novo's move as signaling "we can't allow Eli Lilly to own the next ceiling."

Theme 6: Infectious Disease, the Ebola Bundibugio Outbreak

From Squawk Pod (May 26): Gottlieb described 900-plus cases and 220-plus deaths, the third-largest Ebola outbreak in history. Therapeutic pipeline names included MAP Biopharma's MBP134 (entering clinic), Gilead's obeldesivir (preclinical), Merck's molnupiravir (preclinical), and one cross-reactive component of Regeneron's approved Zaire cocktail (already in clinical use). Vaccines are 6–9 months away, but therapeutics could be available immediately.

⚖️ Active Debates

Debate 1: Lilly vs. Novo on Obesity

Bull case for Novo (Doustdar, The Journal, May 27):

• The Wegovy pill is the only peptide-in-a-pill GLP-1, with 16.6–17% weight loss that beats oral Foundeo
• 1.3M Q1 prescriptions with 80% new patients implies market expansion
• UBT-251 claimed superior to retatrutide on early apple-to-apple data
• $675-per-month pricing positions for mass-market penetration
• The $100B selloff on the cagrisema miss was an overreaction: "The distance between 23% and 25% is 8% difference"

Bull case for Lilly (implicit across multiple episodes):

• Zepbound has surpassed Wegovy in market share in Q1 2026 (The Journal, May 27)
• Zepbound delivered 25% weight loss versus cagrisema's 23% in REDEFINE 4
• Retatrutide carries a 28–30% weight-loss bar (Olson, Knapp)
• Lilly is using GLP-1 cash to diversify into oncology, sleep, and vaccines (roughly $18.6B of M&A, Brew Markets, May 27)
• Biologic designation for retatrutide could lock in 12-year exclusivity and premium pricing (Knapp, On The Pen, May 27)

Bear on Lilly: Knapp flagged retatrutide's 11% dropout at the 12mg dose versus 6.2% at the highest tirzepatide dose, and warned that premium biologic pricing risks political backlash and gray-market proliferation. Olson added that 25% of SURMOUNT-1 weight loss is lean mass, which exacerbates mortality risk.

Bear on Novo: The stock has been "plunging by the most on record," cagrisema missed, injectable share has shifted to Lilly, and UBT-251 is still mid-phase and could disappoint like cagrisema. Doustdar concedes: "It will never go back to what it was."

Net read: Within this small sample, bull-Novo commentary came primarily from Novo's own CEO, while the sell-side voice (Olson) and the competitive structure favor Lilly's lead. The pill is a clear win, but it does not yet reverse the share-loss narrative in injectables. UBT-251 versus retatrutide is the binary that defines the next 18 months.

Debate 2: Oral vs. Injectable GLP-1

Bull oral: Doustdar argues 80% of Wegovy pill users are new to Novo, so the pill is market-expanding rather than a substitute: "If tomorrow people buy more pills from me than injection, then I'll turn the knob in the raw material factory to the right-hand side." Knapp notes younger, injection-averse patients adopting, and physicians who never prescribed GLP-1s now writing pill scripts at roughly $200 per month. Olson cites needle fatigue as a driver of about 50% discontinuation.

Bear oral: Knapp notes oral efficacy still trails injectable (a convenience-versus-potency trade-off), and the oral triple agonist remains unsolved in a crowded field.

Net read: A format-agnostic future. The pill is clearly additive based on Novo's own Q1 data; the cannibalization concern looks overstated.

Debate 3: Retatrutide, Biologic Designation Premium or Access Backfire?

Bull (Knapp, On The Pen, May 27): 12-year exclusivity prevents small-molecule generic competition, supports $2,000–$4,000-plus list pricing, and gives Lilly specialist-channel control.

Bear: It creates PBM gatekeeping, drives gray-market expansion, limits the addressable market, and invites political and IRA backlash. Knapp: "What exactly does Lilly want Retatrutide to become?... These goals do not coexist neatly."

Net read: An open binary. Lilly's pricing decision for retatrutide is one of the most consequential single-stock catalysts in pharma for 2026–2027.

Debate 4: China Biotech, Threat or Asset?

The consensus this week was an asset framing: UBT-251 is held up as proof that Chinese-origin molecules can become global competitive weapons in Big Pharma hands. Knapp called it "really exciting for scalability." The threat framing was not articulated this week.

Debates not covered this week: AI drug discovery (real vs. hype), whether biotech valuations have bottomed (XBI/IBB), pharma tariffs, IRA innovation impact, and manufacturing reshoring viability.

📊 Stock-by-Stock Bull/Bear

Large Pharma

LLY (Eli Lilly)

• Bull (Berry, Brew Markets, May 27): up roughly 50% over the trailing twelve months; aggressive M&A using GLP-1 cash (three vaccine deals at about $3.8B, Contessa for up to $7.8B, Colonia for up to $7.0B, roughly $18.6B total), buying early-stage de-risked assets.
• Bull (Olson, Let's Talk Future, May 27): pipeline includes inflammation targets (NLRP-3, IL-6), with GLP-1s positioned as the "world's first longevity drug," a major TAM reframing toward preventive medicine.
• Bull (Knapp, On The Pen, May 27): retatrutide at roughly 28–30% weight loss in Phase 3, biologic designation for 12-year exclusivity, iloralintide (amylin) in Phase 3, and a potential link to quintuple-agonist scientists.
• Bear (Olson, May 27): SURMOUNT-1 showed roughly 25% lean-mass loss, "you're solving one problem and exacerbating another," opening the door to muscle-sparing competitors.
• Bear (Knapp, May 27): retatrutide's 11% dropout at 12mg versus 6.2% in SURMOUNT-1, with biologic pricing risking gray-market and political backlash.
• No price targets.

NVO (Novo Nordisk)

• Bull (Doustdar, NVO CEO, The Journal, May 27): Wegovy pill at 1.3M Q1 prescriptions, "best US drug launch ever by volume outside vaccines," 80% new customers, 16.6–17% weight loss, and a Q1 earnings beat. UBT-251 may beat retatrutide; an H2 2026 capital markets day is a re-rating catalyst; a disease-modifier narrative spans kidney, liver, and CV.
• Bull (Olson, Let's Talk Future, May 27): inflammation pipeline (NLRP-3, IL-6), with the CSO publicly positioning semaglutide as a longevity drug.
• Bear (multiple, May 27): lost injectable share to Lilly, the cagrisema REDEFINE 4 miss (23% vs. 25% for Zepbound) erased more than $100B of market cap in one day, the stock is "plunging by the most on record," and the 50% Wegovy list-price cut compresses reported revenue. Doustdar is a 30-year Novo lifer (slower cultural-transformation risk), and a semaglutide Alzheimer's trial failed (per Olson).
• No price targets.

PFE (Pfizer): disclosed only as a Gottlieb board seat (Squawk Pod, May 26). No thesis discussed.

Large Biotech

• AMGN (Amgen) Bull (Olson, Let's Talk Future, May 27): forthcoming weight-loss maintenance data could support once-every-2–3-month injectable dosing, well-suited to chronic maintenance and the healthy-aging market. No bear articulated.
• GILD (Gilead) Bull (Gottlieb, Squawk Pod, May 26): obeldesivir shows preclinical efficacy versus Bundibugio Ebola. Bear: preclinical only, no human data on the new strain.
• MRK (Merck) Bull (Gottlieb, May 26): molnupiravir "potentially effective" preclinically versus Bundibugio Ebola, pipeline optionality. Bear: approved for COVID, not Ebola; preclinical repurposing claim only.
• REGN (Regeneron) Bull (Gottlieb, May 26): one of three antibodies in the approved Zaire cocktail shows cross-reactivity to Bundibugio and is already in clinical use. Bear: not a matched product, so commercial uplift is likely modest.

GLP-1 Challengers

• VKTX (Viking Therapeutics) Bull (Olson, Let's Talk Future, May 27): VK2735 has both oral and injectable formulations in development, giving real patient flexibility, and beyond weight loss "significantly reduces inflammatory markers, lowers blood pressure, and reverses prediabetes in a meaningful proportion of patients." Bear: earlier stage than Amgen and Lilly, with data still maturing.
• PTGX (Protagonist Therapeutics) Bull (Knapp, On The Pen, May 27): PN-477, an oral GLP-1 plus GIP plus calcitonin triple agonist, highly differentiated if proven. Bear: preclinical, roughly 7–8 years from patient use.

Small/Mid Biotech Catalyst Names

• Wave Life Sciences (WVE) and iBio (IBIO) Bull (Olson, Let's Talk Future, May 27): both target the activin E (inhibin E gene) pathway for fat-selective, muscle-sparing weight loss. Olson: "inhibiting this pathway appears to allow for fat-selective weight loss, with more muscle mass spared," and he is watching "very closely." Directly addresses the lean-mass bear case on tirzepatide. Bear: early clinical, with large-trial validation pending.
• MAP Biopharmaceuticals (private) Bull (Gottlieb, Squawk Pod, May 26): MBP134 monoclonal antibody for Bundibugio Ebola entering clinical trials with promising preclinical data.
• United Biotechnology (private, China): licensed UBT-251 to Novo for up to $2B (On The Pen, The Journal, May 27).
• BioMed / Bioglutide (private), CAUTION FLAG Bear (Knapp, On The Pen, May 27): NA-931 is claimed as an oral quad agonist with 6.4–6.8% weight loss in Phase 1 over 28 days, but Knapp flags data-integrity concerns: "folks across the Twittersphere who have called into question a lot of the data... things appearing to be copies of other data from other drugs. Almost word for word." Knapp: "Take the hype goggles off... there is reason to be skeptical."
• Hanmi Pharmaceutical (HMMUF, South Korea): HM15275 (GLP-1 plus GIP plus glucagon), preclinical, with 39.9% body-weight change in obese mice versus 15% for semaglutide and 25% for tirzepatide. Roughly 7–8 years away.
• Contessa Pharmaceuticals / Colonia Therapeutics (private acquisition targets): being acquired by Lilly for up to $7.8B (sleep) and $7.0B (oncology) respectively (Brew Markets, May 27).
• CVS Health (CVS) / Cigna (CI, Express Scripts parent) Bear (Knapp, On The Pen, May 27): the Tennessee Fair Rx Act prohibits PBM-pharmacy ownership; audit claims CVS Caremark reimbursed affiliated pharmacies up to 16,000% more than independents; Express Scripts generated roughly $30M in spread pricing from Tennessee employers. Regulatory contagion risk to other states.

💬 Notable Quotes

Mike Doustdar (NVO CEO) on the cagrisema selloff, The Journal, May 27: "The distance between 23% and 25% is 8% difference between those two numbers."

Mike Doustdar, The Journal, May 27: "Many of our colleagues feel like... after we get the sales back on track, it can go back to what it was. And it will never go back to what it was. You need to move forward."

Mike Doustdar on UBT-251 vs. retatrutide, The Journal, May 27: "Based on apple-to-apple comparison of early results, I would say the short answer to your question, yes, it can."

Mike Doustdar on the Wegovy pill, The Journal, May 27: "We have the first and the only peptide in a pill in the world... the patient does not have to compromise between injection and a pill."

Jay Olson (Oppenheimer biotech analyst) on tirzepatide, Let's Talk Future, May 27: "Approximately one quarter of the total weight loss on tirzepatide was lean mass... lean mass loss in middle-aged and older adults is associated with roughly a 30% increased risk of all-cause mortality. So you're solving one problem, that is obesity, and potentially exacerbating another problem in muscle loss."

Jay Olson on the TAM, Let's Talk Future, May 27: "Wall Street analysts forecast the total obesity and healthy aging drug market exceeding $100 billion in annual revenue by the mid-2030s. And we think that estimate could prove conservative once the full preventive medicine opportunity is properly valued."

Dave Knapp on Lilly's retatrutide strategy, On The Pen, May 27: "What exactly does Lilly want Retatrutide to become?... These goals do not coexist neatly."

Dave Knapp on market bifurcation, On The Pen, May 27: "Obesity medicine is slowly splitting into two Americas, one lane that is insurance-controlled, PBM-controlled, tightly managed access... and the harder the traditional system squeezes, the more it opens up lanes for direct-to-consumer."

Dr. Scott Gottlieb on GLP-1 and cancer, Squawk Pod, May 26: "I think there could be something real here. You know, the drug is impacting overall metabolic well-being... We know there's GLP-1 receptors on certain cancers, so there could be a direct effect."

Dr. Scott Gottlieb on Ebola, Squawk Pod, May 26: "The vaccines are at best six to nine months away. The therapeutics could be available right away."

Ann Berry on Lilly M&A, Brew Markets, May 27: "It would appear that the world's largest pharmaceutical company by market cap is using the windfall from its weight loss and diabetes shots to diversify its drug pipeline, acquiring medicines in early stage development rather than pay for existing blockbusters."

🗓️ Catalysts to Watch

🔍 Coverage Gaps

This was a thin, GLP-1-heavy week. Material themes that went unaddressed:

• AI in drug discovery: zero mentions. No commentary on Recursion, Schrodinger, Insilico, or the generalist AI/biotech thesis.
• Biotech M&A outside Lilly's specific deals: no broader deal flow, premiums, sentiment, or BD activity from MRK, BMY, PFE, or JNJ.
• FDA/HHS policy: only the acting FDA Commissioner appointment. No HHS commentary, no PDUFA, no vaccine policy.
• IRA / Medicare negotiation: not discussed.
• Gene and cell therapy: zero coverage.
• Oncology pipeline / ASCO: ASCO 2026 readouts not discussed despite timing.
• Patent cliffs / biosimilars, pharma tariffs, manufacturing reshoring / CDMO capacity: not discussed.
• Tools and CROs: no DHR, TMO, A, IQV, ICLR, or CRL commentary.
• Medtech: no ISRG, MDT, BSX, or EW commentary.
• XBI/IBB valuations / biotech bottom call: not discussed.
• Other GLP-1 challengers: no ALT, ZEAL, Structure Therapeutics, Roche, or Pfizer danuglipron commentary.
• Large pharma absent: BMY, AZN, GSK, NVS, RHHBY, SNY, ABBV, JNJ.
• Large biotech absent: VRTX, BIIB, MRNA, BNTX, ALNY, INCY (REGN and GILD appear only as Ebola pipeline optionality).

🎯 Bottom Line

The most actionable single takeaway is Doustdar's claim that UBT-251 can beat retatrutide on apple-to-apple early data (The Journal, May 27); if credible, it materially changes the Novo/Lilly long-term setup. The most actionable risk flag is Olson's quantification of tirzepatide lean-mass loss and its mortality association, which opens a differentiated bull case for activin E names (Wave Life Sciences, iBio) and longer-interval Amgen dosing. Given thin podcast coverage of M&A, tools/CROs, and medtech this week, this recap is best supplemented with sell-side notes. This is the kind of week where Matterfact's value is in saying plainly that the tape is one-sided rather than padding it out.

Sources

• On The Pen GLP-1 News, Dave Knapp, May 27, 2026
• The Journal, Mike Doustdar (NVO CEO) interview, May 27, 2026
• Let's Talk Future (Oppenheimer), Jay Olson, May 27, 2026
• Brew Markets, Ann Berry, May 27, 2026
• Squawk Pod, Dr. Scott Gottlieb, May 26, 2026

Oil podcast newsletter for May 27–30, 2026. The UAE's OPEC exit leaves Saudi Arabia as the last swing producer while a month-three Hormuz shutdown splits analysts between a Rystad capex supercycle and Arjun Murti's demand-destruction caution.

Oil: OPEC+, Shale & Geopolitics

Week of May 31, 2026

UAE quits OPEC. Hormuz hits month three.

A quick note before we get into it. The cartel just lost a fifth of its spare capacity, the strait is still shut, and the smartest people on the pod tape this week can't agree on whether we're staring at a supercycle or the prelude to a recession. That's not a debate you can hedge by buying the XLE and going to lunch. So let's go through what was actually said, and by whom.

TL;DR

• OPEC just became a one-country show. UAE's exit (effective May 1) cut OPEC spare capacity by roughly 20%, leaving Saudi as essentially the only swing producer left.
• The Hormuz shock is bigger than the headlines: ~12 mbd crude, ~14 mbd liquids, ~85 mtpa LNG offline per Rystad. Most oil comes back by year-end; Qatar LNG takes 1–5 years.
• Two analyst camps, one trade book. Rystad sees a $280B Middle East capex call (very bullish OFS). Murti at Super-Spiked counters: "geopolitical super vol, not super cycle," with demand forced down to 95 mbd and the back end of the curve barely moving.

What's new

1) The UAE walked. OPEC's spare capacity walked with it.

On the RBN Energy Blogcast, Roger Read laid out the math: IEA had pegged OPEC spare capacity at 3.4 mbd pre-crisis, of which UAE held 700 kbd. UAE leaves, OPEC spare drops ~20% to 2.7 mbd, OPEC+ falls from 4.4 to 3.7 mbd. The punchline: meaningful spare capacity is now Saudi Arabia (1.84 mbd) and a generous read of Iraq (520 kbd). That's it. Brent vol gets structurally higher from here, and the US Permian inherits more of the residual swing role whether it wants the job or not.

2) Rystad puts a number on the disruption.

On Let's Talk Energy, Aditya Saraswat (Rystad's head of MENA upstream) gave the most specific shock estimate I've heard: ~12 mbd crude and ~14 mbd liquids shut in, plus ~85 mtpa of LNG offline. Saudi and UAE held production to ~2/3 of pre-conflict via East-West and Fujairah bypasses; Iraq is at ~1/3. Qatar is the carnage: >90% crude offline, 100% LNG offline, with a 1-year minimum and 3–5 year worst-case to restore the LNG trains. That last bit is the part the equity tape hasn't fully digested.

"After normalization, it is logistics, not geology, that makes or breaks the recovery." Aditya Saraswat, Rystad, on Let's Talk Energy

3) Arjun Murti throws cold water on the supercycle.

On Super-Spiked (EP216), the former Goldman energy analyst reframed the whole regime as "geopolitical super vol, not super cycle." If Hormuz stays disrupted, demand gets forced down to ~95 mbd from ~105 mbd pre-crisis (a 10 mbd overhang) and "recession is the most likely clearing mechanism rather than a structural increase in long-dated oil prices." Murti will give you only "maybe $10/bbl" of cost-and-risk premium on the long end. For anyone underwriting a NAV step-up on $90 Brent forever: this is the friction.

4) The $280B capex call no one is talking about.

Back on Let's Talk Energy, Saraswat sketched the Middle East rebuild: ~$60B of incremental repair/bypass spend on top of a ~$120B annual baseline plus ~$100B of greenfield pipeline, call it $280B of capital call, much of it front-loaded. "Companies should book supply chain capacities now as a stop-loss." Translation: pricing power for SLB, HAL, BKR, TechnipFMC, plus the European subsea complex, is being underwritten regardless of where the crude tape settles. Investment decisions, he was explicit, are decoupling from production outages.

5) The structural Hormuz hedge is being poured in concrete right now.

Same episode: the UAE's Jebel Dhanna-to-Fujairah bypass is roughly 50% complete and will double UAE bypass capacity to cover pre-conflict UAE volumes. Saudi East-West expansion is "on the cards, with massive investment levels." Translation for the strip: there's a hard ceiling on how long any sustainable Hormuz risk premium can sit on Brent. 12–24 months from now, ADNOC and Aramco barrels look meaningfully de-risked.

The debate

Bull case (Rystad/Saraswat, Let's Talk Energy): Wartime Middle East equals $280B of forced capex, OPEC has lost its swing producer to defection, and the only way to get more barrels is to spend through the cycle. That's an unambiguous setup for international/offshore OFS, ADNOC and Aramco IOC partners (TotalEnergies, BP, Shell), and the Brent-levered intl E&P bench. Bypass infrastructure also resets the equilibrium higher because it makes the Gulf more investable.

Bear case (Murti, Super-Spiked): A prolonged disruption doesn't lift prices forever, it destroys demand. We end up below 100 mbd and "spend a good part of the remainder of this decade recovering." If you believe that, every long-cycle OFS thesis has a demand-side fuse on it that the bulls aren't pricing.

Both can be right at different points on the curve, and that's the actual trade. Front-end bid on disruption plus Saudi swing. Back-end capped by demand destruction and bypass capacity coming on. The middle is where positioning gets uncomfortable.

Read-throughs

• Brent-levered international E&Ps (Shell, BP, TotalEnergies, Eni, Equinor, PBR): Murti is constructive: "compelling upstream opportunity for Western firms, given improved fiscal terms." Watch for Iran optionality if a nuclear settlement materializes. Saraswat flagged Iran-Iraq border fields (Maroun, Azadegan) and South Pars-area gas as the most likely IOC re-entry targets.
• Offshore drillers + subsea (RIG, VAL, NE, SDRL, FTI, OII): Saraswat called this directly, "offshore is the new onshore" for the Middle East as onshore decline rates bite. Strongest single-line OFS bull thesis of the week.
• Qatar LNG counterparties (Shell, TotalEnergies, COP via QG JVs): The 1–5 year LNG recovery range is the under-discussed risk. If you have these names long, model the lower bound.
• Sanctioned-barrel flows / China: On The Sound of Economics, Alicia Garcia Herrero (Bruegel) and Jonathan Fulton (Atlantic Council) made the point that China has spent four years stockpiling discounted Iranian/Russian/Venezuelan barrels and is less Hormuz-vulnerable than Japan, Korea or SE Asia. Iranian/Venezuelan discounts look like a structural feature, not a bug, relevant for refiner margin dispersion.
• US shale (XOM, CVX, COP, EOG, DVN, CTRA, Permian Resources, Matador): Read's directional read on RBN: Permian could add ~1 mbd over five years, "could be more if the forward curve moves up in the back end." Modest, not heroic.

What didn't get said this week

I'll be honest: US shale M&A didn't show up on the tape at all this week. No deal flow, no Tier-1 inventory talk, no named target/acquirer dynamics, no private-seller chatter, no accretion math. Same for refiner cracks, midstream gatherer specifics, and Venezuela/CVX license policy. The Hormuz war is sucking all the oxygen out of the conversation. We'll keep watching: when the M&A discussion comes back, that's its own signal.

Sources

• Let's Talk Energy, "Why Iranian oil could be the biggest energy story of the decade," Aditya Saraswat, Head of MENA Upstream Research, Rystad Energy (2026-05-27)
• RBN Energy Blogcast, "Canary in a Coal Mine: The UAE's OPEC Exit," Roger Read, RBN Energy (2026-05-27)
• Super-Spiked, "SoH Crisis Drags On, But Some Thematic Clarity Emerging (EP216)," Arjun Murti, former Goldman Sachs senior energy analyst (2026-05-30)
• The Sound of Economics, "Reassessing China's role in the Middle East," Alicia Garcia Herrero (Bruegel) and Jonathan Fulton (Atlantic Council) (2026-05-27)

Neuro and Alzheimer's pipeline newsletter for May 24–31, 2026. Biogen's anti-tau Derenersen misses its Phase II primary but flags an AD subgroup signal, while the blood-biomarker complex keeps racing ahead and big-company launch commentary stays conspicuously quiet.

The Neuro & Alzheimer's Pipeline

Week of May 24–31, 2026

Biogen's tau program got a second act this week, even as the broader trial result disappointed. The diagnostic side of the field keeps racing ahead while the therapeutic side grinds, and the most striking thing about the week's commentary is what it left out: almost nothing on the major launch ramps. Below is the synthesis.

TL;DR

• Biogen's anti-tau Derenersen missed its Phase II primary in the broad CELIA trial, but a pre-specified Alzheimer's subgroup showed slowing of clinical decline, and Biogen says it will engage regulators. Messy, but it keeps post-Leqembi optionality alive.
• The blood-biomarker drumbeat got louder: serum p-tau217 now looks operationally comparable to plasma, and a separate academic team rolled out a 21-protein early-detection panel claiming an 88% cost saving vs. PET.
• Big-company commentary was unusually quiet. No fresh coverage in the last week on Kisunla, Leqembi/IQLIK, Roche trontinemab, AbbVie emraclidine, KarXT/Cobenfy, or CMS coverage. That silence is itself a signal (see "What changed vs last week").

What's new

Biogen's Derenersen, the tau program just got a second act. NeurologyLive's Mind Moments News Minute flagged top-line Phase II CELIA results for Biogen's anti-tau therapy Derenersen: missed the primary endpoint, but a pre-specified AD subgroup showed slowing of clinical decline and Biogen says it will engage regulators on next steps. News read by host Marco Maglio. The narrator also noted "increasing discussion" of stacking anti-amyloid plus anti-tau in combination. For BIIB this is messy (subgroup wins don't ship drugs) but it keeps optionality on the post-Leqembi pipeline alive and complicates the simple bear story that BIIB has nothing behind Leqembi.

Serum p-tau217 now looks as good as plasma, diagnostic friction is dropping fast. Dr. Barack Arslan of Sahlgrenska University Hospital, Gothenburg, told Clinical Chemistry Podcast that serum p-tau217 performs comparably to plasma p-tau217 (different cutoffs, but similar diagnostic value), and that the marker "increases up to two decades before the onset of clinical symptoms." A practicing clinical chemist who ran the assay study. He also flagged that newer brain-derived p-tau217 assays may improve specificity by reducing peripheral-source confounding. This is the bull case for the entire blood-diagnostic complex (C2N PrecivityAD2, Roche Elecsys, Quanterix, Fujirebio, LabCorp/Quest): serum better than plasma means easier draws, easier shipping, easier integration into primary-care workflow.

A new 21-protein panel claims 88% cost savings vs. PET. Dr. Yuanbing Jiang, inventor of PlasmarkAD, said on AUTM on the Air that the panel hit 96% accuracy in Hong Kong Chinese and Spanish cohorts, was licensed to private Cognitect Limited, and has been used in 1,000+ patients within six months of its 2025 Hong Kong launch. Inventor and licensor. His sharpest line: with anti-amyloid mAbs only working in early disease, biomarker-based detection "is not an optional option, it's the key for diagnosis." Take the 96%/88% numbers with the usual academic-claim salt (single-developer data, non-US cohorts) but the directional message lines up with what Roche, Lilly, and C2N have been telling the buy-side.

A KOL's framing of the mAb class: "a beginning, not the solution." Dr. Gil Rubinovich of UCSF's Alzheimer's Disease Research Center gave the longest think-piece this week on Healthy Dialogue, characterizing lecanemab and donanemab as showing roughly 30% slowing of cognitive/functional decline, roughly 30–35% reduction in MCI-to-dementia conversion, and ARIA in roughly 20–30% of patients in Phase 3. A practicing dementia specialist. His most important call: pre-symptomatic prevention trials with both antibodies are expected to read out in roughly 2027–2028, i.e., the next real catalyst for the class isn't a sub-Q launch, it's whether you can treat patients before symptoms appear at all.

The debate

Bulls. Sub-Q lecanemab (IQLIK) is in market, sub-Q donanemab is in development, serum p-tau217 is now operationally comparable to plasma, and a 21-protein panel is claiming 88% cheaper diagnosis than PET. Stack those and the diagnostic-to-treatment funnel goes from "specialist + PET + IV infusion every two weeks" to "PCP draws blood + monthly autoinjector." Add Rubinovich's reminder that 2027–2028 prevention readouts could re-position the class from disease-modifying to disease-preventing, and the multi-billion franchise math gets very real.

Bears. Rubinovich himself called the current generation "a beginning, not the solution": 30% slowing isn't 30% reversal, and 20–30% ARIA hasn't disappeared because the drug is sub-Q. Derenersen missed its primary, which is a reminder that tau remains an unforgiving target; subgroup salvage stories almost never become approved drugs without a confirmatory Phase III. And we don't have a single piece of operator evidence this week about Kisunla or Leqembi/IQLIK unit volumes. When no operator wants to talk about the ramp, that's its own data point.

The cleanest summary of this week: the diagnostic side is racing ahead, the therapeutic side is still grinding.

Stocks in play

Biogen (BIIB): Bull: Derenersen AD-subgroup signal keeps the post-Leqembi pipeline alive; combination amyloid plus tau narrative resurfaces. Bear: A Phase II primary miss is a primary miss; Eisai still owns the lead Leqembi economics. Next catalyst: Biogen's regulator engagement on Derenersen path forward, plus any Leqembi/IQLIK quarterly volume update.

Eli Lilly (LLY): Bull: Rubinovich's framing of 2027–2028 pre-symptomatic prevention readouts puts donanemab in line for a category-redefining indication. Bear: No fresh color on Kisunla launch trajectory this week; silence isn't a positive when you're carrying launch expectations. Next catalyst: Pre-symptomatic donanemab trial updates and any sub-Q development milestone.

Eisai (4523.T): Bull: IQLIK sub-Q lecanemab plus serum p-tau217 evidence both reduce friction on the Leqembi ramp. Bear: No operator color on Leqembi/IQLIK volumes this week. Next catalyst: Quarterly Leqembi sales disclosure.

Roche (ROG.SW / RHHBY): Bull: Elecsys p-tau217 is well-positioned if serum-comparable-to-plasma evidence continues to stack. Bear: No trontinemab or bepranemab color this week, a clean miss on the most-watched non-amyloid program. Next catalyst: Trontinemab Phase III enrollment/initiation updates.

Quanterix (QTRX): Bull: Every "serum p-tau217 is good enough" data point widens the addressable Simoa market. Bear: Not named in this week's coverage; competitive entries from academic groups (PlasmarkAD) and large reference labs continue. Next catalyst: Reference-lab adoption metrics.

Lantheus (LNTH) and GE HealthCare (GEHC): Bull: If serum p-tau217 only handles screening, PET still anchors confirmatory diagnosis and trial enrollment. Bear: The 88% cost-savings claim from PlasmarkAD, if generalized, is precisely the structural threat to amyloid-PET volume. Next catalyst: PET volume disclosure in Q2 prints.

Option Care Health (OPCH): Not mentioned this week; infusion-center thesis remains a function of IV mAb persistence vs. sub-Q migration. Bear watch: every IQLIK autoinjector script is, mechanically, a script not going to an infusion chair.

Read-throughs

• Blood diagnostics (QTRX, C2N, Roche Elecsys, Fujirebio, LabCorp/Quest): Two of this week's episodes were diagnostic-focused. Direction of travel is unmistakable: easier specimen handling, earlier detection, lower cost.
• PET imaging (LNTH, GEHC): Direct competitive threat from cheaper blood panels picks up a fresh data point this week; watch utilization trends.
• Infusion centers (OPCH): Quiet this week; the IQLIK sub-Q migration is the structural story.
• Tau / non-amyloid: The Derenersen miss is a category data point, not just a BIIB story. Roche bepranemab, Eisai E2814, Lilly remternetug all get re-rated on this news, though none surfaced in commentary this week.
• Broader CNS (KarXT/Cobenfy, Vyalev, Huntington's): Zero coverage in the last week.

What changed vs last week

• New: First confirmation of the Derenersen Phase II miss plus AD subgroup signal.
• Reinforced: Serum p-tau217 approximately equals plasma p-tau217 narrative; academic blood-diagnostic competition continues to widen.
• Notable silences (a real signal): No coverage in the last week of Kisunla launch trajectory, Leqembi/IQLIK ramp, Roche trontinemab, bepranemab, AbbVie emraclidine, Vyalev, KarXT/Cobenfy, or CMS NCD/CED policy. When the buy-side and the journalists go quiet on a launch in its first eighteen months, that is itself a data point worth carrying into next week's KOL calls.

Sources

• Healthy Dialogue, A New Era in Dementia: Advances in Diagnostic Blood Tests, Novel Drugs, and the Power of Lifestyle Changes, May 21, 2026 (Dr. Gil Rubinovich, UCSF)
• Clinical Chemistry Podcast, Diagnostic Value of Serum p-tau217 in Alzheimer Disease, May 18, 2026 (Dr. Barack Arslan, Sahlgrenska University Hospital; host Bob Barrett)
• NeurologyLive Mind Moments, New AASM Guidance on Combination Treatment for Chronic Insomnia (News Minute segment), May 29, 2026 (host Marco Maglio)
• AUTM on the Air, Detecting Alzheimer's Earlier with a Simple Blood Test, May 27, 2026 (Dr. Yuanbing Jiang; host Lisa Mueller)

Insurance pricing newsletter for May 24–31, 2026. A quiet tape produced two operator voices, a casualty underwriter and a runoff CEO, independently calling the hard market over, plus a Gallagher Re finding that reframes the entire rate-adequacy debate.

Insurance Pricing Turns

Week of May 24–31, 2026

A quiet week on the tape can still be a loud one for the thesis. Two operators with nothing to gain from the message, a casualty underwriter and a runoff CEO, went on different shows and, within 24 hours of each other, called the hard market over. June 1 is days away. The silence around it from the usual suspects is its own data point.

TL;DR

• Two operator voices independently declared the hard market done this week. Casualty rates that were +10–13% six months ago are now mid-single-digits and headed to flat. Property "race to the bottom" already underway.
• The single most actionable stat of the week: 80–90% of insurance loss-cost growth over the last 18 years has come from non-hazard factors (CPI, materials, labor, social inflation), per a newly released Gallagher Re study, meaning rate-vs-trend math is uglier than the property-cat fear narrative suggests.
• Alt capital is rotating from property to casualty. The Bermuda casualty sidecar is becoming a real product category, watch for second-derivative pressure on casualty pricing right as it becomes the last firm line.

📰 What's New

1. A casualty veteran eulogized the hard market on tape.

On the Insurance Guys Podcast, Ty Robben, former SVP Casualty Underwriting at Palomar Specialty, said flatly: "Hard market's over. Casualty, I think, is the last holdout." He walked through the deceleration in numbers most analysts would kill for: general casualty was "easily high single digits, even getting teens" six months ago, with reinsurers pushing "low teens or 10%." Today, he'd "be surprised if general casualty is getting four or five." A year from now? "I'd be shocked if rates are still positive."

That's not pundit handicapping. That's a guy who quoted the rate trying to put it in your file.

2. The runoff CEO confirmed it from the other side of the trade.

Will Bridger, Group CEO of Compre, told The Voice of Insurance the same thing in different words: "Live market is softening almost all over the place. It's about to soften. It already has." He went on to explain why this matters for legacy/runoff deal flow: when live margins compress, marginal portfolios "suddenly become a little bit more urgent" for capital optimization. That's the cycle telling on itself: when runoff supply picks up, the live underwriters are quietly cleaning house.

3. The most important number you'll read this quarter.

On The Florida Insurance Roundup, Gallagher Re's Chief Science Officer Steve Bowen released a stat that should reframe every rate-adequacy debate at every reinsurer:

"Weather and climate factors played a relatively small part, 10% to 20% of those lost costs... the biggest cost drivers, a whopping 80% to 90%, were linked to non-hazard factors."

Eighteen-year look-back. The 80–90% bucket is oil and asphalt prices, construction materials, labor, CPI, AOB, social inflation.

Bowen also dropped this in passing: "Thunderstorms on an aggregate basis have actually been more expensive than hurricanes over the last 20 to 25 years." SCS losses crossed $10B for the first time in 2008, and have been over $50B annually each of the last three years. The cat budget the Street is modeling is for the wrong peril.

4. Alt capital is migrating into casualty, and they don't know what to charge.

Bridger detailed Compre's Q4 2025 launch of the George Street Re sidecar alongside Caledris (the Trahan/Miller ex-OTPP/ex-Blackstone vehicle), Culpeper, and QBE Re. "There's a real interest in deploying more capital into the casualty markets, and that capital is coming from lots of different places." The honest part: "You're being asked day one to price an event in anywhere between five and seven or even 10 years' time." Property cat you mark to wind; casualty you mark to a jury that hasn't been empaneled.

This is the alt-cap-pressuring-rates story most analysts expect for property, except it's showing up in casualty just as casualty becomes the last firm line. If a wave of inexperienced third-party capital underprices casualty tails in 2026–2027, the reserve-adequacy bill arrives in 2030.

5. Florida tort reform is actually working.

Quiet structural news inside the same Insurance Guys episode: Bradley Flowers of Portal Insurance put it bluntly, "Who would have ever thought tort reform would work?" Robben extrapolated that nationwide casualty reform plus distribution consolidation could enable "a really incredible soft market." The combination, disinflation in social inflation plus fresh sidecar capital, is the bear scenario for casualty rates that nobody's modeling.

⚖️ The Debate

The bull case for the (CB/TRV/AIG/RNR/EG/ACGL) trade is that property-cat is normalizing off a peak we shouldn't have expected to last, attachment-point discipline is holding, casualty firming is offsetting, and investment income on the float gives you a multi-year cushion regardless. We heard none of that on the pods this week.

What we did hear was the other side, stated by people who don't usually get on tape to be bearish:

"Hard market's over. Casualty, I think, is the last holdout.", Ty Robben, Insurance Guys

Combine that with Gallagher Re's 80–90%-of-loss-cost-is-non-hazard finding, and the worry isn't a hurricane season, it's that the industry has been pricing for hazard while the cost curve is being driven by CPI and litigation. Soft market plus persistent non-hazard inflation equals combined ratios that decay faster than reserve releases and investment income can paper over.

The bull side simply wasn't voiced on the tape we follow this week. Worth noting before you treat the bear case as consensus.

🎯 The Names in Play

Specific stock commentary was sparse, but one quote is worth flagging:

Chubb (CB): Robben, looking back at Q3/Q4 2025: "When Chubb and everybody was posting record results... I'm like, yeah, this has gotta be the top." Not a model input. Useful as the gut check of someone who's watched five of these cycles.

Everest (EG): only cited historically, as the underwriter who exited East Coast habitational in 2019–2020 and looked smart for it. The implication: watch what the disciplined names stop writing, not what they say at conferences.

Travelers, AIG, RenaissanceRe, Arch, Kinsale, W.R. Berkley, and Markel: silent this week. The brokers (MMC, AON, AJG, WTW): silent this week. If any of those names get name-checked next week, we'll lead with it.

🔁 Read-Throughs

Pure reinsurers (EG, ACGL): no direct commentary, but Bridger's framing on softening live markets and Robben's mid-single-digit reinsurance casualty rates suggest the rate beta is decelerating into the back half of 2026. Discipline on attachment points was not discussed, the absence is conspicuous five days from 6/1.

ILS / cat-bond managers: Bridger's tell: "In a benign property cat environment, ILS managers are not overly interested in putting tail solutions in because they don't have a lot of trap capital." Translation: cat-bond manager economics are quietly being squeezed by their own success. No 2024-style losses means no trapped capital means thinner premium pools means harder fundraising next vintage.

Brokers benefiting from volume over rate: not addressed on tape this week. Worth pressing on next week.

Primary specialty / E&S (KNSL, WRB, MKL): not addressed. But Robben's commentary on auto and habitational "never getting soft" because of structural social inflation has a clear read-through to E&S placements in distressed classes: the bid for genuinely tough risk stays expensive even as the rest of the market drifts down.

Sources

• The Voice of Insurance, Ep303 Will Bridger Compre: Beyond traditional Legacy (May 26, 2026)
• The Florida Insurance Roundup, Episode 64 – Hidden Cost Drivers of Severe Storms (May 26, 2026)
• The Insurance Guys Podcast, The Greatest Challenges and Opportunities in Casualty Underwriting Today (May 27, 2026)

GLP-1 complex newsletter for the week of May 25–28, 2026. Lilly's retatrutide top-line pulls bariatric surgery into a price fight while Novo's CEO concedes the branded list-price ceiling ahead of ADA.

The GLP-1 Complex

Week of May 25–28, 2026

Two things happened in the last seven days that real money should care about. Eli Lilly's retatrutide put up a number that pulls bariatric surgery's pricing moat into a knife fight, and Novo's CEO walked onto The Journal and quietly conceded the list-price ceiling on branded GLP-1s. Everything else this week is a footnote to those two, but a couple of the footnotes are worth your morning coffee, so let's get into it.

TL;DR

• Retatrutide TRIUMP-1 top-line landed: 28.3% body weight loss at 80 weeks, 45.3% of patients hit the >30% weight-loss bar that historically belonged to surgery, and discontinuations came in below placebo. Full data hits ADA in early June.
• Novo capitulated on list price. Wegovy goes to $675/mo in 2027, a 50% list cut; Ozempic down about 35%. CEO Mike Doustdar called the list-to-net spread "out of whack." The net-price story is now the only story.
• Real-world persistence climbed from 33% to 61% over the last five years, and the anti-inflammatory read on osteoarthritis is getting louder, both quietly bullish for chronic-therapy revenue and quietly bearish for ortho volumes.

🆕 What's new

Retatrutide just made bariatric surgeons nervous. On Diabetes Dialogue's pre-ADA episode, endocrine specialist Natalie Bellini walked through Lilly's TRIUMP-1 top-line: 70.3 lbs, 28.3% body weight, 45.3% of patients >30%, "where bariatric surgery plays a role." The 104-week extension in the higher-BMI cohort hit 30.3% and had not plateaued. The kicker: "The discontinuation rate, ready for this, is lower than placebo." If that holds in the full read-out at ADA, retatrutide isn't just a more powerful drug, it's a more tolerable one, which is the part of the model the Street still underwrites conservatively.

"45.3% of participants hit greater than or equal to 30% weight loss, which is where bariatric surgery plays a role.", Natalie Bellini, Diabetes Dialogue, May 28

Novo's CEO told you the price war is real. On The Journal, Mike Doustdar confirmed Novo is dropping US list to $675/month in 2027, half off Wegovy, a third off Ozempic. He framed it as cleaning up a "list-to-net out of whack," which is CEO-speak for we were already there on rebate; we're just rationalizing optics. Read it that way and you should be tightening your gross-to-net assumptions, not your topline. He also disclosed oral Wegovy is doing >1.3M scripts in Q1 with 80% of pickups being new patients: that's not cannibalization, that's a needle-averse cohort finally entering the funnel.

SURMOUNT-MAINTAIN says the chronic-therapy thesis has teeth. On Docs Who Lift, Spencer and Karl Nadolsky walked through the dose-de-escalation data: of patients who hit about 22% weight loss on max-dose tirzepatide, only 8% needed rescue therapy if they stayed on max vs. 25% who down-titrated to 5mg and 67% who went to placebo. Translation: this is a chronic drug, period. Worth flagging that Karl Nadolsky disclosed on-air he's a "paid speaker for Lilly on orforglipron," so discount his orforglipron commentary accordingly.

Orforglipron pricing matters more than orforglipron data. Same Docs Who Lift episode: ATTAIN-MAINTAIN data showed patients switching from tirzepatide to orforglipron held about 75% of weight loss; the sema-to-orfo switch held about 80%. Standalone, orfo lands at about 11% weight loss, clearly second-tier on efficacy. But here's the spicy bit from Spencer Nadolsky:

"I could totally see [insurers mandating a switch to orforglipron] because of these trials… from a direct-to-consumer cost perspective."

A treating physician anticipating PBM step-therapy onto the cheaper oral. That's exactly what gross-to-net compression looks like before it shows up in a Lilly 10-Q.

Persistence has nearly doubled. Dr. Paul Kolodzik on The Second Opinion Podcast cited 12-month persistence rising from about 33% in 2021 to about 61% today, attributing the move largely to out-of-pocket cost coming down. He didn't cite a study, so anchor to it with a grain of salt, but it directionally aligns with what payers are seeing.

⚖️ The debate

Bull case (loud on the tape this week): 28% weight loss at retatrutide doses with discontinuations below placebo, 45% hitting bariatric-grade weight loss, persistence climbing past 60%, oral Wegovy pulling in needle-averse new patients at 1.3M scripts in a single quarter. The TAM compounds; the medical pool keeps growing; durable chronic dosing is materializing in real-world data.

Bear case (subtler, but in the same tapes): A 50% list cut isn't a victory lap, it's a ceiling. Doustdar himself flagged that e-health/DTC is the fastest-growing channel for both Novo and Lilly, a margin-dilutive mix shift dressed up as growth. Novo's pipeline answer is a Chinese-sourced triple agonist (UBT-251), which is the CEO talking his book at Phase 2. And the same physicians who like the drugs are openly anticipating PBM step-therapy onto cheaper oral GLP-1s.

The fast-followers worth pricing into a bear case, Amgen MariTide, Viking, Structure, Roche petrelintide, were silent on the investor podcasts this week. With ADA the following week, that silence likely doesn't last.

🎯 The names in play

LLY: Bull. The retatrutide top-line is the cleanest tape we've had on the name in months. Next catalyst is the full data drop at ADA in early June, then TRIUMP-2 (T2D) and TRIUMP-3 (CVD) in H2 2026. Watch the tolerability print at full data; if discontinuation truly tracks below placebo, the Street is still under-modeling persistence.

NVO: Mixed. The pricing reset clears uncertainty but caps the upside. Oral Wegovy traction is real and the 80% new-patient mix is a structural positive. But Doustdar volunteering UBT-251 as a retatrutide answer in Phase 2 is exactly the kind of CEO commentary you fade.

DXCM: Material new headline. On Diabetes Dialogue, Diana Isaacs and Bellini disclosed that two scrapped DexCom sensor lots, pulled pre-sterilization for quality failure, were stolen from trucks and resold by third parties. That's a sterility-risk patient-safety event with reputational tail risk. Layer it on Abbott's CE mark for Libre Duo (dual glucose/ketone, 15-day) and the competitive setup just got worse. This deserves a phone call to IR.

SYK / ZBH: Quiet bearish. Kolodzik flagged osteoarthritis pain relief on GLP-1s beyond what weight loss alone explains, attributing it to the anti-inflammatory mechanism. If that read holds in published data, the structural knee/hip surgical pool shrinks, not just delays.

🔁 Read-throughs

Bariatric / ISRG: Bellini explicitly said retatrutide's 45% >30%-weight-loss rate is "getting close to the bariatric surgery data," and Isaacs corroborated that patients are actively delaying surgical referrals to wait for retatrutide. The bariatric volume hit moves from "potential" to "happening."

Sleep apnea (RMD/INSP), cardiac monitoring (IRTC), packaged food (PEP/MDLZ/GIS/HSY), pen-device suppliers (WST, Stevanato), Catalent fill-finish: Not voiced on the investor podcasts this week. Worth noting the staples read-through gap given how loud that debate has been in prior weeks, likely waiting for the next round of grocer scanner data.

🔀 What changed

The price-ceiling debate is effectively settled. Novo's $675 list isn't a hypothetical; it's a 2027 reality, and Lilly's response is now the question, not whether one is coming. Combine that with retatrutide's tolerability print and persistence climbing into the 60s, and the model you're running on branded GLP-1s should look less like a luxury good and more like a chronic specialty drug with secular volume tailwinds and a flat-to-down price curve. That's a different multiple.

The fast-follower silence is conspicuous. ADA week is going to be loud.

Sources

• Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, "CKM Systems, Triple Agonists, and a Sensor Scandal Ahead of ADA" (May 28, 2026)
• The Journal. (WSJ), "Novo Nordisk's CEO Has a Comeback Plan" (May 26, 2026)
• Docs Who Lift, "GLP-1 Maintenance: What Happens When You Lower Your Dose, Switch Medications, or Stop Entirely" (May 25, 2026)
• The Second Opinion Podcast with Dr. Paul Kolodzik, "EP 120 GLP-1 News + Other fun medical facts" (May 28, 2026)

G10 FX newsletter for May 24–31, 2026. JPMorgan's FX desk turns high-conviction short EUR/USD while sterling, the Swissie and the yen barely register on tape, leaving one house's dollar-bull call as the loudest voice of the week.

G10 FX: EUR, GBP, CHF & the Yen Carry

Week of May 24–31, 2026

This was supposed to be the year the dollar quietly faded: ECB nearly done cutting, BoE stuck high, Tokyo with its finger on the trigger. Then JPMorgan walked onto its own podcast on Thursday and politely informed the market that the euro is now a high-conviction short. The other three majors barely showed up on tape this week, which is itself a story.

TL;DR

• JPM's FX team turned firmly bearish EUR/USD. Short-term fair-value box: 1.08–1.14. A roughly 50bp real-rate shift back to the dollar, the seventh straight eurozone growth downgrade, and a French Q1 contraction did the work.
• Carry conditions are still green, but the cushion is paper-thin. Aggregate FX vol below 6.5, post-COVID lows, headroom maybe one vol point. JPM wants AUD/JPY expressed in options, not spot.
• Sterling, Swissie and yen barely showed up on tape. No SNB intervention chatter, no MoF tape-bomb dissection, only a passing EUR/GBP skew aside on cable. Read the silence as a signal, not a thesis.

What's New

The euro's pivot is now JPMorgan's house view. On JPMorgan At Any Rate (May 29), Meera Chandan (Co-Head of FX Strategy, London) called EUR/USD weakness "entrenched," with JPM's short-term fair-value model now at 1.08–1.14. The catalysts she stacked were unusually clean: stagflationary European PMIs ("output measures down, price measures up"), seven straight eurozone growth downgrades, and roughly 50bp of real-rate differentials shifting back toward the dollar. Her line worth keeping:

"It just doesn't compute that EUR/USD hasn't really broken out of its Jan/Feb range, even though you've seen a 40%, 45% increase in Brent and gas prices… almost 50 basis point narrowing in the real yield differentials between Europe and the US." (Meera Chandan)

That sentence is the bear case in a box.

France is doing the bears no favors. Same episode, host Pat Locke flagged the May 29 French Q1 GDP print as a contraction and called French PMIs "terrible," noting JPM's European activity surprise indices have been negative for roughly 2.5 months while the US is neutral-to-positive. None of that is news to anyone watching Paris, but it gives the bearish-EUR turn a country-composition story, not just a macro one.

The dollar is "2% cheap" to real rates. Locke argued DXY has decoupled from the US real-rate move and has catch-up to do. His preferred expressions: short EUR/USD and long USD/CAD with a target of 1.41–1.4150. He also called out two binary June catalysts: a third consecutive US payrolls beat ("would be material… US exceptionalism shot in the arm") and Kevin Walsh's first FOMC meeting as Fed chair, with Fed-speak skewing "increasingly hawkish."

Carry still pays, but the vol cushion is one point thick. Ladislav Jankovic (Senior FX Vol Strategist) put aggregate FX implied vol below 6.5 ("post-COVID lows last seen in 2019/early 2020"), with VIX under 16 and rates vols compressing too. His framing: still "very, very supportive of carry," but at most one vol point of further compression is available. Honest read: realized vol is finding a floor, and risk-reward on running carry naked is deteriorating even as the trade keeps printing.

AUD/JPY is the cleanest cross-yen, but optionalize it. Jankovic specifically named AUD/JPY as an interesting cross-yen carry expression "at this level of vols," and pointedly said to optionalize it rather than run it in spot. In a week with no actual MoF or BoJ chatter on tape, this was the closest thing to an August-2024-redux hedge framework anyone voiced. He also flagged elevated EUR/GBP skew that was already wide before recent UK political stress, a structural fade candidate via options, not a directional cable call.

RBNZ moved the high-yield leg forward. Arindam Sandilya (Co-Head of FX Strategy, Singapore) said the RBNZ came in "a little bit more hawkish than expected," prompting JPM to bring forward NZD hike expectations to 100bp of hikes starting July 2026. NZD outperformed on the week. For the G10 carry hierarchy, that's a meaningful upgrade of the high-yielder leg, particularly against JPY and CHF funders.

The Debate

I'd steel-man both sides, but I have to be honest about what the week's tape actually carried.

The bear-EUR / bull-USD camp is the only camp that walked into the studio. JPM's argument is clean and reinforcing: stagflationary European data, French contraction, real-rate differentials shifting roughly 50bp toward the dollar, the dollar trading 2% cheap to those real rates, and US data into June (payrolls, Walsh) skewed to widen the gap. EUR/USD fair value 1.08–1.14, USD/CAD long to 1.41–1.4150, dollar exceptionalism extended into summer.

The "euro to 1.20, cable to 1.40, carry still pays as the dollar fades" camp, the structural ECB-done-cutting / BoE-stuck-high / SNB-and-Tokyo-quietly-tightening view, did not get voiced on the podcasts we follow this week. Same goes for the "UK gilt accident makes sterling the G10 short" and "BoJ hike plus a risk wobble triggers a violent USD/JPY unwind back through 140" tail cases. Those are real debates; the strategists who'd make them just didn't publish to the pod stream in this window.

Read JPM's call as the highest-conviction G10 view on the recorder this week, not as cross-house consensus. One coordinated firm-wide message, however well-argued, is not the market.

The Trades in Play

The actionable lines on the tape, in conviction order, all from the same JPM episode, which means you're sizing one house's confidence, not corroborated consensus:

• Short EUR/USD. Fair value 1.08–1.14; payrolls and Walsh's first FOMC are the near-term tells.
• Long USD/CAD, 1.41–1.4150. Locke's cleanest dollar expression. Layer in a July-1 USMCA-review option overlay if you want the tail (Jankovic's tip).
• AUD/JPY via options, not spot. Carry's still on, but the realized-vol floor plus August-2024 muscle memory means you pay for the right tail, you don't sell it.
• Fade EUR/GBP skew as a relative-value vol expression. Not a directional cable call.

Read-Throughs

If JPM is right and the real-rate gap keeps tilting dollar-ward, the natural follow-ons:

• Bunds underperform Treasuries as the differential widens back out.
• EUR/JPY drifts heavier, the EUR leg does some of the work the funder used to do alone.
• European exporters get a small FX offset to the activity slowdown.
• No Swiss read-through anyone wants to underwrite this week. With CHF near multi-year highs and Swiss CPI flirting with deflation, the SNB-intervention question hangs over Nestle, Roche, Novartis, Swatch, Richemont, and ABB, but nobody on tape touched it. Worth keeping a finger on for next week.

The bigger asymmetric tail is the one nobody voiced: with aggregate FX vol pinned at post-COVID lows and VIX under 16, the global carry book is sized for a regime it is already at the bottom of. AUD/JPY in options is one way to internalize that. So is buying VIX into June payrolls if you don't already have it.

What Changed

Three weeks ago, "the euro grinds higher to 1.18–1.24" was a reasonable consensus framing. This week, the largest US bank's FX desk politely turned that into a short. That's not a regime change, yet. But it's the kind of shift that, if anyone outside 270 Park Avenue corroborates next week, becomes one.

Sources

• JPMorgan At Any Rate, Global FX: Bearish EUR factors intensify, USD decouples from real rates, and an update on low FX vols (May 29, 2026)

Freight and rails newsletter for May 25–31, 2026. Truckload spot cleared contract for the first time since COVID while a Supreme Court broker-liability ruling repriced insurance overnight and Hub Group disclosed a $77M restatement.

The Freight Cycle: Trucking & Rails

Week of May 25–31, 2026

Quick one this week. The freight tape finally cracked. Spot rates are running above contract for the first time since COVID, asset carriers are saying out loud that they're getting picky again, and a Supreme Court decision on broker liability just doubled some brokers' insurance overnight. Oh, and Hub Group dropped a $77M restatement and lost its CFO and COO in the same breath. Rails? Crickets all week, which is its own data point.

TL;DR

• Truckload spot is now above contract for the first time since COVID. TruckStop says load-to-truck ratios are breaking records on its platform, and at least one mid-cap carrier is openly saying it has pricing leverage again.
• The SCOTUS Montgomery decision is repricing broker liability in real time: broker insurance quotes are already running >2x year-ago within a week of the ruling, and small brokers are starting to fold.
• HUBG is the cleanest single-name event of the week: $77M understated, CFO and COO out the door, securities investigation under way. Rails were silent enough to be worth flagging.

🆕 What's New

1. Spot finally cleared contract. On Freightonomics this week, FreightWaves' Brittany Chisinau put it as plainly as she ever does: "spot rates… they're skyrocketing compared to contract. This is going to put more pressure on the contract market… We have not seen this level since COVID where the spot rate is above [contract]. Contracts continue to grow. I expect that to happen throughout the year." She's also flagging tender rejections holding above 15% the week after Memorial Day, a level she doesn't expect to give back this month.

2. TruckStop is calling a record. John Howland, who runs TruckStop.com and sees load-board data in real time, told FreightWaves' Brake Check: "we're breaking records at TruckStop with the load to truck ratio… we are also moving more freight within our spot market today than we have in a super long time." That's not a forecast, that's an operator describing his own platform. Howland thinks rates "last a little longer."

3. The carriers are starting to pick their freight. The most useful operator voice of the week was Jason Schafflin at McLeod Express on the prior Brake Check episode: "Over the last month and a half, we've gotten a lot more opportunity… So we're just being really selective about what we go after and trying to rate it appropriately." That dates the inflection to roughly mid-April through late May. When a carrier VP says "selective," the contract market usually follows.

4. SCOTUS just repriced broker risk overnight. On the same episode, transportation attorney Craig Helmrich dropped the number that matters:

"I've had brokers in the week since the decision that have gotten quotes for insurance that are more than two times what they saw last year."

Two-x year-on-year, in one week. He also said roughly 40 of the 47 cargo claims on his desk right now trace back to double-brokering, and he expects "an exodus of small brokers." There is a real, modelable cost shock running through the broker P&L this quarter.

5. Hub Group blew up. What The Truck?!? on Thursday flagged the only true single-name event of the week. Host Malcolm Harris: "Their CFO and COO have left the company. The announcement comes as the company is in the process of restating financials after discovering an accounting error of just, I don't know, 77 million understated." Shaw is investigating; prior forecasts can no longer be relied upon.

⚖️ The Debate

The bull case, and this is most of the tape, is that the freight recession is over. Spot-over-contract for the first time in four years isn't subtle. Net FMCSA authorities are still trending negative (Chisinau: "carriers are still going out"). The most credible platform voice (Howland at TruckStop) and the most credible carrier voice (Schafflin at McLeod) are saying the same thing from different angles. Insurance is inflating, regulatory cost is rising, and the marginal carrier can't survive, which is exactly how a turn works.

The bear case is mostly Joe Ezzo at Trimble, who pushed back on WTT: "the overabundance of capacity that is out there [is] still being shed." He's not wrong that the overhang hasn't been cleared.

And Nate Johnson at GLCS dropped the caveat I keep chewing on:

"We have never seen a market shift off of a capacity shortage. It's only been a demand increase… So we are in uncharted territories."

If demand stays soft, supply-driven tightness can unwind on the first volume blip. Jessica Dotson at Triumph said the same thing from the small-carrier seat: rates are better, but "it's fixing so much depletion over this past couple years that it doesn't feel like an increase right now." That's the kind of operator quote that says the carriers themselves don't yet trust this.

The bulls have the better tape this week. But the "supply-driven, not demand-driven" caveat is the right thing to keep on the dashboard.

🎯 The Names in Play

HUBG, actionable, negative. The accounting event is as clean a single-name story as you get. A $77M understatement, simultaneous CFO and COO departures, and a law-firm investigation are a stack of governance flags that make it very hard to put a multiple on near-term numbers. Until the restatement scope is bounded, the price-target conversation collapses into "what do you pay for an intermodal franchise that just lost its top finance and ops officers?"

The public brokers (CHRW, RXO, LSTR), debate is live. The pods split. Broker Dan Lindsay thinks the big public names are the target-rich list for plaintiff lawyers: "It's not going to be the $10 million brokerage with no cash… They're going to go after the larger brokers." Helmrich and Schafflin counter that scale and capital give the publics a moat the mom-and-pops can't match. Neither side is wrong, and that's exactly the dispersion that argues for a long-large / short-small-broker pair rather than directional broker beta here.

Everyone else, no commentary worth trading. I went in wanting more on ODFL, SAIA, XPO, KNX, JBHT, the Class 1s and Class 8. The tape did not deliver. I'd rather flag that honestly than invent a thesis.

🔁 Read-Throughs

• Class 8 OEMs (PCAR, CMI, ALSN, RUSHA): Schafflin noted new EPA-spec trucks are running roughly $15,000 more per unit, and independent shop labor is at $250/hr, "like it's nothing." That's bullish for parts/aftermarket and bearish for replacement-cycle compression, but no episode this week put the bow on it.
• Diesel / fuel surcharge: Ezzo at Trimble sees diesel landing $4.75–$5.25/gal by year-end, noting <10% of US crude is exposed to the Strait of Hormuz. If he's right, that's cleaner FSC math into Q3, relevant for LTL and Class 1 yield-ex-fuel optics even though neither group came up this week.
• Flatbed / data centers: Freightonomics flagged the AI buildout as the marginal demand driver behind flatbed strength: "hyperscalers and AI do not care [about rates]. They are building at a pace." A small but persistent thread; the names with flatbed mix (KNX's Swift unit, TFII's CFI, ARCB) are the ones to keep on the radar.
• Rails (UNP, CSX, NSC, CPKC, CNI) and railcar lessors (GATX, TRN, GBX): Nothing this week. Genuinely no coverage on the pods, and that's notable given how much sell-side ink is being spilled on truck-to-rail conversion. I'll push harder on rails next issue.

🔀 What Changed

The vector shifted from "soft cycle / capacity overhang" to "supply-driven turn with a broker-side dislocation layered on top." A week ago the spot/contract debate was theoretical; this week it's a TruckStop record and an asset carrier saying it can pick freight. HUBG is the only true single-name surprise. And the SCOTUS broker-liability fallout is moving faster than anyone expected: quotes already 2x YoY within seven days of the ruling. If that holds into July renewal cycles, broker margins look very different than the Street currently has them.

Sources

• Freightonomics, Level of concern (2026-05-28)
• FreightCasts / Brake Check, Trucking's Soft Market Is a WAR (2026-05-28)
• FreightCasts / Brake Check, Trucking's New Divide: Adapt or Die (2026-05-26)
• WHAT THE TRUCK?!?, Why Traffic Hellholes Rank HIGHER for World Cup Freight Resiliency (2026-05-29)

Freight and consumer-supply-chain weekly for May 26–29, 2026. The first operator-confirmed tariff bite shows up in cross-border truck volumes, not apparel hangtags, while a Q1 retail melt-up gets increasingly tagged as a tax-refund pull-forward.

Freight & Consumer Supply Chain

Week of May 26–29, 2026

Quick one this week. The apparel-tariff conversation we keep waiting for didn't really show up on the pods, but the tariff bite did, just in a different place: cross-border truck volumes. Meanwhile the K-shaped consumer split got sharper, with affluent spend running hot and lower-income shoppers visibly stretched. Here's what actually moved the thesis.

TL;DR

• The first hard, operator-confirmed sign that tariffs are bending real activity isn't on a Macy's call, it's in 2025 Mexico truck volumes, the first non-recession drop since 2003.
• Walmart, Ross, and Amex card data all point to a Q1 spending surge that hosts on the tape are increasingly attributing to tax refunds, i.e. a pull-forward, not a step-up. Watch H2.
• Theme A (NKE/GPS/M/KSS/VFC tariff math) was quiet on the pods this week. Don't read silence as resolved: the specialty-retail print cycle is right in front of us.

📦 What's New

1. "That screams tariffs." ATA's Bob Costello says it out loud.

On Supply Chain Now's deep-dive into the Q1 U.S. Bank Freight Payment Index, American Trucking Associations chief economist Bob Costello attributed the first non-recession-year drop in Mexico-bound truck volumes since 2003 directly to tariffs. Canada cross-border truck activity is also down, autos especially. Costello added that tariffs on Mexican-built trucks and trailers are suppressing fleet replacement orders: "truck orders going up but mostly replacement activity, not a big capacity build coming." Two takeaways for the book: (i) the inflation we'll soon see on apparel landed cost is being modeled with real, not theoretical, freight inputs, and (ii) FDX/UPS/ODFL/XPO/CHRW pricing power is being propped up by capacity discipline, not demand, an important nuance against the bullish freight tape.

"Truck-transported trade with Canada has been down... 2025 Mexico truck volumes saw the first non-recession-year drop since 2003. That screams tariffs."

Bob Costello, ATA Chief Economist

2. Q1 freight spend "strongest since pandemic boom," but it's a supply story.

Same episode, Bobby Holland of U.S. Bank: national freight spend +12.9% QoQ and +21.8% YoY in Q1, with all five U.S. regions double-digit positive YoY for the first time since Q2 2022. Volumes? Largely unchanged. This is rate-on-capacity, not rate-on-demand, exactly the setup that flips fast if any shipper blinks. Worth pairing with the diesel datapoint Holland flagged: California on-highway diesel hit an all-time high of $7.22/gal on March 30, 2026; the national average sat at $5.60. Landed cost for everything coming out of West Coast ports just got more expensive at exactly the moment retailers are trying to negotiate vendor cost-sharing.

3. Walmart's quarter and the Amex top-end melt-up.

The Watson Weekly's May 29 episode put the K-shape in numbers. Walmart: US store comps +4.1%, revenue +7.3%, global e-commerce +26% (vs. Amazon's ~8%), Walmart Connect ad revenue +44%, US marketplace ~+50%, advertising +37% globally. Hosts cited prior commentary that ~75% of WMT's share gains are coming from affluent customers: the "Whole Foods customer is now also a Walmart customer" story is real and quantified. On the other side: American Express card-member spend +10% (a three-year high), retail spend +11%, luxury +18%, and 70% of new Gen Z Amex accounts on annual-fee cards. Ross Stores comps printed +17%.

4. The pull-forward that scares the bulls.

The Watson Weekly hosts' own framing of those same numbers is the cleanest articulation of the bear case we've heard this week: that +17% Ross comp and the broader Q1 retail melt-up were juiced by tax-refund timing ("that cash was burning holes in pockets") and "that money is mostly spent at this point." If they're right, H2 decel risk is sitting in front of every value/off-price name that just printed a hero comp. Watch Q2 traffic vs. ticket splits closely: refund-driven activity should show as ticket strength followed by traffic fade.

⚖️ The Debate

On the tape this week, only one side of the big debates really showed up. The case that tariffs are biting: confirmed, but biting freight and cross-border first, while the apparel pass-through fight is still ahead. The case that the trade-down into value is real: confirmed in numbers, but the operator-near voices are increasingly hedging it with "this was tax refunds." The bull counter, that the high-income shopper trading down to Walmart and Costco is a durable share-gain tailwind that survives the consumer healing, wasn't voiced on the pods we follow this week. File it under "to be re-litigated when Costco, TJX, and Dollar General print."

The harder debate, can apparel push the blended ~14% tariff through, or does it permanently reset gross margins lower, wasn't engaged on any episode this week. Don't mistake silence for resolution.

🔁 Read-throughs

• Off-price (TJX, ROST, BURL): The +17% Ross bar is now the comp every off-price name will be measured against. If the tax-refund attribution holds, second-derivative risk is real and the easy print is behind us.
• Cross-border freight (CHRW, XPO, ODFL, FDX, UPS): Costello's Mexico/Canada commentary is a direct hit on intermodal and dry-van mix. Capacity-driven rate strength is bullish near-term, fragile longer-term: one shipper blink and the bid disappears.
• Mid-tier department stores (M, KSS): Watson explicitly called Target a share donor to Walmart. If TGT is leaking to WMT, M and KSS are leaking to both WMT and ROST: the squeeze is structural, not cyclical.
• Truck/trailer OEMs (PCAR, WNC, ALSN): Tariffs on Mexican-built equipment are suppressing replacement-cycle orders. That is a fleet-capex headwind hiding inside a "freight rates are great" headline.
• Branded apparel / mid-tier CPG: No direct evidence on the pods this week, but the WMT private-label and marketplace strength keeps the read-through alive. If you're long branded apparel into the back half, you're betting against the same tape that just printed +50% WMT marketplace growth.

🔄 What Changed

The most concrete new datapoint this week is the operator-confirmed cross-border truck-volume compression: that's the cleanest piece of "tariffs are actually doing something" evidence we've heard on the pods so far. The apparel-tariff specifics that the newsletter is built to track stayed quiet; the specialty retail print cycle ahead is where that conversation re-opens. Staying patient there beats forcing it.

Sources

• The Watson Weekly: Walmart's Quarter, Google's Agentic Cart, and the K-Shaped Economy (May 29, 2026). Rick Watson and Jessica Lesesky, hosts (pundit commentary on operator-reported data).
• Supply Chain Now: Analysis of the Q1 2026 U.S. Bank Freight Payment Index (May 26, 2026). Bobby Holland (U.S. Bank, Director of Freight Business Analytics) and Bob Costello (American Trucking Associations, Chief Economist), operator commentary; Corinne Bursa and Scott Luton, hosts.

Foundry and chip-equipment newsletter for the week of May 31, 2026, covering podcasts from May 18–29. An operator confirms CoWoS, HBM, and TSMC 3nm as the binding AI-compute constraints, the memory long/short turns into a named debate, and WFE M&A picks back up.

Foundry & Chip Equipment

Week of May 31, 2026

CoWoS Is the Bottleneck, and the Tape Finally Said It Out Loud

Hi,

Quick one before Sunday slips away. The most interesting thing I heard this week wasn't from a sell-side desk or a guidance bump, it was Cerebras' CEO calmly naming the three places the AI build-out actually breaks: HBM, CoWoS, and TSMC 3nm. Pair that with Nvidia pledging $150B a year into Taiwan and TSMC quietly adding $20B more to Arizona, and the foundry and semicap setup looks tighter, not looser, heading into the back half.

TL;DR

• Operator confirmation that CoWoS, HBM, and TSMC 3nm are the binding AI-compute constraints, straight from an arm's-length customer with no axe to grind. Bullish TSM advanced packaging, bullish the HBM trio, mildly bearish the "CUDA moat" framing.
• Memory is the live pair trade: Goldman's Tim Moe sees a 3–5 year supercycle with Samsung and SK Hynix at 4–5x earnings; a retail-facing pundit is openly calling for Micron to halve. Both views were voiced this week, and that disagreement is the trade.
• WFE M&A is back on: AMAT bought ASMPT's panel-level packaging business, ONTO took a 27% stake in Rigaku, and Axcelis/Veeco are inching toward a China-approval close. Read as confidence in 2026–27 being record WFE years.

What's New

Cerebras' CEO names the three chokepoints, and CoWoS is one of them. On Odd Lots, Andrew Feldman told Joe Weisenthal and Tracy Alloway that the binding constraints on AI compute today are HBM ("under unbelievable supply pressure," "extremely long lead times," "unbelievably expensive"), CoWoS, and TSMC 3nm, and that Cerebras deliberately avoids all three. He said TSMC has given Cerebras "as many wafers as we've needed" and expects data-center power, not silicon, to be the binding constraint "for the next 15 to 18 months." This is the cleanest operator read on the advanced-packaging squeeze we've had all year.

"HBM is under unbelievable supply pressure... CoWoS... TSMC 3nm. That's why we don't use any of them." (Andrew Feldman, Cerebras)

Nvidia is putting $150B a year into Taiwan, plus a "Constellation" HQ. The Rundown flagged Jensen's pledge to spend $150B annually in Taiwan going forward and break ground on a 4,000-person HQ opening in 2030. TSM ripped 4% intraday on the news. Same episode: Micron crossed $1T market cap in 48 trading days (Nvidia took 490 in 2022–23), SK Hynix also crossed $1T, and Zaid Admani took the other side, calling Micron a commodity that could halve in 12–24 months. The bull/bear isn't subtle: this is the memory trade.

TSMC quietly added $20B more to Arizona, and Apple is still roughly 90%+ TSMC. Per Mac OS Ken, citing CC Wei and Ming-Chi Kuo, TSMC is layering another $20B onto Arizona to accelerate by "several quarters," and Intel Foundry's Apple engagement is capped at "low-end legacy iPhone, iPad, Mac processors." TSMC keeps more than 90% of Apple processor volume even if Intel ships on time. Important nuance: chips fabbed in Arizona still come back to Taiwan to be packaged. That sentence alone is the CoWoS thesis.

Goldman's Tim Moe is calling memory a 3–5 year supercycle. On Exchanges, Moe anchored on GS' US semi forecast for 24x token-demand growth from 2026 to 2030, with Samsung and SK Hynix at roughly 4–5x 2026E/2027E earnings and Korean profit growth modeled at +269% consensus / +300% house. He flagged near-term correction risk (RSI around 85, names up 200%+ YTD) but called it a structural cycle, not a pop. TSMC, he noted, is 55% of MSCI Taiwan, so the index is the foundry trade.

The WFE M&A tape just turned active again. On the Chip Stock Investor Podcast, Nicholas Rossolillo flagged three deals worth tracking: AMAT acquired ASMPT's "Next" panel-level substrate deposition business (the picks-and-shovels for next-gen advanced packaging), ONTO took a 27% equity stake in Rigaku for X-ray-based 3D-stack metrology, and the Axcelis/Veeco merger is awaiting China approval with a H2 2026 close. His broader view: 2026 and 2027 are record-revenue years for the "Fab Five" (ASML, AMAT, LRCX, TOELY, KLAC), with a possible mid-cycle hiccup penciled in for 2028, but the longer trajectory through end-of-decade still runs higher.

The Debate

The bull case got louder this week. An operator-grade source (Feldman) confirmed CoWoS, HBM, and TSMC 3nm are the constraints. A house bull (Moe) put a multi-year duration on the memory cycle with cheap multiples. The hyperscaler customer (Nvidia) is doubling down on Taiwan capex. WFE majors are doing M&A, and companies don't roll up adjacent capacity unless they think the cycle has legs. Add the read-through that Arizona wafers still come back to Taiwan for packaging, and the leading-edge plus advanced-packaging premium looks structural, not cyclical.

The bear case is fair to make, but mostly didn't show up on the tape this week. The one bearish operator-adjacent voice was Admani's Micron call (down 50%+ in 12–24 months on commodity dynamics), and that's a memory-pricing argument, not a foundry or WFE argument. The "Intel 18A re-establishes a second source" thread is alive in headlines: Arizona's policy office casually mentioned Intel "attracting customers this past week" on ChinaTalk, but no podcast we follow put up a real bear thesis on TSMC's monopoly or a credible Samsung yield-catch-up case this week. The honest read: this week the pods were one-sided long, and the bear voices we'd want (China pull-forward unwind, mature-node digestion, Samsung yield breakthrough) didn't surface.

The Names in Play

• TSM: operator-confirmed monopoly on the parts that matter (3nm, CoWoS), $20B added to Arizona, anchor of MSCI Taiwan, and the Nvidia $150B pledge is functionally a TSMC volume commitment. Next catalyst: any commentary on N2 booked-through-2028 capacity or CoWoS expansion at the July update.
• AMAT: panel-level packaging M&A says management thinks the back-end is where the next dollar of WFE goes. Bull lean.
• KLAC / ONTO: metrology is the most defensible WFE sub-segment in a 3D-stack world. Rossolillo's framing on recurring service plus 3D-stack QC is the cleanest read for both.
• MU / Samsung / SK Hynix: live disagreement. Moe long, Admani short Micron. Sizing this on conviction means picking a side on memory's commodity-vs-strategic mix.
• INTC: Apple capped at legacy/low-end per Kuo; Arizona policy desk says Intel is "attracting customers" but with no specifics. The 18A external-wins thesis still needs a marquee name on the tape.
• NVDA: Feldman's "CUDA has lost 70% of frontier training share" claim is the bear-adjacent comment of the week. It's one operator's view, but it's the kind of remark that ends up in a short note within a quarter.

Read-Throughs

• Advanced packaging / CoWoS: independently flagged by Feldman and by the Arizona-back-to-Taiwan dynamic. Pure-play packaging exposure (ASMPT's residual business, OSAT names) and substrate suppliers screen better.
• EUV / High-NA: no specific ASML commentary on the pods this week. Backlog and the 2026 guide remain the watch.
• Fabless: Nvidia pledging $150B a year to Taiwan tells you who's price-taker on wafers. AMD, Broadcom, and Qualcomm don't get cheaper allocations because TSMC felt generous.
• China-domestic toolmakers: quiet on the pods this week. The Axcelis/Veeco China-approval delay is the most direct US-side data point.
• Quantum hardware: on Network Break, IBM received a $1B CHIPS Act grant to build the "Andron" 300mm superconducting quantum wafer foundry in Albany (IBM matching with another $1B plus IP); GlobalFoundries received $375M for a multi-modality quantum foundry in exchange for a 1% US government equity stake; D-Wave, Atom Computing, and PsiQuantum are receiving equity-attached grants. It's the first time on this week's tape we have hard quantum-hardware capex numbers, long-dated, but the read-through to advanced packaging and cryogenic/control hardware is now actually a thing, not just a slide.

What Changed

Two genuine shifts: (1) the CoWoS bottleneck moved from sell-side talking point to operator-confirmed constraint, and (2) the memory long/short is now a named debate on the tape rather than a one-sided consensus long. Everything else (TSMC capex acceleration, WFE M&A drumbeat) is a continuation, not a turn.

If a piece of this changes your priors, hit reply and tell me where. The interesting thread next week is whether anyone outside Cerebras' Feldman will stake a public claim on CoWoS lead times. That's the number that prices the whole stack.

Sources

• Odd Lots, "Why Cerebras CEO Andrew Feldman Built The World's Largest Computer Chip" (2026-05-21)
• Chip Stock Investor Podcast, "Wafer Fab Equipment, M&A Moves & The Lab 7 You've Never Heard Of" (2026-05-29)
• Exchanges (Goldman Sachs), "Can the Asia Equity Rally Continue?" (2026-05-18)
• The Rundown, "Nvidia Bets Big on Taiwan, American Airlines Inks Starlink Deal" (2026-05-27)
• Mac OS Ken, "iPhone News, Chip Supply, and Court Cases - MOSK: 05.18.2026" (2026-05-18)
• Network Break, "IBM Gets Big Bucks to Build Quantum Chip Fab; AT&T Sues to Hang Up on Copper Phone Lines" (2026-05-26)
• ChinaTalk, "Arizona's Abundance Playbook" (2026-05-28)

Rates and macro newsletter for the week of May 31, 2026. Across the podcast tape, every serious rates voice has moved from debating cuts to debating a hike as Kevin Warsh takes office, with the December fed funds contract now pricing a move up rather than down.

The Fed & the Front End

Week of May 31, 2026: The hike just became the base case

Three weeks ago the debate was how many cuts this year. This week, every serious rates voice we follow was debating whether the next move is a hike, and Kevin Warsh got sworn in to a job he was hired to do but can no longer credibly do. That gap, between what got Warsh hired and what the data forces him to deliver, is the trade of the next ninety days. Pour the coffee; the easing cycle is on hospice.

TL;DR

• The hike has gone from tail to base case in fed funds futures; the December contract is now pricing a ~25bp move up, not down (The KE Report, Marc Chandler).
• JPM, KeyBank, and Whalen Global all now expect Warsh's first dot plot to show zero cuts in 2026, with a real conversation forming around hiking before year-end (Making Sense, JPM; Key Wealth Matters; The Julia La Roche Show).
• Powell is staying on the Board, the first chair to do that since 1948, and is openly framing it as institutional defense. Warsh inherits a divided room, an oil shock, and a bond market already testing him (Real Estate Conversations; New Books in Economics).

What's new

1. Timiraos's "1999 redux" framing. This is the line I cannot stop thinking about. On Real Estate Conversations, the WSJ's Nick Timiraos, who is essentially the Fed's preferred whisper line, described the internal mood ahead of the June 17 meeting this way:

"They're no longer debating whether to cut. But they're debating, well, do we need to talk about raising? Could this be more of a '99 situation where we need to undo the cuts that we made last year?"

That is the original Fed beat reporter telling you the Overton window inside the Eccles Building has moved from "patient" to "did we make a mistake?" Treat it accordingly.

2. Warsh walks in the same week the bond market pukes. Also from Timiraos:

"The week that he takes office last week, you see 30-year bond yields hitting two-decade highs. So yes, the case for cutting has evaporated between the time he was announced as the president's pick at the end of January and when he gets the job in the middle of May."

In other words, Warsh was hired to cut and the data revoked his mandate before he sat down.

3. JPM goes on the record: zero cuts in 2026, next move is a hike. On JPM's own Making Sense (this aired May 22, flagging as just outside the seven-day window), Chief U.S. Economist Michael Wynn was about as unambiguous as a sell-side house gets:

"The median [dot] would shift to looking for no cuts this year. We have been and continue to look for no cuts this year. And we think the next move will be a hike in the second half of next year. The case for rate cuts anytime soon is a non-starter."

Wynn also pointed to Governor Waller joining the "more neutral bias" camp as the institutional tell.

4. The new dot, the new bias, the new statement language. On The Julia La Roche Show, Chris Whalen of Whalen Global Advisors laid out what to actually watch on June 17:

"I doubt the committee is going to take action as a new chairman is being seated. So I wouldn't expect them to do anything in June. Although, I do believe they will remove the language from the statement that alludes to a cut in the future. I wouldn't be surprised to see a majority of the committee in favor of a rate hike in July."

The point: the trade isn't the rate decision, it's the bias change.

5. Iran/Hormuz is the swing variable. Pretty much every guest converged on this. Timiraos again:

"If you could tell me one thing that would help me understand what is going to happen with interest rates this year, it would be: when does the Strait of Hormuz open?"

And on This Week in Business, Jeremy Siegel had Brent at $107 with the caveat that "if the strait remains closed, it'll just keep on kind of marching up." Headline PCE printed +3.8% YoY, core +3.3%, the highest in three years per KeyBank's Brian Pietrangelo. The Fed's "look-through" doctrine is being tested in real time.

The debate

The hawks have the mic this week, and they earned it. The case, stitched together from the tape: nominal demand growth is steady around 5–6%, Atlanta Fed GDPNow has Q2 tracking +4.3%, core PCE is at three-year highs, jobless claims hit a 50-year low (Siegel's "we're 210 now"), the Strait of Hormuz is shut, and businesses, per Timiraos, "are now learning how to pass along price increases. They have excuses to do it. They can say, well, it's tariffs. Well, it's oil. And consumers are accepting it." Rajeev Sharma at KeyBank put it plainly on Key Wealth Matters:

"Consumer spending remains firm. Growth is not slowing down enough to justify cuts. Labor market is normalizing, but not breaking. In the next 10 months, you're looking at least one rate hike."

The dove case got two voices and they're both worth airing. Danielle DiMartino Booth (QI Research, ex-Dallas Fed) on Brew Markets flagged household unemployment expectations leaping from 61% to 69% in the second half of May, "once you cross 50% of that line of higher unemployment expectations, you're typically already in recession, to say nothing of 69%," alongside a near-record divergence between manager and worker layoffs and a corporate-profit-to-GDI ratio at a record 11.9%, which she reads as a margin-squeeze-then-payroll-cut setup. And Michael Redmond, the Medley Advisors analyst and ex-KC Fed economist, on New Books in Economics argued Warsh, played correctly, "could actually get the committee to a cut much faster than people expect."

The honest read: the labor-cracks/Warsh-cuts thesis was a minority position on the tape this week. We're flagging it, not dismissing it (DiMartino's leading indicators have been early before), but the dispersion was unmistakably one-sided.

The independence question is now a real macro variable. The FT's Claire Jones, also on New Books in Economics, captured the trust deficit:

"People are worried because they're just thinking, what did you have to say in order to get this job? Bond markets like to test a new Fed chair. And we're at a moment where it looks as though the bond markets think the Fed, as it stands, is a little bit too dovish. Does Warsh really want to be making his own life harder and really kind of like taking on the bond vigilantes? I'd say no."

Bloomberg's Katerina Sariva, same episode, confirmed the March dot plot still had one cut penciled in but expected the June dot to drift hawkish: "We could even see an interest rate increase."

The trades the tape actually pointed to

The one episode that translated all this into instruments was Marc Chandler on The KE Report (May 22, flagged):

• Front end / fed funds: December 2026 fed funds futures yield "rose nine basis points this week. Right now it's implying about a 3.85 yield for the end of the year. And that is pricing in just about the 25 basis point rate hike." The hike is "not just a risk scenario, a tail scenario. It's become the base case scenario now." Implied year-end U.S. rate is up ~85bp since the Iran war began.
• Dollar: Chandler runs DXY off the 2-year as a Fed-policy proxy and is constructive on the rate-differential trade. DiMartino's counter on Brew Markets: "It's not yet clear where the dollar is going to shake out. FX volatility is a really good place to be right now."
• Gold: Chandler called it "frustrating," broken below 4,500 with no follow-through, needs to reclaim 4,600 to confirm a low; otherwise downside to ~4,370 (200-day).
• Long end: Timiraos's point on real rates is the asymmetry to remember: "At some point holding steady a nominal rate while inflation rises is actually easing in real terms." That's the bond vigilante's invitation.

Notable silence on the tape this week: no one we listened to talked specifically about KRE, XHB, IWM, or EM carry. I'd love to have an episode to point at on regional banks and homebuilders into a hike-tilt rate path, there wasn't one. Flagging it rather than padding.

What changed

A week ago the question was when Warsh's Fed delivers. This week the question became whether Warsh's Fed even gets to deliver, and the December fed funds contract crossed the threshold where a hike is a base case, not a hedge. The dovish March dot ("one cut") is now the consensus discard; Wynn's call (zero cuts, next move a hike) used to be the brave end of the range, and this week it's basically the new median. That's a real shift, not a vibe.

What didn't change: every guest still treats Iran/Hormuz as the swing factor. If the strait deal Timiraos referenced actually lands, half this hawkish setup deflates in a week.

Sources

• Real Estate Conversations - "It's the start of a new era at the Fed. What happens next?" (May 26, 2026, Nick Timiraos)
• This Week in Business - "AI Stocks, Oil Prices, and the Fed's Next Move" (May 29, 2026, Jeremy Siegel)
• New Books in Economics - "Kevin Warsh: 'What did you have to say in order to get this job?'" (May 30, 2026, Claire Jones, Michael Redmond, Katerina Sariva)
• The Julia La Roche Show - "#374 Chris Whalen: Fed Policy Losing Efficacy, Rate Hike Coming Anyway" (May 30, 2026)
• Key Wealth Matters - "The Rally Rolls On as Risks Start to Build" (May 29, 2026, Rajeev Sharma, Brian Pietrangelo)
• The Dividend Cafe - "The Myth of an Independent Fed" (May 29, 2026, David Bahnsen)
• Brew Markets - "Are Markets Ignoring the Economy?" (May 26, 2026, Danielle DiMartino Booth)
• Making Sense (J.P. Morgan) - "What to expect from a Warsh-led Fed" (May 22, 2026, Michael Wynn)
• The KE Report - "Marc Chandler – Resilient US Economy, Fed Policy Shifts, Dollar & Rates, Gold Outlook" (May 22, 2026)

Digital advertising and retail media weekly for May 24–31, 2026. eMarketer projects Meta passes Google in global ad revenue in 2026, Hightouch raises $150M to attack LiveRamp, and ChatGPT ads look incremental rather than cannibalistic to Search.

Digital Ads & Retail Media

Week of May 31, 2026: eMarketer Flips the Leaderboard, Meta Passes Google in 2026

TL;DR

• eMarketer is calling the crossover. Per numbers cited on Daily Tech News Show, Meta's 2026 global digital ad revenue lands at $243.5B (+24.1%) vs. Google's $239.5B (+11.9%), the first year Meta overtakes Google. Treat as a directional read on the tape, not gospel; it's a third-party forecast that hosts surfaced, not company-disclosed.
• The Publicis-LiveRamp deal is already attracting predators. Hightouch's co-CEO went on Marketecture to position the company as a "plug-and-play replacement for the core LiveRamp technology," timed to a fresh $150M Series D at a $2.75B valuation led by Goldman Sachs and Bain Capital Ventures. Madison and Wall's Brian Wieser has reportedly named Hightouch as the leading substitute. RAMP holders should care.
• Quiet on everyone else. Across 753 episodes scanned, AMZN, TTD, ROKU, DIS, NFLX, WBD, WMT, CART, PINS, SNAP, DV, IAS, CRTO, MGNI, and PUBM all drew zero substantive coverage. Thin tape week.

What's new

1. Meta's projected ad-revenue crossover with Google, and why Advantage+ is doing the work. On Daily Tech News Show, host Jason Howell anchored the week's biggest narrative on eMarketer's 2026 forecast (Meta $243.5B, Google $239.5B) with Advantage+ as the explicit growth engine and over a million advertisers using it monthly. Inventory tailwinds: WhatsApp and Threads ramping. Subscription tiers (Facebook/Instagram Plus at $3.99/mo, WhatsApp Plus at $2.99/mo, Meta AI at $7.99–$19.99/mo) were framed as supplemental, not a pivot away from ads. Why it matters: if the eMarketer math holds, it validates the bull thesis that AI-bid auctions are pulling more SMB and mid-market spend toward Meta faster than Google can re-architect Search around Gemini. Daily Tech News Show, "Meta Risks Subscription Fatigue With New Plans," May 28.

2. An ex-Meta insider names the optimization stack, and starts a stopwatch. On the bossbabe podcast, Brooke Shelton (ex-Meta ad policy and AI enforcement, ex-Meta VC ads incubator) walked through what she described as Meta's internal optimization models: "Lattice," "Andromeda," and "Gem," running on what she called a "two-tower neural network" audience-matching architecture. Her practitioner take: kill all interest targeting, run one campaign per offer, and max out creative volume. The line worth screenshotting: "Creative is your bid. Nothing else." And the implicit catalyst: "There's this nine, maybe 12-month period of this arbitrage opportunity… Meta will generate everything for you. You just push a button and say, I want to spend $100." In other words, by roughly Q1 2027 on her view, Meta closes the loop on end-to-end ad creation. Product names are unverified, but the timing claim is investor-relevant: it implies another year of advertiser ROAS gains before commoditization. the bossbabe podcast, "491: An Ex-Meta Insider's Guide To Scaling Ads With AI," May 26.

3. ChatGPT advertising looks more incremental than cannibalistic, for now. On Marketecture, co-hosts Ari Paparo and Eric Franchi unpacked SimilarWeb CEO data points: 46% of ChatGPT ad exposures begin with no commercial intent; 83% of ChatGPT ad queries wouldn't have triggered a Google Shopping ad; 73% of users continue the conversation after seeing an ad; average CTR ~0.68%, with best-campaign CTR at 5.4%. The hosts' framing is the punchline: conversational intent is a new ad surface that sits adjacent to Google's declared-intent monopoly, not on top of it. Why it matters: this is the cleanest counter to the bear case that GOOGL Search is being structurally hollowed out. Worth caveating, SimilarWeb is the source, not OpenAI. Marketecture, "Episode 175: Tejas Manohar, Hightouch," May 29.

4. Hightouch raises $150M to hunt LiveRamp's onboarding business. Same Marketecture episode: Tejas Manohar, co-CEO of Hightouch, used the platform to position his company directly against LiveRamp's core onboarding workflow ("a plug-and-play replacement for the core LiveRamp technology") and to disclose a $150M Series D at $2.75B, led by Goldman Sachs and Bain Capital Ventures. The hosts flagged that LiveRamp's pending acquisition by Publicis is the catalyst (agencies and brands don't love the idea of routing first-party data through a holding-company-owned identity layer) and that Brian Wieser at Madison and Wall has publicly named Hightouch as the leading substitute. Manohar's claims are competitor talk and should be discounted; the funding and the analyst nod are the actual signal. Marketecture, May 29.

5. AppLovin launches a social app called "Gist." Paparo and Franchi caught it in the same episode: Gist appears designed to generate "exclusive monetizable traffic," i.e., first-party data and inventory that feeds AXON, rather than to build a durable consumer franchise. AppLovin has historically divested owned apps; the hosts read this as a flywheel play, not a TikTok competitor. Marketecture, May 29.

The debate

Bull case: AI tools and retail media are growing the pie and tightening the walled gardens. Meta's projected ad-revenue crossover with Google is, if you believe the eMarketer forecast, the cleanest possible scoreboard for the bull. Advantage+ is pulling spend; WhatsApp and Threads add inventory; AXON keeps minting performance dollars at AppLovin. ChatGPT ads, on the SimilarWeb read, are creating a new conversational-intent surface, incremental rather than extractive. Meanwhile the LiveRamp story is positive for the walled gardens: the more identity gets contested in the open web, the more advertisers default to Meta, Google, and Amazon's closed loops.

Bear case: saturation, cannibalization, and an open-web identity crisis. The ex-Meta insider's nine-to-twelve-month "arbitrage window" cuts both ways. Once Meta automates end-to-end ad creation, advertiser ROAS gains compress and the next dollar of incremental spend gets harder to win. Retail media at ~$129B is real but mature in the US, and we got zero coverage of WMT, CART, AMZN ads, or the CTV ad-tier names this week, a tape silence that aligns with the "deceleration" thesis, even though we should be careful not to over-read absence of news. And the Hightouch raise is a tell on RAMP: when a private $2.75B competitor can plausibly pitch itself as the post-Publicis replacement, RAMP's terminal multiple gets harder to defend.

Stocks in play

META. Bull: eMarketer crossover + Advantage+ as engine + WhatsApp/Threads inventory ramp. Bear: the 9–12 month creative-automation clock starts now per the ex-Meta insider, and once Meta makes the creative, the advertiser's incremental ROAS gain compresses. Next number: Q2 2026 ad pricing vs. impression growth split, and whether Advantage+ advertiser count remains above the 1M monthly threshold cited this week.

GOOGL. Bull: SimilarWeb's 83%-non-overlap data point, ChatGPT ads are incremental, not cannibalistic to Search. Bear: eMarketer's projected 11.9% growth vs. Meta's 24.1% is the slowest-growing scoreboard line in big-cap ads. Next number: Search RPM / paid-click trend in Q2; any sell-side check on Performance Max share gains.

APP. Bull: "Gist" launch implies AppLovin is actively investing in first-party data flywheels for AXON. Bear: social app launches with no organic distribution have historically not worked for ad-tech companies. Next number: DAU/MAU disclosure for Gist (if any) and AXON e-commerce revenue line in the next quarterly.

RAMP. Bull: the Publicis deal closes and the combined entity defends RampID via agency leverage. Bear: $2.75B Hightouch + Wieser endorsement = the substitute is already named. Next number: customer retention disclosure post-deal, and whether any major holdco brand defects publicly.

OpenAI (not listed). Daily Tech News Show cited an OpenAI 2026 ad revenue expectation of $2.5B (source unspecified, host-asserted). Worth flagging as a tape datapoint, not a fact.

Read-throughs

• Emerging-platform ad players (RDDT, PINS, SNAP): Reddit got named only as a destination platform in Hightouch's agentic stack. Pinterest and Snap drew zero coverage this week.
• Retail media (WMT, CART, AMZN): Zero coverage. No Walmart Connect commentary, no Instacart ad attach-rate updates, no Amazon DSP / Prime Video ad-tier signal. For a category that's supposedly the fastest-growing line in digital, the podcast silence is notable.
• CTV and streaming (ROKU, DIS, NFLX, WBD): Zero coverage. No upfront/scatter commentary, no ad-tier subscriber updates, no TTD Kokai or UID2 discussion.
• Ad measurement & SSPs (DV, IAS, CRTO, MGNI, PUBM): Zero coverage. The only adjacent commentary was the Hightouch-vs-LiveRamp identity dispute.

What changed vs last week

Thin tape. Three relevant episodes across 753 scanned, the lowest signal week we've had in a while. The week was dominated by Meta (all three episodes touched it, two centrally), with secondary read-throughs to Google (forecast crossover + ChatGPT ad incrementality), LiveRamp (Hightouch's competitive attack), and AppLovin (the Gist launch). No movement on retail media, CTV, or measurement, categories that usually carry at least one podcast hit per week. Memorial Day weekend likely explains some of the editorial gap; expect the volume to normalize next week as we move into June and the run-up to Q2 prints.

Forecasts cited from eMarketer and SimilarWeb were surfaced by podcast hosts; treat as directional reads, not as primary disclosures. Hightouch's competitive claims against LiveRamp are first-party assertions from a competitor, so discount accordingly.

Metals and materials weekly for May 26–29, 2026. A wall-to-wall copper tape converges on a $6+ structural-deficit thesis, while the under-priced read-through, China's sulfuric acid export ban, points straight at phosphate fertilizers.

Industrial Materials

Week of May 26–29, 2026

Hi,

Sometimes the most important trade of the week shows up sideways. This week's podcast tape was wall-to-wall copper, but the line worth circling came inside a copper episode and points straight at phosphate fertilizers. If you only have ten minutes today, read this for the sulfur story; the rest is supporting evidence.

TL;DR

• Copper is now a $6+ commodity with operators calling it a floor, not a peak. Spot $6.30–$6.50/lb, COMEX-LME arb ~$500/mt, Grasberg offline until 2028, and a U.S. primary-copper tariff decision on the calendar.
• The under-priced story is sulfuric acid. China banned sulfuric acid exports on May 1; ~50% of global sulfur transits Hormuz; sulfur prices +~80%. This hits ~17% of global copper supply (SX-EW, mostly DRC), and it is the dominant input cost for phosphate fertilizers. MOS and NTR phosphate exposure is the read-through nobody's talking about.
• Rare earths, lithium, and U.S. steel were quiet on the pods this week. Aluminum got one mention (4-year high, China capacity throttle). I'd rather flag that than fabricate the missing legs.

What's New

1. The single most important episode of the week: Scott-Gray on the Hormuz/sulfur shock. On The Derivative ("'Dr. Copper': From Chilean Mines to Chinese Smelters to AI Data Centers," May 28), StoneX senior metals demand analyst Natalie Scott-Gray laid out the cleanest framing I've heard on copper this year. Two numbers to take away: she calls the U.S. refined-copper tariff deadline (July 30, with a proposed step-up to 15% by early 2027 and 30% by 2028) "arguably the most significant thing in the copper market that will happen this year"; and she flags China's May 1 ban on sulfuric acid exports as the supply shock the market hasn't priced. SX-EW is ~17% of global copper, ~60% of which sits in the DRC, with "2 to 3 months" of sulfur stocks. Co-host Kurt Nelson (SummerHaven, CPER ETF) added: "I haven't seen that flow through price yet."

2. Tariff arbitrage already happened, $1.6 million tonnes of it. Same episode: roughly 1.6 Mt of refined copper has already shipped to the U.S. on the CME-LME arb in the last year, with the spread peaking at "$3,000 premium, if not more." Q1 2026 global visible stocks (COMEX+LME+SHFE) hit a record, with the bulk in the U.S. Translation: a lot of the front-end of the tariff trade is in the price. The back-end, what happens to ex-U.S. inventories when the bonded copper stops flowing, is not.

3. Operator base case: $6 is a base, not a peak. On The KE Report ("Investors Rotating Money In Metals," May 28), Junior Stock Review's Brian Leni reported, from a direct conversation with an Australian concentrate trader, that smelter TC/RCs are persistently negative: "there's just no supply for these smelting operations. The negative treatment charges is here to stay." On Wall Street Unplugged (May 27), Coppernico CEO Ivan Bebek confirmed Grasberg "won't be able to go back into production until 2028" after the pit-wall collapse. He thinks "the price of copper is going to double in the next few years." When operators with skin in the game say "double from here," I don't dismiss it, but I do underwrite it.

4. The economics of new copper supply are still ugly, and that's the bull case. On Mining Stock Daily ("Live from the Deutsche Goldmesse," May 26), Marimaca CEO Hayden Locke benchmarked his $587M capex against peers: "the average capital cost two years ago was over $3 billion." Locke's AISC of ~$2.30/lb against a $6+ spot is the kind of margin that gets DFS projects financed; the problem is "the cupboards are very bare" of sub-billion-dollar capex projects. Greenfield lead time is now widely cited at 12–17 years.

5. Sell-side base-metals desk: floors have been reset. On The KE Report (Darrell Fletcher, May 27), Bannockburn's commodities MD pointed to LMEX +13% YTD, copper Dec-2028 contango at ~$7.00/lb, and aluminum at a 4-year high on China's capacity throttle (Midwest premium ~$1.15–$1.16/lb; LME aluminum >$3,600/mt). His read: "base-metal floors have really been reset."

The Debate

"By 2028, we hit a massive deficit in all sorts of critical minerals.", Tracy Shuchart, Mining Stock Daily, May 29

The bull case got the airtime this week. Six years of underinvestment, declining ore grades, AI/data-center demand layered on EV and grid, Grasberg out until 2028, Kamoa-Kakula flooding (output cut ~28% per Scott-Gray), and Chile earthquake disruption. Plus the resource-nationalism stack: Zimbabwe lithium ban, DRC cobalt restrictions, China's sulfuric acid ban. The structural-deficit thesis pegged to ~2030 was repeated, in some form, on every single episode this week.

The bear case, in fairness, was barely voiced on the pods this week. The honest pushback would be: record visible inventories in Q1, a meaningful chunk of the U.S. tariff trade already in the price, a hawkish Lisa Cook reminding everyone that the Fed cross-current is real (Mining Stock Daily morning briefing, May 28), and the awkward fact that nobody on the pod circuit this week made the demand-air-pocket argument with conviction. When the tape is this one-sided, that itself is a signal, usually that positioning is getting crowded.

The Names Actually Moved

• FCX: Grasberg restart pushed to 2028 by multiple operator/CEO speakers. That's a real production hole.
• TECK: Confirmed ~10% holder of Coppernico (per Bebek); Anglo merger forming the ~$80B base-metals co. Strategic signaling matters here.
• MOS / NTR: Not mentioned by name on any episode this week, but the sulfuric acid input is the most under-discussed read-through in the tape. Do the work on phosphate cost curves before next week.
• MARI (Marimaca): Fully permitted, DFS done, AISC ~$2.30/lb, FID mid-2027, a rare developer at sub-billion capex.

Read-Throughs

• Copper royalties/streamers (FNV, WPM, RGLD, TFPM, OR): structural beneficiaries of any sustained re-rate, with no operational acid exposure. Nick Hodge (KE Report, May 29) noted the PICK ETF +~47% since October on a similar setup.
• Phosphate (MOS, NTR phosphate, OCP): cost-curve read-through from sulfur +80% and the China acid ban is direct and underappreciated. Phosphate processing is acid-intensive.
• Aluminum (AA, CENX): 4-year highs on China capacity discipline (45.5 Mt domestic ceiling) per Scott-Gray on The Derivative. Midwest premium structurally elevated.
• Magnets / rare earths (MP, LYC, NEO): silent on the pods this week. With the April 2025 controls still in force and the one-year suspension running to November 2026, no operator voiced an updated view, which doesn't mean nothing is happening, it means we wait.

What Changed

The Hormuz/sulfur thread is the only genuinely new cross-asset story to surface this week. The structural copper deficit thesis is not new; what is new is that operators and analysts independently converged on it on the same week, at $6+ spot, with Grasberg's 2028 timeline now confirmed by a CEO with a strategic stake. The fertilizer angle is the second-derivative trade most people will miss because it broke inside a copper podcast.

Your weekly note

Sources

• The Derivative, "'Dr. Copper': From Chilean Mines to Chinese Smelters to AI Data Centers in the US", Kurt Nelson & Natalie Scott-Gray, May 28, 2026
• The KE Report, "Darrell Fletcher - Navigating Global Commodity Trends & Structural Shifts: Oil, Nat Gas, Copper, Critical Minerals, Gold," May 27, 2026
• Mining Stock Daily, "Tracy Shuchart: Markets Still Don't Understand the Commodity Crunch," May 29, 2026
• The KE Report, "Brian Leni - Investors Rotating Money In Metals: Copper & Copper Stock Outlooks," May 28, 2026
• The KE Report, "Nick Hodge – Macro Market Movers, 2 Site Visits, and Investing Strategies in Copper, Gold, And Critical Minerals Stocks," May 29, 2026
• Wall Street Unplugged, "Ivan Bebek's new project could become the world's largest copper mine," May 27, 2026
• Mining Stock Daily, "Live from the Deutsche Goldmesse: Marimaca Copper Targets 2027 Construction Decision as Pampa Medina Emerges as Major Chilean Copper Discovery," May 26, 2026
• Mining Stock Daily, "Live from Frankfurt at the Deutsche Goldmesse: Pan Global Advances Spain Copper-Gold Portfolio with New Funding and Expanded Drill Plans," May 26, 2026
• ITM Trading Podcast, "CEO Reveals $45M Copper-Gold Monster: 15,000m Drill Program Starting NOW!" May 27, 2026
• Mining Stock Daily, "Morning Briefing: A Combination of Factors Driving Metals Lower this Morning," May 28, 2026

Consumer staples and food & grocery newsletter for the week of May 31, 2026. A Conagra operator interview pushes back on the GLP-1-kills-packaged-food short with verified-purchase panel data, while Kroger's new CEO makes the price war official.

The Consumer Staples Brief

Week of May 31, 2026

Hi,

Quiet week on the tape, but the one operator interview that landed is the kind you read twice. Bob Nolan, who runs growth science at Conagra, sat down with The CPG Guys and quietly torched the consensus GLP-1-kills-packaged-food narrative with his own panel data. Meanwhile, Greg Foran's first real move at Kroger is exactly the price war the Street feared. Let's get into it.

TL;DR

• Conagra's verified-purchase GLP-1 panel says users spend slightly more on food, not less, with frozen single-serve, meat snacks, bars, and energy as winners; candy, cookies, sweet baked goods, and alcohol "getting crushed." Direct bullish read on CAG, direct bearish read on HSY confection.
• Walmart Connect grew +44% in Q1 FY2027 (with Vizio integration), U.S. comps +4.1%, U.S. e-comm +26%. The trade-spend gravity well keeps deepening for every CPG that sells into Bentonville.
• Kroger's new CEO is going aggressive on price. Greg Foran flagged "significant price reductions across all banners," direct importing, and roughly 80 new stores in 2027 (2x this year's pace). Promotional pressure flows straight to KHC/CAG/CPB/K/MDLZ shelf economics.

What's new this week

1) Conagra has a GLP-1 data set, and it doesn't say what you think it says. On The CPG Guys (Avoiding the Validation Trap with Conagra Brands' Bob Nolan, May 27, 2026), Nolan walked through a monthly verified-purchase panel of GLP-1 users versus matched non-users. The headline: GLP-1 users spend slightly more on food, not less, the opposite of the self-reported 2023 surveys that crushed food multiples. The shape of the spend changes, though. Single-serve frozen meals, frozen appetizers, frozen vegetables, meat snacks, energy drinks, and bars are winners. Sweet baked goods, candy, cookies, and alcohol are "getting crushed in the data every time we see it." Every calorie, in Nolan's words, "needs to have a purpose." For a CAG holder this is the cleanest pushback yet on the GLP-1 short. For HSY, it is the opposite.

2) Conagra's innovation engine, by the numbers. Same episode: Nolan said the industry's two-year new-food failure rate is roughly 80%, and Conagra has cut its own to about half that (implying roughly 40%) by reallocating around $15M out of traditional concept-validation research and into behavioral signals (foodservice menus, natural-channel scan, e-commerce receipts, social). Mega Breakfast Bowls went from insight to shelf in two months. Healthy Choice now wears an "OnTrack" badge to flag GLP-1 suitability without reformulating. Take the hit-rate claim with the usual operator-attribution discount, but the speed and the data infrastructure are real, and they show up in shelf velocity.

3) Walmart's flywheel keeps compounding, and ads are the engine. Per Commerce Riff with Sri & PVSB (The CPG Guys, May 26, 2026): Walmart Q1 FY2027 revenue $177.8B (+7.3%), U.S. comp +4.1%, U.S. e-comm +26%, Sam's e-comm +23%, International e-comm +27%. The really interesting line is the ad stack: global advertising +37%, U.S. advertising +36%, Walmart Connect (with Vizio data integrated) +44%. Operating income only grew +5% on roughly 250 bps of fuel and distribution pressure, so the consumer business is doing the heavy lifting and ads are doing the margin lifting. Note Target's print in contrast: sales +6.7%, but EPS fell to $1.71 from $2.27 a year ago.

4) Kroger's price-war pivot is here. From the same Commerce Riff episode, citing a Bloomberg sit-down: new CEO Greg Foran has committed to "significant price reductions across all banners," direct importing to lower COGS, and roughly 80 new stores in 2027 (roughly double this year's pace) with potential Northeast and Florida M&A on top. He explicitly named Aldi and Trader Joe's alongside Walmart, Amazon, and Costco as the threats.

5) Center-store's structural problem, named out loud. Pundit, not operator, but worth flagging because the framing keeps showing up: PVSB argued legacy grocers "continue to allocate massive floor space to declining center-store categories" while fresh and prepared meals drive the actual traffic. It's a view, not a number, but it's the directional headwind every center-store CFO is privately modeling.

The debate

The tape this week is one-sided, and the side it argues is selectively bullish on the right packaged-food portfolios, and broadly bearish on retailer-CPG economics.

The bull case, per Nolan: the GLP-1 panic was driven by surveys, not receipts. Receipt-level data shows users redirecting spend toward exactly the categories CAG (and by extension, frozen-heavy peers) over-index on. Innovation cycle times are collapsing. If you believe behavioral data over survey data, frozen single-serve and protein-forward portfolios are net beneficiaries of a structural diet shift, not victims.

The bear case wasn't directly voiced on this week's pods, but it's implicit in the Kroger and Walmart numbers: shelf-space is being rationalized, Walmart Connect's +44% is somebody's trade-spend dollars, and Kroger is about to swing the price hammer on every supplier into its store. Even if the volume base holds, the unit economics for the brands on those shelves are getting squeezed from both ends.

"The evidence on tallow is up a thousand percent, but it's still very small.", Bob Nolan, The CPG Guys, May 27, 2026

The structural-deflation / private-label-keeps-eating-pricing-power case wasn't argued on the tape this week; the cocoa/coffee shows we follow simply didn't print.

The names in play

CAG, incrementally constructive. Operator-disclosed GLP-1 data, faster innovation cycle, OnTrack badging, and the foodservice to natural to grocery pipeline are all positive thesis inputs. No financial guidance was given, so this is qualitative, but the data infrastructure described is a real moat versus peers still relying on concept tests. Next catalyst: CAG's fiscal Q4 print and any color on GLP-1 cohort dollar share by category.

HSY, incrementally cautious. A peer's verified-purchase panel calling out candy and cookies as GLP-1 losers is not a thesis-changer on its own, but it's another data point in the wrong direction, layered on the cocoa cost problem the tape didn't cover this week. Watch for the next print's commentary on volume elasticity in seasonal confection.

WMT, the platform is winning, the margin mix is shifting. +44% Walmart Connect growth is the cleanest evidence yet that the ad stack is the operating-margin story. The OI miss versus revenue isn't a thesis-breaker if the ad/marketplace mix keeps compounding.

KR, caution. Foran's playbook (price down, capex up, store-count up) is a multi-year setup; near-term it pressures gross margin and EPS optics. The flip side is share gain, but Walmart's e-comm at +26% suggests the share war is uphill.

CPB, K, MDLZ, KDP, UL, DASH, CART, COST, ACI, TGT, THS: no actionable name-specific operator commentary on the tape this week.

Read-throughs

• Confectioners and packaged coffee (HSY, MDLZ, KDP): Adjacent operator data on GLP-1 substitution is unhelpful for sugar-forward portfolios. No cocoa or arabica/robusta commentary on the pods this week; the cost-side debate will have to wait for next week's tape.
• Foodservice as a leading indicator: CAG explicitly buys QSR/fast-casual menu data, treats a roughly 2-year lag from natural-channel placement to mainstream grocery, and is currently mining chicken-protein surge and global/ethnic cuisine signals. If you cover frozen, watch what's hot at Sweetgreen, Chipotle, Wingstop.
• CPG retail-media budgets: Walmart Connect's +44% has to come from somewhere, likely from Meta/Google performance spend and from in-store trade. Either way, it's gross margin out of brand P&Ls and into Walmart's.
• Private label / hard discount: No dedicated coverage this week, but Foran's explicit Aldi-and-Trader-Joe's call-out confirms the discounter share-gain narrative is being taken seriously at the C-suite level of the #2 U.S. grocer.

What changed

The new datapoints this week: (a) a credible operator-disclosed panel pushing back on the GLP-1 short of packaged food, and (b) the price-war flag at Kroger going from rumor to official strategy. Cocoa, coffee, quick-commerce unit economics, and private-label co-manufacturers were silent on the pods we follow; we'll pick them up when they print.

Sources

• The CPG Guys, Avoiding the Validation Trap with Conagra Brands' Bob Nolan, May 27, 2026
• The CPG Guys, Commerce Riff with Sri & PVSB, May 26, 2026

Capital-markets newsletter for May 24–31, 2026. The headline IPO of the decade is suddenly real and Q2 fee pools are running hot, even as Blankfein and the private-credit data flag a sponsor exit crisis hiding underneath the reopening.

Capital Markets: IPOs, M&A & Exchanges

Week of May 24–31, 2026

Friends, one of the strangest setups I can remember. The headline IPO of the decade is suddenly real, S&P targets are flying to 8,000, and Jamie Dimon is telling the Bernstein audience his trading book is up roughly 11 percent, and at the same exact moment, the man who built modern Goldman is on television explaining why private-equity sponsors aren't selling into the best financing window in history. That gap is the whole story this week, so let's pull on it.

TL;DR

• SpaceX is going public into a forced-bid index window. FTSE Russell confirmed fast-entry eligibility; Jefferies' framing is 265x 2027 EBITDA. The flow mechanics, not the multiple, are what underwriters and arb desks are now wargaming.
• Q2 capital-markets fees are tracking up double-digits, but capital allocation is frozen. Dimon flagged JPM trading up roughly 11 percent YoY, IB up 10 percent plus. In the same breath: "I'm not that fond of buying stock at these prices."
• Private credit is the canary nobody on the Street wants to name. April default rate hit a record 6.0 percent; non-traded BDCs saw the first-ever Q1 net outflows; GS BDC troubled assets jumped 190bps QoQ. This is not a banking crisis. It's an exit crisis.

What's New

1) SpaceX has its index ticket, and the underwriters now have a problem. On the May 27 Squawk on the Street, Carl Quintanilla, David Faber and Jim Cramer walked through the FTSE Russell confirmation that SpaceX will be eligible for fast-entry inclusion in the Russell U.S. Equity and FTSE Global indices, with NASDAQ 100 inclusion debated. As Faber put it, "the underwriters are going to have a lot on their plate to balance," meaning the IPO is going to print into a wall of index-fund forced buying on day one. Halo names (LUNR, RKLB, RDW) were already bid 3-4 percent intraday. This is the live ECM event of 2026 and it lands directly in the GS/MS book.

2) Jefferies put a number on it. On May 26 Bloomberg Surveillance, Jefferies A&D analyst Sheila Kahyaoglu framed SpaceX at "265x 2027 EBITDA" against Musk's $26T space-economy TAM and flagged the index-inclusion mechanics as a real disruption risk to orderly price discovery. Her comp: AVEX as the most recent A&D IPO benchmark. This is the first cite-worthy sell-side math on the deal.

3) Dimon: fees good, deals not. Via the same Squawk tape relaying his Bernstein Financial Services Conference appearance, Jamie Dimon told the room JPM Q2 trading is tracking up roughly 11 percent YoY and IB up 10 percent plus YoY, a clean read-through to GS and MS Q2 prints. But:

"Asset prices are high, including J.P. Morgan stock. So, I'm not that fond of buying stock at these prices or companies. And we're quite patient with capital."

That's a CEO running the biggest balance sheet in American finance saying he won't use it at these levels. Read that twice.

4) Blankfein names the elephant. On May 29's The Forum with Becky Quick, former GS CEO Lloyd Blankfein gave the most quotable diagnosis of the PE exit problem I've heard this cycle:

"We've just had the highest equity markets ever and the best financing markets ever. And assets are getting kind of aged on balance sheets. So that must mean for people who are highly motivated to sell them or not selling them because the price isn't being met because they're probably marked."

In plain English: sponsors aren't selling because the marks are wrong. He pointed to LP secondaries trading at discounts, endowment liquidations, and the rise of continuation vehicles as symptoms of the same drought. On private credit he was more measured ("I don't think private credit by itself is that substantial or that bad... I'm more worried about the kindling than I am about the loose cigarette butt") but warned the workout architecture is structurally broken: there is no Fed-convening-16-banks scenario for a private-credit blowup. You'd need "Citi Field."

5) The private-credit data caught up to the rhetoric. On May 26's Eurodollar University, Jeff Snider aggregated the most important number set of the week, sourced to Fitch, Robert Stanger & Co., and primary GS BDC filings, all independently verifiable:

• Fitch: US private-credit default rate hit 6.0 percent in April 2026, a new record.
• Non-traded BDCs experienced their first-ever Q1 net outflows, roughly $7B redeemed vs. roughly $5B raised, per Stanger CEO Kevin Gannon. Total Q1 redemption requests over $15B. Many funds enforcing 5 percent withdrawal gates.
• GS BDC's May filing: most-troubled holdings rose to 4.7 percent of portfolio at cost, up 190bps QoQ.
• New Mountain Finance bought a Q1 loan at roughly 65 cents that has since rallied roughly 10 cents, implying the prior holder dumped it roughly 35 percent below par.

If you own asset-managers on the alts re-rating thesis, this is the data set that decides whether 2026 is the year the FRE multiple expands or the year the credit multiple compresses.

The Debate

The bull case (which the tape supports loudly): This is a durable multi-year reopening. Q2 IB and trading fees are up double-digits at the bellwether (Dimon). The IPO window has cracked open with SpaceX, and Brian Belski on the May 29 Bloomberg Surveillance tape argues OpenAI's public messaging has gotten "much more conservative relative to what it was 6 months ago... they're preparing to become a public company." Goldman, Deutsche Bank and Morgan Stanley all yanked S&P 500 PTs to 8,000. GSAM's Lindsay Rosner notes IG credit is the tightest since 1998 and HY/EM the tightest since 2007, and even she says, "There's no pushback. There's no hesitancy" on new issuance. The whole complex (GS, MS, EVR, MC, JEF, NDAQ as listing venue, LSEG via FTSE Russell index revenue) gets paid.

The bear case (where the tape is, frankly, more interesting): Blankfein and Snider are calling the same animal from different ends. If sponsors aren't selling because the marks are wrong, then the announced-M&A backlog and the IPO calendar are less leading than the bull case assumes: they reflect the deals that clear, not the inventory of assets that should be moving but can't. And if private-credit defaults are at a record and the marginal LP is redeeming for the first time ever, then the leveraged-finance feeder system for sponsor M&A is quietly tightening even with IG spreads at 1998 tights. GS credit strategist Amanda Lyman essentially conceded this on May 26: "You shouldn't be banking on a material rally in interest rates or a material tightening in spreads. You should really be owning credit for the carry and the income." Translation from sell-side-ese: this is as good as it gets.

The Names in Play

GS, MS: Direct beneficiaries of the Q2 fee print Dimon previewed. Bonus: G-SIB living wills cleared with no shortcomings, removing a regulatory overhang, and GS finally settled the 1MDB shareholder class for $500M, per The Banker Next Door on 5/29. Watch the Warren-vs-Morgan-Stanley exemption headline as a low-probability tail.

JEF, EVR, MC: Jefferies put the first number on SpaceX. The boutiques are the highest-beta way to play any actual reopening; they're also the most exposed if Blankfein is right and the inventory just sits.

BX, KKR, APO, ARES, OWL: The PE complex is the trade where both sides of the debate are simultaneously true. Earnings power on fundraising plus AUM is fine. The exit math is broken. Mark accordingly.

Read-throughs

• Boutiques (EVR, MC, JEF): Highest operating leverage to the announced-M&A turn. JEF's SpaceX coverage is a tell: they're positioning for ECM share.
• Private-credit BDCs and asset managers (ARCC, MAIN, BXSL, GBDC, NMFC, OBDC): The redemption-gate dynamic is real. NMFC's secondary-market loan purchase at roughly 65 cents is the kind of data point that gets aggregated into a fund-level NAV write-down two quarters later.
• Index/data franchises (LSEG, NDAQ): FTSE Russell's fast-entry confirmation is a real, if modest, AUM-linked revenue event for LSEG and a listing/data competitive moment for NDAQ.
• The exchanges proper (ICE, CME, CBOE): No substantive operator commentary on the tape this week. The 0DTE, OTC-to-cleared, and capture-rate threads were quiet. Worth watching whether June pre-announcements break the silence.
• Prediction markets (Kalshi, Polymarket, HOOD event contracts): No episodes touched this in the last seven days. Last week's regulatory thread did not advance.

What Changed

The shift this week is the juxtaposition, not any one data point. A month ago, the bear case on capital markets was "rates are too high, deals won't print." This week the bear case mutated into "deals can print, sponsors won't sell," and the GS BDC filing put hard numbers on the credit side of that argument for the first time in this cycle. If you've been long the IB complex purely on the fee-pool re-rating, the debate just got a real second leg.

That's it for this week. Reply with what you're seeing on your tape, especially if any of you are hearing real operator commentary on the exchanges and prediction-market side that didn't make it to the major pods. I want to be writing about CME and Kalshi next week and the shows didn't give me much to work with.

Sources

• Squawk on the Street, 9AM HOUR: $1T Micron and the "Green" Chips, Goldman Ups S&P 500 PT to 8,000, SpaceX IPO "Fast Entry", 5/27/26 (CNBC, 2026-05-27)
• The Forum with Becky Quick, Inside the Next Financial Crisis with Lloyd Blankfein (2026-05-29)
• Bloomberg Surveillance, Stocks Rise as Iran Peace Hopes Hold (2026-05-26)
• Bloomberg Surveillance, Equity and Bond Signals (2026-05-29)
• Eurodollar University, Goldman Sachs Just Confirmed the Worst-Case Scenario (2026-05-26)
• The Banker Next Door, Bank News: CEO apologies, EOs, Living wills, Charters, Exemptions, and Fines! (2026-05-29)

Brands newsletter for the week of May 31, 2026 (developments May 26–29). The sneaker tape ran loud while luxury stayed quiet: a real but slow Nike turnaround, Dick's as the cleanest way to play it, and a sober On Holding tear-down.

Brands: Luxury, Sneakers & Apparel

Week of May 31, 2026

Quiet week on the luxury pods: the European megabrand tape barely whispered. The noise this week was on the sneaker side, and the loudest argument was that Nike is, in fact, fixing itself, the bears just don't believe it yet, and the cleanest way to play the comeback isn't Nike at all. It's the wholesaler Nike abandoned and is now begging back.

TL;DR

• Nike is carrying a 650bp tariff gash on gross margin and tracking sub-6% operating margin for FY26 vs. a ~13% decade average. UBS still won't recommend the stock, but the bull cohort says the North America inflection is already here.
• Dick's Sporting Goods is the most levered way to be long the Nike comeback: Nike is unwinding DTC and routing product back through DKS just as youth-sports spend is up 70% since 2019 and Foot Locker's mall footprint is now an asset, not a project.
• On Holding is a great brand wrapped around two ugly concentrations: Asia is 17% of revenue but houses 38 of 67 stores, and Dick's is 58.2% of wholesale. The live tear-down landed on "not right now, revisit in six months."

What's new

1. Nike: the tariff number finally has a decimal point. On Barron's Streetwise, "Jordan, Wemby, and Why Nike's Turnaround Hasn't Taken Flight" (May 29), Jay Soule, footwear analyst at UBS, walked through the math: operating margin sub-6% for the fiscal year ending May 2026 against a ~13% decade average, Jordan brand revenue down 16% YoY to $7.3B in FY25, Greater China down 7% on top of last year's -17%, and tariffs alone clipping 650bps off gross margin. UBS is not yet recommending the stock. The bull case now requires you to believe three independent things: tariffs annualize, China stops bleeding, and innovation comes back. Three fixes, not one.

2. The bull retort: North America already at +3%. Same episode, Chris Rossback, CIO of Jay Stern Asset Management, made the bull case in plain terms: North America inflecting +3%, the tariff comp starts getting easier from here, and the 2026 FIFA World Cup is a global brand catalyst sized to actually move numbers. The split is clean: sell-side is in show-me mode, the value-PM cohort is buying it.

"Nike has a rabid following... the shift from sport-specific to vertical men's/women's/kids retail is a Harvard business case study at this point." Trip Randall, CEO of Superfeet (25 years at Nike), on The Kara Goldin Show, Ep. 844, May 27, 2026.

That's the bull and bear in two sentences from someone who knows where the bodies are buried.

3. The Dick's trade: Nike on the shelf, plus a $40B youth-sports boom. Andy Swan, co-founder of Likefolio, on Schwab Network's Ca$htag$ (May 26), laid out the structural case: Nike is unwinding DTC-only and putting product back through Dick's, a direct revenue tailwind. Layer on a $40B youth-sports category where baseball spending is up 70% since 2019, the Game Changer app running ~$150M/year with a new AI coaching feature, and the Foot Locker deal (initially unloved) now being re-rated as a real-estate and mall-expertise asset, with House of Sport megastores generating higher revenue per square foot than standard locations. Stock at 52-week highs, up ~33% YoY into the May 27 print. There's a reason.

4. On Holding: the live tear-down nobody on the buy-side will admit to listening to. A retail-investor podcast, Investing for Beginners' "Live Research: On Holding (ONON), Great Growth, Big Questions" (May 28), did the cleanest bear-case work I saw all week. Revenue grew from under $300M to $3.8B (~50% CAGR) yet the stock is flat over the same period. Footwear is $2.8B, apparel is $160M: the diversification story isn't built. Asia is 17% of revenue but houses 38 of 67 retail stores. Dick's is 58.2% of wholesale revenue. The 20-F admits "limited experience" with LightSpray, the scaling technology underwriting the next gross-margin leg. Hosts Stephen Morris and Andrew Sather landed on "not a hard pass, but not right now, revisit in six months." Treat as directional rather than authoritative (these aren't sell-side), but the data points are pulled straight from the filing.

5. The China sneaker threat is back in the conversation. Same Streetwise episode. Sean Go, sneaker collector, and Chris Chase, Wear Testers YouTube, argued the Chinese domestic brands (Li-Ning, Anta, Wade) have closed the quality gap while Nike's takedown models have actually deteriorated. That's operator-adjacent ground truth, not a sell-side model. It's also the part of the Nike China story you don't get from quarterly disclosure.

The debate

This week the tape was lopsided. The case being voiced loudly: Nike is fixing the right things, the challenger cycle isn't structurally taking durable share (it's mostly brand rotation that scale and innovation can reverse), and Dick's is the cheaper way to own the same trade.

The other side of the debate, that the soft-luxury slowdown is genuinely structural because the aspirational consumer has disappeared, and that On and Hoka are compounding share Nike will not get back, wasn't really voiced on the pods we follow this week. The European luxury commentary on the institutional shows was thin to silent. Noted, and we'll come back to it when the tape gives us something to chew on. The dog that didn't bark is still data.

The names in play

• NKE. Bear (Soule, UBS): the turnaround takes longer than the market expects. Bull (Rossback): NA already +3%, tariff comp easier, World Cup catalyst. Watch: gross-margin recovery cadence, Greater China comp, Q1 FY27 print.
• DKS. Bull (Swan, Likefolio): Nike wholesale return, youth-sports unit economics, Foot Locker as a real-estate asset. Earnings landed May 27 into a 52-week high.
• ONON. Cautious (Investing for Beginners): brand is real, moat is thin, DKS concentration and LightSpray scaling are the two risks to size.
• DECK / Hoka. Backstory only this week (Ecommerce on Tap): origin story, no deceleration debate aired.
• LULU, SKX, EL, RMS, MC, KER, CFR, FL standalone. Silent on the pods we follow this week.

Read-throughs

• Foot Locker quietly re-rated inside the DKS bull case as a real-estate and mall-expertise asset, not a turnaround project (Ca$htag$, May 26).
• Indie footwear / DTC: multiple founders on Retail War Games (May 29) said they moved factories out of China ("we moved like four different factories. It was a mess" - Blake Brown, Fooley Footwear) and either ate the tariff or pushed price ~20% ("we raised prices ~20% and ran A/B testing, trading revenue growth for margin" - Hayat Chaudhary, Luxome). Directional for the small-cap apparel tape, not a public-co read.
• Adidas, New Balance, ASICS, Brooks, Salomon: named as Nike-share beneficiaries on Streetwise, no dedicated coverage.
• Beauty (EL, LRLCY, COTY), travel retail / Hainan / CDF, Macau, contract manufacturers (Pou Chen, Yue Yuen, Feng Tay), Swatch, Rolex secondary: all silent. The absence itself tells you where buy-side podcast attention is, and isn't, this week.

What changed

Two things actually shifted this week. First, the Nike tariff drag finally has a credible number on it: 650bps off gross margin, from a footwear analyst on a credible show, which lets you model the bridge to FY27 instead of waving hands. Second, the Dick's bull case got operator-grade detail: youth-sports unit economics, Game Changer app run-rate, House of Sport per-square-foot lift, Nike wholesale flow returning in size. The Nike-comes-back-to-wholesale story is no longer a setup. It's a print.

Sources

• "Jordan, Wemby, and Why Nike's Turnaround Hasn't Taken Flight" - Barron's Streetwise, May 29, 2026
• "Ca$htag$: DKS Builds Earnings Momentum as NKE Returns to Wholesale" - Schwab Network, May 26, 2026
• "Live Research: On Holding (ONON), Great Growth, Big Questions" - The Investing for Beginners Podcast, May 28, 2026
• "844 Trip Randall: CEO of Superfeet" - The Kara Goldin Show, May 27, 2026
• "Fashion, Design & Luxury Identity | Retail Collective Summit" - Retail War Games, May 29, 2026
• "How Hoka Built a Billion-Dollar Shoe Brand" - Ecommerce on Tap, May 26, 2026

Brands newsletter for May 24–31, 2026. A thin primary-commentary tape leaves Nike as the only name with substantive coverage, sharpening the bull/bear standoff on its wholesale relaunch, margins, and basketball marketing vacuum.

Brands Weekly

Week of May 24–31, 2026

Luxury, Sneakers, Apparel, week ending May 31, 2026

The tape was thin this week, and that is the story. Only one episode carried substantive primary commentary on the brands complex: Barron's Streetwise, "Jordan, Wemby, and Why Nike's Turnaround Hasn't Taken Flight," May 29, 2026. European soft luxury (LVMH, RMS, CFR, KER), the Chinese luxury consumer, ONON, DECK/HOKA, LULU, ADS, BIRK, EL/OR/COTY/ELF/ULTA, Sands China, TPR/RL/LEVI/CPRI, and the Asian footwear OEMs were all silent. With Q1 readouts behind us and Q2 reporting still weeks away, the primary-commentary cycle is in a lull. We use the quiet to set the playbook.

🥊 The Nike Standoff Sharpened, Did Not Resolve

The Hill turnaround actions are now concrete on the tape, not theoretical: pulled-back Jordan Retro releases, pulled-back Dunk allocations, and an explicit wholesale re-engagement that names Foot Locker and concedes "humbler economics," a clean reversal of the Donahoe-era DTC push.

The macro arithmetic is also on tape. North America came in +3% YoY last quarter (footwear-led, apparel and equipment still down), with the bull, Chris Rossback (CIO, J. Stern, long NKE), flagging "inflection in gross margins on an underlying basis" in the U.S. and a 650 bps tariff-related cost hit set to lap. He frames the World Cup as a back-half lever:

"Over 50% of [the selling opportunity] is still to come."

He layers cost-base relief from 2026 layoffs on top.

The bear, Jay Soule (UBS footwear), does not argue the direction; he argues the timing and the stock. NKE at roughly 24x FY-ahead EPS already prices a fast turn. FY ending May 2026 op margin is projected below 6% against a decade-average of 13% through May 2024, and Soule's frame is that Adidas runs about 8%, Puma and Under Armour lower: the historical double-digit Nike margin may not be a structural baseline you can will back into existence.

His brand-equity flag is sharper still: sportswear and apparel has crept to roughly 50% of sales against an internal Nike ceiling once stated as "never exceed 30%," performance-DNA dilution that took years to build and will take years to walk back.

The Jordan Number Anchors the Bear Case

Jordan Brand FY May 2025 was $7.3B (15% of total Nike), down 16% YoY. Sean Go (sneaker reviewer) on the Air Jordan 40 at $205:

"A nice looking shoe, but you don't have people clamoring to buy it because Michael Jordan's been retired for so long. The kids now don't have that connection to him as a player."

Soule's marketing-vacuum read-through extends the bear: SGA carries flopper baggage, Jokic has no sneaker cachet, Wembanyama at 7'4" is "less relatable," and Cooper Flagg, the next consensus NBA superstar, is signed to New Balance, not Nike. That is a multi-year overhang on basketball-category sneaker-culture marketing leverage.

👟 The Most Actionable Read-Through Is Shelf-Availability, Not Brand Sentiment

Sean Go: "We're seeing less Nikes and Jordans at Foot Locker and Dick's Sporting Goods," with consumers defaulting to New Balance and ASICS "because that's what's available." The Barron's Streetwise framing groups New Balance, HOKA, and On as the three primary insurgents pulled forward by the lifestyle and running aesthetic shift ("dad shoes and tech wear") and by Nike's allocation discipline.

The PM takeaway is sharper than the consensus narrative. In the near term, meaning the next two to three order cycles, FL and DKS comp mix is being carried by NB and ASICS, not by HOKA / ONON refresh, and not yet by Nike's wholesale relaunch. That is asymmetric: it should support FL/DKS gross profit dollar per square foot through summer, but the brand mix is not equity-friendly for FL (lower exclusivity premium on NB/ASICS than on Jordan).

Medium-term, Nike's wholesale return is a direct shelf-share threat to ONON and HOKA at the same doors that have been their lifestyle launchpads, a thesis pressure point that DECK and ONON longs will need to underwrite into FY27 plans.

🇨🇳 The China Sub-Text Matters More Than the Silence Implies

The single fresh China data point is from Chris Chase (Wear Testers): Chinese domestic brands, Li-Ning and Anta/Wade, have moved from "Walmart quality" to "if it's not right there with what you would expect a top tier shoe to be, it's exceeding that," a structural reason Western performance brands lose share in China beyond cyclical demand.

NKE Greater China was −7% last quarter against a −17% comp; Rossback called it "fixable," not brand rejection. The honest synthesis is that both are partially right, cycle and structural, but it is the structural overlay that should re-rate the long-run China sneakers TAM lower for every Western brand, not just Nike. Read-through to HOKA's China entry pace and to LULU's China growth narrative: the threshold for "winning on premium product quality" is no longer a soft one.

📈 Adidas: Small But Real

Two tangential mentions worth flagging. Adidas op margin was roughly 8% last year, Soule's benchmark for "what major-sneaker margins look like off the Nike peak." And Sean Go: "Adidas has done really well with Anthony Edwards and his tremendous success in the league," a positive incremental signal on the Adidas basketball reset under Bjorn Gulden, against a weakened Jordan.

🔭 What to Watch Into Next Week

1. NKE FQ4 (May 2026) earnings late June, the only event that resolves the bull/bear standoff on tape. Watch NA wholesale order book, Jordan unit sell-through, China underlying ex-tariff, and any first read on FY27 op-margin trajectory.
2. European luxury reads start in early-to-mid July. Set up positioning on LVMH F&LG organic and Richemont Jewellery Maisons China commentary now while the names are quiet.
3. ASICS as the cleanest "Nike wholesale rotation" beneficiary. No US listing, but a useful read-through for FL/DKS apparel margin mix and for the HOKA/ONON shelf-share thesis.

🤫 Silent Themes (Flagged Honestly)

European soft luxury (LVMH, RMS, CFR, KER), the Chinese luxury consumer specifically, ONON fundamentals, DECK/HOKA fundamentals, SKX (post-3G), LULU, BIRK, EL, L'Oréal, COTY, Shiseido, ULTA, ELF, RL, TPR, CPRI, LEVI, Sands China, travel retail, luxury landlords, and the Asian footwear OEMs (Pou Chen, Yue Yuen, Feng Tay) were all silent on the May 24–31, 2026 podcast tape. We did not pad.

Sources

• Barron's Streetwise, "Jordan, Wemby, and Why Nike's Turnaround Hasn't Taken Flight," May 29, 2026

Brands weekly for the week ending May 31, 2026. Hard luxury keeps lapping soft on the Bernstein/Solca framework, Demna's Gucci debut reads mixed, and the Estee Lauder-Puig merger collapses.

Brands: Luxury, Sneakers & Apparel Weekly

Week ending Sunday, May 31, 2026

The tape this week was Solca-shaped: Bernstein's Luca Solca went on BOF with the cleanest framework of the cycle, and Bloomberg Intelligence buried the Estee Lauder-Puig merger. Below is what mattered, with links.

1. The Solca wedge: Cartier/Van Cleef keep lapping Vuitton/Dior bags

Bernstein's organic-growth gap between Richemont jewelry and LVMH F&LG: +20pts in Q2 2025, +19pts in Q3, +17pts in Q4. Solca's framing is structural:

"Jewelry has become cheaper relative to leather goods as consumers now have the option to spend $5,000 or even $10,000 for a reputed brand handbag. But they can spend the same amount of money or even less for a piece of jewelry or a watch from Cartier... This cycle, I don't think is going to end abruptly."

Long CFR SW / short MC FP is still on; no catalyst yet to flip.

2. China: U-shaped, very concentrated, and Hermes traffic is declining

Bernstein's proprietary store-traffic survey (weekend before Chinese New Year 2026 vs 2025): overall traffic +47% YoY but "incredibly concentrated." Chanel and Dior, both with new creative directors, were "miles ahead." Hermes was explicitly named as declining. First on-the-record data point we have seen this cycle calling Hermes out in a Chinese tier-1 traffic read. Solca attributes it to "doing more of the same" while peers ride creative-reset energy.

"China is not producing the same amount of new consumers as in the past."

If you own RMS FP at 50x on Birkin allocation scarcity, this is the tape that says aspirational demand may finally be cracking even at the top.

3. Demna's Gucci debut: a step, not a V

Kering bulls need a runway-to-register conversion this year. Solca is on the record cautious: F/W26 Milan ready-to-wear was "more Gucci than what we had seen for a few years," but handbags and footwear got "much more mixed reaction... overall negative reaction, as this failed so far to excite." Bottom line: "We don't see the prospects of a V-shaped quick recovery." Bernstein is "prudent on the Gucci revival." Imran Amed: "I left that show feeling more confused than I did clear about where the brand is going." The "Gucci Core" New York show, entry-price focused, is the strategic clarity test. KER FP at this multiple needs Demna to convert; nothing this week says he yet is.

4. Prada/Versace: Guerra goes big, Solca goes skeptical

Prada Group CEO Andrea Guerra framed the Versace deal as an option, not the base case: Prada + Miu Miu alone targets "somewhere close to €10 billion as an ambition" before Versace contributes. On Versace: "has been a little bit mismanaged as a brand, not as a business... we don't think we have to be successful tomorrow morning." Solca pushed back: "Prada has a poor track record of M&A if we think about Helmut Lang, Jill Sander, Church, these were not good acquisitions," though he likes new designer Peter Mulier (ex-Alaia). Guerra also made the most honest pricing admission of the week:

"This industry has lost 1 consumer out of 5 in the last 3-4 years... You should never talk about pricing because you should be so happy that you give me your credit card without even asking what is the price."

5. Nike: the turnaround is real, the pace is not

Two voices on Friday's Barron's Streetwise give you the whole debate. Jay Soule (UBS) is on the sidelines: NKE FY26 operating margin projected below 6% vs a decade average of 13%; fewer than half of Street analysts now rate it a buy vs more than 75% at the 2021 peak.

"What's in the stock price is an expectation that the turnaround will happen fast... it might not happen as fast as Wall Street wants."

Chris Rossback (Jay Stern CIO) is constructive: North America +3%, China -7% vs -17% a year ago, 650bp tariff hit annualizing, World Cup 2026 selling-in "over 50% still to come." Jordan Brand FY25 revenue $7.3B (15% of NKE), -16% YoY. CFO Matt Friend has flagged Q1 FY27 as the final quarter of YoY tariff drag, with margin expansion the quarter after. The setup: one more bad quarter, then the GM bridge inflects.

6. The Foot Locker tell: Nike under-allocation now visible at retail

Sean Go on Barron's confirmed what channel checks have been hinting at:

"We're seeing less Nikes and Jordans at Foot Locker and Dick's Sporting Goods... New Balances, ASICs, a lot of even casual consumers are turning towards those brands because that's what's available."

FL is 60% Nike-exposed (Stacey Whitlitz). On + HOKA continue to print. Whitlitz: "On's numbers, they were fantastic... Hoka's numbers, they were better." The trade still works: long ONON/DECK, watch FL into next print.

7. Estee Lauder-Puig dies; EL stock relieved

Big single-name news: the EL-Puig merger collapsed around May 22. EL rose on the day, Puig fell, the reverse of the announcement reaction. Deborah Aitken (Bloomberg Intelligence) flagged the reported sticking point as Charlotte Tilbury valuation (Puig holds 78-79%, put/call to 2031). EL has now booked three consecutive years of annual sales declines, fragrance is only about 19% of mix, and PRGP targets $1.0-1.2B in savings starting FY27. Aitken's structural view: "Estee Lauder needs, for me, more in fragrances." She also flagged travel-retail headwinds tied to Iran "since the middle of March," relevant for EL/L'Oreal/Coty channel reads. Expect both names to pursue independent bolt-ons.

8. Lancome bets on longevity; Amazon out-beauties Ulta

L'Oreal's Lancome launched Absolue Longevity MD with Swiss biotech Timeline (Urolithin-A/Mitopure). Brand President Vania Lacascade: "the biggest leap of innovations since Genifique that we launched in 2009." Channel math: Amazon Q1 2026 beauty $8.1B (+13% YoY), March spring sale $1.5B (+20%); Ulta Q1 2026 = $2.77B, roughly a third of Amazon. Standout K-beauty winner: MediCube at $24M in the spring sale, +140% YoY. ULTA's defense remains loyalty.

9. Wholesale's loudest pitch in years: Pete Nordstrom

For apparel-vendor exposure: Pete Nordstrom (Co-CEO JWN) made the most explicit public case yet for wholesale's comeback, with a name-drop of LVMH: "even in a place like LVMH... they will tell you that in the U.S. market, there is a multi-brand store that's part of the recipe." He has removed the "governor" on Nordstrom Rack: it could grow from about 200 to potentially 500 stores vs TJX's 2,000+.

What's Quiet

Silent this week: Macau / Sands China; mall landlords (SPG, MAC, SKT, Hongkong Land, Wharf REIC); Asian contract manufacturers (Pou Chen 9904 TT, Yue Yuen 551 HK, Feng Tay 9910 TT); BIRK, RL, TPR, CPRI, LEVI; SKX post-3G; AmorePacific / LG H&H; Hainan / daigou flows; watch secondary market. Nothing on tape worth your time.

Brands desk

Sources

• The Business of Fashion Podcast, May 15, 2026
• In Good Company with Nicolai Tangen, Apr 10, 2026
• Barron's Streetwise, May 29, 2026
• CNBC Fast Money, Mar 31, 2026
• CNBC The Exchange, Apr 1, 2026
• Bloomberg Intelligence, May 22, 2026
• Glossy Beauty Podcast, May 21, 2026
• Glossy Beauty Podcast, May 14, 2026
• Remarkable Retail Podcast, May 5, 2026